No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, d2wipC1, 1.0000, 0.00, 1.000, 291, 291, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
2, d2wxvC1, 0.9983, 0.25, 1.000, 298, 291, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
3, d2bkzC2, 0.9983, 0.26, 1.000, 297, 291, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
4, d2c4gC2, 0.9975, 0.31, 1.000, 298, 291, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
5, d1vywC1, 0.9973, 0.32, 1.000, 298, 291, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
6, d2wihC1, 0.9968, 0.35, 1.000, 298, 291, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
7, d2wpaC1, 0.9953, 0.43, 1.000, 298, 291, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
8, d3f5xC_, 0.9950, 0.47, 1.000, 298, 291, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
9, d2bpmC2, 0.9950, 0.45, 1.000, 298, 291, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
10, d2i40C_, 0.9948, 0.46, 1.000, 296, 291, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
11, d1fvvC_, 0.9948, 0.46, 1.000, 298, 291, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
12, d5if1C_, 0.9945, 0.48, 1.000, 296, 291, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
13, d2v22A_, 0.9940, 0.50, 1.000, 296, 291, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
14, d2uueA_, 0.9937, 0.51, 1.000, 296, 291, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
15, d2c5tA_, 0.9937, 0.51, 1.000, 296, 291,  
16, d2c5oA_, 0.9934, 0.53, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
17, d1ol1A_, 0.9932, 0.52, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
18, d1ol2A_, 0.9931, 0.53, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
19, d2whbA_, 0.9930, 0.54, 1.000, 296, 291, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
20, d2c5pA_, 0.9929, 0.55, 1.000, 296, 291,  
21, d2wevA_, 0.9928, 0.55, 1.000, 296, 291, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
22, d2c5xA_, 0.9926, 0.56, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
23, d2bkzA2, 0.9926, 0.79, 1.000, 298, 291, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
24, d2c5oC_, 0.9925, 0.56, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
25, d1finA_, 0.9925, 0.61, 1.000, 298, 291, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
26, d1urcA_, 0.9924, 0.57, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
27, d2c5nA_, 0.9923, 0.57, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
28, d3f5xA_, 0.9921, 0.45, 1.000, 297, 290, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
29, d2whaA_, 0.9916, 0.60, 1.000, 296, 291,  
30, d2x1nA_, 0.9915, 0.61, 1.000, 296, 291, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
31, d2wipA1, 0.9913, 0.83, 1.000, 293, 291, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
32, d2uueC_, 0.9909, 0.63, 1.000, 296, 291, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
33, d2c5tC_, 0.9906, 0.64, 1.000, 296, 291,  
34, d1okwA_, 0.9906, 0.63, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
35, d2v22C_, 0.9904, 0.65, 1.000, 296, 291, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
36, d1vywA1, 0.9904, 0.85, 1.000, 298, 291, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
37, d2whbC_, 0.9903, 0.64, 1.000, 296, 291, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
38, d2c5vA_, 0.9901, 0.68, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
39, d1okuA_, 0.9900, 0.68, 1.000, 296, 291,  
40, d1finC_, 0.9899, 0.68, 1.000, 298, 291, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
41, d2wxvA1, 0.9898, 0.85, 1.000, 298, 291, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
42, d2whaC_, 0.9898, 0.67, 1.000, 296, 291,  
43, d2x1nC_, 0.9896, 0.68, 1.000, 296, 291, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
44, d2wihA1, 0.9896, 0.87, 1.000, 298, 291, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
45, d2c4gA2, 0.9895, 0.83, 1.000, 297, 291, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
46, d2bpmA2, 0.9895, 0.86, 1.000, 298, 291, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
47, d2c5vC_, 0.9890, 0.71, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
48, d1okuC_, 0.9889, 0.71, 1.000, 296, 291,  
49, d1fvvA_, 0.9889, 0.80, 1.000, 298, 291, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
50, d2wpaA1, 0.9888, 0.90, 1.000, 298, 291, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
51, d1urcC_, 0.9888, 0.76, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
52, d1ol1C_, 0.9886, 0.72, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
53, d1okwC_, 0.9886, 0.71, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
54, d5if1A_, 0.9884, 0.87, 1.000, 298, 291, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
55, d2wfyC_, 0.9884, 0.71, 1.000, 296, 291, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
56, d2c5xC_, 0.9883, 0.73, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
57, d2c5nC_, 0.9879, 0.78, 1.000, 296, 291, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
58, d2wfyA_, 0.9874, 0.63, 1.000, 295, 290, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
59, d1okvA_, 0.9870, 0.63, 1.000, 295, 290, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
60, d2c5pC_, 0.9862, 0.83, 1.000, 296, 291,  
61, d4fx3C_, 0.9858, 0.90, 1.000, 298, 291, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
62, d2wevC_, 0.9855, 0.85, 1.000, 296, 291, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
63, d1ol2C_, 0.9851, 0.85, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
64, d4fx3A_, 0.9837, 0.96, 1.000, 298, 291, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
65, d1okvC_, 0.9835, 0.89, 1.000, 296, 291, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
66, d4cfwC1, 0.9796, 0.80, 0.983, 295, 289, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
67, d4cfmA1, 0.9796, 0.80, 0.983, 295, 289, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
68, d1h1qA1, 0.9795, 0.80, 0.983, 295, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
69, d2cjmC_, 0.9792, 0.80, 0.983, 294, 289, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
70, d1h1rA1, 0.9792, 0.81, 0.983, 295, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
71, d5nevC1, 0.9791, 0.83, 0.983, 295, 289, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
72, d1e9hA_, 0.9790, 0.82, 0.983, 295, 289, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
73, d1jstC_, 0.9788, 0.82, 0.983, 297, 289, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
74, d1pkdA1, 0.9786, 0.83, 0.983, 295, 289, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
75, d1h1qC1, 0.9786, 0.82, 0.983, 295, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
76, d1pkdC1, 0.9785, 0.83, 0.983, 295, 289, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
77, d5cyiC1, 0.9784, 0.83, 0.983, 295, 289, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
78, d1e9hC1, 0.9784, 0.83, 0.983, 295, 289, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
79, d2uzeA_, 0.9782, 0.84, 0.983, 295, 289, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
80, d2wmbA1, 0.9781, 0.84, 0.983, 295, 289, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
81, d1gy3C_, 0.9778, 0.85, 0.983, 295, 289, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
82, d2uzlC_, 0.9777, 0.86, 0.983, 295, 289, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
83, d2uzlA_, 0.9777, 0.86, 0.983, 295, 289, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
84, d1h1sA1, 0.9777, 0.85, 0.983, 295, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
85, d3eidA_, 0.9776, 0.46, 1.000, 292, 286, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
86, d2uzeC_, 0.9776, 0.87, 0.983, 295, 289, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
87, d1h26A1, 0.9776, 0.86, 0.983, 295, 289, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
88, d1h1sC1, 0.9773, 0.86, 0.983, 295, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
89, d1oiyC1, 0.9769, 0.87, 0.983, 295, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
90, d1h27A1, 0.9769, 0.87, 0.983, 295, 289, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
91, d1h1rC1, 0.9769, 0.86, 0.983, 295, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
92, d3ddpA1, 0.9768, 0.88, 0.983, 296, 289, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
93, d1h28A1, 0.9766, 0.87, 0.983, 295, 289, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
94, d2iw8A1, 0.9765, 0.88, 0.965, 296, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
95, d1gy3A_, 0.9765, 0.88, 0.983, 295, 289, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
96, d5cyiA1, 0.9762, 0.97, 0.983, 297, 289, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
97, d1h28C1, 0.9762, 0.89, 0.983, 295, 289, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
98, d2uzdC_, 0.9761, 0.90, 0.983, 295, 289, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
99, d2c6tC_, 0.9759, 0.90, 0.983, 295, 289, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
100, d1p5eA1, 0.9759, 0.90, 0.983, 295, 289, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
101, d2uzbA_, 0.9757, 0.91, 0.983, 295, 289, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
102, d2g9xA2, 0.9756, 0.90, 0.979, 297, 289, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
103, d1oi9A1, 0.9756, 0.82, 0.983, 294, 288, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
104, d2cciA2, 0.9752, 0.92, 0.983, 295, 289, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
105, d2wmaA1, 0.9750, 0.95, 0.983, 295, 289, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
106, d4cfvA1, 0.9749, 0.96, 0.979, 297, 289, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
107, d4eooC1, 0.9748, 0.92, 0.979, 295, 289, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
108, d1qmzC1, 0.9747, 0.93, 0.983, 295, 289, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
109, d1qmzA1, 0.9747, 0.93, 0.983, 295, 289, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
110, d5nevA1, 0.9745, 0.85, 0.983, 294, 288, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
111, d2i40A_, 0.9745, 0.45, 1.000, 291, 285, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
112, d4eopC1, 0.9743, 0.93, 0.979, 295, 289, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
113, d1jstA_, 0.9740, 0.94, 0.983, 297, 289, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
114, d3tnwC_, 0.9736, 0.78, 0.983, 291, 287, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
115, d4bcnC1, 0.9735, 0.78, 0.983, 293, 287, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
116, d3dogA1, 0.9734, 0.88, 0.976, 296, 288, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
117, d4bcpA1, 0.9733, 1.04, 0.979, 297, 289, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
118, d4bcnA1, 0.9732, 0.79, 0.983, 295, 287, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
119, d4cfnC1, 0.9731, 0.80, 0.983, 293, 287, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
120, d1p5eC1, 0.9730, 0.98, 0.983, 295, 289, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
121, d4eolC1, 0.9729, 0.97, 0.972, 296, 289, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
122, d4cfwA1, 0.9727, 1.10, 0.983, 297, 289, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
123, d4bcoA1, 0.9727, 1.04, 0.979, 297, 289, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
124, d4bcmC1, 0.9726, 0.80, 0.983, 293, 287, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
125, d4eosC1, 0.9724, 0.98, 0.983, 295, 289, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
126, d3qhrC1, 0.9723, 1.08, 0.983, 295, 289, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
127, d3eidC_, 0.9722, 0.54, 1.000, 290, 285, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
128, d3qhrA1, 0.9720, 1.08, 0.983, 295, 289, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
129, d4eoiC1, 0.9719, 0.98, 0.976, 295, 289, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
130, d4eokC1, 0.9717, 1.01, 0.972, 296, 289, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
131, d2cciC2, 0.9717, 1.01, 0.983, 295, 289, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
132, d4ii5C_, 0.9716, 1.09, 0.983, 295, 289, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
133, d4ii5A_, 0.9715, 1.09, 0.983, 295, 289, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
134, d4i3zA_, 0.9715, 1.09, 0.983, 295, 289, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
135, d4cfuA1, 0.9715, 0.83, 0.976, 295, 287, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
136, d4i3zC_, 0.9714, 1.09, 0.983, 295, 289, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
137, d3bhvA1, 0.9714, 0.84, 0.976, 295, 287, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
138, d2cchA2, 0.9714, 1.11, 0.983, 295, 289, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
139, d2iw6C2, 0.9712, 0.91, 0.979, 294, 288, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
140, d4eonC1, 0.9710, 1.00, 0.972, 296, 289, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
141, d3bhuA1, 0.9710, 0.85, 0.979, 295, 287, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
142, d5lmkA1, 0.9709, 0.86, 0.979, 295, 287, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
143, d4eomA1, 0.9709, 0.86, 0.962, 294, 287, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
144, d3bhtA2, 0.9709, 0.85, 0.979, 295, 287, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
145, d2cchC2, 0.9709, 1.14, 0.983, 295, 289, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
146, d3qhwA1, 0.9706, 1.12, 0.983, 295, 289, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
147, d2uzdA_, 0.9706, 1.02, 0.983, 295, 289, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
148, d3qhwC1, 0.9705, 1.12, 0.983, 295, 289, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
149, d2c6tA_, 0.9702, 1.03, 0.983, 295, 289, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
150, d3ddqA1, 0.9696, 0.88, 0.979, 295, 287, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
151, d3ddpC1, 0.9693, 1.10, 0.979, 297, 289, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
152, d4eonA1, 0.9692, 1.19, 0.972, 297, 289, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
153, d4bcmA1, 0.9690, 0.81, 0.983, 292, 286, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
154, d1oiyA1, 0.9690, 0.81, 0.983, 292, 286, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
155, d4cfnA1, 0.9689, 0.82, 0.983, 293, 286, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
156, d3tnwA1, 0.9688, 0.81, 0.983, 294, 286, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
157, d3my5A1, 0.9684, 0.82, 0.976, 294, 286, CDK2/CYCLINA IN COMPLEX WITH DRB
158, d1oguA1, 0.9684, 0.83, 0.976, 293, 286, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
159, d4eoqA1, 0.9680, 0.84, 0.976, 293, 286, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
160, d1oi9C1, 0.9680, 1.06, 0.983, 295, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
161, d1h25A1, 0.9680, 0.83, 0.983, 292, 286, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
162, d1oiuA1, 0.9679, 0.84, 0.976, 293, 286, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
163, d1h24A1, 0.9679, 0.84, 0.983, 292, 286, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
164, d1h24C1, 0.9676, 0.85, 0.983, 292, 286, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
165, d2uzbC_, 0.9670, 0.87, 0.983, 292, 286, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
166, d4eooA1, 0.9666, 0.78, 0.972, 292, 285, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
167, d4eopA1, 0.9659, 1.02, 0.979, 294, 287, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
168, d2iw6A1, 0.9653, 0.82, 0.979, 291, 285, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
169, d2iw9A2, 0.9652, 0.83, 0.972, 292, 285, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
170, d1h1pA1, 0.9651, 1.13, 0.983, 295, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
171, d4eosA1, 0.9650, 0.93, 0.983, 293, 286, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
172, d4eorA1, 0.9631, 0.88, 0.975, 292, 285, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
173, d5uq2A_, 0.9630, 1.39, 0.983, 296, 290, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
174, d4eojA1, 0.9628, 0.88, 0.968, 293, 285, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
175, d4eoiA1, 0.9625, 0.91, 0.975, 293, 285, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
176, d1h1pC1, 0.9615, 1.20, 0.983, 295, 289, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
177, d1h27C1, 0.9597, 0.87, 0.982, 290, 284, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
178, d4eolA1, 0.9595, 1.05, 0.969, 293, 286, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
179, d4bckA1, 0.9579, 1.31, 0.983, 296, 289, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
180, d4eokA1, 0.9563, 1.04, 0.972, 292, 285, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
181, d4bckC1, 0.9553, 1.19, 0.983, 291, 287, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
182, d1fq1B_, 0.9550, 1.41, 0.983, 295, 289, CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
183, d4bcqC1, 0.9549, 1.19, 0.983, 291, 287, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
184, d4bcqA1, 0.9511, 1.37, 0.983, 289, 288, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
185, d5l2wA1, 0.9480, 1.23, 0.982, 296, 283, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
186, d2cjmA_, 0.9461, 0.89, 0.982, 285, 280, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
187, d1w98A2, 0.9459, 1.27, 0.982, 296, 283, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
188, d1f5qA_, 0.9445, 1.95, 0.997, 296, 291, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
189, d2jgzA_, 0.9422, 1.11, 0.982, 288, 281, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
190, d4nstC_, 0.9289, 1.88, 0.413, 317, 288, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
191, d4cxaA_, 0.9288, 1.80, 0.411, 329, 287, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
192, d1unlA_, 0.9271, 1.73, 0.583, 292, 283, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
193, d1jsuA_, 0.9268, 1.87, 0.936, 285, 281, P27(KIP1)/CYCLIN A/CDK2 COMPLEX
194, d5acbD_, 0.9256, 1.80, 0.418, 319, 287, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
195, d4nstA_, 0.9254, 1.94, 0.413, 322, 288, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
196, d5acbC_, 0.9244, 1.92, 0.417, 324, 288, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
197, d1ungA_, 0.9227, 1.85, 0.583, 288, 283, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
198, d4un0C_, 0.9226, 1.90, 0.418, 308, 287, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
199, d4krcA_, 0.9226, 1.76, 0.567, 297, 284, CRYSTAL STRUCTURE OF PHO85-PCL10-ATP-GAMMA-S COMPLEX
200, d5efqC_, 0.9220, 2.00, 0.420, 325, 288, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
201, d4imyC_, 0.9220, 2.03, 0.406, 310, 288, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
202, d3o0gA_, 0.9220, 1.70, 0.587, 289, 281, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
203, d4imyA_, 0.9218, 2.03, 0.406, 314, 288, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
204, d4imyE_, 0.9216, 1.98, 0.408, 313, 287, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
205, d3miaA_, 0.9213, 2.07, 0.403, 324, 288, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
206, d5efqA_, 0.9209, 2.05, 0.420, 321, 288, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
207, d4krdA_, 0.9202, 1.58, 0.569, 294, 281, CRYSTAL STRUCTURE OF PHO85-PCL10 COMPLEX
208, d1f5qC_, 0.9199, 1.95, 0.958, 288, 283, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
209, d4cjyC_, 0.9194, 1.96, 0.411, 303, 287,  
210, d3mi9A_, 0.9191, 2.10, 0.403, 328, 288, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
211, d4bchA_, 0.9190, 2.05, 0.406, 308, 288, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
212, d3lq5A_, 0.9185, 2.02, 0.404, 307, 287, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
213, d4cxaC_, 0.9175, 1.91, 0.418, 330, 285, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
214, d4or5F_, 0.9174, 2.12, 0.403, 324, 288, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
215, d4bcgA_, 0.9167, 2.03, 0.404, 312, 287, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
216, d3my1A_, 0.9162, 2.02, 0.401, 314, 287, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
217, d1h25C1, 0.9161, 0.86, 0.982, 277, 271, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
218, d1unlB_, 0.9151, 1.93, 0.572, 292, 283, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
219, d4or5A_, 0.9143, 2.15, 0.403, 319, 288, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
220, d4yc3A1, 0.9134, 1.93, 0.644, 294, 281, CDK1/CYCLINB1/CKS2 APO
221, d4bciA_, 0.9128, 1.98, 0.407, 308, 285, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
222, d4bcfA_, 0.9124, 2.05, 0.409, 307, 286, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
223, d4bcjA_, 0.9122, 2.11, 0.404, 309, 287, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
224, d3tn8A_, 0.9100, 2.06, 0.411, 304, 285, CDK9/CYCLIN T IN COMPLEX WITH CAN508
225, d4ogrE_, 0.9086, 2.22, 0.406, 310, 288, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
226, d4ogrA_, 0.9063, 2.24, 0.406, 314, 288, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
227, d5hq0A1, 0.9060, 2.14, 0.668, 289, 283, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
228, d4y72A1, 0.9060, 2.14, 0.668, 289, 283, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
229, d4eojC1, 0.9058, 1.30, 0.949, 278, 272, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
230, d2pk9A_, 0.9055, 1.65, 0.567, 287, 277, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
231, d1h4lB_, 0.9039, 1.53, 0.584, 278, 274, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
232, d1h4lA_, 0.9026, 1.55, 0.584, 278, 274, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
233, d4ogrI_, 0.9024, 2.31, 0.403, 318, 288, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
234, d2pmiC_, 0.9017, 1.66, 0.569, 285, 276, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
235, d4ez7A1, 0.9015, 2.10, 0.961, 298, 280, CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1- NAPHTHALENE SULFONIC ACID
236, d5a14A_, 0.9014, 1.92, 0.975, 284, 276, HUMAN CDK2 WITH TYPE II INHIBITOR
237, d1j1bA_, 0.9008, 2.02, 0.320, 354, 281, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
238, d3blrA_, 0.9005, 2.06, 0.404, 300, 282, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
239, d1j1cA_, 0.9005, 2.02, 0.320, 354, 281, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
240, d3pxzA1, 0.8995, 2.28, 0.971, 298, 280, CDK2 TERNARY COMPLEX WITH JWS648 AND ANS
241, d1j1cB_, 0.8995, 2.05, 0.320, 364, 281, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
242, d3i4bB_, 0.8994, 2.04, 0.320, 347, 281, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
243, d3blqA_, 0.8994, 1.81, 0.406, 295, 278, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
244, d1j1bB_, 0.8988, 2.05, 0.320, 364, 281, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
245, d5lqfA1, 0.8983, 1.82, 0.653, 284, 277, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
246, d3pxfA1, 0.8983, 2.27, 0.975, 298, 280, CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
247, d3i4bA_, 0.8982, 2.07, 0.320, 359, 281, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
248, d2gphA_, 0.8975, 2.09, 0.363, 345, 281, DOCKING MOTIF INTERACTIONS IN THE MAP KINASE ERK2
249, d1q41B_, 0.8974, 2.07, 0.320, 343, 281, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
250, d4acgB_, 0.8969, 2.07, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
251, d4ic7A_, 0.8966, 2.06, 0.389, 355, 280, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
252, d4achB_, 0.8961, 2.09, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
253, d4acgA_, 0.8961, 2.10, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
254, d1unhB_, 0.8961, 1.52, 0.588, 276, 272, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
255, d4nm0A1, 0.8958, 2.09, 0.320, 355, 281, CRYSTAL STRUCTURE OF PEPTIDE INHIBITOR-FREE GSK-3/AXIN COMPLEX
256, d3qyiA_, 0.8953, 2.14, 0.367, 346, 281,  
257, d4acdB_, 0.8950, 2.11, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
258, d4accA_, 0.8950, 2.10, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
259, d4achA_, 0.8948, 2.12, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
260, d4acdA_, 0.8947, 2.11, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
261, d4accB_, 0.8946, 2.11, 0.320, 350, 281, GSK3B IN COMPLEX WITH INHIBITOR
262, d1unhA_, 0.8946, 1.55, 0.588, 276, 272, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
263, d1h8fB_, 0.8945, 2.10, 0.320, 350, 281, GLYCOGEN SYNTHASE KINASE 3 BETA.
264, d5f94A_, 0.8942, 2.12, 0.320, 346, 281, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
265, d1h8fA_, 0.8942, 2.11, 0.320, 352, 281, GLYCOGEN SYNTHASE KINASE 3 BETA.
266, d5f94B_, 0.8941, 2.12, 0.320, 349, 281, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
267, d3pupB_, 0.8937, 2.08, 0.321, 347, 280, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
268, d2jldA_, 0.8937, 2.08, 0.321, 349, 280, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
269, d5lqfD1, 0.8936, 1.88, 0.652, 282, 276, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
270, d3pupA_, 0.8936, 2.08, 0.321, 346, 280, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
271, d4nm5A1, 0.8935, 2.17, 0.324, 360, 281, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 C-MOTIF
272, d2g9xC2, 0.8935, 0.93, 0.974, 273, 265, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
273, p3zu7A_, 0.8932, 2.22, 0.359, 344, 281, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE MAP KINASE ERK2
274, d4ptcA_, 0.8931, 2.13, 0.320, 342, 281, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
275, p3zuvC_, 0.8931, 2.06, 0.369, 357, 279, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
276, d1r0eB_, 0.8931, 2.11, 0.320, 344, 281, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
277, d2jldB_, 0.8929, 2.08, 0.321, 349, 280, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
278, d4iz5B_, 0.8928, 2.07, 0.361, 347, 280, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
279, d4iz5A_, 0.8928, 2.06, 0.361, 347, 280, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
280, d4iz5D_, 0.8927, 2.07, 0.361, 347, 280, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
281, d4iz5C_, 0.8927, 2.07, 0.361, 347, 280, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
282, d3m1sB_, 0.8927, 2.09, 0.321, 349, 280, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
283, d5hlnA_, 0.8924, 2.08, 0.321, 346, 280, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
284, d1o9uA_, 0.8924, 2.09, 0.321, 349, 280, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE
285, d4pteB_, 0.8923, 2.16, 0.320, 347, 281, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
286, d4eoqC1, 0.8923, 0.98, 0.977, 271, 265, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
287, d1r0eA_, 0.8923, 2.13, 0.320, 344, 281, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
288, d3m1sA_, 0.8921, 2.06, 0.323, 348, 279, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
289, d3erkA_, 0.8921, 2.19, 0.367, 350, 281, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025
290, d2o5kA1, 0.8921, 2.17, 0.320, 350, 281, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A BENZOIMIDAZOL INHIBITOR
291, d5nhlA_, 0.8920, 2.24, 0.367, 345, 281, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
292, d4ptcB_, 0.8920, 2.15, 0.320, 347, 281, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
293, d4nm7A1, 0.8920, 2.20, 0.324, 354, 281, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 E-MOTIF
294, d1ykrA_, 0.8920, 2.53, 0.982, 298, 285, CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR
295, d4qteA_, 0.8918, 2.26, 0.363, 348, 281, STRUCTURE OF ERK2 IN COMPLEX WITH VTX-11E 4-{2-[(2-CHLORO-4- FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3- CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
296, d4eomC1, 0.8918, 0.99, 0.966, 271, 265, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
297, d1uv5A_, 0.8918, 2.15, 0.320, 348, 281, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3 -OXIME
298, d5nhvA_, 0.8917, 2.25, 0.370, 345, 281, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
299, p3zuvA_, 0.8917, 2.21, 0.371, 357, 280, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
300, d2pmiA_, 0.8917, 1.78, 0.566, 284, 274, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
301, d4ic7D_, 0.8915, 2.13, 0.389, 353, 280, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
302, d5v60A_, 0.8914, 2.24, 0.364, 347, 280, PHOSPHO-ERK2 BOUND TO AMP-PCP
303, d3sd0B_, 0.8914, 2.18, 0.320, 349, 281, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
304, d5nhpA_, 0.8913, 2.26, 0.367, 338, 281, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
305, p5v61A_, 0.8911, 2.11, 0.366, 348, 279, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP2
306, d2erkA_, 0.8910, 2.21, 0.368, 351, 280, PHOSPHORYLATED MAP KINASE ERK2
307, d5ke0A_, 0.8909, 2.26, 0.367, 340, 281, DISCOVERY OF 1-1H-PYRAZOLO 43-C PYRIDINE-6-YL UREA INHIBITORS OF EXTRACELLULAR SIGNAL REGULATED KINASE ERK FOR THE TREATMENT OF CANCERS
308, d4pteA_, 0.8909, 2.06, 0.326, 341, 279, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
309, d5u6iA_, 0.8906, 2.14, 0.368, 339, 280, DISCOVERY OF MLI-2 AN ORALLY AVAILABLE AND SELECTIVE LRRK2 INHIBITOR THAT REDUCES BRAIN KINASE ACTIVITY
310, d5hd7A_, 0.8906, 2.26, 0.363, 347, 281, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT MUTANT SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
311, d3zrkB_, 0.8906, 2.20, 0.324, 348, 281, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
312, d3sayB_, 0.8904, 2.13, 0.321, 347, 280, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
313, d5hlnB_, 0.8901, 2.13, 0.321, 346, 280, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
314, d2ojjA_, 0.8901, 2.29, 0.367, 344, 281, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-N-(1-(3- CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
315, d3sd0A_, 0.8900, 2.19, 0.320, 350, 281, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
316, d5nhoA_, 0.8899, 2.27, 0.367, 343, 281, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
317, d5nhhA_, 0.8899, 2.28, 0.367, 348, 281, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
318, d4cfuC1, 0.8898, 0.85, 0.981, 269, 263, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
319, d3blhA1, 0.8898, 1.74, 0.415, 291, 275, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
320, d1q5kA_, 0.8898, 2.04, 0.327, 345, 278, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
321, p5v62A_, 0.8897, 2.13, 0.366, 349, 279, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP3
322, d3bhvC1, 0.8896, 0.85, 0.981, 269, 263, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
323, d1pyxA_, 0.8896, 1.98, 0.329, 343, 277, GSK-3 BETA COMPLEXED WITH AMP-PNP
324, d2z7lA_, 0.8895, 2.28, 0.370, 329, 281, UNPHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE ERK2 IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN 2-YL]AMINO}PHENYL)ACETIC ACID
325, d4qtbA_, 0.8894, 2.27, 0.370, 351, 281, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
326, d3sayA_, 0.8893, 2.05, 0.324, 347, 278, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
327, d2ojiA_, 0.8893, 2.28, 0.363, 344, 281, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
328, p6g93A_, 0.8890, 2.13, 0.366, 343, 279, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
329, d4qyyA_, 0.8890, 2.29, 0.367, 337, 281, DISCOVERY OF NOVEL DUAL MECHANISM ERK INHIBITORS BY AFFINITY SELECTION SCREENING OF AN INACTIVE KINASE STATE
330, p4h3qA_, 0.8890, 2.27, 0.359, 352, 281, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
331, d3bhtC1, 0.8890, 0.87, 0.981, 269, 263, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
332, d2ojgA_, 0.8890, 2.31, 0.367, 337, 281, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH NN-DIMETHYL-4-(4- PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
333, p6g9aA_, 0.8888, 2.13, 0.366, 341, 279, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
334, d1oguC1, 0.8888, 0.88, 0.981, 269, 263, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
335, d1golA_, 0.8888, 2.27, 0.356, 357, 281, COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52
336, d4erkA_, 0.8887, 2.27, 0.359, 350, 281, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE
337, d3zrlB_, 0.8887, 2.25, 0.320, 347, 281, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
338, d4bcpC1, 0.8886, 0.88, 0.981, 266, 263, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
339, d1erkA_, 0.8886, 2.27, 0.367, 357, 281, STRUCTURE OF SIGNAL-REGULATED KINASE
340, d4iz7A_, 0.8884, 2.08, 0.363, 344, 278, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
341, d3bhuC1, 0.8884, 0.88, 0.981, 269, 263, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
342, p6gdqA_, 0.8883, 2.26, 0.364, 339, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
343, d5hd4A_, 0.8882, 2.30, 0.367, 347, 281, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT WILD TYPE SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
344, d5f95A_, 0.8882, 2.05, 0.327, 345, 278, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
345, d3zrmB_, 0.8882, 2.26, 0.320, 347, 281, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
346, p6g97A_, 0.8881, 2.13, 0.366, 344, 279, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
347, d4qtbB_, 0.8881, 2.30, 0.370, 348, 281, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
348, d5byzA_, 0.8879, 2.15, 0.391, 348, 279, ERK5 IN COMPLEX WITH SMALL MOLECULE
349, d4s2zA_, 0.8879, 2.29, 0.359, 346, 281, ERK2 INTRINSICALLY ACTIVE MUTANT R65S
350, d4fv3A_, 0.8878, 2.28, 0.364, 346, 280, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK6
351, d4xrlA_, 0.8877, 2.24, 0.371, 337, 280, CRYSTAL STRUCTURE AT ROOM TEMPERATURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
352, d4j71A_, 0.8877, 2.17, 0.321, 347, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
353, d4kd1A_, 0.8876, 2.61, 0.982, 298, 285, CDK2 IN COMPLEX WITH DINACICLIB
354, d4izaA_, 0.8876, 2.30, 0.359, 346, 281, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
355, d3f88A_, 0.8876, 2.06, 0.327, 340, 278, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
356, d4nifB_, 0.8873, 2.14, 0.369, 349, 279, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
357, d3pxqA1, 0.8873, 2.08, 0.996, 294, 275, CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
358, d5nguA_, 0.8872, 2.26, 0.371, 339, 280, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
359, d5byyA_, 0.8872, 1.95, 0.388, 338, 276, ERK5 IN COMPLEX WITH SMALL MOLECULE
360, p4fmqA_, 0.8872, 2.25, 0.361, 350, 280, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
361, d5nhjA_, 0.8871, 2.31, 0.367, 345, 281, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
362, d4zsjA_, 0.8871, 2.10, 0.391, 344, 279, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
363, p6g9hA_, 0.8869, 2.27, 0.364, 343, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
364, d4nifE_, 0.8869, 2.15, 0.369, 348, 279, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
365, d3q3bA_, 0.8869, 2.04, 0.325, 344, 277, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
366, d3f88B_, 0.8868, 2.10, 0.324, 340, 278, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
367, d4fv2A_, 0.8867, 2.30, 0.368, 344, 280, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK5
368, d2b53A_, 0.8867, 2.36, 0.925, 294, 280, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN- 234325
369, d5umoA_, 0.8866, 2.29, 0.359, 347, 281, STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE
370, d1pmeA_, 0.8866, 2.25, 0.368, 333, 280, STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE
371, d4s34A_, 0.8865, 2.30, 0.363, 343, 281, ERK2 (I84A) IN COMPLEX WITH AMP-PNP
372, d5nhfA_, 0.8863, 2.28, 0.371, 339, 280, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
373, d3q3bB_, 0.8859, 1.98, 0.330, 341, 276, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
374, d4s33A_, 0.8857, 2.34, 0.367, 347, 281, ERK2 R65S MUTANT COMPLEXED WITH AMP-PNP
375, d2b54A_, 0.8857, 2.72, 0.968, 298, 284, HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN- 232305
376, p6g9mA_, 0.8856, 2.30, 0.364, 341, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
377, d4s30A_, 0.8854, 2.32, 0.363, 342, 281, ERK2 INTRINSICALLY ACTIVE MUTANT (I84A)
378, d3zrkA_, 0.8854, 2.14, 0.319, 345, 279, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
379, d1pyxB_, 0.8854, 1.92, 0.331, 338, 275, GSK-3 BETA COMPLEXED WITH AMP-PNP
380, d4qnyB_, 0.8852, 2.29, 0.313, 339, 281, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
381, d4zsgA_, 0.8851, 2.14, 0.384, 347, 279, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
382, d4gt3A_, 0.8851, 2.29, 0.371, 347, 280, ATP-BOUND FORM OF THE ERK2 KINASE
383, d4bcoC1, 0.8851, 0.89, 0.981, 268, 262, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
384, d4g6oA_, 0.8850, 2.26, 0.366, 339, 279, CRYSTAL STRUCTURE OF THE ERK2
385, d2zoqA_, 0.8850, 2.33, 0.370, 351, 281, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
386, d4j71B_, 0.8848, 2.19, 0.321, 347, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
387, d1buhA_, 0.8848, 2.24, 0.946, 287, 276, CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1
388, d4fv1A_, 0.8846, 2.33, 0.368, 342, 280, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK4
389, d4s31A_, 0.8844, 2.34, 0.359, 347, 281, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 1 WTERK2 AT 1.45A
390, d4fuxA_, 0.8843, 2.28, 0.364, 342, 280, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E75
391, d3r63A_, 0.8841, 2.34, 0.359, 347, 281, STRUCTURE OF ERK2 (SPE) MUTANT (S246E)
392, p6g9dA_, 0.8840, 2.31, 0.368, 345, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
393, d4eorC1, 0.8840, 1.01, 0.939, 269, 263, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
394, d1tvoA_, 0.8839, 2.34, 0.363, 350, 281, THE STRUCTURE OF ERK2 IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
395, p6g91A_, 0.8838, 2.31, 0.368, 344, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
396, d4zzmA_, 0.8838, 2.30, 0.371, 344, 280, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
397, d3zrlA_, 0.8838, 2.17, 0.319, 345, 279, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
398, d3nizA1, 0.8838, 2.20, 0.598, 284, 276, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH ADP BOUND.
399, d2ow3B_, 0.8837, 2.25, 0.325, 351, 280, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
400, d3zrmA_, 0.8836, 2.17, 0.319, 344, 279, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
401, d3r83A_, 0.8836, 2.47, 0.940, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-92
402, d1q3wB_, 0.8836, 2.02, 0.330, 341, 276, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
403, d4s32A_, 0.8835, 2.36, 0.367, 346, 281, CRYSTAL STRUCTURE OF ERK2 AMP-PNP COMPLEX
404, d3qqlA_, 0.8835, 2.45, 0.940, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR L3
405, p6g8xA_, 0.8834, 2.32, 0.368, 338, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
406, d4zzoA_, 0.8832, 2.30, 0.371, 339, 280, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
407, d4zznA_, 0.8832, 2.30, 0.371, 338, 280, HUMAN ERK2 IN COMPLEX WITH AN INHIBITOR
408, d4zslA_, 0.8832, 2.12, 0.392, 341, 278, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
409, d2zoqB_, 0.8832, 2.37, 0.370, 351, 281, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
410, d2ow3A_, 0.8832, 2.25, 0.329, 346, 280, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
411, p6ge0A_, 0.8831, 2.29, 0.369, 343, 279, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
412, p5nzzG_, 0.8831, 2.22, 0.375, 342, 277, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
413, d4g6nA_, 0.8831, 2.31, 0.368, 341, 280, CRYSTAL STRUCTURE OF THE ERK2
414, d4fv7A_, 0.8831, 2.14, 0.367, 342, 278, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E94
415, d4xozA_, 0.8830, 2.28, 0.361, 341, 280, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
416, d1xo2B_, 0.8830, 1.97, 0.482, 289, 278, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
417, d5lcjA_, 0.8829, 2.31, 0.364, 345, 280, IN-GEL ACTIVITY-BASED PROTEIN PROFILING OF A CLICKABLE COVALENT ERK 1/2 INHIBITOR
418, d4j1rC_, 0.8828, 2.25, 0.321, 344, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
419, d4j1rA_, 0.8827, 2.25, 0.321, 343, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
420, p6g9nA_, 0.8826, 2.35, 0.361, 344, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
421, d4j1rD_, 0.8826, 2.25, 0.321, 345, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
422, d3du8A_, 0.8826, 1.99, 0.331, 336, 275, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
423, p5o7iA_, 0.8823, 2.14, 0.385, 340, 278, ERK5 IN COMPLEX WITH A PYRROLE INHIBITOR 
424, d4xj0A_, 0.8823, 2.26, 0.366, 345, 279, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
425, d3pj8A1, 0.8823, 2.33, 0.989, 287, 279, STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[43-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE.
426, d5aneA_, 0.8822, 2.49, 0.982, 294, 281, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-METHOXY-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
427, d4gcjA1, 0.8822, 2.28, 0.986, 298, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
428, d3r8pA_, 0.8822, 2.45, 0.940, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-6
429, d1q3wA_, 0.8821, 2.12, 0.325, 344, 277, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
430, p6g92A_, 0.8820, 2.34, 0.368, 343, 280, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
431, d4xneA_, 0.8820, 2.26, 0.362, 344, 279, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
432, d4qnyA_, 0.8819, 2.29, 0.314, 333, 280, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
433, d3du8B_, 0.8818, 2.01, 0.331, 339, 275, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
434, d4gvaA_, 0.8817, 2.30, 0.364, 345, 280, ADP-BOUND FORM OF THE ERK2 KINASE
435, p5nzzE_, 0.8815, 2.24, 0.375, 343, 277, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
436, d4qp1A_, 0.8815, 2.26, 0.358, 342, 279, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
437, d3gb2A_, 0.8815, 2.09, 0.332, 340, 277, GSK3BETA INHIBITOR COMPLEX
438, d1pw2A_, 0.8814, 2.53, 0.979, 294, 281, APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
439, d2iw9C2, 0.8811, 0.90, 0.977, 267, 261, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
440, d5anjA_, 0.8809, 2.67, 0.979, 291, 283, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH N-(9H-PURIN-6-YL) THIOPHENE-2-CARBOXAMIDE  PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
441, d1i09B_, 0.8809, 2.02, 0.330, 341, 276, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
442, d1v0oA_, 0.8808, 1.91, 0.624, 276, 271, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
443, d4xrjA_, 0.8807, 2.27, 0.362, 344, 279, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
444, d4mygA_, 0.8806, 2.15, 0.384, 335, 276, MAPK13 ACTIVE FORM
445, p5nzzF_, 0.8805, 2.20, 0.373, 341, 276, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
446, d4gsbA_, 0.8805, 2.28, 0.373, 343, 279, MONOCLINIC CRYSTAL FORM OF THE APO-ERK2
447, d1q3dB_, 0.8804, 2.14, 0.330, 339, 276, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
448, d1wzyA_, 0.8802, 2.36, 0.370, 350, 281, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A PYRAZOLOPYRIDAZINE DERIVATIVE
449, d2f49A_, 0.8801, 2.08, 0.382, 335, 275, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
450, d4xp2A_, 0.8799, 2.30, 0.366, 337, 279, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
451, d4lynA_, 0.8799, 2.43, 0.996, 287, 280, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH (2S)-N-(5-(((5-TERT-BUTYL-13-OXAZOL-2-YL)METHYL)SULFANYL)-13- THIAZOL-2-YL)-2-PHENYLPROPANAMIDE
452, d4afjB_, 0.8799, 2.18, 0.325, 346, 277, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
453, d2clxA_, 0.8797, 2.48, 0.979, 293, 280, 4-ARYLAZO-35-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY CRYSTAL STRUCTURE IN COMPLEX WITH CDK2 SELECTIVITY AND CELLULAR EFFECTS
454, d1hckA_, 0.8797, 2.54, 0.979, 294, 281, HUMAN CYCLIN-DEPENDENT KINASE 2
455, d3qyzA_, 0.8795, 2.37, 0.371, 339, 280, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
456, d3qywA_, 0.8795, 2.34, 0.364, 340, 280, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
457, d5lckA_, 0.8793, 2.32, 0.362, 345, 279, A CLICKABLE COVALENT ERK 1/2 INHIBITOR
458, d3f7zB1, 0.8793, 2.10, 0.322, 338, 276, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
459, d4qpaB_, 0.8792, 2.36, 0.357, 345, 280, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
460, d3qtwA_, 0.8792, 2.51, 0.943, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-13
461, d2exmA_, 0.8792, 2.77, 0.982, 298, 284, HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
462, d4j1rB_, 0.8790, 2.18, 0.327, 346, 278, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
463, d3rm6A_, 0.8790, 2.38, 0.943, 293, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-80
464, d3qxoA_, 0.8788, 2.61, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84
465, d1q4lA_, 0.8788, 2.00, 0.328, 342, 274, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
466, d2b9iA_, 0.8787, 2.17, 0.380, 338, 276, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM MSG5
467, d3r71A_, 0.8786, 2.57, 0.979, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-162
468, p6g9jA_, 0.8785, 2.31, 0.367, 347, 278, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
469, d3rpoA_, 0.8785, 2.55, 0.975, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156
470, d3r7yA_, 0.8785, 2.57, 0.982, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88
471, d1q41A_, 0.8784, 2.00, 0.332, 339, 274, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
472, d1hclA_, 0.8784, 2.58, 0.982, 294, 281, HUMAN CYCLIN-DEPENDENT KINASE 2
473, d3r1qA_, 0.8783, 2.53, 0.936, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102
474, d3qx2A_, 0.8783, 2.56, 0.979, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190
475, d1h26C1, 0.8782, 0.88, 0.981, 266, 260, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
476, p6gdmA_, 0.8781, 2.23, 0.372, 341, 277, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
477, d4afjA_, 0.8780, 2.10, 0.326, 342, 276, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
478, d4qp1B_, 0.8778, 2.38, 0.364, 343, 280, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
479, d5hlpA_, 0.8776, 2.11, 0.330, 337, 276, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
480, d2fysA_, 0.8776, 2.29, 0.369, 348, 279, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
481, d4xp3A_, 0.8774, 2.41, 0.371, 339, 280, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
482, d4fv0A_, 0.8774, 2.28, 0.363, 341, 278, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK3
483, d1q3dA_, 0.8774, 2.07, 0.331, 339, 275, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
484, d1pxjA_, 0.8774, 2.57, 0.979, 294, 281, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
485, d1pxoA_, 0.8773, 2.54, 0.982, 294, 281, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YL]-(3-NITRO-PHENYL)-AMINE
486, d3r28A_, 0.8772, 2.54, 0.936, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140
487, d3qzhA_, 0.8771, 2.60, 0.936, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124
488, d2a0cX_, 0.8771, 2.63, 0.975, 294, 282, HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II A NOVEL 269- TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
489, d4cfmC1, 0.8770, 0.83, 0.981, 265, 259, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
490, d2fa2A_, 0.8770, 2.11, 0.382, 333, 275, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
491, d3r6xA_, 0.8767, 2.53, 0.940, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158
492, d4cfvC1, 0.8765, 0.84, 0.981, 263, 259, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
493, d3raiA_, 0.8764, 2.56, 0.940, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160
494, d3py1A1, 0.8764, 2.44, 0.986, 298, 280, CDK2 TERNARY COMPLEX WITH SU9516 AND ANS
495, d3my5C1, 0.8764, 0.85, 0.981, 265, 259, CDK2/CYCLINA IN COMPLEX WITH DRB
496, d3qwkA_, 0.8763, 2.53, 0.975, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150
497, d3pxrA_, 0.8763, 2.65, 0.975, 294, 282, APO CDK2 CRYSTALLIZED FROM JEFFAMINE
498, d3o71A_, 0.8763, 2.24, 0.371, 340, 278, CRYSTAL STRUCTURE OF ERK2/DCC PEPTIDE COMPLEX
499, d3lfnA_, 0.8763, 2.20, 0.996, 285, 276, CRYSTAL STRUCTURE OF CDK2 WITH SAR57 AN AMINOINDAZOLE TYPE INHIBITOR
500, d1pxiA_, 0.8763, 2.60, 0.979, 294, 281, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(25-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN-2- YLAMINE
501, d1gngA_, 0.8763, 2.37, 0.325, 348, 280, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
502, d4erwA_, 0.8762, 2.55, 0.964, 292, 279, CDK2 IN COMPLEX WITH STAUROSPORINE
503, d3qzfA_, 0.8761, 2.61, 0.975, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52
504, d3juhA_, 0.8761, 2.37, 0.301, 334, 279, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
505, d4un0D_, 0.8760, 1.62, 0.428, 276, 269, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
506, d3royA_, 0.8760, 2.65, 0.936, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154
507, d3r7vA_, 0.8760, 2.52, 0.975, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9
508, d3qziA_, 0.8760, 2.62, 0.936, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-126
509, d3qx4A_, 0.8760, 2.56, 0.975, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78
510, d2jd5B_, 0.8760, 2.04, 0.312, 360, 276, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
511, d2f49B_, 0.8760, 2.12, 0.382, 337, 275, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
512, d1q5kB_, 0.8760, 2.11, 0.335, 344, 275, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
513, d1oirA_, 0.8760, 2.27, 0.956, 286, 275, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
514, d3r73A_, 0.8759, 2.55, 0.940, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164
515, d2ds1A_, 0.8759, 2.41, 0.942, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
516, d1wccA_, 0.8759, 2.17, 0.996, 283, 276, SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY
517, d3py3A1, 0.8757, 2.02, 0.369, 352, 274, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38ALPHA MAP KINASE
518, d1q99B_, 0.8757, 2.05, 0.312, 364, 276, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
519, d4iq6B_, 0.8755, 1.98, 0.333, 332, 273, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
520, p4h3pA_, 0.8755, 2.32, 0.368, 342, 277, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
521, d3tiyA_, 0.8755, 2.57, 0.964, 293, 281, CDK2 IN COMPLEX WITH NSC 35676
522, d3r7eA_, 0.8755, 2.65, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67
523, d4qp8B_, 0.8754, 2.03, 0.374, 337, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
524, d4ptgA_, 0.8754, 2.01, 0.337, 333, 273, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
525, d3qwjA_, 0.8754, 2.65, 0.975, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142
526, d3r1sA_, 0.8753, 2.57, 0.975, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127
527, d2b9hA_, 0.8753, 2.16, 0.382, 337, 275, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM STE7
528, d3rk9A_, 0.8752, 2.66, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-74
529, d3bw5A_, 0.8752, 2.38, 0.305, 334, 279,  
530, d2b9jA_, 0.8752, 2.17, 0.382, 337, 275, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM FAR1
531, d3rm7A_, 0.8751, 2.64, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91
532, d2c5yA_, 0.8751, 2.45, 0.978, 290, 278, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
533, d1q97B_, 0.8751, 2.06, 0.312, 361, 276, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
534, d3rk5A_, 0.8750, 2.61, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-72
535, d2wmbC1, 0.8750, 0.88, 0.981, 265, 259, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
536, d3rniA_, 0.8749, 2.49, 0.975, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR RC-3-86
537, d1ymiA_, 0.8748, 2.39, 0.305, 334, 279,  
538, d3qqfA_, 0.8747, 2.65, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR L1
539, d4iz7C_, 0.8746, 2.17, 0.364, 340, 275, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
540, d3r1yA_, 0.8746, 2.69, 0.936, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134
541, d4au8B_, 0.8745, 1.78, 0.593, 277, 270, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
542, d1q8zB_, 0.8744, 2.07, 0.312, 364, 276, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
543, d4mygB_, 0.8743, 2.01, 0.387, 335, 274, MAPK13 ACTIVE FORM
544, d3rkbA_, 0.8743, 2.67, 0.979, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR RC-2-73
545, d3dogC1, 0.8743, 0.90, 0.973, 266, 259, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
546, d3rk7A_, 0.8741, 2.67, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-71
547, d3h30A_, 0.8741, 2.32, 0.299, 333, 278, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
548, d2xmyA_, 0.8741, 2.76, 0.968, 295, 283, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
549, d3f7zA1, 0.8740, 2.02, 0.322, 338, 273, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
550, d3r9dA_, 0.8739, 2.58, 0.975, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR RC-2-135
551, d2xnbA_, 0.8739, 2.68, 0.982, 296, 282, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
552, d2f2cB_, 0.8737, 1.76, 0.493, 280, 270, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
553, d3qrtA_, 0.8736, 2.60, 0.926, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55
554, d1b38A_, 0.8736, 2.41, 0.949, 290, 277, HUMAN CYCLIN-DEPENDENT KINASE 2
555, d5m4cA_, 0.8735, 2.33, 0.300, 329, 277, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER LOW-SALT CONDITIONS
556, d3sa0A_, 0.8734, 2.44, 0.369, 354, 279, COMPLEX OF ERK2 WITH NORATHYRIOL
557, d1q8yB_, 0.8734, 2.08, 0.312, 357, 276, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
558, d4xp0A_, 0.8733, 2.31, 0.375, 336, 277, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
559, d3juhB_, 0.8733, 2.42, 0.305, 334, 279, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
560, d2rkpA_, 0.8731, 2.40, 0.297, 334, 279,  
561, d2fa2B_, 0.8731, 2.18, 0.382, 332, 275, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
562, d3qu0A_, 0.8730, 2.70, 0.975, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-38
563, d3ns9A_, 0.8730, 2.38, 0.975, 289, 276, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194
564, d3lfqA_, 0.8729, 2.36, 0.957, 289, 276, CRYSTAL STRUCTURE OF CDK2 WITH SAR60 AN AMINOINDAZOLE TYPE INHIBITOR
565, d5nqcA_, 0.8728, 2.33, 0.299, 331, 278, CK2ALPHA IN COMPLEX WITH NMR154
566, d4ez3A_, 0.8726, 2.53, 0.975, 294, 280, CDK2 IN COMPLEX WITH NSC 134199
567, d4rj3A_, 0.8725, 2.38, 0.953, 287, 276, CDK2 WITH EGFR INHIBITOR COMPOUND 8
568, d3lfsA_, 0.8725, 2.44, 0.953, 290, 277, CRYSTAL STRUCTURE OF CDK2 WITH SAR37 AN AMINOINDAZOLE TYPE INHIBITOR
569, d1h0uA_, 0.8725, 2.47, 0.953, 291, 278,  
570, d1jwhA_, 0.8724, 2.31, 0.296, 336, 277, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
571, d4zxtA_, 0.8722, 2.46, 0.369, 348, 279, COMPLEX OF ERK2 WITH CATECHOL
572, d1h01A_, 0.8722, 2.34, 0.956, 286, 275, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
573, d1aq1A_, 0.8722, 1.83, 0.970, 277, 269, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE
574, d2vtoA_, 0.8720, 2.17, 0.967, 283, 274, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
575, d2jd5A_, 0.8720, 2.03, 0.314, 353, 274, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
576, d1pxpA_, 0.8720, 2.69, 0.972, 294, 282, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- N N -DIMETHYL-BENZENE-14-DIAMINE
577, p6cpwA_, 0.8719, 2.32, 0.370, 328, 276, DISCOVERY OF 3(S)-THIOMETHYL PYRROLIDINE ERK INHIBITORS FOR ONCOLOGY 
578, d4qp7A_, 0.8719, 2.17, 0.372, 337, 274, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
579, d4fkuA_, 0.8719, 2.61, 0.979, 293, 280, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
580, d3uliA_, 0.8719, 2.30, 0.960, 286, 277, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE
581, d2b52A_, 0.8719, 2.15, 0.985, 283, 274, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH- 042562
582, d1oiuC1, 0.8719, 0.88, 0.981, 264, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
583, d4n0sA_, 0.8718, 2.40, 0.371, 348, 278, COMPLEX OF ERK2 WITH CAFFEIC ACID
584, d4qp4A_, 0.8717, 2.17, 0.372, 337, 274, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
585, d3ql8A_, 0.8717, 2.69, 0.965, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260
586, d2vtmA_, 0.8716, 2.47, 0.953, 290, 277, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
587, d1gngB_, 0.8716, 2.40, 0.325, 355, 280, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
588, d3qtzA_, 0.8715, 2.66, 0.975, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-36
589, d2r3fA_, 0.8715, 2.44, 0.953, 290, 277, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
590, d3qtqA_, 0.8714, 2.63, 0.975, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR RC-1-137
591, d5m4fA_, 0.8713, 2.33, 0.300, 330, 277, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER LOW-SALT CONDITIONS
592, d1h0vA_, 0.8713, 2.50, 0.953, 288, 278, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5 -YL]METHOXYPURINE
593, d5jq5A_, 0.8712, 2.30, 0.953, 287, 274, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0942
594, d4ek4A_, 0.8712, 2.40, 0.953, 287, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
595, d3ddqC1, 0.8712, 0.90, 0.973, 265, 258, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
596, d4qp9A_, 0.8711, 2.11, 0.374, 335, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-PROPYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
597, d3c9wB2, 0.8711, 2.04, 0.373, 335, 271, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
598, d3c9wA2, 0.8711, 2.04, 0.373, 335, 271, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
599, d4b99A_, 0.8710, 2.21, 0.396, 335, 273, CRYSTAL STRUCTURE OF MAPK7 (ERK5) WITH INHIBITOR
600, d3rpvA_, 0.8710, 2.65, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-88
601, d2vtlA_, 0.8710, 2.46, 0.953, 290, 277, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
602, d3wblA_, 0.8708, 2.24, 0.996, 283, 275, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR
603, d1q97A_, 0.8708, 1.99, 0.311, 351, 273, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
604, d3qxpA_, 0.8707, 2.39, 0.935, 294, 278, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
605, d1h07A_, 0.8707, 2.34, 0.960, 285, 275, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
606, d5lmkC1, 0.8706, 0.91, 0.981, 264, 258, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
607, d4ek5A_, 0.8706, 2.43, 0.953, 289, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
608, d3ti1A_, 0.8706, 2.72, 0.947, 294, 282, CDK2 IN COMPLEX WITH SUNITINIB
609, d1q8zA_, 0.8706, 2.10, 0.309, 354, 275, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
610, p5oo0A_, 0.8705, 2.47, 0.975, 288, 277, CDK2(WT) COVALENT ADDUCT WITH D28 AT C177
611, d4fklA_, 0.8705, 2.46, 0.953, 290, 277, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
612, d4au8A1, 0.8705, 1.67, 0.584, 274, 267, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
613, d1q99A_, 0.8705, 2.10, 0.309, 354, 275, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
614, d2c6lA_, 0.8704, 2.54, 0.968, 291, 278, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
615, d4ek3A_, 0.8703, 2.43, 0.953, 287, 276, CRYSTAL STRUCTURE OF APO CDK2
616, d3qruA_, 0.8703, 2.59, 0.929, 295, 282, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12
617, d2uzoA_, 0.8703, 2.53, 0.946, 290, 279, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
618, d1v0oB_, 0.8703, 1.94, 0.628, 274, 269, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
619, d1gz8A_, 0.8703, 2.47, 0.953, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3 -METHYL-2 -OXO)BUTOXYPURINE
620, d3qqkA_, 0.8701, 2.57, 0.968, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR L4
621, d2r3rA_, 0.8701, 2.47, 0.953, 290, 277, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
622, d1ungB_, 0.8701, 1.54, 0.581, 268, 265, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
623, d2c69A_, 0.8700, 2.59, 0.964, 292, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
624, d5hlpB_, 0.8699, 2.09, 0.330, 335, 273, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
625, d3rjcA_, 0.8698, 2.60, 0.950, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR L4-12
626, d2vtsA_, 0.8698, 2.18, 0.985, 282, 273, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
627, d5ievA_, 0.8697, 2.21, 0.993, 284, 275, CRYSTAL STRUCTURE OF BAY 1000394 (RONICICLIB) BOUND TO CDK2
628, d3r8zA_, 0.8697, 2.56, 0.986, 290, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-1-136
629, d2c68A_, 0.8697, 2.58, 0.950, 290, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
630, d1b39A_, 0.8697, 2.46, 0.949, 290, 277, HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
631, p3teiA_, 0.8696, 2.23, 0.369, 339, 274, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
632, d3qtxA_, 0.8696, 2.70, 0.954, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-35
633, d3nszA_, 0.8696, 2.20, 0.295, 327, 275, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH AMPPN
634, d3iggA_, 0.8696, 2.50, 0.949, 290, 277, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFQ WITH CDK-2
635, d2c6kA_, 0.8696, 2.60, 0.982, 292, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
636, d1q8yA_, 0.8696, 2.07, 0.307, 351, 274, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
637, p2gmxA_, 0.8695, 2.20, 0.355, 357, 276, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
638, d1y8yA_, 0.8695, 2.56, 0.953, 292, 279, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
639, d5iexA_, 0.8694, 2.34, 0.989, 285, 277, CRYSTAL STRUCTURE OF (RS)-S-{4-[(5-BROMO-4-{[(2R3R)-2-HYDROXY-1- METHYLPROPYL]OXY}- PYRIMIDIN-2-YL)AMINO]PHENYL}-S- CYCLOPROPYLSULFOXIMIDE BOUND TO CDK2
640, p2no3A_, 0.8694, 2.39, 0.356, 357, 278, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
641, d2r3oA_, 0.8692, 2.43, 0.953, 289, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
642, d2r3hA_, 0.8692, 2.42, 0.953, 289, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
643, d1ckpA_, 0.8692, 2.03, 0.967, 279, 272, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
644, d4qtaA_, 0.8691, 1.99, 0.370, 335, 270, STRUCTURE OF HUMAN ERK2 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
645, d2v0dA_, 0.8691, 2.59, 0.964, 292, 279, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
646, d4n4sA_, 0.8690, 2.22, 0.372, 342, 277, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
647, d2iw8C2, 0.8690, 0.95, 0.969, 264, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
648, d2b9fA_, 0.8690, 2.28, 0.382, 337, 275, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED FUS3
649, d4fkvA_, 0.8689, 2.17, 0.996, 282, 274, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
650, d2a4lA_, 0.8689, 2.31, 0.963, 286, 273, HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE
651, d2c6oA_, 0.8688, 2.58, 0.946, 290, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
652, p4md9P_, 0.8687, 2.41, 0.296, 328, 277, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
653, d3r8uA_, 0.8687, 2.67, 0.975, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR RC-1-132
654, d3w8lA_, 0.8686, 2.28, 0.301, 326, 276, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
655, d3r9hA_, 0.8686, 2.77, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-142
656, d5ieyA_, 0.8685, 2.41, 0.993, 286, 277, CRYSTAL STRUCTURE OF A CDK INHIBITOR BOUND TO CDK2
657, d1y91A_, 0.8684, 2.12, 0.971, 286, 273, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
658, d1q4lB_, 0.8684, 2.08, 0.324, 337, 272, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
659, d1cm8B_, 0.8684, 2.26, 0.370, 327, 273, PHOSPHORYLATED MAP KINASE P38-GAMMA
660, d1cm8A_, 0.8684, 2.26, 0.370, 327, 273, PHOSPHORYLATED MAP KINASE P38-GAMMA
661, d2w17A_, 0.8683, 2.07, 0.971, 278, 272, CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE COMPOUND (S)-8B
662, d2zjwA_, 0.8682, 2.29, 0.301, 332, 276, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH ELLAGIC ACID
663, d3fwqB_, 0.8681, 2.47, 0.294, 334, 279, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
664, d2vtpA_, 0.8681, 2.20, 0.967, 281, 273, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
665, d1pxlA_, 0.8681, 2.44, 0.978, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- (4-TRIFLUOROMETHYL-PHENYL)-AMINE
666, d3tizA_, 0.8679, 2.64, 0.929, 293, 281, CDK2 IN COMPLEX WITH NSC 111848
667, d3h30B_, 0.8679, 2.40, 0.299, 333, 278, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
668, d3qqjA_, 0.8678, 2.68, 0.975, 294, 281, CDK2 IN COMPLEX WITH INHIBITOR L2
669, d2c6mA_, 0.8678, 2.62, 0.964, 290, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
670, d2c6iA_, 0.8678, 2.63, 0.961, 292, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
671, d1pf8A_, 0.8678, 2.53, 0.986, 298, 280, CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR
672, d4qp3A_, 0.8677, 2.17, 0.363, 339, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
673, d2oxyA_, 0.8677, 2.40, 0.300, 327, 277, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
674, d2vtrA_, 0.8676, 2.50, 0.957, 290, 277, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
675, p5ooiA_, 0.8675, 2.43, 0.303, 329, 277, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
676, d5b0xA_, 0.8675, 2.41, 0.300, 329, 277, CRYSTAL STRUCTURE OF THE CK2A/BENZOIC ACID DERIVATIVE COMPLEX
677, d3kxhA_, 0.8675, 2.40, 0.300, 326, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR (2-DYMETHYLAMMINO-4567-TETRABROMOBENZOIMIDAZOL-1YL- ACETIC ACID (K66)
678, d2wmaC1, 0.8675, 0.99, 0.973, 264, 258, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
679, d2w1hA_, 0.8675, 2.31, 0.996, 283, 276, FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA (AT9283) A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY
680, d1howA_, 0.8675, 2.19, 0.316, 346, 275, THE X-RAY CRYSTAL STRUCTURE OF SKY1P AN SR PROTEIN KINASE IN YEAST
681, d3s00A_, 0.8674, 2.76, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR L4-14
682, d5k5nA_, 0.8673, 2.06, 0.331, 331, 272, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
683, d5n1vB_, 0.8670, 2.44, 0.300, 331, 277, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
684, d3qqgA_, 0.8670, 2.73, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR L2-5
685, d1j91B_, 0.8670, 2.39, 0.300, 327, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
686, d5n1vA_, 0.8669, 2.44, 0.300, 331, 277, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
687, d3s2pA_, 0.8669, 2.06, 0.967, 279, 272, CRYSTAL STRUCTURE OF CDK2 WITH A 2-AMINOPYRIMIDINE COMPOUND
688, d2r3pA_, 0.8668, 2.47, 0.953, 289, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
689, d2r3gA_, 0.8668, 2.37, 0.960, 287, 274, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
690, d5k4jA1, 0.8667, 2.15, 0.971, 281, 273, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH COMPOUND 22
691, d4fkiA_, 0.8667, 2.21, 0.971, 287, 273, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
692, p4md9K_, 0.8666, 2.41, 0.296, 328, 277, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
693, d4dglC_, 0.8666, 2.40, 0.292, 334, 277, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
694, d3qtuA_, 0.8666, 2.74, 0.908, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-2-132
695, d3ofmA_, 0.8666, 2.44, 0.300, 325, 277, STRUCTURE OF A HUMAN CK2ALPHA PRIME THE PARALOG ISOFORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM HOMO SAPIENS
696, d2oxyB_, 0.8666, 2.41, 0.300, 327, 277, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
697, d5csvA_, 0.8665, 2.28, 0.305, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 6 BOUND
698, d4o6eA_, 0.8664, 2.07, 0.374, 328, 270, DISCOVERY OF 5678-TETRAHYDROPYRIDO[34-D]PYRIMIDINE INHIBITORS OF ERK2
699, d3s0oA_, 0.8664, 2.70, 0.925, 293, 281, CDK2 IN COMPLEX WITH INHIBITOR RC-1-138
700, d3r8lA_, 0.8664, 2.74, 0.933, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR L3-4
701, d1e1vA_, 0.8664, 2.54, 0.978, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
702, p4md9G_, 0.8663, 2.31, 0.297, 329, 276, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
703, d3wikA_, 0.8662, 2.39, 0.296, 334, 277, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND10 COMPLEX
704, d3fwqA_, 0.8662, 2.50, 0.294, 334, 279, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
705, d2eufB_, 0.8662, 1.81, 0.500, 282, 268, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
706, d1pjkA_, 0.8662, 2.32, 0.301, 331, 276, CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
707, p4md9E_, 0.8661, 2.31, 0.297, 329, 276, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
708, d5xvuA_, 0.8660, 2.24, 0.302, 321, 275, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
709, p4md8G_, 0.8660, 2.46, 0.296, 332, 277, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
710, d1w8cA_, 0.8660, 2.53, 0.953, 290, 277, CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H- PURIN-2-YLAMINE AND MONOMERIC CDK2
711, d1h0wA_, 0.8660, 2.26, 0.960, 283, 275, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL]METHOXYPURINE
712, d4fuyA_, 0.8659, 2.24, 0.377, 329, 273, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK2
713, d3fz1A_, 0.8659, 2.22, 0.967, 284, 274, CRYSTAL STRUCTURE OF A BENZTHIOPHENE INHIBITOR BOUND TO HUMAN CYCLIN-DEPENDENT KINASE-2 (CDK-2)
714, d1j91A_, 0.8659, 2.45, 0.300, 327, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
715, d5cspA_, 0.8658, 2.28, 0.305, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
716, d4qp2B_, 0.8658, 2.17, 0.368, 329, 272, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
717, d4cjyD_, 0.8658, 1.56, 0.426, 272, 265,  
718, p5nzzH_, 0.8657, 2.19, 0.379, 335, 272, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
719, d4qp6A_, 0.8657, 2.20, 0.363, 339, 273, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
720, d4qp2A_, 0.8657, 2.21, 0.363, 336, 273, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
721, p4md8E_, 0.8657, 2.46, 0.296, 332, 277, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
722, d4grbA_, 0.8657, 2.26, 0.298, 327, 275, CASEIN KINASE 2 (CK2) BOUND TO INHIBITOR
723, d5cu4A_, 0.8656, 2.34, 0.301, 327, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
724, p3vuiA_, 0.8656, 2.19, 0.358, 355, 274, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
725, d1ds5B_, 0.8656, 2.44, 0.300, 328, 277, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
726, p5oulA_, 0.8655, 2.39, 0.301, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 9
727, p3vuhA_, 0.8655, 2.19, 0.358, 355, 274, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M3 IN MAP KINASE JNK1
728, p4h3pD_, 0.8654, 2.26, 0.370, 338, 273, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
729, p3vugA_, 0.8654, 2.19, 0.358, 356, 274, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
730, d3q9wA_, 0.8654, 2.29, 0.305, 328, 275, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 8.5
731, d3c13A_, 0.8654, 2.29, 0.305, 328, 275, LOW PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
732, d3axwA_, 0.8654, 2.46, 0.300, 329, 277, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA COMPLEXED WITH A POTENT INHIBITOR
733, d3unkA_, 0.8653, 2.84, 0.972, 295, 283, CDK2 IN COMPLEX WITH INHIBITOR YL5-083
734, d5xvuB_, 0.8652, 2.26, 0.302, 321, 275, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
735, p4md9L_, 0.8652, 2.48, 0.296, 328, 277, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
736, d2r3iA_, 0.8652, 2.49, 0.953, 289, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
737, d1jsvA_, 0.8652, 2.41, 0.960, 287, 274, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE
738, d5ct0A_, 0.8651, 2.25, 0.298, 326, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
739, d3q9yA_, 0.8651, 2.34, 0.301, 327, 276, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 8.5
740, p4md9F_, 0.8650, 2.32, 0.297, 327, 276, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
741, p3vudA_, 0.8650, 2.19, 0.358, 355, 274, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
742, d3owlA_, 0.8650, 2.46, 0.300, 330, 277, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
743, d2fysB_, 0.8650, 2.38, 0.370, 338, 276, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
744, d1na7A_, 0.8650, 2.32, 0.301, 326, 276, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2
745, d5mmrA_, 0.8649, 2.26, 0.298, 326, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
746, d4rllA_, 0.8649, 2.35, 0.301, 329, 276, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
747, p4ib5C_, 0.8649, 2.48, 0.300, 332, 277, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
748, d3bqcA_, 0.8649, 2.30, 0.305, 328, 275, HIGH PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
749, d5xvuC_, 0.8648, 2.27, 0.302, 321, 275, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
750, d5motA_, 0.8648, 2.30, 0.305, 328, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0627 BOUND
751, d5mhqA1, 0.8648, 2.41, 0.956, 288, 275, CCT068127 IN COMPLEX WITH CDK2
752, d5clpB_, 0.8648, 2.33, 0.301, 327, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
753, d4xj0B_, 0.8648, 2.27, 0.372, 338, 274, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
754, d4izaC_, 0.8648, 2.08, 0.365, 335, 271, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
755, d1e1xA_, 0.8648, 2.55, 0.953, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
756, d3qzgA_, 0.8647, 2.75, 0.936, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76
757, p2no3B_, 0.8647, 2.50, 0.356, 357, 278, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
758, p4md8H_, 0.8645, 2.47, 0.296, 331, 277, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
759, d4md7H_, 0.8645, 2.41, 0.304, 330, 276, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
760, d2r64A_, 0.8645, 2.10, 0.967, 279, 272, CRYSTAL STRUCTURE OF A 3-AMINOINDAZOLE COMPOUND WITH CDK2
761, p2h96A_, 0.8645, 2.53, 0.356, 358, 278, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
762, d1pxnA_, 0.8645, 2.78, 0.972, 294, 282, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL
763, d4fkgA_, 0.8644, 2.20, 0.971, 286, 272, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
764, d3sqqA_, 0.8644, 2.29, 0.982, 288, 275, CDK2 IN COMPLEX WITH INHIBITOR RC-3-96
765, d5mp8A_, 0.8643, 2.21, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
766, d4md7G_, 0.8643, 2.42, 0.304, 332, 276, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
767, p3vukA_, 0.8643, 2.19, 0.358, 355, 274, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M5 IN MAP KINASE JNK1
768, d2vv9A_, 0.8643, 2.12, 0.960, 279, 272, CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE
769, d5t1hA_, 0.8642, 2.48, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2
770, d3amyA_, 0.8642, 2.16, 0.297, 318, 273, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH APIGENIN
771, d5cx9A_, 0.8641, 2.37, 0.301, 328, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
772, d4md7E_, 0.8641, 2.46, 0.300, 332, 277, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
773, d3r7iA_, 0.8641, 2.39, 0.964, 282, 275, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-74
774, d1lr4A_, 0.8641, 2.45, 0.300, 327, 277, ROOM TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
775, d5modA_, 0.8640, 2.28, 0.298, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
776, p4nh1B_, 0.8640, 2.47, 0.300, 332, 277, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
777, d3u87A_, 0.8640, 2.48, 0.300, 329, 277, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
778, d3owjA_, 0.8640, 2.40, 0.301, 328, 276, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A PYRIDOCARBAZOLE DERIVATIVE INHIBITOR
779, d1ds5C_, 0.8640, 2.46, 0.300, 328, 277, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
780, d5cvhA_, 0.8639, 2.33, 0.298, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA
781, d5cu2A_, 0.8639, 2.36, 0.301, 328, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
782, p4md8F_, 0.8639, 2.48, 0.296, 332, 277, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
783, d4fkwA_, 0.8639, 2.09, 0.996, 280, 272, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
784, d2w06A_, 0.8639, 2.30, 0.967, 282, 274, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5C
785, d1pxkA_, 0.8639, 2.56, 0.953, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]- N -HYDROXYIMINOFORMAMIDE
786, p5otzA_, 0.8638, 2.36, 0.301, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 1
787, d5cu0A_, 0.8638, 2.28, 0.298, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
788, d5ctpB_, 0.8638, 2.38, 0.301, 327, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
789, d5cquA_, 0.8638, 2.36, 0.301, 328, 276, MONOCLINIC COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
790, p4nh1A_, 0.8638, 2.47, 0.300, 330, 277, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
791, d4bxbA_, 0.8638, 2.36, 0.301, 328, 276,  
792, d2uznA_, 0.8638, 2.22, 0.971, 279, 272, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
793, d5h8bA_, 0.8637, 2.49, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
794, d3rp0C_, 0.8637, 2.48, 0.300, 329, 277,  
795, d2bhhA_, 0.8637, 1.74, 0.974, 274, 267, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE
796, d5m56B_, 0.8636, 2.50, 0.303, 328, 277, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
797, d3wowA_, 0.8636, 2.32, 0.297, 334, 276, CRYSTAL STRUCTURE OF HUMAN CK2A WITH AMPPNP
798, d3r8vA_, 0.8636, 2.83, 0.975, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-1-135
799, d3qqhA_, 0.8636, 2.79, 0.975, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR L2-2
800, p3v3vA_, 0.8635, 2.18, 0.363, 351, 273, STRUCTURAL AND FUNCTIONAL ANALYSIS OF QUERCETAGETIN A NATURAL JNK1 INHIBITOR
801, d1lp4A_, 0.8635, 2.45, 0.300, 327, 277, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 WITH MG-AMPPNP
802, d5mmfA_, 0.8634, 2.28, 0.298, 326, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
803, d4anmA1, 0.8634, 2.46, 0.300, 327, 277, COMPLEX OF CK2 WITH A CDC7 INHIBITOR
804, d1fvtA_, 0.8634, 2.15, 0.967, 282, 273, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR
805, p5os8A_, 0.8633, 2.37, 0.301, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 11
806, d3le6A_, 0.8633, 2.35, 0.949, 283, 272, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR
807, d2qc6A_, 0.8633, 2.46, 0.300, 326, 277, PROTEIN KINASE CK2 IN COMPLEX WITH DBC
808, d2pvrA_, 0.8633, 2.38, 0.301, 328, 276, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (C- TERMINAL DELETION MUTANT 1-335) IN COMPLEX WITH TWO SULFATE IONS
809, d3pe2A_, 0.8632, 2.38, 0.301, 327, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR CX-5011
810, d1dawA_, 0.8632, 2.45, 0.300, 327, 277, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP
811, d5mo8A_, 0.8631, 2.30, 0.298, 325, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
812, d3wilA_, 0.8631, 2.36, 0.301, 331, 276, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND3 COMPLEX
813, d5larA_, 0.8629, 2.38, 0.367, 350, 278, CRYSTAL STRUCTURE OF P38 ALPHA MAPK14 IN COMPLEX WITH VPC00628
814, d3w55A_, 0.8629, 2.19, 0.368, 335, 272, THE STRUCTURE OF ERK2 IN COMPLEX WITH FR148083
815, d2e14A_, 0.8629, 2.19, 0.368, 335, 272,  
816, d1dayA_, 0.8629, 2.44, 0.300, 327, 277, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP
817, p5owlB_, 0.8628, 2.49, 0.300, 332, 277, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
818, p5n9kA_, 0.8628, 2.38, 0.301, 329, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF107 (5)
819, d5moeA_, 0.8628, 2.26, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
820, d3rpsA_, 0.8628, 2.28, 0.298, 334, 275, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
821, d3mb6A_, 0.8628, 2.38, 0.305, 329, 275, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (CPA)
822, d1ds5A_, 0.8628, 2.47, 0.300, 328, 277, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
823, p4md9M_, 0.8627, 2.39, 0.293, 331, 276, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
824, p4looA_, 0.8627, 2.27, 0.376, 349, 274, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (MONOCLINIC CRYSTAL FORM)
825, d5mpjA_, 0.8626, 2.35, 0.298, 326, 275, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
826, d5mohA_, 0.8626, 2.25, 0.303, 326, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0583 BOUND.
827, d5mo7A_, 0.8626, 2.32, 0.298, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
828, p4ux9B_, 0.8626, 2.11, 0.362, 327, 271, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
829, d4qp3B_, 0.8626, 2.22, 0.379, 331, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
830, d4md7F_, 0.8626, 2.48, 0.300, 332, 277, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
831, d3pzhA_, 0.8626, 2.47, 0.300, 327, 277, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH EMODIN AT 1.92 A RESOLUTION
832, d3owkA_, 0.8626, 2.52, 0.300, 330, 277, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
833, d4dgoA_, 0.8625, 2.47, 0.300, 325, 277, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH TYRPHOSTIN AG99
834, d3pvgA_, 0.8625, 2.47, 0.300, 326, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMO-1-CARBOXYMETHYLBENZIMIDAZOLE (K68)
835, d4ubaB_, 0.8624, 2.37, 0.297, 333, 276, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
836, d3ig7A_, 0.8624, 2.07, 0.967, 278, 271, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFP WITH CDK-2
837, d1zoeA_, 0.8624, 2.47, 0.300, 325, 277, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
838, d3kxjA_, 0.8623, 2.47, 0.300, 326, 277,  
839, d1lpuA_, 0.8623, 2.47, 0.300, 327, 277, LOW TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
840, d1h00A_, 0.8623, 2.16, 0.985, 278, 272, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
841, d5h8eA_, 0.8622, 2.50, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
842, d3pwdA_, 0.8622, 2.49, 0.300, 327, 277, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH NBC (Z1)
843, d3pe1A_, 0.8622, 2.39, 0.301, 327, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-4945
844, d5mo5A_, 0.8621, 2.25, 0.299, 326, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
845, d4qp6B_, 0.8621, 2.23, 0.379, 334, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
846, d3oz6A_, 0.8621, 2.53, 0.368, 343, 277, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
847, d1ds5D_, 0.8621, 2.48, 0.300, 328, 277, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
848, d1di8A_, 0.8621, 2.22, 1.000, 283, 273, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-67-DIMETHOXYQUINAZOLINE
849, p5n9nA_, 0.8620, 2.40, 0.301, 329, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF85 (4A)
850, d5mowA1, 0.8620, 2.28, 0.299, 326, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
851, d5mo7B_, 0.8620, 2.27, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
852, d3kxnA_, 0.8620, 2.46, 0.300, 327, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR TETRAIODOBENZIMIDAZOLE (K88)
853, d3at2A_, 0.8620, 2.37, 0.297, 334, 276, CRYSTAL STRUCTURE OF CK2ALPHA
854, d1m2pA_, 0.8620, 2.48, 0.300, 325, 277, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO- ANTHRAQUINONE/CK2 KINASE COMPLEX
855, d4fbxA_, 0.8619, 2.29, 0.302, 333, 275, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT CRYSTALLIZED IN THE PRESENCE OF A BISUBSTRATE INHIBITOR
856, d3rp0B_, 0.8619, 2.49, 0.296, 329, 277,  
857, d1pxmA_, 0.8619, 2.67, 0.946, 290, 278, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL
858, d5movA_, 0.8618, 2.29, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0633 BOUND
859, d2r3mA_, 0.8618, 2.03, 0.970, 278, 270, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
860, p3o17A_, 0.8617, 2.41, 0.361, 357, 277, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
861, p3e3bX_, 0.8617, 2.37, 0.301, 334, 276, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2ALPHA PRIME WITH A POTENT INDAZOLE-DERIVATIVE INHIBITOR
862, d2r3qA_, 0.8617, 2.40, 0.963, 286, 273, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
863, d1om1A_, 0.8617, 2.49, 0.300, 325, 277, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH IQA
864, d1h08A_, 0.8616, 2.43, 0.993, 283, 274, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
865, d3q9xB_, 0.8615, 2.45, 0.304, 330, 276, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
866, d3ngaA_, 0.8615, 2.51, 0.300, 331, 277, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
867, d1w0xC_, 0.8615, 2.26, 0.982, 280, 273, CRYSTAL STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE.
868, d3rp0A_, 0.8614, 2.52, 0.296, 329, 277,  
869, d2w05A_, 0.8614, 2.06, 0.970, 276, 269, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5B
870, d2oxxA_, 0.8614, 2.49, 0.300, 325, 277, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
871, d5cu3A_, 0.8613, 2.29, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
872, d4fkjA_, 0.8613, 2.13, 0.974, 278, 271, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
873, d3u87B_, 0.8613, 2.52, 0.300, 329, 277, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
874, d3r9oA_, 0.8613, 2.34, 0.989, 282, 274, CDK2 IN COMPLEX WITH INHIBITOR RC-2-143
875, d1m2rA_, 0.8613, 2.53, 0.300, 327, 277, CRYSTAL STRUCTURE OF 58-DI-AMINO-14-DI-HYDROXY- ANTHRAQUINONE/CK2 KINASE COMPLEX
876, d1ke6A_, 0.8613, 2.25, 0.967, 280, 273, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4- [2-(7-OXO-67-DIHYDRO-8H-[13]THIAZOLO[54-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
877, d5cqwA_, 0.8612, 2.52, 0.300, 331, 277, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
878, d4fkqA_, 0.8612, 2.29, 0.964, 283, 275, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
879, d4bxaA_, 0.8612, 2.52, 0.300, 331, 277,  
880, d3r0tA_, 0.8612, 2.41, 0.301, 327, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-5279
881, d3pxyA_, 0.8612, 2.82, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR JWS648
882, p5n9lA_, 0.8611, 2.40, 0.301, 329, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE DIBENZOFURAN INHIBITOR TF (4B)
883, d5cu0B_, 0.8611, 2.33, 0.295, 325, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
884, d4qp8A_, 0.8611, 2.13, 0.373, 335, 271, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
885, d4dgnA_, 0.8611, 2.49, 0.300, 325, 277, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR LUTEOLIN
886, d5k5nB_, 0.8610, 2.14, 0.333, 334, 270, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
887, d5h8gA_, 0.8610, 2.21, 0.300, 324, 273, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7B
888, d3r7uA_, 0.8610, 2.32, 0.967, 282, 274, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-75
889, d5mmrB_, 0.8609, 2.27, 0.296, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
890, d5cvfA_, 0.8609, 2.30, 0.303, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
891, d5cu6A_, 0.8609, 2.45, 0.301, 327, 276, CRYSTAL STRUCTURE OF CK2ALPHA
892, p2pvnA_, 0.8609, 2.48, 0.296, 327, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
893, d2oxdA_, 0.8609, 2.47, 0.300, 325, 277, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE K17 K22 AND K32 INHIBITORS
894, p4ux9A_, 0.8608, 2.24, 0.360, 343, 272, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
895, p4jqeA_, 0.8608, 2.55, 0.278, 369, 277, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH AMPPN
896, d4ek6A_, 0.8608, 2.09, 0.978, 278, 270, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
897, d3kxgA_, 0.8608, 2.49, 0.300, 326, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 34567-PENTABROMO-1H-INDAZOLE (K64)
898, d1zohA_, 0.8608, 2.50, 0.300, 326, 277, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
899, d4qpaA_, 0.8607, 2.28, 0.375, 331, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
900, d3qa0B_, 0.8607, 2.47, 0.304, 330, 276, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
901, d3q04A_, 0.8607, 2.39, 0.301, 328, 276, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 8.5
902, d1jamA_, 0.8607, 2.50, 0.300, 327, 277, CRYSTAL STRUCTURE OF APO-FORM OF Z. MAYS CK2 PROTEIN KINASE ALPHA SUBUNIT
903, p5otyA_, 0.8606, 2.43, 0.301, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712
904, d4dgmA_, 0.8606, 2.50, 0.300, 326, 277, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR APIGENIN
905, d3ngaB_, 0.8606, 2.53, 0.300, 331, 277, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
906, d2vtaA_, 0.8606, 2.14, 0.974, 278, 271, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
907, d1ke7A_, 0.8606, 2.25, 0.967, 281, 273, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(22- DIOXIDO-13-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5- (13-OXAZOL-5-YL)-13-DIHYDRO-2H-INDOL-2-ONE
908, d1jowB_, 0.8606, 1.78, 0.494, 277, 267, CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
909, p3u9cA_, 0.8604, 2.48, 0.304, 331, 276, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
910, d4ub7A_, 0.8603, 2.35, 0.293, 334, 276, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26) SHOWING AN EXTREME DISTORTION OF THE ATP-BINDING LOOP COMBINED WITH A PI-HALOGEN BOND
911, p4md9H_, 0.8603, 2.40, 0.297, 328, 276, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
912, d4ek8A_, 0.8602, 2.27, 0.971, 280, 272, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
913, d5mo6A_, 0.8601, 2.30, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
914, d3fl5A_, 0.8601, 2.50, 0.300, 324, 277, PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR QUINALIZARIN
915, d2vtiA_, 0.8601, 2.31, 0.982, 280, 273, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
916, d5m4uA_, 0.8600, 2.44, 0.304, 332, 276, ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
917, d3qa0A_, 0.8599, 2.55, 0.300, 330, 277, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
918, d3py0A_, 0.8599, 2.80, 0.972, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR SU9516
919, d5m56A_, 0.8598, 2.55, 0.303, 331, 277, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
920, d5m4iA_, 0.8598, 2.36, 0.293, 331, 276, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
921, d5aniA_, 0.8598, 2.25, 0.963, 280, 272, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-CHLORO-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
922, d2vthA_, 0.8598, 2.15, 0.974, 278, 271, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN
923, p4ux9C_, 0.8597, 2.08, 0.363, 333, 270, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
924, d3u4uA_, 0.8597, 2.34, 0.298, 327, 275, CASEIN KINASE 2 IN COMPLEX WITH AZ-INHIBITOR
925, d3kxmA_, 0.8597, 2.51, 0.300, 326, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR K74
926, p5omyA_, 0.8596, 2.43, 0.301, 332, 276, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
927, d5mo6B_, 0.8596, 2.30, 0.296, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
928, d5kwhA_, 0.8596, 2.55, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2
929, d5buiA_, 0.8596, 2.24, 0.368, 338, 272, ERK2 COMPLEXED WITH 2-PYRIDIYL TETRAHYDROAZAINDAZOLE
930, d4fkrA_, 0.8596, 2.34, 0.978, 282, 274, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
931, d3od6X_, 0.8596, 2.36, 0.373, 344, 276, CRYSTAL STRUCTURE OF P38ALPHA Y323T ACTIVE MUTANT
932, d5modB_, 0.8595, 2.31, 0.296, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
933, d2f9gA_, 0.8595, 2.15, 0.385, 332, 270, CRYSTAL STRUCTURE OF FUS3 PHOSPHORYLATED ON TYR182
934, d1ke8A_, 0.8595, 2.23, 0.982, 282, 273, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO- 12-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(13- THIAZOL-2-YL)BENZENESULFONAMIDE
935, p5owlA_, 0.8594, 2.55, 0.300, 331, 277, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
936, p2pvmA_, 0.8594, 2.52, 0.296, 327, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
937, d1zogA_, 0.8594, 2.50, 0.300, 325, 277, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES
938, d1dm2A_, 0.8594, 1.82, 0.966, 274, 267, HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
939, d5mo5B_, 0.8593, 2.31, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
940, d5mmfB_, 0.8592, 2.31, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
941, d5jq8A_, 0.8592, 2.18, 0.967, 278, 270, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0943
942, d5cu3B_, 0.8592, 2.33, 0.299, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
943, d3ezvA_, 0.8592, 2.09, 0.963, 277, 270, CDK-2 WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
944, d2j9mA_, 0.8592, 1.86, 0.966, 275, 268, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE
945, d5mo8B_, 0.8591, 2.33, 0.299, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
946, d3rp0D_, 0.8590, 2.56, 0.296, 329, 277,  
947, p3u9cB_, 0.8589, 2.48, 0.304, 331, 276, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
948, p3be9A_, 0.8589, 2.52, 0.296, 327, 277, STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC PYRAZOLO[15-A] [135]TRIAZINE COMPOUNDS AS POTENT INHIBITORS OF PROTEIN KINASE CK2 AND THEIR ANTICANCER ACTIVITIES
949, p2h96B_, 0.8589, 2.40, 0.355, 357, 276, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
950, d5ct0B_, 0.8588, 2.31, 0.296, 326, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
951, d5cshA_, 0.8587, 2.32, 0.299, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
952, d5cqwB_, 0.8587, 2.55, 0.300, 331, 277, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
953, d4yc6E_, 0.8587, 2.61, 0.663, 285, 273, CDK1/CKS1
954, d4fktA_, 0.8587, 2.28, 0.971, 278, 272, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
955, d4bxaB_, 0.8587, 2.55, 0.300, 331, 277,  
956, d4qp4B_, 0.8586, 2.23, 0.371, 335, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
957, p2pvhA_, 0.8586, 2.53, 0.296, 327, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
958, d3mb7A_, 0.8585, 2.47, 0.301, 330, 276, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (AMR)
959, d5ku8A_, 0.8584, 2.52, 0.301, 328, 276, CRYSTAL STRUCTURE OF CK2
960, d5h8bB_, 0.8584, 2.56, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
961, d4qp7B_, 0.8584, 2.17, 0.373, 335, 271, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
962, d4kwpA_, 0.8584, 2.43, 0.301, 329, 276, CRYSTAL STRUCTURE OF HUMAN CK2-ALPHA IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR (K164) AT 1.25 A RESOLUTION
963, d3rzbA_, 0.8584, 2.31, 0.982, 282, 273, CDK2 IN COMPLEX WITH INHIBITOR RC-2-23
964, d1vyzA_, 0.8584, 2.16, 0.978, 279, 270, STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
965, d5cx9B_, 0.8583, 2.32, 0.296, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
966, d5cvgA_, 0.8583, 2.24, 0.305, 326, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH A NOVEL CLOSED CONFORMATION OF THE AD LOOP
967, d5ctpA_, 0.8583, 2.32, 0.296, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
968, p2g01A_, 0.8583, 2.40, 0.355, 355, 276, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
969, d1g5sA_, 0.8583, 1.85, 0.985, 275, 267, CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717
970, d5h8eB_, 0.8582, 2.57, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
971, d4fksA_, 0.8582, 2.10, 0.974, 275, 270, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
972, d3q9xA_, 0.8582, 2.57, 0.300, 330, 277, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
973, p2pvjA_, 0.8582, 2.54, 0.296, 326, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
974, d4ubaA_, 0.8581, 2.42, 0.297, 333, 276, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
975, p4gubA_, 0.8581, 2.46, 0.301, 329, 276, CASEIN KINASE II BOUND TO INHIBITOR
976, d3rpsB_, 0.8581, 2.44, 0.297, 334, 276, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
977, d3i60A_, 0.8581, 1.98, 0.376, 335, 266, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-4-(2-(2-CHLOROPHENYLAMINO)-5- METHYLPYRIMIDIN-4-YL)-N-(2-HYDROXY-1-PHENYLETHYL)-1H-PYRROLE-2- CARBOXAMIDE
978, d3e3pA_, 0.8581, 2.39, 0.337, 337, 276, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
979, p4ib5B_, 0.8580, 2.58, 0.292, 329, 277, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
980, d4fkpA_, 0.8580, 2.28, 0.971, 279, 272, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
981, d5t1hB_, 0.8579, 2.57, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2
982, d5mpjB_, 0.8579, 2.35, 0.299, 324, 274, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
983, d4rlkA_, 0.8579, 2.54, 0.300, 327, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
984, d4bzdA_, 0.8579, 2.04, 0.963, 277, 270, STRUCTURE OF CDK2 IN COMPLEX WITH A BENZIMIDAZOPYRIMIDINE
985, p2pvkA_, 0.8578, 2.54, 0.296, 327, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
986, d5cvhB_, 0.8577, 2.35, 0.299, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA
987, d3warA_, 0.8577, 2.53, 0.296, 334, 277, CRYSTAL STRUCTURE OF HUMAN CK2A
988, d1ke5A_, 0.8577, 2.30, 0.982, 281, 273, CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-12-DIHYDRO-3H- INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
989, d5cu2B_, 0.8576, 2.33, 0.296, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
990, d5mowB_, 0.8575, 2.35, 0.299, 324, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
991, d4xoyA_, 0.8575, 2.45, 0.364, 326, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
992, d1ke9A_, 0.8575, 2.18, 0.971, 281, 272, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4- ({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2- OXO-23-DIHYDRO-1H-INDOLE
993, d3q9zB_, 0.8574, 2.51, 0.304, 332, 276, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
994, d3at3A_, 0.8573, 2.47, 0.301, 332, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVATIVE
995, d2vtqA_, 0.8573, 1.96, 0.974, 274, 267, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
996, d4ptgB_, 0.8572, 2.04, 0.332, 332, 268, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
997, d3e3pB_, 0.8571, 2.51, 0.329, 337, 277, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
998, d2r3kA_, 0.8571, 2.12, 0.970, 277, 270, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
999, d5k4iA_, 0.8570, 2.02, 0.373, 336, 268, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH COMPOUND 22
1000, d5f95B_, 0.8569, 2.10, 0.331, 338, 269, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
1001, d4yc6G_, 0.8569, 2.60, 0.615, 285, 273, CDK1/CKS1
1002, p2pvlA_, 0.8569, 2.56, 0.296, 327, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1003, d1m2qA_, 0.8569, 2.60, 0.300, 327, 277, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO-XANTEN-9- ONE/CK2 KINASE COMPLEX
1004, d5kwhB_, 0.8567, 2.59, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2
1005, d3w8lB_, 0.8567, 2.48, 0.301, 326, 276, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
1006, d5moeB_, 0.8564, 2.30, 0.293, 323, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1007, p4mwhA_, 0.8564, 2.60, 0.278, 371, 277, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1008, d4ewqA_, 0.8564, 2.45, 0.366, 346, 273, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A PYRIDAZINE BASED INHIBITOR
1009, p4fi1A_, 0.8563, 2.61, 0.278, 371, 277, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1010, d3unjA_, 0.8563, 2.79, 0.926, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR YL1-038-31
1011, d3qtrA_, 0.8563, 2.33, 0.960, 282, 273, CDK2 IN COMPLEX WITH INHIBITOR RC-1-148
1012, d2btsA_, 0.8563, 1.88, 0.970, 274, 267, STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
1013, d1f0qA_, 0.8561, 2.59, 0.296, 329, 277, CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN
1014, d3o2mB_, 0.8560, 2.34, 0.361, 358, 274, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
1015, p4lfiA_, 0.8558, 2.61, 0.278, 370, 277, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1016, d3o2mA_, 0.8558, 2.44, 0.359, 358, 276, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
1017, d3at4A_, 0.8558, 2.49, 0.301, 331, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVERTIVE
1018, d5ku8B_, 0.8557, 2.60, 0.300, 331, 277, CRYSTAL STRUCTURE OF CK2
1019, d4yc6A_, 0.8557, 2.63, 0.663, 285, 273, CDK1/CKS1
1020, d5anoA_, 0.8556, 2.17, 0.978, 277, 270, CRYSTAL STRUCTURE OF CDK2 PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1021, d4yc6C_, 0.8556, 2.62, 0.663, 285, 273, CDK1/CKS1
1022, d2vtnA_, 0.8555, 1.93, 0.970, 274, 267, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1023, d4aguC_, 0.8554, 2.03, 0.390, 278, 267, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1024, d4n4sB_, 0.8553, 2.14, 0.368, 337, 272, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
1025, p4lfiB_, 0.8553, 2.60, 0.278, 371, 277, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1026, d5cs6A_, 0.8552, 2.55, 0.298, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
1027, d2vu3A_, 0.8552, 1.94, 0.993, 285, 267, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1028, p2gmxB_, 0.8552, 2.40, 0.355, 357, 276, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
1029, d4acmA_, 0.8551, 2.04, 0.970, 277, 269, CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL] SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
1030, d2pk9C_, 0.8550, 1.59, 0.575, 266, 261, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
1031, d1giiA_, 0.8550, 2.28, 0.971, 279, 272, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1032, d2r3jA_, 0.8549, 2.16, 0.970, 278, 270, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1033, d3o0gB_, 0.8547, 1.58, 0.590, 264, 261, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
1034, d2vtjA_, 0.8547, 2.05, 0.978, 276, 269, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1035, d2b55A_, 0.8547, 2.04, 0.996, 276, 268, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH INDENOPYRAXOLE DIN-101312
1036, d5ci6B_, 0.8546, 2.14, 0.353, 350, 269, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
1037, p3o17B_, 0.8545, 2.53, 0.361, 357, 277, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
1038, d3l1sB_, 0.8544, 1.98, 0.331, 330, 266, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
1039, d1jwhB_, 0.8544, 2.46, 0.297, 335, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
1040, d3l1sA_, 0.8543, 1.99, 0.331, 336, 266, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
1041, d5mp8B_, 0.8542, 2.28, 0.298, 323, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1042, p6ehuA_, 0.8541, 2.52, 0.301, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1043, d4fv6A_, 0.8541, 1.92, 0.374, 332, 265, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E57
1044, p4ib5A_, 0.8538, 2.57, 0.304, 331, 276, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1045, d4aa4A_, 0.8538, 2.43, 0.381, 347, 273, P38ALPHA MAP KINASE BOUND TO CMPD 22
1046, p3nieA_, 0.8538, 2.68, 0.395, 369, 276, CRYSTAL STRUCTURE OF PF11_0147
1047, d2qkrA1, 0.8537, 1.98, 0.577, 269, 265, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH INDIRUBIN 3 -MONOXIME BOUND
1048, d1gihA_, 0.8535, 2.10, 0.989, 276, 269, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1049, d3sw4A_, 0.8534, 2.22, 0.970, 279, 271, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1050, d5cshB_, 0.8530, 2.29, 0.303, 323, 271, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
1051, d2r7iA_, 0.8530, 2.53, 0.297, 322, 276, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1052, d3q9zA_, 0.8528, 2.62, 0.300, 332, 277, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1053, d4fv8A_, 0.8527, 1.95, 0.377, 333, 265, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E63
1054, d3rpyA_, 0.8525, 2.08, 0.959, 277, 269, CDK2 IN COMPLEX WITH INHIBITOR RC-2-40
1055, d2vttA_, 0.8525, 1.85, 0.989, 272, 265, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1056, d1h06A_, 0.8525, 2.06, 0.981, 277, 269,  
1057, d3rmfA_, 0.8524, 2.14, 0.970, 278, 270, CDK2 IN COMPLEX WITH INHIBITOR RC-2-33
1058, d2r7iC_, 0.8524, 2.48, 0.298, 321, 275, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1059, d2r3nA_, 0.8524, 2.05, 0.963, 275, 268, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1060, d3qtsA_, 0.8523, 2.35, 0.967, 282, 273, CDK2 IN COMPLEX WITH INHIBITOR RC-2-12
1061, d4nj3A_, 0.8522, 2.05, 0.993, 277, 268, MODULATING THE INTERACTION BETWEEN CDK2 AND CYCLIN A WITH A QUINOLINE- BASED INHIBITOR
1062, d3nwwA_, 0.8522, 2.17, 0.375, 339, 269, P38 ALPHA KINASE COMPLEXED WITH A 2-AMINOTHIAZOL-5-YL-PYRIMIDINE BASED INHIBITOR
1063, d5ci6A_, 0.8521, 2.20, 0.357, 335, 269, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
1064, d2btrA_, 0.8521, 2.01, 0.996, 275, 267, STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
1065, d2duvA_, 0.8517, 1.81, 0.989, 272, 265, STRUCTURE OF CDK2 WITH A 3-HYDROXYCHROMONES
1066, d5andA_, 0.8515, 2.11, 0.963, 273, 268, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 2-IMIDAZOL-1-YL-1H- BENZIMIDAZOLE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1067, d3rahA_, 0.8514, 2.35, 0.967, 282, 273, CDK2 IN COMPLEX WITH INHIBITOR RC-2-22
1068, d1r78A_, 0.8513, 1.92, 0.989, 273, 266, CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR
1069, d1urwA_, 0.8512, 2.07, 0.981, 274, 268, CDK2 IN COMPLEX WITH AN IMIDAZO[12-B]PYRIDAZINE
1070, d3r8mA_, 0.8511, 2.59, 0.971, 286, 276, CDK2 IN COMPLEX WITH INHIBITOR L3-3
1071, d3bx5A_, 0.8511, 2.20, 0.379, 338, 269, P38 ALPHA MAP KINASE COMPLEXED WITH BMS-640994
1072, d1v0bA_, 0.8511, 2.90, 0.607, 286, 275, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
1073, d4i5hA_, 0.8510, 2.12, 0.376, 335, 266, CRYSTAL STRUCTURE OF A DOUBLE MUTANT RAT ERK2 COMPLEXED WITH A TYPE II QUINAZOLINE INHIBITOR
1074, d3mvlA_, 0.8509, 2.10, 0.381, 339, 268, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
1075, d1v0pA_, 0.8509, 2.54, 0.616, 277, 271, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
1076, d3s1hA_, 0.8508, 2.09, 0.963, 277, 269, CDK2 IN COMPLEX WITH INHIBITOR RC-2-39
1077, d3ezrA_, 0.8508, 1.90, 0.970, 273, 266, CDK-2 WITH INDAZOLE INHIBITOR 17 BOUND AT ITS ACTIVE SITE
1078, d2r3lA_, 0.8507, 2.03, 0.970, 275, 268, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1079, d5clpA_, 0.8506, 2.35, 0.303, 322, 271, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
1080, d1p2aA_, 0.8506, 1.94, 0.970, 271, 267, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A TRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR
1081, d4aacA_, 0.8505, 2.37, 0.384, 350, 271, P38ALPHA MAP KINASE BOUND TO CMPD 29
1082, d3rprA_, 0.8505, 2.37, 0.967, 282, 273, CDK2 IN COMPLEX WITH INHIBITOR RC-2-49
1083, d5fp6A_, 0.8503, 2.33, 0.971, 278, 272, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 3-(47-DICHLORO-1H-INDOL-3-YL)PROP-2-YN-1-OL (AT17833) IN AN ALTERNATE BINDING SITE.
1084, d3dt1A2, 0.8503, 2.54, 0.377, 352, 273, P38 COMPLEXED WITH A QUINAZOLINE INHIBITOR
1085, d4fv4A_, 0.8502, 2.10, 0.377, 329, 265, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK7
1086, d2bheA_, 0.8502, 1.96, 0.966, 274, 267, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE
1087, d2r7iB_, 0.8501, 2.48, 0.299, 322, 274, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1088, d5ankA_, 0.8499, 2.03, 0.974, 273, 266, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 246-TRIOXO-1- PHENYL-HEXAHYDROPYRIMIDINE-5-CARBOXAMIDE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1089, d3rakA_, 0.8498, 2.12, 0.974, 277, 269, CDK2 IN COMPLEX WITH INHIBITOR RC-2-32
1090, p4jr7A_, 0.8495, 2.62, 0.280, 367, 275, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1091, d3r9nA_, 0.8495, 2.49, 0.967, 282, 274, CDK2 IN COMPLEX WITH INHIBITOR RC-2-21
1092, d1oitA_, 0.8495, 1.95, 0.974, 273, 265, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
1093, d3sw7A_, 0.8494, 2.16, 0.959, 278, 270, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1094, d3hl7A_, 0.8494, 2.09, 0.378, 336, 267, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH SD-0006
1095, d3ralA_, 0.8492, 2.16, 0.974, 277, 269, CDK2 IN COMPLEX WITH INHIBITOR RC-2-34
1096, d2r7iD_, 0.8492, 2.49, 0.299, 322, 274, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1097, p2g01B_, 0.8490, 2.60, 0.357, 356, 277, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
1098, p6ehuB_, 0.8489, 2.60, 0.301, 327, 276, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1099, p5lw1H_, 0.8488, 2.30, 0.343, 355, 271, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1100, d4dglD_, 0.8488, 2.68, 0.300, 328, 277, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
1101, p5lw1B_, 0.8487, 2.31, 0.343, 355, 271, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1102, p5ax3A_, 0.8487, 2.10, 0.376, 329, 266, CRYSTAL STRUCTURE OF ERK2 COMPLEXED WITH ALLOSTERIC AND ATP- COMPETITIVE INHIBITORS.
1103, p3nieB_, 0.8487, 2.69, 0.396, 367, 275, CRYSTAL STRUCTURE OF PF11_0147
1104, p3n9xB_, 0.8487, 2.79, 0.404, 362, 277, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
1105, d4fkoA_, 0.8484, 2.26, 0.956, 291, 271, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1106, p4f9bA_, 0.8483, 2.48, 0.259, 318, 274, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
1107, d1v1kA_, 0.8483, 2.12, 0.981, 277, 269, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1108, p5xyyA_, 0.8482, 2.61, 0.381, 350, 273, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
1109, d4iq6A_, 0.8482, 2.02, 0.336, 324, 265, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
1110, d4aguA_, 0.8482, 2.13, 0.391, 277, 266, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1111, d2i6lA_, 0.8482, 2.43, 0.328, 292, 271, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
1112, d4bghA_, 0.8479, 2.11, 0.989, 275, 268, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PAN-CDK INHIBITOR
1113, d3e7oA_, 0.8477, 2.47, 0.341, 342, 273, CRYSTAL STRUCTURE OF JNK2
1114, d2ozaB_, 0.8476, 2.42, 0.373, 340, 271, STRUCTURE OF P38ALPHA COMPLEX
1115, d3ds6D_, 0.8469, 2.55, 0.374, 349, 273, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1116, d5m44A_, 0.8467, 2.56, 0.296, 329, 274, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
1117, p6gihA_, 0.8466, 2.49, 0.304, 324, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH CAM187 BOUND 
1118, p5lw1E_, 0.8466, 2.33, 0.343, 355, 271, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1119, d1pyeA_, 0.8465, 1.86, 0.977, 266, 262, CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR
1120, d3hllA_, 0.8464, 2.10, 0.368, 337, 266, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH PH-797804
1121, d3gfeA_, 0.8464, 2.59, 0.377, 352, 273, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR
1122, d1oukA_, 0.8462, 2.67, 0.374, 348, 273, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR
1123, d4f9wA_, 0.8461, 2.08, 0.376, 336, 266, HUMAN P38ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
1124, d4eh2A_, 0.8461, 2.13, 0.368, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F1 AND RL87
1125, d3i5zA_, 0.8461, 2.01, 0.376, 331, 263, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-N-(2-HYDROXY-1-PHENYLETHYL)-4- (5-METHYL-2-(PHENYLAMINO)PYRIMIDIN-4-YL)-1H-PYRROLE-2-CARBOXAMIDE
1126, d1ob3A_, 0.8461, 2.57, 0.616, 277, 271, STRUCTURE OF P. FALCIPARUM PFPK5
1127, d3gc9B_, 0.8460, 2.31, 0.364, 339, 269, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
1128, d1ouyA_, 0.8459, 2.65, 0.381, 350, 273, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROPYRIDO- PYRIMIDINE INHIBITOR
1129, d4fa2A_, 0.8458, 2.15, 0.376, 339, 266, HUMAN P38 ALPHA MITOGEN-ACTIVATED KINASE IN COMPLEX WITH SB239063
1130, d4aa5A_, 0.8458, 2.53, 0.391, 340, 271, P38ALPHA MAP KINASE BOUND TO CMPD 33
1131, d2fvdA_, 0.8457, 1.90, 0.981, 284, 265, CYCLIN DEPENDENT KINASE 2 (CDK2) WITH DIAMINOPYRIMIDINE INHIBITOR
1132, d4zthA_, 0.8456, 2.16, 0.376, 339, 266, STRUCTURE OF HUMAN P38AMAPK-ARYLPYRIDAZINYLPYRIDINE FRAGMENT COMPLEX USED IN INHIBITOR DISCOVERY
1133, d3v6rA_, 0.8456, 2.50, 0.352, 349, 273, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1134, d3kf7A_, 0.8456, 2.09, 0.368, 337, 266, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A TRIAZOLOPYRIMIDINE COMPOUND
1135, d3gc8B_, 0.8456, 2.39, 0.368, 346, 269, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
1136, d5bveA_, 0.8455, 1.89, 0.374, 330, 262, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
1137, d2zazA_, 0.8455, 2.64, 0.377, 345, 273, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH 4-ANILINO QUINOLINE INHIBITOR
1138, d1wbwA_, 0.8453, 2.66, 0.381, 351, 273, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1139, d4f9yA_, 0.8452, 2.13, 0.378, 339, 267, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
1140, d4fv9A_, 0.8451, 1.97, 0.376, 331, 263, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E71
1141, d2rg6A_, 0.8451, 2.27, 0.383, 335, 269, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11J
1142, d4kinB_, 0.8450, 2.47, 0.376, 341, 271, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1143, d4fv5A_, 0.8450, 2.01, 0.373, 330, 263, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK9
1144, d3s3iA_, 0.8449, 2.60, 0.377, 349, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1145, d3rocA_, 0.8449, 2.12, 0.372, 337, 266, CRYSTAL STRUCTURE OF HUMAN P38 ALPHA COMPLEXED WITH A PYRIMIDINONE COMPOUND
1146, d3v6sA_, 0.8447, 2.50, 0.355, 349, 273, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1147, d3itzA1, 0.8447, 2.60, 0.374, 353, 273, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDAZINE INHIBITOR
1148, d3d7zA_, 0.8447, 2.61, 0.379, 348, 272, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
1149, d2zb1A_, 0.8447, 2.49, 0.369, 345, 271, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
1150, d3mvlB_, 0.8446, 2.20, 0.381, 339, 268, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
1151, d3mptA_, 0.8446, 2.59, 0.364, 347, 272, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A PYRROLE-2- CARBOXAMIDE INHIBITOR
1152, d5bvdA_, 0.8445, 1.91, 0.374, 330, 262, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
1153, p4lopD_, 0.8444, 2.50, 0.368, 351, 272, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1154, d1m7qA_, 0.8444, 2.66, 0.374, 348, 273, CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
1155, d2zb0A_, 0.8443, 2.61, 0.381, 349, 273, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
1156, d3flsA_, 0.8442, 2.58, 0.369, 343, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((R)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
1157, d2lgcA1, 0.8442, 2.32, 0.381, 353, 268, JOINT NMR AND X-RAY REFINEMENT REVEALS THE STRUCTURE OF A NOVEL DIBENZO[AD]CYCLOHEPTENONE INHIBITOR/P38 MAP KINASE COMPLEX IN SOLUTION
1158, d3ocgA_, 0.8441, 2.14, 0.372, 336, 266, P38 ALPHA KINASE COMPLEXED WITH A 5-AMINO-PYRAZOLE BASED INHIBITOR
1159, d4kipA_, 0.8440, 2.30, 0.369, 337, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
1160, d2balA_, 0.8440, 2.22, 0.371, 337, 267, P38ALPHA MAP KINASE BOUND TO PYRAZOLOAMINE
1161, d1ywrA_, 0.8440, 2.23, 0.381, 338, 268, CRYSTAL STRUCTURE ANALYSIS OF INACTIVE P38 KINASE DOMAIN IN COMPLEX WITH A MONOCYCLIC PYRAZOLONE INHIBITOR
1162, d3ds6A_, 0.8439, 2.53, 0.359, 343, 273, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1163, d4d1xA_, 0.8438, 2.08, 0.974, 274, 266, CDK2 IN COMPLEX WITH LUCIFERIN
1164, d3obgA_, 0.8438, 2.09, 0.376, 332, 266, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
1165, p3n9xA_, 0.8438, 2.70, 0.411, 374, 275, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
1166, d4aguB_, 0.8437, 2.17, 0.392, 276, 265, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1167, d1di9A_, 0.8437, 2.61, 0.381, 348, 273, THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-67- DIMETHOXYQUINAZOLINE
1168, d5bujA_, 0.8436, 1.97, 0.373, 331, 263, ERK2 COMPLEXED WITH A N-H TETRAHYDROAZAINDAZOLE
1169, d3rinA_, 0.8436, 2.62, 0.381, 349, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1170, d3e92A_, 0.8436, 2.53, 0.376, 348, 271, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
1171, d3bv2A_, 0.8436, 2.21, 0.376, 337, 266, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 30
1172, d1r3cA_, 0.8434, 2.63, 0.374, 349, 273, THE STRUCTURE OF P38ALPHA C162S MUTANT
1173, d5awmA_, 0.8433, 2.35, 0.343, 345, 271, THE CRYSTAL STRUCTURE OF JNK FROM DROSOPHILA MELANOGASTER REVEALS AN EVOLUTIONARILY CONSERVED TOPOLOGY WITH THAT OF MAMMALIAN JNK PROTEINS.
1174, d4eh6A_, 0.8433, 2.14, 0.370, 335, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F5 AND RL87
1175, d1i09A_, 0.8433, 2.08, 0.336, 338, 265, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
1176, d4kinC_, 0.8432, 2.37, 0.378, 338, 270, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1177, p4lopB_, 0.8431, 2.35, 0.356, 350, 270, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1178, d3gc8A_, 0.8431, 2.43, 0.362, 347, 268, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
1179, d3mvmB_, 0.8430, 2.29, 0.384, 332, 268, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
1180, d2ghmA_, 0.8430, 2.27, 0.378, 336, 267, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-895449
1181, d2pkjA_, 0.8428, 2.19, 0.375, 332, 267,  
1182, d1w84A_, 0.8428, 2.63, 0.374, 351, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1183, d3mpaA_, 0.8427, 2.01, 0.367, 331, 264, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1184, d3fmhA_, 0.8427, 2.57, 0.369, 347, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((R)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1185, d3u8wA_, 0.8426, 2.62, 0.374, 349, 273, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A TRIAZOLOPYRIDAZINONE INHIBITOR
1186, d3mh0A_, 0.8425, 2.19, 0.375, 332, 267, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1187, d2rg5A_, 0.8424, 2.30, 0.384, 333, 268, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11B
1188, p4lopA_, 0.8423, 2.52, 0.368, 351, 272, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1189, d3flyA_, 0.8423, 2.56, 0.369, 347, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-ISOPROPYLAMINO-8-METHYL-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1190, d4eh7A_, 0.8422, 2.22, 0.372, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F6 AND RL87
1191, d4eh3A_, 0.8422, 2.22, 0.368, 339, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F2 AND RL87
1192, d1ua2C_, 0.8422, 2.01, 0.445, 286, 263, CRYSTAL STRUCTURE OF HUMAN CDK7
1193, d5n66A_, 0.8421, 2.14, 0.366, 332, 265, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9J
1194, d3zyaA1, 0.8421, 2.27, 0.367, 341, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO- DIBENZOSUBERONE
1195, d4o2zA1, 0.8420, 2.35, 0.337, 357, 267, CRYSTAL STRUCTURE OF MPK3 FROM LEISHMANIA DONOVANI LDBPK_100540 IN THE PRESENCE OF NVP-BBT594
1196, d3gc9A_, 0.8420, 2.21, 0.361, 335, 266, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
1197, d3flqA_, 0.8420, 2.71, 0.381, 345, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((S)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN
1198, d3fklA_, 0.8420, 2.33, 0.381, 344, 268, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO9552
1199, d1ua2B_, 0.8420, 2.04, 0.449, 286, 263, CRYSTAL STRUCTURE OF HUMAN CDK7
1200, d4eh8A_, 0.8419, 2.16, 0.370, 336, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F7 AND RL87
1201, d3oz6B_, 0.8418, 2.84, 0.378, 341, 275, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
1202, d2gtnA_, 0.8418, 2.15, 0.374, 337, 265, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-951717
1203, p4loqB_, 0.8417, 2.34, 0.356, 351, 270, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1204, p4loqD_, 0.8414, 2.35, 0.356, 351, 270, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1205, d4ehvA_, 0.8414, 2.29, 0.376, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F10 AND RL87
1206, d2ptoA_, 0.8414, 2.01, 0.367, 330, 264,  
1207, d1gijA_, 0.8414, 2.07, 0.970, 273, 266, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1208, d5bueA_, 0.8412, 2.01, 0.373, 329, 263, ERK2 COMPLEXED WITH N-BENZYLPYRIDONE TETRAHYDROAZAINDAZOLE
1209, d4kipB_, 0.8412, 2.30, 0.386, 338, 267, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
1210, d1oveA_, 0.8412, 2.65, 0.374, 349, 273, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROQUINOLINONE
1211, d3ds6C_, 0.8411, 2.52, 0.377, 349, 273, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1212, d1zzlA_, 0.8411, 2.70, 0.374, 351, 273, CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE
1213, d1bl6A_, 0.8411, 2.76, 0.369, 351, 274, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995
1214, d1zyjA_, 0.8409, 2.19, 0.372, 331, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1A
1215, d1w82A_, 0.8409, 2.64, 0.376, 351, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1216, d1ua2D_, 0.8408, 2.04, 0.445, 286, 263, CRYSTAL STRUCTURE OF HUMAN CDK7
1217, d5d1jA_, 0.8407, 1.73, 0.992, 265, 260, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(11-DIMETHYLETHYL)-2-OXAZOLYL] METHYL]THIO]-2-THIAZOLYL]- 4-PIPERIDINECARBOXAMIDE (BMS-387032)
1218, d3flzA_, 0.8407, 2.58, 0.369, 347, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 8-METHYL-6-PHENOXY-2- (TETRAHYDRO-PYRAN-4-YLAMINO)-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
1219, p4loqA_, 0.8406, 2.34, 0.356, 352, 270, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1220, d3mvmA_, 0.8406, 2.39, 0.383, 335, 269, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
1221, d3hv3A_, 0.8406, 2.22, 0.365, 335, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL49
1222, d3bv3A_, 0.8406, 2.25, 0.372, 338, 266, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 2
1223, d1yw2A_, 0.8406, 2.12, 0.374, 341, 265, MUTATED MUS MUSCULUS P38 KINASE (MP38)
1224, d3hp5A_, 0.8405, 2.16, 0.370, 330, 265, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIMIDOPYRIDAZINONE COMPOUND
1225, d3mh2A_, 0.8404, 2.02, 0.367, 330, 264, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1226, d3hp2A_, 0.8403, 2.18, 0.374, 341, 265, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIDINONE COMPOUND
1227, d3fmkA_, 0.8403, 2.59, 0.373, 346, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((S)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1228, d3flwA_, 0.8402, 2.55, 0.370, 345, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH PAMAPIMOD
1229, d3queA_, 0.8399, 2.18, 0.374, 343, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH SKEPINONE-L
1230, d4kiqC_, 0.8398, 2.33, 0.369, 338, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1231, d1w7hA_, 0.8398, 2.65, 0.370, 351, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1232, d3gcqA_, 0.8397, 2.24, 0.365, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL45
1233, d1oiqA_, 0.8397, 1.85, 0.973, 264, 261, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
1234, d3nnuA_, 0.8396, 2.66, 0.376, 348, 271, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP1376
1235, d3fknA_, 0.8396, 2.56, 0.363, 346, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO7125
1236, d3nnwA_, 0.8395, 2.66, 0.376, 349, 271, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP802
1237, d3nnvA_, 0.8395, 2.62, 0.376, 348, 271, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP437
1238, d4kiqB_, 0.8394, 2.34, 0.369, 338, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1239, d3fmmA_, 0.8394, 2.61, 0.362, 346, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6226
1240, d1wboA_, 0.8392, 2.71, 0.377, 351, 273, FRAGMENT BASED P38 INHIBITORS
1241, d3gp0A1, 0.8390, 2.13, 0.360, 332, 264, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 11 (P38 BETA) IN COMPLEX WITH NILOTINIB
1242, d5etcA_, 0.8389, 2.71, 0.370, 355, 273, STRUCTURE OF INACTIVE MAPK14 WITH ORDERED ACTIVATION LOOP
1243, d3iphA_, 0.8389, 2.50, 0.368, 345, 269, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH A BIPHENYLAMIDE INHIBITOR
1244, d3ds6B_, 0.8388, 2.55, 0.374, 343, 273, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1245, d1a9uA_, 0.8388, 2.63, 0.355, 351, 273, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580
1246, d3fmjA_, 0.8387, 2.69, 0.371, 344, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 4-(5-METHYL-3-PHENYL- ISOXAZOL-4-YL)-PYRIMIDIN-2-YLAMINE
1247, d3o8uA_, 0.8386, 2.20, 0.374, 332, 265, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1248, d4ynoA_, 0.8385, 2.54, 0.385, 342, 270, CRYSTAL STRUCTURE OF MAPK13 AT INACTIVE FORM
1249, d3fmnA_, 0.8385, 2.58, 0.367, 341, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO2530
1250, p3lhjA_, 0.8384, 2.21, 0.376, 341, 266, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR.
1251, d1bmkA_, 0.8384, 2.79, 0.369, 351, 274, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655
1252, d5cs6B_, 0.8383, 2.24, 0.308, 316, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
1253, d1yqjA2, 0.8383, 2.67, 0.355, 351, 273, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH A SELECTIVE PYRIDAZINE INHIBITOR
1254, d4kiqD_, 0.8382, 2.36, 0.369, 338, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1255, d3mw1A_, 0.8381, 2.66, 0.375, 342, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1256, d3gc0A_, 0.8381, 2.40, 0.539, 278, 267, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA IN COMPLEX WITH AMP
1257, d2ghlA_, 0.8381, 2.22, 0.374, 334, 265, MUTANT MUS MUSCULUS P38 KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-874743
1258, d1bl7A_, 0.8380, 2.70, 0.359, 351, 273, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025
1259, d4kinD_, 0.8379, 2.48, 0.374, 339, 270, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1260, d4r3cA_, 0.8378, 2.05, 0.373, 335, 263, CRYSTAL STRUCTURE OF P38 ALPHA MAP KINASE IN COMPLEX WITH A NOVEL ISOFORM SELECTIVE DRUG CANDIDATE
1261, d3uvqA_, 0.8378, 2.08, 0.373, 333, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOSUBERONE DERIVATIVE
1262, d2yixA_, 0.8378, 2.65, 0.379, 351, 272, TRIAZOLOPYRIDINE INHIBITORS OF P38
1263, d4ic8B_, 0.8375, 2.55, 0.365, 336, 271, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
1264, d3p7bA_, 0.8375, 2.27, 0.376, 332, 266, P38 INHIBITOR-BOUND
1265, p4lopC_, 0.8374, 2.20, 0.370, 341, 265, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1266, d3o8pA_, 0.8372, 2.20, 0.362, 336, 265, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1267, d3fmlA_, 0.8372, 2.64, 0.362, 342, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6224
1268, d3o8tA_, 0.8370, 2.29, 0.372, 332, 266, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG-MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1269, d4w4yA_, 0.8369, 2.66, 0.352, 350, 273, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-METHYLPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1270, d3hrbA_, 0.8369, 2.75, 0.381, 344, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1271, d2puuA_, 0.8369, 2.19, 0.370, 330, 265, CRYSTAL STRUCTURE OF P38 COMPLEX WITH 1-(5-TERT-BUTYL-2-P- TOLYL-2H-PYRAZOL-3-YL)-3-[4-(6-MORPHOLIN-4-YLMETHYL- PYRIDIN-3-YL)NAPHTHALEN-1-YL]UREA
1272, d1wbvA_, 0.8369, 2.67, 0.373, 351, 271, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1273, d5bvfA_, 0.8368, 1.86, 0.371, 327, 259, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
1274, d3gc7A_, 0.8367, 2.70, 0.370, 349, 273, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH A DIHYDROQUINAZOLINONE
1275, d2i0hA_, 0.8367, 2.71, 0.370, 349, 273, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH AN ARYLPYRIDAZINONE
1276, d1wbtA_, 0.8367, 2.69, 0.376, 351, 271, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1277, d3p5kA_, 0.8366, 2.28, 0.376, 332, 266, P38 INHIBITOR-BOUND
1278, d3newA_, 0.8366, 2.20, 0.370, 334, 265, P38-ALPHA COMPLEXED WITH COMPOUND 10
1279, d3mh3A_, 0.8366, 2.20, 0.362, 334, 265, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1280, d2ptjA_, 0.8366, 2.20, 0.358, 334, 265,  
1281, d1zz2A_, 0.8366, 2.37, 0.381, 337, 268, TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING A COMMON DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT BINDING MODES
1282, d4eh4A_, 0.8365, 2.23, 0.375, 337, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F3 AND RL87
1283, d3qudA_, 0.8365, 2.30, 0.372, 345, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO-BENZOPHENONE
1284, d4kinA_, 0.8362, 2.52, 0.379, 338, 269, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1285, d3p79A_, 0.8362, 2.28, 0.376, 332, 266, P38 INHIBITOR-BOUND
1286, d3p78A_, 0.8362, 2.28, 0.376, 332, 266, P38 INHIBITOR-BOUND
1287, d1p38A_, 0.8362, 2.73, 0.359, 351, 273, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTOMS RESOLUTION
1288, d1ua2A_, 0.8360, 2.11, 0.445, 286, 263, CRYSTAL STRUCTURE OF HUMAN CDK7
1289, d5angA_, 0.8359, 1.96, 0.962, 268, 262, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 7-HYDROXY-4-( MORPHOLINOMETHYL)CHROMEN-2-ONE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1290, d4y5hA_, 0.8359, 2.59, 0.358, 349, 271, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1291, d4y46A_, 0.8359, 2.58, 0.358, 340, 271, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1292, d1wbsA_, 0.8357, 2.72, 0.376, 351, 271, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1293, d4w4xA_, 0.8356, 2.66, 0.352, 342, 273, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-FLUOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1294, d4w4vA_, 0.8356, 2.73, 0.358, 342, 274, JNK2/3 IN COMPLEX WITH 3-(4-{[(2-CHLOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1295, d4kiqA_, 0.8356, 2.37, 0.373, 338, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1296, d3oc1A_, 0.8355, 2.21, 0.370, 330, 265, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1297, d3mh1A_, 0.8355, 2.22, 0.366, 337, 265, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1298, d2gfsA_, 0.8354, 2.63, 0.359, 344, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3201195
1299, d3p7cA_, 0.8353, 2.22, 0.377, 332, 265, P38 INHIBITOR-BOUND
1300, d2pv8A_, 0.8353, 2.22, 0.366, 337, 265,  
1301, d3fkoA_, 0.8351, 2.59, 0.372, 343, 269, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3668
1302, d4qtdA_, 0.8350, 2.54, 0.348, 355, 270, STRUCTURE OF HUMAN JNK1 IN COMPLEX WITH SCH772984 AND THE AMPPNP- HYDROLYSED TRIPHOSPHATE REVEALING THE SECOND TYPE-I BINDING MODE
1303, d3e93A_, 0.8350, 2.68, 0.378, 346, 270, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
1304, d1w83A_, 0.8350, 2.75, 0.376, 351, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1305, d5mz3A_, 0.8349, 2.74, 0.376, 350, 271, P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-METHYL-3-(4455- TETRAMETHYL-132-DIOXABOROLAN-2-YL)PHENYL)-3-(TRIFLUOROMETHYL) BENZAMIDE]
1306, d3kq7A_, 0.8349, 2.68, 0.376, 348, 271, STRUCTURE OF HUMAN P38ALPHA WITH N-[4-METHYL-3-(6-{[2-(1- METHYLPYRROLIDIN-2-YL)ETHYL]AMINO}PYRIDINE-3-AMIDO)PHENYL]- 2-(MORPHOLIN-4-YL)PYRIDINE-4-CARBOXAMIDE
1307, d1r39A_, 0.8349, 2.63, 0.358, 345, 271, THE STRUCTURE OF P38ALPHA
1308, d4yr8A_, 0.8347, 2.26, 0.351, 320, 265, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1309, d3hv4A_, 0.8346, 2.43, 0.378, 339, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
1310, d3hv6A_, 0.8345, 2.20, 0.375, 331, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH RL39
1311, d3fsfA_, 0.8345, 2.71, 0.365, 340, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 3-(26- DICHLORO-PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]- 1-METHYL-34-DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
1312, d4kkeA_, 0.8344, 2.61, 0.358, 354, 271, THE CRYSTAL STRUCTURE OF AMP-BOUND JNK3
1313, d4l8mA_, 0.8343, 2.26, 0.375, 339, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOXEPINONE
1314, d3uvpA_, 0.8342, 2.35, 0.367, 334, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZAMIDE SUBSTITUTED BENZOSUBERONE
1315, d3objA_, 0.8342, 2.36, 0.375, 332, 267, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
1316, d5o8uA_, 0.8341, 2.17, 0.364, 331, 264, COVALENT INHIBITOR 4B BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S252C
1317, d5ekoA_, 0.8341, 2.51, 0.375, 341, 269, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
1318, p4ux9D_, 0.8341, 2.77, 0.350, 344, 274, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
1319, d4awiA_, 0.8339, 2.49, 0.351, 352, 268, HUMAN JNK1ALPHA KINASE WITH 4-PHENYL-7-AZAINDOLE IKK2 INHIBITOR.
1320, d4dljA_, 0.8338, 2.16, 0.365, 336, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH RL163
1321, d3fskA_, 0.8337, 2.56, 0.362, 342, 268, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6257
1322, d4kkgA_, 0.8336, 2.57, 0.359, 353, 270, CRYSTAL STRUCTURE OF APO AND AMP-BOUND JNK3
1323, d3gcuA_, 0.8336, 2.45, 0.378, 339, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
1324, d3tg1A_, 0.8333, 2.16, 0.367, 334, 264, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH A MAPK DOCKING PARTNER
1325, d1wbnA_, 0.8331, 2.72, 0.376, 351, 271, FRAGMENT BASED P38 INHIBITORS
1326, d4kkhA_, 0.8330, 2.64, 0.358, 351, 271, THE CRYSTAL STRUCTURE OF INHIBITOR-BOUND JNK3
1327, d4ditA_, 0.8330, 2.08, 0.337, 328, 261, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A IMIDAZOPYRIDINE INHIBITOR
1328, d4w4wA_, 0.8329, 2.64, 0.358, 349, 271, JNK2/3 IN COMPLEX WITH N-(2-METHYLPYRIDIN-4-YL)-3-{4- [(PHENYLCARBAMOYL)AMINO]-1H-PYRAZOL-1-YL}BENZAMIDE
1329, d4dliA_, 0.8329, 2.26, 0.371, 334, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH RL87
1330, d2onlB1, 0.8329, 2.47, 0.377, 339, 268, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1331, d3hvcA_, 0.8327, 1.99, 0.381, 327, 260, CRYSTAL STRUCTURE OF HUMAN P38ALPHA MAP KINASE
1332, d2p5aA_, 0.8327, 1.99, 0.381, 327, 260,  
1333, d3hv5A_, 0.8324, 2.47, 0.378, 339, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
1334, d3pg1A_, 0.8322, 2.11, 0.333, 341, 264, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR (1.95 ANGS RESOLUTION)
1335, d3hegA_, 0.8322, 2.31, 0.368, 333, 266, P38 IN COMPLEX WITH SORAFENIB
1336, d3gbzA_, 0.8321, 2.36, 0.545, 274, 266, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA
1337, d3c5uA_, 0.8319, 2.26, 0.368, 338, 266, P38 ALPHA MAP KINASE COMPLEXED WITH A BENZOTHIAZOLE BASED INHIBITOR
1338, d1lewA_, 0.8319, 2.44, 0.381, 341, 268, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS NUCLEAR SUBSTRATE MEF2A
1339, d4tyhB_, 0.8318, 2.33, 0.377, 335, 265, TERNARY COMPLEX OF P38 AND MK2 WITH A P38 INHIBITOR
1340, d4eh9A_, 0.8317, 2.28, 0.376, 334, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F11 AND RL87
1341, d3cg2A_, 0.8317, 2.23, 0.384, 327, 263,  
1342, d1wfcA_, 0.8317, 2.67, 0.357, 340, 269, STRUCTURE OF APO UNPHOSPHORYLATED P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN
1343, d4eymA_, 0.8316, 2.48, 0.381, 340, 268, MAPK13 COMPLEX WITH INHIBITOR
1344, p6f5eB_, 0.8315, 2.27, 0.362, 346, 265, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1345, p5lenB_, 0.8315, 2.27, 0.362, 346, 265, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX WITH JNK1A1 AND JIP1 PEPTIDE
1346, d4yr8E_, 0.8314, 2.36, 0.350, 317, 266, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1347, d5etiA1, 0.8313, 2.76, 0.368, 352, 272, STRUCTURE OF DEAD KINASE MAPK14
1348, d2onlA1, 0.8312, 2.40, 0.378, 338, 267, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1349, d5fp5A_, 0.8311, 1.89, 0.985, 264, 260, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 4-FLUOROBENZOIC ACID (AT222) IN AN ALTERNATE BINDING SITE.
1350, d2okrA_, 0.8310, 2.49, 0.377, 339, 268, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1351, d1lezA_, 0.8310, 2.49, 0.383, 343, 269, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS ACTIVATOR MKK3B
1352, d3cgoA_, 0.8308, 2.54, 0.362, 332, 268, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
1353, d5mtxA_, 0.8307, 2.24, 0.366, 331, 265, DIBENZOOXEPINONE INHIBITOR 12B IN COMPLEX WITH P38 MAPK
1354, d3flnC_, 0.8307, 2.58, 0.371, 343, 267, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH R1487
1355, d4eyjA_, 0.8306, 2.35, 0.383, 338, 266, MAPK13 COMPLEX WITH INHIBITOR
1356, d2gtmA_, 0.8306, 2.15, 0.378, 341, 262, MUTATED MOUSE P38 MAP KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-892579
1357, p5o90A_, 0.8305, 2.23, 0.382, 330, 262, CRYSTAL STRUCTURE OF A P38ALPHA T185G MUTANT IN COMPLEX WITH TAB1 PEPTIDE.
1358, d4ka3A_, 0.8303, 2.40, 0.367, 340, 267, STRUCTURE OF MAP KINASE IN COMPLEX WITH A DOCKING PEPTIDE
1359, d3lfbA_, 0.8301, 2.35, 0.376, 333, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL98
1360, d3l8xA_, 0.8299, 2.17, 0.379, 326, 261, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-PYRIMIDINE BASED INHIBITOR
1361, d3cgfA_, 0.8299, 2.53, 0.362, 346, 268, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
1362, d5n68A_, 0.8298, 2.10, 0.372, 328, 261, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9M
1363, d3v6rB_, 0.8298, 2.46, 0.354, 346, 268, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1364, d2wajA_, 0.8298, 2.53, 0.361, 348, 269, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH A 1-ARYL-34- DIHYDROISOQUINOLINE INHIBITOR
1365, d1kv1A_, 0.8297, 2.20, 0.378, 331, 262, P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1
1366, d3nnxA_, 0.8295, 2.14, 0.387, 336, 261, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38 ALPHA IN COMPLEX WITH DP802
1367, d3mgyA_, 0.8293, 2.26, 0.375, 329, 264, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1368, d2p33A_, 0.8293, 2.55, 0.362, 332, 268, SYNTHESIS AND SAR OF AMINOPYRIMIDINES AS NOVEL C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1369, d3ctqA_, 0.8292, 2.39, 0.376, 336, 266, STRUCTURE OF MAP KINASE P38 IN COMPLEX WITH A 1-O-TOLYL-12 3-TRIAZOLE-4-CARBOXAMIDE
1370, d3pzeA_, 0.8291, 2.44, 0.350, 347, 266, JNK1 IN COMPLEX WITH INHIBITOR
1371, d2zdtA_, 0.8290, 2.58, 0.362, 342, 268, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
1372, d2qd9A_, 0.8289, 2.22, 0.373, 330, 263, P38 ALPHA MAP KINASE INHIBITOR BASED ON HETEROBICYCLIC SCAFFOLDS
1373, d1jnkA_, 0.8288, 2.56, 0.362, 346, 268, THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP
1374, d3k3iA_, 0.8286, 2.21, 0.378, 332, 262, P38ALPHA BOUND TO NOVEL DGF-OUT COMPOUND PF-00215955
1375, d2pv5A_, 0.8286, 2.26, 0.371, 329, 264,  
1376, p4h3bA_, 0.8285, 2.27, 0.374, 351, 265, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
1377, p4h3bC_, 0.8284, 2.27, 0.374, 351, 265, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
1378, d3ptgA_, 0.8284, 2.29, 0.374, 340, 265, DESIGN AND SYNTHESIS OF A NOVEL ORALLY EFFICACIOUS TRI-SUBSTITUTED THIOPHENE BASED JNK INHIBITOR
1379, d3p7aA_, 0.8283, 2.40, 0.376, 332, 266, P38 INHIBITOR-BOUND
1380, d3hecA_, 0.8283, 2.35, 0.370, 329, 265, P38 IN COMPLEX WITH IMATINIB
1381, d5mtyA_, 0.8282, 2.26, 0.367, 328, 264, DIBENZOSUBERONE INHIBITOR 8E IN COMPLEX WITH P38 MAPK
1382, p5xyxA_, 0.8281, 2.56, 0.372, 337, 266, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
1383, d3lffA_, 0.8281, 2.35, 0.370, 335, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH RL166
1384, d5uojA_, 0.8280, 2.45, 0.360, 343, 267, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTROMS RESOLUTION
1385, d4h36A_, 0.8280, 2.27, 0.374, 353, 265, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH ATF2 PEPTIDE
1386, d3npcA_, 0.8280, 2.29, 0.360, 357, 264, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
1387, d3gi3A_, 0.8279, 2.38, 0.370, 330, 265, CRYSTAL STRUCTURE OF A N-PHENYL-N -NAPHTHYLUREA ANALOG IN COMPLEX WITH P38 MAP KINASE
1388, d4u79A_, 0.8278, 2.46, 0.360, 337, 267, CRYSTAL STRUCTURE OF HUMAN JNK3 IN COMPLEX WITH A BENZENESULFONAMIDE INHIBITOR.
1389, d1pmuA_, 0.8278, 2.51, 0.357, 342, 269, THE CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PHENANTROLINE INHIBITOR
1390, d3hv7A_, 0.8277, 2.31, 0.380, 330, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH RL38
1391, d3fc1X_, 0.8277, 2.24, 0.369, 330, 263, CRYSTAL STRUCTURE OF P38 KINASE BOUND TO PYRIMIDO-PYRIDAZINONE INHIBITOR
1392, d3d83A_, 0.8272, 2.72, 0.379, 347, 269, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
1393, d1oz1A_, 0.8270, 2.75, 0.383, 344, 269, P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR
1394, d3g90X_, 0.8268, 2.58, 0.362, 345, 268, JNK-3 BOUND TO (Z)-5-FLUORO-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL) METHYL)-3-(HYDROXYIMINO)INDOLIN-2-ONE
1395, d5eknA_, 0.8267, 2.31, 0.375, 336, 264, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
1396, p4loqC_, 0.8267, 2.21, 0.370, 337, 262, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1397, d3npcB_, 0.8267, 2.20, 0.363, 356, 262, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
1398, d2okrD_, 0.8266, 2.42, 0.376, 339, 266, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1399, p5etaB_, 0.8262, 2.17, 0.374, 335, 262, STRUCTURE OF MAPK14 WITH BOUND THE KIM DOMAIN OF THE TOXOPLASMA PROTEIN GRA24
1400, d1ukiA_, 0.8262, 2.28, 0.362, 328, 265, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
1401, d4x21A_, 0.8261, 2.35, 0.364, 336, 264, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
1402, d3g9nA_, 0.8261, 2.64, 0.361, 346, 269, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-PHENYLINDOLIN-2-ONE
1403, d3hv4B_, 0.8260, 2.46, 0.380, 338, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
1404, d1pmnA_, 0.8260, 2.73, 0.361, 344, 269, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE- PYRIMIDINE INHIBITOR
1405, d4ic8A_, 0.8258, 2.62, 0.384, 325, 268, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
1406, d2o0uA_, 0.8257, 2.54, 0.363, 331, 267, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-{3-CYANO-6-[3-(1- PIPERIDINYL)PROPANOYL]-4567-TETRAHYDROTHIENO[23-C]PYRIDIN-2-YL}- 1-NAPHTHALENECARBOXAMIDE
1407, d3iw6A_, 0.8256, 2.39, 0.376, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZYLPIPERAZIN- PYRROL
1408, d3ha8A_, 0.8256, 2.27, 0.364, 342, 264, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/COMPOUND 14B
1409, d4d1zA_, 0.8254, 1.82, 0.984, 258, 257, CDK2 IN COMPLEX WITH A LUCIFERIN DERIVATE
1410, d5n67A_, 0.8251, 2.16, 0.377, 327, 260, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9L
1411, d3hv5B_, 0.8251, 2.48, 0.380, 339, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
1412, d5tbeA_, 0.8249, 2.18, 0.378, 332, 262, HUMAN P38ALPHA MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 2
1413, d3p4kA_, 0.8249, 2.39, 0.380, 338, 266, THE THIRD CONFORMATION OF P38A MAP KINASE OBSERVED IN PHOSPHORYLATED P38A AND IN SOLUTION
1414, p2xs0A_, 0.8249, 2.23, 0.346, 346, 263, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
1415, d3gcuB_, 0.8248, 2.48, 0.380, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
1416, d4bgqA_, 0.8246, 2.23, 0.378, 276, 262, CRYSTAL STRUCTURE OF THE HUMAN CDKL5 KINASE DOMAIN
1417, d4a9yA_, 0.8246, 2.32, 0.380, 334, 263, P38ALPHA MAP KINASE BOUND TO CMPD 8
1418, d2bakA_, 0.8246, 2.32, 0.380, 334, 263, P38ALPHA MAP KINASE BOUND TO MPAQ
1419, d3s4qA_, 0.8243, 2.30, 0.375, 326, 261, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-TRIAZINE BASED INHIBITOR
1420, p4whzA_, 0.8240, 2.65, 0.362, 342, 268, DESIGN AND SYNTHESIS OF HIGHLY POTENT AND ISOFORM SELECTIVE JNK3 INHIBITORS: SAR STUDIES ON AMINOPYRAZOLE DERIVATIVES
1421, d3iw7A_, 0.8239, 2.42, 0.376, 335, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH AN IMIDAZO-PYRIDINE
1422, d3da6A_, 0.8238, 2.48, 0.363, 328, 267, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-METHYL- 4-(3-(2-(METHYLAMINO)PYRIMIDIN-4-YL)PYRIDIN-2-YLOXY) NAPHTHALEN-1-YL)-1H-BENZO[D]IMIDAZOL-2-AMINE
1423, d3gcvA_, 0.8237, 2.31, 0.376, 338, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH RL62
1424, d3e7oB_, 0.8237, 2.16, 0.349, 326, 261, CRYSTAL STRUCTURE OF JNK2
1425, d5tcoA_, 0.8236, 2.23, 0.366, 327, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 1
1426, d3ttiA_, 0.8236, 2.65, 0.362, 341, 268, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-930 AN ORALLY ACTIVE ANTI-FIBROTIC JNK INHIBITOR
1427, d1jvpP_, 0.8234, 2.30, 0.954, 268, 261, CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) IN COMPLEX WITH PKF049-365
1428, d3lfeA_, 0.8232, 2.42, 0.376, 334, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL116
1429, d3eljA_, 0.8232, 2.59, 0.352, 347, 267, JNK1 COMPLEXED WITH A BIS-ANILINO-PYRROLOPYRIMIDINE INHIBITOR.
1430, d5n65A_, 0.8230, 2.31, 0.367, 333, 264, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9H
1431, d3lfcA_, 0.8226, 2.44, 0.372, 334, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL99
1432, d3k3jA_, 0.8225, 2.24, 0.368, 329, 261, P38ALPHA BOUND TO NOVEL DFG-OUT COMPOUND PF-00416121
1433, d1ianA_, 0.8225, 2.12, 0.378, 328, 259, HUMAN P38 MAP KINASE INHIBITOR COMPLEX
1434, d5o8vA_, 0.8223, 2.17, 0.375, 328, 259, COVALENT INHIBITOR 4A BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S251C
1435, d3fl4A_, 0.8222, 2.56, 0.375, 339, 264, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO5634
1436, d2o2uA_, 0.8220, 2.34, 0.364, 319, 264, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-CYANO-4567- TETRAHYDRO-1-BENZOTHIEN-2-YL)-2-FLUOROBENZAMIDE
1437, d3v6sB_, 0.8219, 2.27, 0.361, 340, 263, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1438, d3pg3A_, 0.8219, 2.45, 0.368, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL182
1439, d3g9lX_, 0.8215, 2.53, 0.361, 336, 266, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-STYRYLINDOLIN-2-ONE
1440, d4eh5A_, 0.8211, 2.16, 0.375, 329, 259, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F4 AND RL87
1441, d3rtpA_, 0.8209, 2.27, 0.363, 331, 262, DESIGN AND SYNTHESIS OF BRAIN PENETRANT SELECTIVE JNK INHIBITORS WITH IMPROVED PHARMACOKINETIC PROPERTIES FOR THE PREVENTION OF NEURODEGENERATION
1442, d3fi4A_, 0.8208, 2.60, 0.383, 339, 264, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO4499
1443, d5n64A_, 0.8207, 2.22, 0.369, 329, 260, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9G
1444, d3ttjA_, 0.8207, 2.50, 0.361, 333, 266, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-359 A JNK INHIBITOR FOR THE PREVENTION OF ISCHEMIA-REPERFUSION INJURY
1445, d5n63A_, 0.8204, 2.24, 0.378, 325, 259, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9C
1446, d3zduA_, 0.8204, 2.79, 0.344, 297, 270, CRYSTAL STRUCTURE OF THE HUMAN CDKL3 KINASE DOMAIN
1447, d2ewaA_, 0.8202, 2.14, 0.382, 330, 259, DUAL BINDING MODE OF PYRIDINYLIMIDAZOLE TO MAP KINASE P38
1448, d4x21B_, 0.8200, 2.33, 0.364, 336, 264, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
1449, d3oy1A_, 0.8200, 2.48, 0.364, 329, 264, HIGHLY SELECTIVE C-JUN N-TERMINAL KINASE (JNK) 2 AND 3 INHIBITORS WITH IN VITRO CNS-LIKE PHARMACOKINETIC PROPERTIES
1450, d3oefX_, 0.8200, 2.45, 0.375, 334, 264, CRYSTAL STRUCTURE OF Y323F INACTIVE MUTANT OF P38ALPHA MAP KINASE
1451, d4l7fA1, 0.8199, 2.50, 0.356, 343, 264, CO-CRYSTAL STRUCTURE OF JNK1 AND AX13587
1452, d1pmvA_, 0.8198, 2.66, 0.362, 347, 268, THE STRUCTURE OF JNK3 IN COMPLEX WITH A DIHYDROANTHRAPYRAZOLE INHIBITOR
1453, d2zduA_, 0.8197, 2.43, 0.364, 330, 264, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
1454, p3vulA_, 0.8195, 2.35, 0.357, 344, 263, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
1455, d3iw5A_, 0.8194, 2.48, 0.365, 336, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH AN INDOLE DERIVATIVE
1456, d2ok1A_, 0.8189, 2.54, 0.362, 333, 265, CRYSTAL STRUCTURE OF JNK3 BOUND TO N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1457, d4z9lA_, 0.8185, 2.47, 0.362, 333, 265, THE STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE-PYRIMIDINE INHIBITOR
1458, d3hubA_, 0.8185, 2.37, 0.366, 335, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH SCIOS-469
1459, d1v0pB_, 0.8185, 1.92, 0.589, 258, 253, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
1460, d3lfaA_, 0.8182, 2.41, 0.360, 333, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH DASATINIB
1461, d1blxA_, 0.8182, 2.91, 0.468, 305, 269, P19INK4D/CDK6 COMPLEX
1462, d4tthB_, 0.8181, 1.64, 0.524, 256, 252, CRYSTAL STRUCTURE OF A CDK6/VCYCLIN COMPLEX WITH INHIBITOR BOUND
1463, p4h39A_, 0.8180, 2.30, 0.365, 340, 263, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH JIP1 PEPTIDE
1464, d3uvrA_, 0.8178, 2.55, 0.377, 331, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH KM064
1465, d3zsiA_, 0.8176, 2.22, 0.378, 326, 259, X-RAY STRUCTURE OF P38ALPHA BOUND TO VX-745
1466, d1g3nE_, 0.8175, 2.67, 0.479, 293, 265, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
1467, d4p41B_, 0.8172, 1.65, 0.524, 256, 252,  
1468, d1v0bB_, 0.8170, 2.13, 0.584, 261, 257, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
1469, d4geoA_, 0.8167, 2.35, 0.372, 326, 261, P38A MAP KINASE DEF-POCKET PENTA MUTANT (M194A L195A H228A I229A Y258A)
1470, d1g3nA_, 0.8167, 2.68, 0.479, 293, 265, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
1471, d3zshA_, 0.8165, 2.42, 0.367, 331, 264, X-RAY STRUCTURE OF P38ALPHA BOUND TO SCIO-469
1472, d4e6cA_, 0.8164, 2.32, 0.374, 330, 262, P38A-PERIFOSINE COMPLEX
1473, d3hucA_, 0.8164, 2.56, 0.365, 337, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL40
1474, d3uibA_, 0.8163, 2.24, 0.342, 309, 257, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR IN COMPLEX WITH SB203580
1475, p3vumA_, 0.8160, 2.29, 0.360, 347, 261, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M7 IN MAP KINASE JNK1
1476, d3fv8A_, 0.8157, 2.25, 0.369, 331, 260, JNK3 BOUND TO PIPERAZINE AMIDE INHIBITOR SR2774.
1477, d2yiwA_, 0.8157, 2.10, 0.379, 325, 256, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE
1478, d1kv2A_, 0.8157, 1.99, 0.380, 325, 255, HUMAN P38 MAP KINASE IN COMPLEX WITH BIRB 796
1479, d3l8sA_, 0.8156, 2.50, 0.366, 334, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH CP-547632
1480, d1ukhA_, 0.8155, 2.12, 0.351, 321, 259, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
1481, d2excX_, 0.8153, 2.43, 0.364, 335, 264, INHIBITOR COMPLEX OF JNK3
1482, d3fi2A_, 0.8150, 2.53, 0.367, 326, 264, CRYSTAL STRUCTURE OF JNK3 WITH AMINO-PYRAZOLE INHIBITOR SR- 3451
1483, d3oxiA_, 0.8145, 2.36, 0.366, 322, 262, DESIGN AND SYNTHESIS OF DISUBSTITUTED THIOPHENE AND THIAZOLE BASED INHIBITORS OF JNK FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
1484, d3iw8A_, 0.8142, 2.57, 0.368, 334, 266, STRUCTURE OF INACTIVE HUMAN P38 MAP KINASE IN COMPLEX WITH A THIAZOLE-UREA
1485, d3gcsA_, 0.8138, 2.46, 0.377, 331, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH SORAFENIB
1486, d1ob3B_, 0.8136, 2.08, 0.571, 258, 254, STRUCTURE OF P. FALCIPARUM PFPK5
1487, d3kvxA_, 0.8134, 2.31, 0.369, 327, 260, JNK3 BOUND TO AMINOPYRIMIDINE INHIBITOR SR-3562
1488, d2hy81_, 0.8134, 2.15, 0.301, 293, 256, PAK1 COMPLEX WITH ST2001
1489, d2yisA_, 0.8131, 2.12, 0.379, 325, 256, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE.
1490, d2b1pA_, 0.8129, 2.51, 0.357, 331, 263, INHIBITOR COMPLEX OF JNK3
1491, d4yr8C_, 0.8128, 2.33, 0.352, 318, 261, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1492, d4e5bA_, 0.8126, 2.24, 0.375, 324, 259, STRUCTURE OF P38A MAP KINASE WITHOUT BOG
1493, d4aa0A_, 0.8121, 2.31, 0.378, 328, 259, P38ALPHA MAP KINASE BOUND TO CMPD 2
1494, p3lfdA_, 0.8121, 2.62, 0.368, 331, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL113
1495, d4e6aA_, 0.8120, 2.38, 0.372, 324, 261, P38A-PIA23 COMPLEX
1496, d2baqA_, 0.8118, 2.26, 0.393, 329, 257, P38ALPHA BOUND TO RO3201195
1497, d3coiA1, 0.8117, 2.88, 0.385, 342, 270, CRYSTAL STRUCTURE OF P38DELTA KINASE
1498, d4bbmA1, 0.8105, 3.38, 0.395, 306, 276, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
1499, d3odzX_, 0.8103, 2.71, 0.367, 335, 264, CRYSTAL STRUCTURE OF P38ALPHA Y323R ACTIVE MUTANT
1500, d3q53A_, 0.8095, 2.15, 0.298, 291, 255, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN IN COMPLEX WITH ATP
1501, d2fsmX_, 0.8089, 2.34, 0.373, 326, 260, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-B
1502, d2npqA_, 0.8085, 2.35, 0.369, 326, 260, A NOVEL LIPID BINDING SITE IN THE P38 ALPHA MAP KINASE
1503, d3iw4C_, 0.8081, 2.30, 0.261, 332, 257, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1504, d2xrwA1, 0.8074, 2.36, 0.353, 346, 258, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
1505, d2fslX_, 0.8073, 2.48, 0.368, 332, 261, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-A
1506, d2r9sB_, 0.8069, 2.38, 0.363, 325, 259, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
1507, d4e5aX_, 0.8068, 2.37, 0.375, 332, 259, THE W197A MUTANT OF P38A MAP KINASE
1508, d1yhwA_, 0.8066, 2.24, 0.285, 293, 256, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH ONE POINT MUTATIONS (K299R)
1509, d3gcpA_, 0.8065, 2.60, 0.370, 337, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH SB203580
1510, d1yhvA_, 0.8065, 2.25, 0.285, 293, 256, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH TWO POINT MUTATIONS (K299R T423E)
1511, d2jedB1, 0.8064, 2.36, 0.280, 315, 257, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1512, d3zsgA_, 0.8063, 2.70, 0.365, 337, 266, X-RAY STRUCTURE OF P38ALPHA BOUND TO TAK-715
1513, d3zs5A1, 0.8063, 2.72, 0.365, 339, 266, STRUCTURAL BASIS FOR KINASE SELECTIVITY OF THREE CLINICAL P38ALPHA INHIBITORS
1514, d3ocbA_, 0.8061, 2.33, 0.273, 315, 256, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
1515, d3g33C_, 0.8061, 2.91, 0.472, 291, 265, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
1516, d2fstX_, 0.8055, 2.34, 0.375, 324, 259, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327L) ACTIVATING MUTANT
1517, d3fi3A_, 0.8054, 2.60, 0.363, 328, 262, CRYSTAL STRUCTURE OF JNK3 WITH INDAZOLE INHIBITOR SR-3737
1518, d5dfpA_, 0.8053, 2.19, 0.302, 292, 255, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND FRAX1036
1519, d4eqcA1, 0.8053, 2.22, 0.302, 292, 255, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN IN COMPLEX WITH FRAX597 INHIBITOR
1520, d3iw4B_, 0.8052, 2.32, 0.261, 325, 257, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1521, d4dawA_, 0.8048, 2.25, 0.302, 293, 255, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH THE RUTHENIUM PHTHALIMIDE COMPLEX
1522, d2r9sA_, 0.8047, 2.44, 0.363, 325, 259, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
1523, d3g33A_, 0.8044, 2.91, 0.472, 291, 265, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
1524, d4e8aA_, 0.8042, 2.39, 0.371, 327, 259, THE CRYSTAL STRUCTURE OF P38A MAP KINASE IN COMPLEX WITH PIA24
1525, d5veeA_, 0.8040, 2.31, 0.267, 289, 255, PAK4 KINASE DOMAIN IN COMPLEX WITH FRAX486
1526, d3q52A_, 0.8038, 2.23, 0.298, 292, 255, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN
1527, d3fxzA_, 0.8038, 2.24, 0.286, 292, 255, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX LAMBDA-FL172
1528, d3cqwA_, 0.8033, 2.26, 0.275, 318, 255, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1529, d3ocbB_, 0.8030, 2.30, 0.278, 319, 255, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
1530, d3iw4A_, 0.8030, 2.38, 0.261, 330, 257, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1531, d2y7jA_, 0.8022, 2.23, 0.285, 284, 253, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1532, d2jedA_, 0.8021, 2.36, 0.281, 324, 256, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1533, d2fsoX_, 0.8020, 2.34, 0.376, 325, 258, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A) ACTIVATING MUTANT
1534, d4aaaA1, 0.8017, 2.97, 0.398, 290, 269, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN
1535, d5deyA_, 0.8015, 2.32, 0.281, 295, 256, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
1536, d1u5qA_, 0.8014, 2.34, 0.272, 308, 257, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1537, d3ow4A_, 0.8013, 2.30, 0.275, 317, 255, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1538, d5ml5A_, 0.8009, 2.56, 0.368, 326, 261, HUMAN P38ALPHA MAPK IN COMPLEX WITH IMIDAZOLYL PYRIDINE INHIBITOR 11B
1539, d2jdoA_, 0.8009, 2.32, 0.275, 314, 255, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1540, d5dewA_, 0.8008, 2.32, 0.281, 295, 256, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
1541, d1u5rA_, 0.8008, 2.35, 0.272, 308, 257, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1542, d3fy0A_, 0.8005, 2.31, 0.286, 292, 255, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX DW1
1543, d2x39A_, 0.8004, 2.33, 0.278, 316, 255, STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB
1544, d2biyA_, 0.8004, 2.36, 0.270, 287, 256, STRUCTURE OF PDK1-S241A MUTANT KINASE DOMAIN
1545, d2y7jC_, 0.8003, 2.29, 0.285, 284, 253, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1546, d2gcdA_, 0.8003, 2.37, 0.272, 308, 257, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1547, d3mvhA_, 0.8000, 2.25, 0.280, 311, 254, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1548, d2i6lB_, 0.8000, 2.80, 0.323, 269, 260, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
1549, d2bajA2, 0.8000, 2.54, 0.389, 334, 257, P38ALPHA BOUND TO PYRAZOLOUREA
1550, d2ou7A_, 0.7996, 2.35, 0.246, 292, 256, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1551, d4nusA_, 0.7991, 2.59, 0.286, 301, 259, RSK2 N-TERMINAL KINASE IN COMPLEX WITH LJH685
1552, d2owbA_, 0.7990, 2.36, 0.246, 294, 256, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1553, d4j53A_, 0.7989, 2.36, 0.246, 293, 256, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH TAK-960
1554, d2gcdB_, 0.7988, 2.39, 0.272, 308, 257, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1555, d1stcE_, 0.7987, 2.34, 0.263, 334, 255, CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE
1556, d3mv5A_, 0.7979, 2.34, 0.275, 315, 255, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1557, d4q9zB_, 0.7978, 2.44, 0.277, 308, 256, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1558, d4nw5A1, 0.7978, 2.31, 0.293, 296, 256, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 8
1559, d3a8xA1, 0.7978, 2.29, 0.275, 331, 255, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1560, d5l2sA_, 0.7977, 2.24, 0.492, 263, 254, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND ABEMACICLIB.
1561, d4nw6A1, 0.7977, 2.32, 0.293, 296, 256, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 27
1562, d4b6lA_, 0.7977, 2.44, 0.265, 281, 257, DISCOVERY OF ORAL POLO-LIKE KINASE (PLK) INHIBITORS WITH ENHANCED SELECTIVITY PROFILE USING RESIDUE TARGETED DRUG DESIGN
1563, d1u5qB_, 0.7977, 2.40, 0.272, 308, 257, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1564, d2yacA_, 0.7976, 2.38, 0.246, 290, 256, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH NMS-P937
1565, d3thbA_, 0.7975, 2.36, 0.246, 287, 256, STRUCTURE OF PLK1 KINASE DOMAIN IN COMPLEX WITH A BENZOLACTAM-DERIVED INHIBITOR
1566, d5f9eB_, 0.7974, 2.43, 0.277, 293, 256, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1567, d3o7lD_, 0.7974, 2.31, 0.263, 333, 255, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
1568, d1u5rB_, 0.7973, 2.42, 0.272, 308, 257, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1569, d3pvwA2, 0.7972, 2.51, 0.252, 343, 258, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD103A)
1570, d3kb7A_, 0.7969, 2.40, 0.246, 289, 256, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1571, d3rcjA_, 0.7967, 2.37, 0.275, 281, 255, RAPID PREPARATION OF TRIAZOLYL SUBSTITUTED NH-HETEROCYCLIC KINASE INHIBITORS VIA ONE-POT SONOGASHIRA COUPLING TMS-DEPROTECTION CUAAC SEQUENCE
1572, d1bx6A_, 0.7967, 2.39, 0.263, 337, 255, CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1573, d2xh5A_, 0.7966, 2.30, 0.276, 316, 254, STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB
1574, d3nuxA_, 0.7965, 2.27, 0.488, 261, 254, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
1575, d3fc2A_, 0.7965, 2.39, 0.246, 293, 256, PLK1 IN COMPLEX WITH BI6727
1576, d2uw9A_, 0.7965, 2.40, 0.275, 316, 255, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1577, d4ra4A_, 0.7964, 2.37, 0.263, 317, 255, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE C ALPHA IN COMPLEX WITH COMPOUND 28 ((R)-6-((3S4S)-13-DIMETHYL-PIPERIDIN-4-YL)-7-(2-FLUORO- PHENYL)-4-METHYL-210-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1578, d4q9zA1, 0.7963, 2.42, 0.282, 330, 255, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1579, d4a4lA_, 0.7963, 2.39, 0.246, 290, 256, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO-PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR
1580, d5ta6A_, 0.7961, 2.40, 0.246, 294, 256, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR.
1581, d4ra5A1, 0.7961, 2.44, 0.282, 331, 255, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1582, d3ow4B_, 0.7960, 2.33, 0.280, 317, 254, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1583, d3iecA_, 0.7960, 2.23, 0.313, 311, 252, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1584, d5mrdA_, 0.7959, 2.49, 0.273, 283, 256, HUMAN PDK1-PKCIOTA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS267 BOUND TO THE PIF-POCKET
1585, d4j52A_, 0.7959, 2.41, 0.246, 293, 256, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A PYRIMIDODIAZEPINONE INHIBITOR
1586, d3iecC_, 0.7958, 2.26, 0.313, 311, 252, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1587, d5lvmA_, 0.7957, 2.49, 0.273, 283, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENINE BOUND TO THE ATP- BINDING SITE
1588, d5f9eA1, 0.7954, 2.51, 0.281, 331, 256, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1589, d3pvuA2, 0.7954, 2.55, 0.244, 340, 258, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD101)
1590, d5lvlA_, 0.7953, 2.43, 0.271, 285, 255, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND PS653 BOUND TO THE ATP-BINDING SITE
1591, d4a4oA_, 0.7953, 2.42, 0.246, 290, 256, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2- (2-AMINO-PYRIMIDIN-4-YL)-1567-TETRAHYDRO-PYRROLOPYRIDIN- 4-ONE INHIBITOR
1592, d2bujA1, 0.7953, 2.43, 0.242, 283, 256, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
1593, d1h1wA_, 0.7953, 2.44, 0.267, 284, 255, HIGH RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PDK1 CATALYTIC DOMAIN
1594, d4eklA_, 0.7952, 2.39, 0.275, 329, 255, AKT1 WITH GDC0068
1595, d3qklA_, 0.7952, 2.42, 0.275, 317, 255, SPIROCHROMANE AKT INHIBITORS
1596, d2i0eA_, 0.7952, 2.38, 0.250, 326, 256, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
1597, d3rwqA_, 0.7951, 2.45, 0.267, 283, 255, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
1598, d2rkuA_, 0.7951, 2.41, 0.246, 294, 256, STRUCTURE OF PLK1 IN COMPLEX WITH BI2536
1599, d3a8xB1, 0.7950, 2.06, 0.282, 325, 252, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1600, d2y7jB_, 0.7949, 2.43, 0.280, 281, 254, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1601, d4gv1A1, 0.7948, 2.34, 0.276, 328, 254, PKB ALPHA IN COMPLEX WITH AZD5363
1602, d1zysA_, 0.7947, 2.58, 0.265, 271, 257, CO-CRYSTAL STRUCTURE OF CHECKPOINT KINASE CHK1 WITH A PYRROLO-PYRIDINE INHIBITOR
1603, d1uvrA_, 0.7947, 2.42, 0.267, 284, 255, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-8
1604, d3hrfA_, 0.7946, 2.46, 0.271, 284, 255, CRYSTAL STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN ALLOSTERIC ACTIVATOR BOUND TO THE PIF-POCKET
1605, d3hrcA_, 0.7946, 2.53, 0.273, 279, 256, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ATP
1606, d3cquA_, 0.7946, 2.42, 0.275, 318, 255, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1607, d4rqvA_, 0.7945, 2.45, 0.267, 288, 255, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS2
1608, d2welA_, 0.7944, 2.43, 0.294, 304, 255, CRYSTAL STRUCTURE OF SU6656-BOUND CALCIUM/CALMODULIN- DEPENDENT PROTEIN KINASE II DELTA IN COMPLEX WITH CALMODULIN
1609, d1cmkE_, 0.7942, 2.41, 0.267, 348, 255, CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
1610, d5lvoA_, 0.7941, 2.52, 0.273, 285, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PSE10 BOUND TO THE PIF-POCKET
1611, d1ctpE_, 0.7940, 2.42, 0.263, 332, 255, STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
1612, d5lvnA_, 0.7939, 2.53, 0.273, 283, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENOSINE BOUND TO THE ATP- BINDING SITE
1613, d4xx9A_, 0.7939, 2.52, 0.273, 288, 256, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RF4
1614, d4rqkA_, 0.7938, 2.45, 0.267, 285, 255, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS1
1615, d3iecD_, 0.7938, 2.31, 0.313, 311, 252, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1616, d3iecB_, 0.7938, 2.27, 0.313, 313, 252, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1617, d2ydiA_, 0.7938, 2.73, 0.264, 279, 258, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
1618, d1ql6A_, 0.7938, 2.44, 0.283, 281, 254, THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES
1619, d4c2vA_, 0.7937, 2.20, 0.298, 270, 252, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
1620, d2f57A1, 0.7937, 2.46, 0.255, 290, 255, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
1621, d4ct1A_, 0.7936, 2.52, 0.277, 283, 256, HUMAN PDK1-PKCZETA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS315 BOUND TO THE PIF-POCKET
1622, d4a06A_, 0.7936, 2.38, 0.268, 282, 254, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS114 BOUND TO THE PIF-POCKET
1623, d2jdrA_, 0.7936, 2.34, 0.280, 316, 254, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A- 443654
1624, d5vedA_, 0.7935, 2.43, 0.268, 289, 254, PAK4 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1625, d3l9mA_, 0.7935, 2.38, 0.268, 338, 254, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
1626, d3d5uA_, 0.7935, 2.40, 0.258, 288, 256, CRYSTAL STRUCTURE OF A WILDTYPE POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
1627, d3a8wB1, 0.7935, 2.23, 0.273, 324, 253, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1628, d2x8dA_, 0.7934, 2.61, 0.268, 279, 257, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
1629, d4ra5B_, 0.7932, 2.42, 0.282, 310, 255, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1630, d5ta8A_, 0.7931, 2.47, 0.250, 294, 256, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR
1631, d5l2tA_, 0.7931, 2.18, 0.496, 261, 252, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND RIBOCICLIB.
1632, d3krwA2, 0.7930, 2.61, 0.264, 349, 258, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (SOAK)
1633, d4w8eA_, 0.7929, 2.40, 0.276, 290, 254, STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF-06645342)
1634, d1okyA_, 0.7929, 2.34, 0.273, 281, 253, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1635, d5ackA_, 0.7928, 2.50, 0.267, 286, 255, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND 7 BOUND TO THE PIF-POCKET
1636, d2f57B1, 0.7928, 2.40, 0.272, 293, 254, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
1637, d4qmwA_, 0.7925, 2.41, 0.252, 286, 254, MST3 IN COMPLEX WITH PP-121 1-CYCLOPENTYL-3-(1H-PYRROLO[23- B]PYRIDIN-5-YL)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
1638, d3otuA_, 0.7924, 2.52, 0.276, 276, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR JS30
1639, d1smhA_, 0.7924, 2.38, 0.264, 348, 254, PROTEIN KINASE A VARIANT COMPLEX WITH COMPLETELY ORDERED N- TERMINAL HELIX
1640, d2bcjA3, 0.7923, 2.56, 0.245, 348, 257, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GALPHA-Q AND GBETAGAMMA SUBUNITS
1641, d1szmA_, 0.7923, 2.38, 0.264, 317, 254, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
1642, d4figB_, 0.7920, 2.40, 0.268, 292, 254, CATALYTIC DOMAIN OF HUMAN PAK4
1643, d4figA_, 0.7920, 2.40, 0.268, 292, 254, CATALYTIC DOMAIN OF HUMAN PAK4
1644, d1phkA_, 0.7920, 2.46, 0.283, 277, 254, TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE SUBSTRATE-ANALOGUE AND PRODUCT
1645, d4ntsB_, 0.7919, 2.40, 0.255, 341, 255, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
1646, d2x4zA1, 0.7919, 2.46, 0.256, 289, 254, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH PF-03758309
1647, d4o0rA_, 0.7918, 2.53, 0.281, 293, 256, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1648, d3l9lA_, 0.7918, 2.40, 0.272, 338, 254, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
1649, d1zrzA_, 0.7918, 2.40, 0.275, 310, 255, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF ATYPICAL PROTEIN KINASE C-IOTA
1650, d1rejA_, 0.7918, 2.40, 0.264, 333, 254, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 1
1651, d3qkkA_, 0.7915, 2.46, 0.275, 326, 255, SPIROCHROMANE AKT INHIBITORS
1652, d3ag9B_, 0.7914, 2.40, 0.264, 317, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
1653, d2w99B_, 0.7913, 3.15, 0.474, 291, 266, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
1654, d4qmzA_, 0.7912, 2.44, 0.276, 286, 254, MST3 IN COMPLEX WITH SUNITINIB
1655, d2uw7A_, 0.7912, 2.44, 0.260, 335, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1656, d3a7iA_, 0.7911, 2.42, 0.276, 286, 254, HUMAN MST3 KINASE IN COMPLEX WITH ADENINE
1657, d2jdvA_, 0.7911, 2.45, 0.260, 334, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH A-443654
1658, d3krxA2, 0.7910, 2.63, 0.264, 349, 258, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (CO-CRYSTAL)
1659, d4o0tA_, 0.7909, 2.56, 0.281, 292, 256, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1660, d4a07A_, 0.7909, 2.43, 0.268, 282, 254, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS171 BOUND TO THE PIF-POCKET
1661, d3ztxA_, 0.7909, 2.38, 0.289, 269, 253, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
1662, d3d5wA_, 0.7909, 2.39, 0.264, 284, 254, CRYSTAL STRUCTURE OF A PHOSPHORYLATED POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH ADP.
1663, d1xh5A_, 0.7909, 2.36, 0.253, 335, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1664, d4o0vA1, 0.7908, 2.47, 0.268, 289, 254, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1665, d3a8wA1, 0.7908, 2.07, 0.279, 323, 251, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1666, d1xhaA_, 0.7908, 2.40, 0.264, 348, 254, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1667, d4qmxA_, 0.7907, 2.43, 0.252, 287, 254, MST3 IN COMPLEX WITH SARACATINIB
1668, d3db6A_, 0.7907, 2.44, 0.254, 287, 256, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 902
1669, d1xh8A_, 0.7907, 2.39, 0.264, 337, 254, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1670, d3pscA2, 0.7906, 2.45, 0.246, 344, 256, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
1671, d4hyiA_, 0.7905, 2.49, 0.267, 269, 255, X-RAY CRYSTAL STRUCTURE OF COMPOUND 40 BOUND TO HUMAN CHK1 KINASE DOMAIN
1672, d5bmsA1, 0.7904, 2.49, 0.268, 289, 254, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 4 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
1673, d4b8mA_, 0.7904, 2.30, 0.290, 270, 252, AURORA B KINASE IN COMPLEX WITH VX-680
1674, d2uztA_, 0.7904, 2.49, 0.263, 336, 255, PKA STRUCTURES OF AKT INDAZOLE-PYRIDINE INHIBITORS
1675, d2bfxA_, 0.7903, 2.38, 0.292, 269, 253, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
1676, d1j3hA_, 0.7903, 2.38, 0.260, 329, 254, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
1677, d4o0yA1, 0.7902, 2.48, 0.268, 289, 254, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1678, d2vrxA_, 0.7902, 2.37, 0.292, 268, 253, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
1679, d1svhA_, 0.7902, 2.36, 0.253, 335, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 8
1680, d5l2iA_, 0.7901, 2.32, 0.484, 260, 252, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND PALBOCICLIB.
1681, d5kbqA_, 0.7901, 2.48, 0.282, 289, 255, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
1682, d2vo0A_, 0.7901, 2.47, 0.260, 340, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
1683, d4ks8A_, 0.7900, 2.51, 0.291, 286, 254, PAK6 KINASE DOMAIN IN COMPLEX WITH SUNITINIB
1684, d3orxC_, 0.7900, 2.47, 0.273, 283, 256, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1685, d3l9mB_, 0.7900, 2.44, 0.268, 336, 254, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
1686, d2vgoA_, 0.7900, 2.30, 0.290, 268, 252, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
1687, d1bkxA_, 0.7900, 2.34, 0.253, 337, 253, A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY
1688, d4qmlA_, 0.7899, 2.45, 0.276, 280, 254, MST3 IN COMPLEX WITH AMP-PNP
1689, d3orxA_, 0.7899, 2.47, 0.273, 283, 256, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1690, d3kk8A_, 0.7899, 2.67, 0.300, 283, 257, CAMKII SUBSTRATE COMPLEX A
1691, d4jdiA_, 0.7898, 2.39, 0.269, 289, 253, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
1692, d3orxD_, 0.7898, 2.48, 0.273, 282, 256, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1693, d4ks7A_, 0.7897, 2.47, 0.276, 286, 254, PAK6 KINASE DOMAIN IN COMPLEX WITH PF-3758309
1694, d2vgpA_, 0.7897, 2.30, 0.290, 265, 252, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
1695, d1ia8A_, 0.7897, 2.60, 0.267, 272, 255, THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1
1696, d4o0xA1, 0.7896, 2.49, 0.268, 289, 254, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1697, d1uu7A_, 0.7896, 2.39, 0.269, 280, 253, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-2
1698, d2uw6A_, 0.7894, 2.43, 0.261, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (S)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1699, d4jdhA_, 0.7892, 2.40, 0.269, 289, 253, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
1700, d4crsA1, 0.7892, 2.45, 0.280, 329, 254, HUMAN PROTEIN KINASE N2 (PKN2 PRKCL2) IN COMPLEX WITH ATPGAMMAS
1701, d3orxB_, 0.7892, 2.44, 0.271, 280, 255, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1702, d1j3hB_, 0.7891, 2.41, 0.260, 327, 254, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
1703, d4qmmA_, 0.7890, 2.44, 0.272, 288, 254, MST3 IN COMPLEX WITH AT-9283 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]- 1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
1704, d2y7jD_, 0.7890, 2.39, 0.262, 281, 252, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1705, d4c2wA_, 0.7889, 2.41, 0.292, 268, 253, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
1706, d1rekA_, 0.7889, 2.42, 0.268, 336, 254, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 8
1707, d5he2A2, 0.7888, 2.50, 0.250, 353, 256, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224406
1708, d2ywpA_, 0.7888, 2.56, 0.267, 269, 255, CRYSTAL STRUCTURE OF CHK1 WITH A UREA INHIBITOR
1709, d2uw0A_, 0.7888, 2.44, 0.261, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  6-(4-(4-(4- CHLORO-PHENYL)-PIPERIDIN-4-YL)-PHENYL)-9H-PURINE
1710, d2uvyA_, 0.7888, 2.44, 0.261, 333, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH METHYL-(4-(9H- PURIN-6-YL)-BENZYL)-AMINE
1711, d4qmnA_, 0.7887, 2.47, 0.276, 283, 254, MST3 IN COMPLEX WITH BOSUTINIB
1712, d3e5aA_, 0.7887, 2.43, 0.298, 264, 252, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH VX-680 AND TPX2
1713, d2jdtA_, 0.7887, 2.46, 0.260, 334, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1714, d2fgaA_, 0.7887, 2.56, 0.267, 269, 255,  
1715, d2bfxB_, 0.7887, 2.45, 0.269, 275, 253, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
1716, d4qmyA_, 0.7886, 2.45, 0.276, 287, 254, MST3 IN COMPLEX WITH STAUROSPORINE
1717, d4qmtA_, 0.7886, 2.48, 0.272, 284, 254, MST3 IN COMPLEX WITH HESPERADIN
1718, d4qmsA_, 0.7886, 2.44, 0.276, 283, 254, MST3 IN COMPLEX WITH DASATINIB
1719, d2uw4A_, 0.7886, 2.47, 0.260, 334, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-(5-METHYL- 1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1720, d2i0eB_, 0.7886, 2.44, 0.250, 300, 256, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
1721, d5he0A2, 0.7885, 2.51, 0.262, 346, 256, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG215022
1722, d4pnkA2, 0.7885, 2.48, 0.250, 350, 256, G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GSK180736A
1723, d6aywB_, 0.7884, 2.60, 0.294, 293, 255, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1724, d4qnaA_, 0.7884, 2.46, 0.276, 284, 254, MST3 IN COMPLEX WITH 2-(46-DIAMINO-135-TRIAZIN-2-YL)PHENOL
1725, d2bfyA_, 0.7884, 2.42, 0.289, 270, 253, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
1726, d1o6kA_, 0.7884, 2.40, 0.280, 317, 254, STRUCTURE OF ACTIVATED FORM OF PKB KINASE DOMAIN S474D WITH GSK3 PEPTIDE AND AMP-PNP
1727, d5h9bA_, 0.7883, 2.49, 0.324, 269, 253, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/AMPPN
1728, d4ntsA_, 0.7883, 2.49, 0.247, 341, 255, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
1729, d4aw0A_, 0.7883, 2.59, 0.275, 283, 255, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS182 BOUND TO THE PIF-POCKET
1730, d3l9lB_, 0.7883, 2.39, 0.257, 337, 253, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
1731, d1zltA_, 0.7883, 2.48, 0.268, 272, 254, CRYSTAL STRUCTURE OF CHK1 COMPLEXED WITH A HYMENALDISINE ANALOG
1732, d1xh9A_, 0.7883, 2.40, 0.257, 336, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1733, d3qkmA_, 0.7882, 2.41, 0.276, 329, 254, SPIROCYCLIC SULFONAMIDES AS AKT INHIBITORS
1734, d2uvxA_, 0.7882, 2.49, 0.260, 335, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 7-AZAINDOLE
1735, d1ym7D3, 0.7882, 2.45, 0.246, 340, 256, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1736, d1ym7A3, 0.7882, 2.45, 0.246, 347, 256, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1737, d3agmA_, 0.7881, 2.46, 0.268, 337, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-670
1738, d2vnwA_, 0.7881, 2.45, 0.261, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)METHANAMINE
1739, d2ojfE_, 0.7881, 2.51, 0.263, 336, 255, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1740, d1ym7C3, 0.7881, 2.45, 0.246, 346, 256, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1741, d4qmuA_, 0.7880, 2.47, 0.252, 286, 254, MST3 IN COMPLEX WITH JNJ-7706621 4-({5-AMINO-1-[(26-DIFLUOROPHENYL) CARBONYL]-1H-124-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE
1742, d2e9oA_, 0.7880, 2.48, 0.268, 269, 254, STRUCTURE OF H-CHK1 COMPLEXED WITH AA582939
1743, d1ym7B3, 0.7880, 2.45, 0.246, 347, 256, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1744, d5li9A1, 0.7879, 2.38, 0.273, 328, 253, STRUCTURE OF A NUCLEOTIDE-BOUND FORM OF PKCIOTA CORE KINASE DOMAIN
1745, d2xckA_, 0.7879, 2.36, 0.267, 275, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1746, d4c2vB_, 0.7878, 2.45, 0.289, 280, 253, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
1747, d2vo3A_, 0.7878, 2.45, 0.261, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
1748, d4b8mB_, 0.7877, 2.39, 0.286, 279, 252, AURORA B KINASE IN COMPLEX WITH VX-680
1749, d1o6lA_, 0.7877, 2.41, 0.280, 316, 254, CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B (PKB-PIF CHIMERA) TERNARY COMPLEX WITH AMP-PNP AND GSK3 PEPTIDE
1750, d4otdA_, 0.7876, 2.46, 0.283, 334, 254, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN
1751, d4c2wB_, 0.7876, 2.37, 0.286, 277, 252, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
1752, d3e87B_, 0.7876, 2.43, 0.276, 321, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1753, d3e87A_, 0.7876, 2.43, 0.276, 321, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1754, d3cikA2, 0.7876, 2.52, 0.246, 347, 256, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
1755, d5li1A1, 0.7875, 2.45, 0.283, 329, 254, STRUCTURE OF A PAR3-INHIBITORY PEPTIDE BOUND TO PKCIOTA CORE KINASE DOMAIN
1756, d5he1A2, 0.7875, 2.52, 0.258, 342, 256, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224062
1757, d3dneA_, 0.7875, 2.41, 0.253, 336, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1758, d2uw3A_, 0.7875, 2.46, 0.261, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 5-METHYL-4- PHENYL-1H-PYRAZOLE
1759, d1xjdA_, 0.7875, 2.34, 0.287, 280, 251, CRYSTAL STRUCTURE OF PKC-THETA COMPLEXED WITH STAUROSPORINE AT 2A RESOLUTION
1760, d1q8wA_, 0.7875, 2.37, 0.265, 334, 253, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR FASUDIL (HA-1077)
1761, d1omwA3, 0.7875, 2.58, 0.245, 344, 257, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN G PROTEIN-COUPLED RECEPTOR KINASE 2 AND HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNITS
1762, d4ez5A_, 0.7874, 2.28, 0.494, 258, 251, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
1763, d2q0nA_, 0.7874, 2.48, 0.272, 293, 254, STRUCTURE OF HUMAN P21 ACTIVATING KINASE 4 (PAK4) IN COMPLEX WITH A CONSENSUS PEPTIDE
1764, d4yr8F_, 0.7873, 2.36, 0.369, 300, 252, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1765, d2ghgA1, 0.7873, 2.56, 0.267, 269, 255, H-CHK1 COMPLEXED WITH A431994
1766, d2aypA_, 0.7873, 2.43, 0.268, 268, 254, CRYSTAL STRUCTURE OF CHK1 WITH AN INDOL INHIBITOR
1767, d2f7xE_, 0.7872, 2.51, 0.263, 336, 255, PROTEIN KINASE A BOUND TO (S)-2-(1H-INDOL-3-YL)-1-[5-((E)-2- PYRIDIN-4-YL-VINYL)-PYRIDIN-3-YLOXYMETHYL]-ETHYLAMINE
1768, d1q61A_, 0.7872, 2.43, 0.253, 335, 253, PKA TRIPLE MUTANT MODEL OF PKB
1769, d4w8dA_, 0.7871, 2.47, 0.272, 289, 254, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06454589).
1770, d3ztxB_, 0.7870, 2.53, 0.289, 272, 253, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
1771, d3l9nA_, 0.7870, 2.45, 0.268, 332, 254, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 27
1772, d2cgxA_, 0.7870, 2.49, 0.272, 265, 254, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
1773, d2vrxB_, 0.7869, 2.52, 0.292, 274, 253, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
1774, d2oh0E_, 0.7869, 2.51, 0.263, 336, 255, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1775, d5ukmA2, 0.7868, 2.54, 0.250, 353, 256, BOVINE GRK2 IN COMPLEX WITH HUMAN GBETAGAMMA SUBUNITS AND CCG258208 (14AS)
1776, d4fijA_, 0.7868, 2.44, 0.277, 291, 253, CATALYTIC DOMAIN OF HUMAN PAK4
1777, d3mfuA_, 0.7868, 2.80, 0.305, 302, 256, CASK-4M CAM KINASE DOMAIN AMPPNP-MN2+
1778, d3e88A_, 0.7868, 2.44, 0.280, 319, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1779, d3ckxA_, 0.7868, 2.30, 0.270, 276, 252, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24) IN COMPLEX WITH STAUROSPORINE
1780, d2vnyA_, 0.7868, 2.47, 0.261, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)AMINE
1781, d2f7zE_, 0.7868, 2.48, 0.252, 336, 254, PROTEIN KINASE A BOUND TO (R)-1-(1H-INDOL-3-YLMETHYL)-2-(2- PYRIDIN-4-YL-[17]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
1782, d2brbA_, 0.7868, 2.65, 0.271, 272, 255, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1783, d5k3yA_, 0.7867, 2.43, 0.289, 267, 253, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
1784, d4i6fA_, 0.7867, 2.58, 0.240, 285, 258, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
1785, d3e88B_, 0.7867, 2.44, 0.280, 319, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1786, d2hxqA_, 0.7867, 2.63, 0.267, 272, 255, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2
1787, d5dh3B_, 0.7865, 2.46, 0.275, 283, 255, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
1788, d4qmvA_, 0.7865, 2.47, 0.272, 288, 254, MST3 IN COMPLEX WITH PF-03814735 N-{2-[(1S4R)-6-{[4- (CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1234- TETRAHYDRO-14-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE
1789, d2vgpB_, 0.7865, 2.40, 0.266, 277, 252, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
1790, d2vgoB_, 0.7865, 2.34, 0.267, 277, 251, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
1791, d2uzuE_, 0.7865, 2.52, 0.263, 336, 255, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1792, d3d0eB_, 0.7864, 2.47, 0.280, 322, 254, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1793, d2xchA_, 0.7864, 2.36, 0.275, 278, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1794, d2f7eE_, 0.7864, 2.53, 0.263, 336, 255, PKA COMPLEXED WITH (S)-2-(1H-INDOL-3-YL)-1-(5-ISOQUINOLIN-6- YL-PYRIDIN-3-YLOXYMETHYL-ETYLAMINE
1795, d3d0eA_, 0.7863, 2.47, 0.276, 322, 254, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1796, d3ambA_, 0.7863, 2.50, 0.272, 340, 254, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR VX- 680
1797, d3a7gB_, 0.7863, 2.41, 0.276, 290, 254, HUMAN MST3 KINASE
1798, d4ct2A_, 0.7861, 2.19, 0.280, 277, 250, HUMAN PDK1-PKCZETA KINASE CHIMERA
1799, d4ae6A_, 0.7861, 2.48, 0.259, 319, 255, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
1800, d3e8dB_, 0.7861, 2.46, 0.280, 317, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1801, d3e8dA_, 0.7861, 2.46, 0.280, 315, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1802, d3a7hB_, 0.7861, 2.41, 0.276, 290, 254, HUMAN MST3 KINASE IN COMPLEX WITH ATP
1803, d2vo6A_, 0.7861, 2.49, 0.261, 335, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4- CHLOROBENZYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YLAMINE
1804, d2e9uA_, 0.7861, 2.61, 0.267, 269, 255, STRUCTURE OF H-CHK1 COMPLEXED WITH A780125
1805, d2cgvA_, 0.7861, 2.44, 0.273, 264, 253, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
1806, d2gnlA_, 0.7860, 2.52, 0.276, 338, 254, PKA THREEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR H- 1152P
1807, d1xh6A_, 0.7860, 2.43, 0.253, 331, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1808, d4u8zA_, 0.7859, 2.46, 0.272, 289, 254, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06447475)
1809, d4otgA_, 0.7859, 2.38, 0.281, 322, 253, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH LESTAURTINIB
1810, d4i6bA_, 0.7859, 2.61, 0.240, 285, 258, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
1811, d3nayB_, 0.7859, 2.34, 0.279, 278, 251, PDK1 IN COMPLEX WITH INHIBITOR MP6
1812, d2gnjA_, 0.7859, 2.45, 0.265, 335, 253, PKA THREE FOLD MUTANT MODEL OF RHO-KINASE WITH Y-27632
1813, d1fotA_, 0.7859, 2.45, 0.236, 299, 254, STRUCTURE OF THE UNLIGANDED CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT FROM SACCHAROMYCES CEREVISIAE
1814, d5vefA_, 0.7858, 2.46, 0.269, 289, 253, PAK4 KINASE DOMAIN IN COMPLEX WITH FASUDIL
1815, d4o22A1, 0.7858, 2.35, 0.254, 333, 252, BINARY COMPLEX OF METAL-FREE PKAC WITH SP20.
1816, d4i6hA_, 0.7858, 2.59, 0.240, 285, 258, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE ALPHA-SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
1817, d2hxlA_, 0.7858, 2.53, 0.272, 272, 254, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1
1818, d2e9nA_, 0.7858, 2.52, 0.268, 269, 254, STRUCTURE OF H-CHK1 COMPLEXED WITH A767085
1819, d1re8A_, 0.7858, 2.48, 0.264, 337, 254, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 2
1820, d5vloB_, 0.7857, 2.63, 0.294, 293, 255, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1821, d4i5pA_, 0.7857, 2.60, 0.240, 284, 258, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
1822, d2uw5A_, 0.7857, 2.50, 0.261, 333, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (R)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1823, d2uvzA_, 0.7857, 2.48, 0.261, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH C-PHENYL-C-(4-( 9H-PURIN-6-YL)-PHENYL)-METHYLAMINE
1824, d4qmoA_, 0.7856, 2.46, 0.272, 288, 254, MST3 IN COMPLEX WITH IMIDAZOLO-OXINDOLE PKR INHIBITOR C16
1825, d4jdkA_, 0.7856, 2.40, 0.270, 288, 252, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
1826, d2c1bA_, 0.7856, 2.46, 0.253, 335, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ( 4R2S)-5 -(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2- YLMETHANESULFONYL)ISOQUINOLINE
1827, d4fihA_, 0.7855, 2.47, 0.269, 291, 253, CATALYTIC DOMAIN OF HUMAN PAK4 WITH QKFTGLPRQW PEPTIDE
1828, d3amaA_, 0.7855, 2.46, 0.261, 342, 253, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR JNJ- 7706621
1829, d2uzwE_, 0.7855, 2.48, 0.252, 336, 254, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1830, d1sveA_, 0.7855, 2.43, 0.253, 341, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 1
1831, d6aywA_, 0.7854, 2.48, 0.295, 293, 254, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1832, d2c1aA_, 0.7854, 2.51, 0.264, 335, 254, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
1833, d2br1A_, 0.7854, 2.65, 0.271, 272, 255, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1834, d1xh4A_, 0.7854, 2.40, 0.254, 334, 252, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1835, d6babD_, 0.7853, 2.64, 0.294, 291, 255, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1836, d3c0iA_, 0.7853, 2.87, 0.301, 298, 256, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P212121 FORM
1837, d3aglB_, 0.7853, 2.43, 0.269, 335, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
1838, d2uzvA_, 0.7853, 2.46, 0.264, 336, 254, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1839, d1svgA_, 0.7853, 2.43, 0.253, 338, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 4
1840, d1q62A_, 0.7853, 2.48, 0.249, 336, 253, PKA DOUBLE MUTANT MODEL OF PKB
1841, d3mfsA_, 0.7852, 2.83, 0.305, 303, 256, CASK-4M CAM KINASE DOMAIN AMPPNP
1842, d5vloA_, 0.7851, 2.49, 0.295, 290, 254, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1843, d5ho7A_, 0.7851, 2.38, 0.275, 280, 251, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1844, d3ag9A_, 0.7851, 2.49, 0.260, 323, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
1845, d4yxrA_, 0.7850, 2.46, 0.253, 334, 253, CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH INHIBITOR.
1846, d3sc1A_, 0.7850, 2.37, 0.275, 278, 251, NOVEL ISOQUINOLONE PDK1 INHIBITORS DISCOVERED THROUGH FRAGMENT-BASED LEAD DISCOVERY
1847, d3dndA_, 0.7850, 2.44, 0.253, 334, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1848, d2gdoA_, 0.7849, 2.44, 0.269, 269, 253, 4-(AMINOALKYLAMINO)-3-BENZIMIDAZOLE-QUINOLINONES AS POTENT CHK1 INHIBITORS
1849, d1xh7A_, 0.7849, 2.48, 0.265, 337, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1850, d1vebA_, 0.7848, 2.51, 0.264, 338, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 5
1851, d4aw1A_, 0.7847, 2.47, 0.270, 283, 252, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS210 BOUND TO THE PIF-POCKET
1852, d2vo7A_, 0.7847, 2.47, 0.253, 335, 253, STRUCTURE OF PKA COMPLEXED WITH 4-(4-CHLOROBENZYL)-1-(7H- PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN-4-YLAMINE
1853, d2cguA_, 0.7847, 2.46, 0.273, 263, 253, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
1854, d4jdjA_, 0.7846, 2.42, 0.270, 288, 252, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
1855, d3oogA_, 0.7846, 2.47, 0.257, 333, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH A SMALL FRAGMENT
1856, d2gnfA_, 0.7846, 2.51, 0.280, 339, 254, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH Y- 27632
1857, d1ydsE_, 0.7846, 2.45, 0.253, 334, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H8 PROTEIN KINASE INHIBITOR [N-(2-METHYLAMINO)ETHYL]-5- ISOQUINOLINESULFONAMIDE
1858, d3pooA_, 0.7845, 2.38, 0.258, 331, 252, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1859, d2qvsE_, 0.7845, 2.51, 0.259, 323, 255, CRYSTAL STRUCTURE OF TYPE IIA HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
1860, d4zy4A_, 0.7844, 2.30, 0.283, 288, 251, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
1861, d4qmqA_, 0.7844, 2.47, 0.272, 289, 254, MST3 IN COMPLEX WITH CP-673451
1862, d3a7jA_, 0.7844, 2.58, 0.252, 286, 254, HUMAN MST3 KINASE IN COMPLEX WITH MNADP
1863, d1ydrE_, 0.7844, 2.51, 0.264, 334, 254, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5- ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
1864, d5fg8A_, 0.7842, 2.55, 0.320, 269, 253, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
1865, d2gnhA_, 0.7842, 2.51, 0.280, 338, 254, PKA FIVE FOLD MUTANT MODEL OF RHO-KINASE WITH H1152P
1866, d5k3yB_, 0.7841, 2.36, 0.267, 277, 251, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
1867, d2brnA_, 0.7841, 2.59, 0.264, 268, 254, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1868, d2vn9B_, 0.7840, 2.58, 0.290, 301, 255, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
1869, d5ig1A_, 0.7839, 2.71, 0.282, 300, 255, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
1870, d4qmpA_, 0.7838, 2.50, 0.272, 289, 254, MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
1871, d2xikA_, 0.7838, 2.52, 0.277, 288, 253, STRUCTURE OF HUMAN YSK1 (YEAST SPS1-STE20-RELATED KINASE 1)
1872, d2gngA_, 0.7838, 2.51, 0.280, 338, 254, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE
1873, d2bfyB_, 0.7838, 2.45, 0.270, 278, 252, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
1874, d5he3A2, 0.7836, 2.60, 0.246, 346, 256, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224411
1875, d3c0hB_, 0.7836, 2.83, 0.297, 300, 256, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
1876, d2gu8A_, 0.7836, 2.38, 0.254, 335, 252, DISCOVERY OF 2-PYRIMIDYL-5-AMIDOTHIOPHENES AS NOVEL AND POTENT INHIBITORS FOR AKT: SYNTHESIS AND SAR STUDIES
1877, d3mfrA_, 0.7835, 2.83, 0.305, 302, 256, CASK-4M CAM KINASE DOMAIN NATIVE
1878, d2w9zB_, 0.7835, 3.23, 0.475, 287, 265, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
1879, d2vn9A_, 0.7835, 2.59, 0.290, 301, 255, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
1880, d2erzE_, 0.7835, 2.53, 0.264, 334, 254, CRYSTAL STRUCTURE OF C-AMP DEPENDENT KINASE (PKA) BOUND TO HYDROXYFASUDIL
1881, d2uw8A_, 0.7834, 2.51, 0.261, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-CHLORO- PHENYL)-2-PHENYL-ETHYLAMINE
1882, d5eykB_, 0.7832, 2.44, 0.270, 275, 252, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
1883, d4qo9B_, 0.7831, 2.59, 0.252, 285, 254, MST3 IN COMPLEX WITH DANUSERTIB
1884, d2gfcA_, 0.7830, 2.48, 0.253, 335, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1885, d3p0mA_, 0.7829, 2.48, 0.257, 335, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1886, d3e8eI_, 0.7829, 2.46, 0.253, 345, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1887, d2c3kA_, 0.7829, 2.46, 0.274, 262, 252, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
1888, d2broA_, 0.7828, 2.72, 0.267, 272, 255, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1889, d4l67A_, 0.7827, 2.62, 0.272, 289, 254, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF PAK4
1890, d3v5wA2, 0.7827, 2.62, 0.246, 355, 256, HUMAN G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH SOLUBLE GBETAGAMMA SUBUNITS AND PAROXETINE
1891, d2gniA_, 0.7827, 2.47, 0.269, 338, 253, PKA FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR FASUDIL (HA1077)
1892, d5dh3A_, 0.7826, 2.54, 0.275, 287, 255, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
1893, d3o7lB_, 0.7826, 2.46, 0.245, 326, 253, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
1894, d3nayA_, 0.7826, 2.39, 0.275, 278, 251, PDK1 IN COMPLEX WITH INHIBITOR MP6
1895, d3c0hA_, 0.7825, 2.89, 0.297, 300, 256, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
1896, d1ydtE_, 0.7825, 2.48, 0.253, 334, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2- (4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE
1897, d4ewhB_, 0.7823, 2.48, 0.252, 273, 254, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
1898, d4bbmB1, 0.7823, 3.10, 0.408, 288, 260, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
1899, d3mftA_, 0.7823, 3.02, 0.298, 302, 258, CASK-4M CAM KINASE DOMAIN MN2+
1900, d2e9vA_, 0.7823, 2.55, 0.268, 268, 254, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
1901, d4ewhA_, 0.7822, 2.48, 0.252, 274, 254, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
1902, d3e8cD_, 0.7822, 2.54, 0.264, 344, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1903, d1q8uA_, 0.7822, 2.54, 0.264, 341, 254, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR H-1152P
1904, d5uklA2, 0.7821, 2.54, 0.247, 353, 255, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG222886 (14BD)
1905, d3nx8A_, 0.7821, 2.55, 0.268, 333, 254, HUMAN CAMP DEPENDENT PROTEIN KINASE IN COMPLEX WITH PHENOL
1906, d3e8cF_, 0.7821, 2.54, 0.264, 341, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1907, d1jluE_, 0.7821, 2.49, 0.253, 337, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PHOSPHORYLATED SUBSTRATE PEPTIDE AND DETERGENT
1908, d3e8cE_, 0.7820, 2.54, 0.264, 336, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1909, d3e8cC_, 0.7820, 2.55, 0.264, 341, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1910, d3e8cB_, 0.7820, 2.54, 0.264, 344, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1911, d3e8cA_, 0.7820, 2.55, 0.264, 341, 254, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1912, d2cgwA_, 0.7820, 2.44, 0.270, 262, 252, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
1913, d1q8tA_, 0.7820, 2.49, 0.253, 338, 253, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH RHO-KINASE INHIBITOR Y-27632
1914, d1jbpE_, 0.7820, 2.48, 0.253, 339, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE COMPLEXED WITH A SUBSTRATE PEPTIDE ADP AND DETERGENT
1915, d4ae9A_, 0.7819, 2.49, 0.264, 321, 254, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
1916, d3rwpA_, 0.7819, 2.42, 0.272, 277, 250, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
1917, d3iopA_, 0.7819, 2.39, 0.272, 275, 250, PDK-1 IN COMPLEX WITH THE INHIBITOR COMPOUND-8I
1918, d5jznB_, 0.7818, 2.20, 0.296, 266, 247, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
1919, d5hngA_, 0.7818, 2.44, 0.271, 280, 251, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1920, d4auaA_, 0.7818, 2.19, 0.498, 256, 249, LIGANDED X-RAY CRYSTAL STRUCTURE OF CYCLIN DEPENDENT KINASE 6 (CDK6)
1921, d3tnqB_, 0.7818, 2.53, 0.265, 331, 253, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1922, d3oxtA_, 0.7818, 2.34, 0.263, 335, 251, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1923, d2cdzA_, 0.7818, 2.52, 0.270, 289, 252, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A
1924, d5i0bA_, 0.7815, 2.41, 0.271, 288, 251, STRUCTURE OF PAK4
1925, d3nusA_, 0.7815, 2.30, 0.273, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT8
1926, d3mvjE_, 0.7815, 2.53, 0.268, 334, 254, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
1927, d2c30A_, 0.7815, 2.73, 0.259, 289, 255, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 6
1928, d5oq5A_, 0.7814, 2.46, 0.270, 265, 252, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
1929, d4fsnA_, 0.7814, 2.48, 0.271, 270, 251, CRYSTAL STRUCTURE OF THE CHK1
1930, d3idbA_, 0.7813, 2.51, 0.253, 341, 253, CRYSTAL STRUCTURE OF (108-268)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
1931, d1okzA_, 0.7813, 2.29, 0.273, 276, 249, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH UCN-01
1932, d4wbbB_, 0.7812, 2.53, 0.265, 334, 253, SINGLE TURNOVER AUTOPHOSPHORYLATION CYCLE OF THE PKA RIIB HOLOENZYME
1933, d3nuuA_, 0.7812, 2.30, 0.273, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT11
1934, d4appA1, 0.7811, 2.54, 0.257, 290, 253, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH (S)-N-(5-(3-BENZYL-1-METHYLPIPERAZINE-4- CARBONYL)-66-DIMETHYL-1456-TETRAHYDROPYRROLO(34-C) PYRAZOL-3-YL)-3-PHENOXYBENZAMIDE
1935, d3nuyA_, 0.7811, 2.31, 0.273, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT17
1936, d3h9oA_, 0.7811, 2.41, 0.272, 275, 250, PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK-1) IN COMPLEX WITH COMPOUND 9
1937, d2qurA_, 0.7811, 2.48, 0.253, 338, 253, CRYSTAL STRUCTURE OF F327A/K285P MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
1938, d2hz4A_, 0.7810, 2.52, 0.226, 262, 252, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
1939, d4qyeA_, 0.7809, 2.50, 0.271, 271, 251, CHK1 KINASE DOMAIN IN COMPLEX WITH DIARYLPYRAZINE COMPOUND 1
1940, d2e9vB_, 0.7809, 2.56, 0.268, 268, 254, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
1941, d4rvkA_, 0.7808, 2.38, 0.272, 264, 250, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 8: N-[3-(6-CYANO-9H- PYRROLO[23-B:54-C ]DIPYRIDIN-3-YL)PHENYL]ACETAMIDE
1942, d1q24A_, 0.7808, 2.53, 0.249, 335, 253, PKA DOUBLE MUTANT MODEL OF PKB IN COMPLEX WITH MGATP
1943, d3ow3A_, 0.7807, 2.42, 0.254, 334, 252, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1944, d1eh4B_, 0.7807, 2.55, 0.180, 293, 256, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
1945, d5ho8A_, 0.7806, 2.30, 0.273, 278, 249, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1946, d3orzB_, 0.7806, 2.49, 0.275, 278, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
1947, d3nunA_, 0.7806, 2.34, 0.273, 278, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH LEAD COMPOUND
1948, d3e8eP_, 0.7806, 2.51, 0.253, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1949, d1sykB_, 0.7806, 2.55, 0.252, 323, 254, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
1950, d1sykA_, 0.7806, 2.55, 0.252, 348, 254, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
1951, d3orzD_, 0.7805, 2.49, 0.275, 278, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
1952, d4j96B_, 0.7804, 2.81, 0.235, 305, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
1953, d1uu8A_, 0.7804, 2.30, 0.277, 277, 249, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-1
1954, d2bdwB_, 0.7803, 2.69, 0.297, 309, 256, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
1955, d3qd3A_, 0.7802, 2.34, 0.273, 278, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL {(3R6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE
1956, d2v7oA1, 0.7802, 2.68, 0.302, 297, 255, CRYSTAL STRUCTURE OF HUMAN CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II GAMMA
1957, d1nvsA_, 0.7802, 2.39, 0.272, 264, 250, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/SB218078
1958, d5ui0B_, 0.7801, 2.81, 0.231, 304, 255, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
1959, d2jdsA_, 0.7801, 2.48, 0.254, 334, 252, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A- 443654
1960, d3c0gB_, 0.7800, 2.87, 0.294, 320, 255, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
1961, d3bhhB1, 0.7800, 2.74, 0.314, 288, 255, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
1962, d1nvrA_, 0.7800, 2.40, 0.272, 264, 250, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/STAUROSPORINE
1963, d4qyfA_, 0.7799, 2.40, 0.272, 269, 250, CHK1 KINASE DOMAIN IN COMPLEX WITH AMINOPYRAZINE COMPOUND 13
1964, d3qcqA_, 0.7799, 2.35, 0.273, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-(3- AMINO-1H-INDAZOL-6-YL)-N4-ETHYL-24-PYRIMIDINEDIAMINE
1965, d3odyX_, 0.7799, 2.82, 0.373, 321, 255, CRYSTAL STRUCTURE OF P38ALPHA Y323Q ACTIVE MUTANT
1966, d2brmA_, 0.7799, 2.56, 0.261, 263, 253, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1967, d3nupA_, 0.7798, 2.21, 0.492, 252, 248, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
1968, d3c0gA_, 0.7798, 2.88, 0.294, 309, 255, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
1969, d3fjqE_, 0.7797, 2.54, 0.253, 334, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA IN COMPLEX WITH PEPTIDE INHIBITOR PKI ALPHA (6-25)
1970, d1nvqA_, 0.7797, 2.40, 0.272, 264, 250, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/UCN-01
1971, d4njdA1, 0.7796, 2.66, 0.268, 289, 254, STRUCTURE OF P21-ACTIVATED KINASE 4 WITH A NOVEL INHIBITOR KY-04031
1972, d3qcxA_, 0.7796, 2.35, 0.273, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-{2- AMINO-6-[(3R)-3-METHYL-4-MORPHOLINYL]-4-PYRIMIDINYL}-1H-INDAZOL-3- AMINE
1973, d6babB_, 0.7795, 2.64, 0.300, 285, 253, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1974, d3qcsA_, 0.7795, 2.36, 0.273, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-[2- AMINO-6-(4-MORPHOLINYL)-4-PYRIMIDINYL]-1H-INDAZOL-3-AMINE
1975, d3f3zA_, 0.7795, 2.54, 0.262, 271, 252, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840 IN PRESENCE OF INDIRUBIN E804
1976, d6b16A_, 0.7794, 2.28, 0.285, 285, 249, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
1977, d5jznA_, 0.7793, 2.23, 0.287, 268, 247, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
1978, d4ft9A_, 0.7793, 2.41, 0.272, 270, 250, CRYSTAL STRUCTURE OF THE CHK1
1979, d3dlsA_, 0.7793, 2.50, 0.258, 285, 252, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
1980, d1fmoE_, 0.7793, 2.53, 0.253, 336, 253, CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE
1981, d4o21A_, 0.7792, 2.50, 0.254, 333, 252, PRODUCT COMPLEX OF METAL-FREE PKAC ATP-GAMMA-S AND SP20.
1982, d1apmE_, 0.7792, 2.53, 0.253, 338, 253, 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT
1983, d4j7bA_, 0.7791, 2.33, 0.269, 284, 249, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
1984, d3eqrB_, 0.7791, 2.37, 0.251, 271, 251, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
1985, d2qhmA_, 0.7791, 2.41, 0.272, 268, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2A
1986, d5oorA_, 0.7790, 2.34, 0.269, 273, 249, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH STAUROSPORINE
1987, d3e8eE_, 0.7790, 2.51, 0.253, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1988, d4xliB_, 0.7789, 2.49, 0.226, 264, 252, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
1989, d3tkiA_, 0.7789, 2.52, 0.271, 272, 251, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S25
1990, d3qamE_, 0.7789, 2.55, 0.249, 348, 253, CRYSTAL STRUCTURE OF GLU208ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1991, d3e8eA_, 0.7789, 2.54, 0.253, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1992, d1atpE_, 0.7788, 2.54, 0.253, 334, 253, 2.2 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH MNATP AND A PEPTIDE INHIBITOR
1993, d3gu5A1, 0.7787, 2.48, 0.262, 276, 252, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP-MG2+
1994, d3e8eB_, 0.7787, 2.53, 0.253, 337, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1995, d4j98B_, 0.7786, 2.56, 0.242, 304, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
1996, d3ionA_, 0.7786, 2.41, 0.273, 274, 249, PDK1 IN COMPLEX WITH COMPOUND 8H
1997, d4ftiA_, 0.7785, 2.54, 0.271, 270, 251, CRYSTAL STRUCTURE OF THE CHK1
1998, d2z8cA1, 0.7785, 2.72, 0.197, 297, 254, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN-2- YL]AMINO}PHENYL)ACETIC ACID
1999, d3w2qA1, 0.7783, 2.76, 0.198, 306, 257, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH HKI-272
2000, d2c3jA_, 0.7783, 2.40, 0.268, 257, 250, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
2001, d1uu3A_, 0.7783, 2.40, 0.273, 276, 249, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH LY333531
2002, d1rdqE_, 0.7783, 2.46, 0.250, 340, 252, HYDROLYSIS OF ATP IN THE CRYSTAL OF Y204A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
2003, d4zy6A_, 0.7782, 2.24, 0.286, 284, 248, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
2004, d4rvmA_, 0.7782, 2.42, 0.272, 264, 250, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 19
2005, d4qo9A_, 0.7782, 2.57, 0.277, 280, 253, MST3 IN COMPLEX WITH DANUSERTIB
2006, d4hyhA_, 0.7782, 2.38, 0.272, 263, 250, X-RAY CRYSTAL STRUCTURE OF COMPOUND 39 BOUND TO HUMAN CHK1 KINASE DOMAIN
2007, d5jzjA_, 0.7781, 2.23, 0.285, 271, 246, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
2008, d3ue4B_, 0.7780, 2.63, 0.217, 268, 253, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
2009, d3qcyA_, 0.7780, 2.31, 0.274, 275, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 4-[2- AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-N-PHENYL-2- MORPHOLINECARBOXAMIDE
2010, d3orzC_, 0.7779, 2.50, 0.272, 276, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2011, d3orzA_, 0.7779, 2.51, 0.272, 276, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2012, d2cpkE_, 0.7779, 2.52, 0.254, 333, 252, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE
2013, d3orxE_, 0.7778, 2.38, 0.276, 274, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2014, d2r7bA_, 0.7778, 2.39, 0.273, 274, 249, CRYSTAL STRUCTURE OF THE PHOSPHOINOSITIDE-DEPENDENT KINASE- 1 (PDK-1)CATALYTIC DOMAIN BOUND TO A DIBENZONAPHTHYRIDINE INHIBITOR
2015, d2hogA_, 0.7778, 2.43, 0.272, 272, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 20
2016, d2eb2A_, 0.7778, 2.73, 0.195, 305, 256, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (G719S)
2017, d1uu9A_, 0.7778, 2.38, 0.273, 276, 249, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-3
2018, d3bhhA1, 0.7777, 2.78, 0.318, 287, 255, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2019, d2qhnA_, 0.7777, 2.43, 0.272, 268, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1A
2020, d2hy0A_, 0.7777, 2.44, 0.272, 272, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 22
2021, d4j7bD_, 0.7776, 2.34, 0.270, 281, 248, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
2022, d4ftuA_, 0.7776, 2.50, 0.272, 270, 250, CRYSTAL STRUCTURE OF THE CHK1
2023, d3e8eL_, 0.7776, 2.53, 0.253, 336, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2024, d2f4jA_, 0.7776, 2.68, 0.228, 287, 254, STRUCTURE OF THE KINASE DOMAIN OF AN IMATINIB-RESISTANT ABL MUTANT IN COMPLEX WITH THE AURORA KINASE INHIBITOR VX-680
2025, d5xdkA_, 0.7774, 2.75, 0.199, 307, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH CO-1686
2026, d5oopA_, 0.7774, 2.38, 0.264, 261, 250, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMP-PNP
2027, d4rvlA_, 0.7773, 2.38, 0.273, 258, 249, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 7: 3-(2- HYDROXYPHENYL)-9H-PYRROLO[23-B:54-C ]DIPYRIDINE-6-CARBONITRILE
2028, d3mvjB_, 0.7773, 2.59, 0.260, 320, 254, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
2029, d2pe2A_, 0.7773, 2.43, 0.273, 275, 249, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-OXO-5-UREIDO-12-DIHYDRO-INDOL-(3Z)-YLIDENEMETHYL]-1H- PYRROL-3-YL}-N-(2-PIPERIDIN-1-YL-ETHYL)-BENZAMIDE COMPLEX
2030, d2pe0A_, 0.7773, 2.42, 0.273, 275, 249, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-HYDROXY-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-13-DIHYDRO- INDOL-2-ONE COMPLEX
2031, d1jksA_, 0.7773, 2.50, 0.262, 280, 252, 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2032, d1jkkA_, 0.7773, 2.50, 0.262, 277, 252, 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.
2033, d4x6rA_, 0.7772, 2.57, 0.265, 347, 253, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
2034, d3qalE_, 0.7772, 2.58, 0.249, 339, 253, CRYSTAL STRUCTURE OF ARG280ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
2035, d3gu4A1, 0.7771, 2.50, 0.262, 276, 252, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP
2036, d1ig1A_, 0.7771, 2.51, 0.262, 280, 252, 1.8A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MN.
2037, d4ft5A_, 0.7769, 2.51, 0.272, 265, 250, CRYSTAL STRUCTURE OF THE CHK1
2038, d4fsrA_, 0.7769, 2.44, 0.272, 269, 250, CRYSTAL STRUCTURE OF THE CHK1
2039, d5ui0A_, 0.7768, 2.65, 0.237, 301, 253, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
2040, d3nlbA_, 0.7768, 2.53, 0.271, 261, 251, NOVEL KINASE PROFILE HIGHLIGHTS THE TEMPORAL BASIS OF CONTEXT DEPENDENT CHECKPOINT PATHWAYS TO CELL DEATH
2041, d1u7eA_, 0.7768, 2.58, 0.253, 338, 253,  
2042, d1jklA_, 0.7768, 2.51, 0.262, 280, 252, 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE
2043, d5uyjA1, 0.7767, 2.46, 0.284, 279, 250, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2044, d2c3lA_, 0.7767, 2.48, 0.272, 265, 250, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
2045, d5hkmA_, 0.7766, 2.32, 0.274, 272, 248, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2046, d3orxG_, 0.7766, 2.35, 0.277, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2047, d3orxF_, 0.7766, 2.35, 0.277, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2048, d4twpB_, 0.7765, 2.62, 0.225, 271, 253, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
2049, d3fhiA_, 0.7765, 2.58, 0.253, 336, 253, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE CATALYTIC AND REGULATORY (RI{ALPHA}) SUBUNITS OF PKA
2050, d5ukkA2, 0.7764, 2.68, 0.258, 348, 256, HUMAN GRK2 IN COMPLEX WITH HUMAN G-BETA-GAMMA SUBUNITS AND CCG211998 (14AK)
2051, d5e8xA_, 0.7764, 2.69, 0.217, 304, 253, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F) IN COMPLEX WITH STAUROSPORINE
2052, d3orxH_, 0.7764, 2.35, 0.277, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2053, d3ha6A1, 0.7764, 2.34, 0.298, 262, 248, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH TPX2 AND COMPOUND 10
2054, d3dfcB1, 0.7764, 2.50, 0.262, 276, 252, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH AMPPNP
2055, d3comA_, 0.7764, 2.48, 0.281, 264, 253, CRYSTAL STRUCTURE OF MST1 KINASE
2056, d1z5mA_, 0.7764, 2.44, 0.273, 275, 249, CRYSTAL STRUCTURE OF N1-[3-[[5-BROMO-2-[[3-[(1-PYRROLIDINYLCARBONYL) AMINO]PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PROPYL]-22- DIMETHYLPROPANEDIAMIDE COMPLEXED WITH HUMAN PDK1
2057, d4j96A_, 0.7763, 2.86, 0.235, 302, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
2058, d4i23A_, 0.7763, 2.72, 0.196, 304, 255, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH DACOMITINIB (SOAKED)
2059, d3gu7A1, 0.7762, 2.52, 0.262, 276, 252, CRYSTAL STRUCTURE OF DAPKQ23V-ADP-MG2+
2060, d3d5xA_, 0.7762, 2.31, 0.257, 279, 249, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH WORTMANNIN.
2061, d5ugbA_, 0.7761, 2.62, 0.201, 307, 254, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN IN COMPLEX WITH 4-(4-{[2- {[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9-(PROPAN-2-YL)-9H-PURIN-6- YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
2062, d4j97D_, 0.7761, 2.60, 0.242, 285, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
2063, d4ae6B_, 0.7761, 2.64, 0.260, 321, 254, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
2064, d3a7gA_, 0.7760, 2.66, 0.276, 289, 254, HUMAN MST3 KINASE
2065, d4zy5A_, 0.7759, 2.29, 0.286, 283, 248, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
2066, d4qygB_, 0.7759, 2.45, 0.272, 264, 250, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
2067, d4ft7A_, 0.7759, 2.42, 0.273, 270, 249, CRYSTAL STRUCTURE OF THE CHK1
2068, d3ot3A_, 0.7759, 2.43, 0.273, 259, 249, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22K BOUND TO HUMAN CHK1 KINASE DOMAIN
2069, d3lcdA_, 0.7759, 2.49, 0.214, 290, 252, INHIBITOR BOUND TO A DFG-IN STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
2070, d3dlsD_, 0.7759, 2.44, 0.252, 284, 250, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2071, d3dgkA1, 0.7759, 2.52, 0.262, 276, 252, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN
2072, d1m52B_, 0.7759, 2.44, 0.219, 272, 251, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
2073, d5op7A_, 0.7758, 2.34, 0.265, 261, 249, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
2074, d4qyhB_, 0.7758, 2.45, 0.272, 264, 250, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
2075, d2r0uA_, 0.7758, 2.46, 0.272, 269, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 54
2076, d2qcsA_, 0.7758, 2.55, 0.254, 335, 252, A COMPLEX STRUCTURE BETWEEN THE CATALYTIC AND REGULATORY SUBUNIT OF PROTEIN KINASE A THAT REPRESENTS THE INHIBITED STATE
2077, d5eykA_, 0.7757, 2.40, 0.297, 263, 249, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
2078, d4j97A_, 0.7757, 2.60, 0.242, 282, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
2079, d4pf4A1, 0.7756, 2.53, 0.262, 277, 252, 1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1 AA 1-277
2080, d4fszA_, 0.7756, 2.53, 0.272, 268, 250, CRYSTAL STRUCTURE OF THE CHK1
2081, d3mvjA_, 0.7756, 2.59, 0.257, 334, 253, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
2082, d3gu6A1, 0.7756, 2.53, 0.262, 276, 252, CRYSTAL STRUCTURE OF DAPKQ23V-ADP
2083, d2x7fB_, 0.7756, 2.26, 0.254, 288, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2084, d2w4jA_, 0.7756, 2.54, 0.262, 276, 252, X-RAY STRUCTURE OF A DAP-KINASE 2-277
2085, d4xeyA_, 0.7755, 2.44, 0.219, 269, 251, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
2086, d4j98A_, 0.7755, 2.73, 0.241, 304, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
2087, d3w2oA1, 0.7755, 2.83, 0.198, 304, 257, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH TAK-285
2088, d4x6qC_, 0.7754, 2.53, 0.254, 334, 252, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
2089, d2x7fC_, 0.7754, 2.12, 0.252, 285, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2090, d2phkA_, 0.7754, 2.61, 0.285, 277, 253, THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION
2091, d1eh4A_, 0.7754, 2.61, 0.184, 293, 256, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
2092, d3comB_, 0.7753, 2.57, 0.271, 279, 255, CRYSTAL STRUCTURE OF MST1 KINASE
2093, d2xynC_, 0.7753, 2.39, 0.224, 262, 250, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
2094, d4qygA_, 0.7752, 2.49, 0.272, 264, 250, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
2095, d3tnpF_, 0.7752, 2.53, 0.254, 334, 252, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2096, d3tnpC_, 0.7752, 2.53, 0.254, 334, 252, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2097, d3up2A_, 0.7750, 2.42, 0.296, 266, 250, AURORA A IN COMPLEX WITH RPM1686
2098, d3a7hA_, 0.7750, 2.69, 0.260, 289, 254, HUMAN MST3 KINASE IN COMPLEX WITH ATP
2099, d1cdkB_, 0.7750, 2.49, 0.258, 342, 252, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
2100, d5ootA_, 0.7749, 2.32, 0.266, 260, 248, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
2101, d4j99B_, 0.7749, 2.68, 0.245, 291, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
2102, d4j97C_, 0.7749, 2.61, 0.242, 283, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
2103, d4j95B_, 0.7749, 2.62, 0.242, 282, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
2104, d4j97B_, 0.7748, 2.73, 0.241, 283, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
2105, d3gu8A1, 0.7747, 2.53, 0.262, 276, 252, CRYSTAL STRUCTURE OF DAPKL93G WITH N6-CYCLOPENTYLADENOSINE
2106, d3eqrA_, 0.7746, 2.53, 0.251, 270, 251, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
2107, d3a7fA_, 0.7746, 2.46, 0.272, 283, 250, HUMAN MST3 KINASE
2108, d4b4lA_, 0.7745, 2.77, 0.251, 299, 255, CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT
2109, d3uodA_, 0.7745, 2.34, 0.297, 266, 249, AURORA A IN COMPLEX WITH RPM1693
2110, d2v7aB_, 0.7745, 2.62, 0.229, 268, 253, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
2111, d2pe1A_, 0.7745, 2.46, 0.273, 275, 249, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-OXO-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-23-DIHYDRO-1H- INDOL-5-YL}-UREA {BX-517} COMPLEX
2112, d1rqqB_, 0.7745, 2.86, 0.204, 294, 255, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
2113, d4fzaB1, 0.7744, 2.72, 0.256, 280, 254, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX
2114, d1m52A_, 0.7744, 2.47, 0.223, 271, 251, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
2115, d5opvA_, 0.7743, 2.38, 0.266, 261, 248, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
2116, d5em8A_, 0.7743, 2.69, 0.197, 303, 254, EGFR KINASE DOMAIN WITH PYRIDONE COMPOUND 13: 4-[(2-METHOXYPHENYL) AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2-OXIDANYLIDENE-1~{H}- PYRIDINE-3-CARBOXAMIDE
2117, d2e9pA_, 0.7743, 2.80, 0.268, 269, 254, STRUCTURE OF H-CHK1 COMPLEXED WITH A771129
2118, d3bwjA_, 0.7742, 2.58, 0.254, 338, 252, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR LEAD COMPOUND ARC-1034
2119, d4qyhA_, 0.7741, 2.51, 0.272, 264, 250, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
2120, d3qd4A_, 0.7741, 2.34, 0.271, 276, 247, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL{(3R5R)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-5-METHYL-3-PIPERIDINYL}CARBAMATE
2121, d3nsvC_, 0.7741, 2.41, 0.224, 262, 250,  
2122, d4ft3A_, 0.7740, 2.34, 0.274, 269, 248, CRYSTAL STRUCTURE OF THE CHK1
2123, d3jvrA_, 0.7740, 2.33, 0.271, 258, 247, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
2124, d3ehaA1, 0.7740, 2.49, 0.263, 275, 251, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH AMPPNP
2125, d3bu6A_, 0.7740, 2.81, 0.201, 294, 254, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PHOSPHOPEPTIDE
2126, d2gs6A2, 0.7740, 2.66, 0.197, 308, 254, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AN ATP ANALOG-PEPTIDE CONJUGATE
2127, d2gqgB1, 0.7740, 2.66, 0.226, 270, 252, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
2128, d3c4eB_, 0.7739, 2.39, 0.265, 273, 249, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2129, d1l3rE_, 0.7739, 2.36, 0.256, 338, 250, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
2130, d4hnfB_, 0.7738, 2.67, 0.187, 290, 256, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
2131, d3w2pA1, 0.7738, 2.81, 0.198, 307, 257, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 2
2132, d2v7aA_, 0.7738, 2.61, 0.226, 269, 252, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
2133, d5w4wB_, 0.7737, 2.73, 0.176, 291, 256, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2134, d5auyA_, 0.7737, 2.49, 0.263, 275, 251, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH MORIN.
2135, d3c4eA_, 0.7737, 2.39, 0.265, 273, 249, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2136, d5jzjB_, 0.7735, 2.07, 0.296, 261, 243, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
2137, d5uy6A1, 0.7734, 2.45, 0.289, 280, 249, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2138, d5av3A_, 0.7734, 2.52, 0.263, 275, 251, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF IODIDE IONS.
2139, d5flfB_, 0.7733, 2.71, 0.242, 292, 252, DISEASE LINKED MUTATION IN FGFR
2140, d5eg3A_, 0.7733, 2.76, 0.235, 301, 255, CRYSTAL STRUCTURE OF THE ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH THE CSH2 DOMAIN OF PHOSPHOLIPASE C GAMMA (PLCGAMMA)
2141, d5xgnA_, 0.7732, 2.66, 0.206, 302, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
2142, d4yo4A1, 0.7732, 2.57, 0.262, 276, 252, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT PHTHALAZINE
2143, d2xuuA_, 0.7732, 2.68, 0.252, 301, 254, CRYSTAL STRUCTURE OF A DAP-KINASE 1 MUTANT
2144, d4btkA_, 0.7731, 2.71, 0.191, 287, 257, TTBK1 IN COMPLEX WITH INHIBITOR
2145, d4j99C_, 0.7730, 2.75, 0.245, 291, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
2146, d4ft0A_, 0.7730, 2.40, 0.274, 266, 248, CRYSTAL STRUCTURE OF THE CHK1
2147, d4fsyA_, 0.7730, 2.53, 0.277, 267, 249, CRYSTAL STRUCTURE OF THE CHK1
2148, d4deaA_, 0.7730, 2.34, 0.297, 266, 249, AURORA A IN COMPLEX WITH YL1-038-18
2149, d3ue4A_, 0.7730, 2.53, 0.219, 270, 251, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
2150, d3dlsF_, 0.7730, 2.21, 0.255, 281, 247, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2151, d3dlsC_, 0.7730, 2.44, 0.261, 281, 249, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2152, d2ivsA_, 0.7730, 2.67, 0.238, 284, 252, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
2153, d2g2hB_, 0.7730, 2.74, 0.213, 272, 253, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2154, d1szmB_, 0.7730, 2.79, 0.240, 320, 254, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
2155, d5w4wA_, 0.7729, 2.74, 0.176, 291, 256, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2156, d3dlsE_, 0.7729, 2.24, 0.262, 282, 248, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2157, d5av2A_, 0.7728, 2.53, 0.263, 275, 251, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2158, d4yc8B_, 0.7728, 2.51, 0.220, 264, 250, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
2159, d4fttA_, 0.7728, 2.42, 0.274, 266, 248, CRYSTAL STRUCTURE OF THE CHK1
2160, d3uzpA_, 0.7728, 2.71, 0.195, 292, 256, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
2161, d3f5uA1, 0.7728, 2.52, 0.259, 275, 251, CRYSTAL STRUCTURE OF THE DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH AMPPNP AND MG2+
2162, d2gs2A_, 0.7728, 2.72, 0.197, 305, 254, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN
2163, d5auvA_, 0.7727, 2.52, 0.263, 275, 251, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH APIGENIN.
2164, d3qd0A_, 0.7727, 2.37, 0.271, 274, 247, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH (2R5S)- 1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-N- PHENYL-3-PIPERIDINECARBOXAMIDE
2165, d6brcA1, 0.7726, 2.41, 0.286, 263, 248, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
2166, d5op5A_, 0.7726, 2.30, 0.267, 259, 247, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
2167, d5av1A_, 0.7726, 2.52, 0.263, 275, 251, CRYSTAL STRUCTURE OF DAPK1 IN THE PRESENCE OF BROMIDE IONS.
2168, d2wmvA_, 0.7726, 2.27, 0.272, 251, 246, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2169, d5flfA_, 0.7725, 2.69, 0.242, 296, 252, DISEASE LINKED MUTATION IN FGFR
2170, d4u45A_, 0.7725, 2.51, 0.259, 289, 251, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
2171, d3f5gA1, 0.7725, 2.53, 0.263, 275, 251, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH ADP AND MG2+
2172, d2j0iA_, 0.7725, 2.59, 0.274, 289, 252, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
2173, d5hibA_, 0.7724, 2.72, 0.189, 314, 254, EGFR KINASE DOMAIN MUTANT TMLR WITH A PYRAZOLOPYRIMIDINE INHIBITOR
2174, d4ypdA1, 0.7724, 2.59, 0.262, 276, 252, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT 4-METHYLPYRIDAZINE
2175, d3zh8C_, 0.7724, 2.66, 0.283, 312, 254, A NOVEL SMALL MOLECULE APKC INHIBITOR
2176, d2yexA_, 0.7724, 2.79, 0.263, 269, 255, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
2177, d2pvyD_, 0.7724, 2.72, 0.238, 283, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
2178, d1kobA_, 0.7724, 2.95, 0.237, 352, 257, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
2179, d5flfC_, 0.7723, 2.80, 0.237, 283, 253, DISEASE LINKED MUTATION IN FGFR
2180, d5c1qB_, 0.7723, 2.42, 0.269, 273, 249, SERINE/THREONINE-PROTEIN KINASE PIM-1
2181, d2bvaB_, 0.7723, 2.26, 0.258, 274, 248, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
2182, d1xwsA_, 0.7722, 2.40, 0.265, 273, 249, CRYSTAL STRUCTURE OF THE HUMAN PIM1 KINASE DOMAIN
2183, d4xliA_, 0.7721, 2.30, 0.223, 264, 247, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
2184, d4ll5A_, 0.7721, 2.42, 0.265, 268, 249, CRYSTAL STRUCTURE OF PIM-1 IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
2185, d4ftcA_, 0.7721, 2.42, 0.274, 266, 248, CRYSTAL STRUCTURE OF THE CHK1
2186, d3vbtA_, 0.7721, 2.32, 0.258, 267, 248, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2187, d2j5eA_, 0.7721, 2.88, 0.202, 309, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 13-JAB
2188, d5av0A_, 0.7720, 2.53, 0.263, 275, 251, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH 73 4 - TRIHYDROXYISOFLAVONE.
2189, d4zogB_, 0.7720, 2.71, 0.222, 268, 252, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
2190, d4u44A_, 0.7720, 2.42, 0.256, 286, 250, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
2191, d4ae9B_, 0.7720, 2.84, 0.248, 321, 254, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
2192, d3uo5A_, 0.7720, 2.38, 0.297, 267, 249, AURORA A IN COMPLEX WITH YL1-038-31
2193, d3c4eC_, 0.7720, 2.40, 0.261, 272, 249, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2194, d2zm3B2, 0.7720, 2.66, 0.201, 295, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2195, d2oi4X_, 0.7720, 2.27, 0.266, 275, 248, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH FLUORINATED RUTHENIUM PYRIDOCARBAZOLE
2196, d1cdkA_, 0.7720, 2.64, 0.257, 342, 253, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
2197, d5telA_, 0.7719, 2.46, 0.265, 273, 249, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2198, d5auxA_, 0.7719, 2.53, 0.263, 275, 251, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH KAEMPFEROL.
2199, d4tw9B_, 0.7719, 2.72, 0.191, 289, 256, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
2200, d3bu5A_, 0.7719, 2.77, 0.198, 291, 253, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE AND ATP
2201, d2j2iB_, 0.7719, 2.29, 0.266, 273, 248, CRYSTAL STRUCTURE OF THE HUMAB PIM1 IN COMPLEX WITH LY333531
2202, d2hz4C_, 0.7719, 2.46, 0.221, 259, 249, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
2203, d1kobB_, 0.7719, 2.96, 0.237, 352, 257, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
2204, d1koaA2, 0.7719, 2.89, 0.234, 350, 256, TWITCHIN KINASE FRAGMENT (C.ELEGANS) AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
2205, d5ig1B_, 0.7718, 2.85, 0.276, 304, 254, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
2206, d5flfD_, 0.7718, 2.70, 0.242, 290, 252, DISEASE LINKED MUTATION IN FGFR
2207, d4twcB_, 0.7718, 2.71, 0.191, 292, 256, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
2208, d3zh8A_, 0.7718, 2.68, 0.283, 318, 254, A NOVEL SMALL MOLECULE APKC INHIBITOR
2209, d3b2tA_, 0.7718, 2.82, 0.240, 288, 254, STRUCTURE OF PHOSPHOTRANSFERASE
2210, d2xynA_, 0.7718, 2.47, 0.216, 264, 250, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
2211, d5b2lA_, 0.7717, 2.47, 0.228, 288, 250, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
2212, d4nfmA_, 0.7717, 2.66, 0.191, 293, 256, HUMAN TAU TUBULIN KINASE 1 (TTBK1)
2213, d3vbyA_, 0.7717, 2.33, 0.266, 267, 248, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2214, d3eh9A1, 0.7717, 2.55, 0.263, 274, 251, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH ADP
2215, d2bzhB_, 0.7717, 2.40, 0.265, 275, 249, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
2216, d3bu3A_, 0.7716, 2.90, 0.200, 294, 255, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE
2217, d2qg5B1, 0.7716, 2.63, 0.266, 275, 252, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
2218, d2brgA_, 0.7716, 2.31, 0.271, 257, 247, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2219, d5opuA_, 0.7715, 2.38, 0.270, 261, 248, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
2220, d3uysC_, 0.7714, 2.71, 0.187, 286, 256, CRYSTAL STRUCTURE OF APO HUMAN CK1D
2221, d3eqpB_, 0.7714, 2.58, 0.251, 270, 251, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
2222, d1yxsA_, 0.7714, 2.45, 0.265, 274, 249, CRYSTAL STRUCTURE OF KINASE PIM1 WITH P123M MUTATION
2223, d4wt6A_, 0.7712, 2.43, 0.261, 273, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIADIAZOLAMINE-INDOLE INHIBITOR.
2224, d3uo4A_, 0.7712, 2.35, 0.297, 266, 249, AURORA A IN COMPLEX WITH RPM1680
2225, d2pvfA_, 0.7712, 3.00, 0.230, 285, 256, CRYSTAL STRUCTURE OF TYROSINE PHOSPHORYLATED ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH ATP ANALOG AND SUBSTRATE PEPTIDE
2226, d6bkuA1, 0.7711, 2.34, 0.287, 264, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO GSK650394
2227, d3zh8B_, 0.7711, 2.68, 0.283, 317, 254, A NOVEL SMALL MOLECULE APKC INHIBITOR
2228, d2r2pA1, 0.7711, 2.44, 0.207, 276, 251, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 5 (EPHA5)
2229, d1m17A_, 0.7711, 2.77, 0.209, 312, 254, EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE DOMAIN WITH 4-ANILINOQUINAZOLINE INHIBITOR ERLOTINIB
2230, d5w4wC_, 0.7710, 2.76, 0.172, 284, 256, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2231, d5dgzA_, 0.7710, 2.44, 0.265, 273, 249, DISCOVERY OF 35-SUBSTITUTED 6-AZAINDAZOLES AS POTENT PAN-PIM INHIBITORS
2232, d4xlvA_, 0.7710, 2.94, 0.200, 307, 255, CRYSTAL STRUCTURE OF THE ACTIVATED INSULIN RECEPTOR TYROSINE KINASE DIMER
2233, d4ftrA_, 0.7710, 2.39, 0.275, 258, 247, CRYSTAL STRUCTURE OF THE CHK1
2234, d3aglA_, 0.7710, 2.68, 0.268, 338, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
2235, d2pvyA_, 0.7710, 2.62, 0.239, 288, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
2236, d2itqA_, 0.7710, 2.58, 0.206, 300, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AFN941
2237, d2bzjA_, 0.7710, 2.44, 0.265, 273, 249, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3
2238, d5kgdA_, 0.7709, 2.30, 0.262, 273, 248, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-PYRIDIN-3-YL-1~{H}- BENZIMIDAZOLE
2239, d4hokW_, 0.7709, 2.81, 0.184, 289, 256, CRYSTAL STRUCTURE OF APO CK1E
2240, d3nsvA_, 0.7709, 2.49, 0.216, 264, 250,  
2241, d3bhhD1, 0.7709, 2.70, 0.303, 285, 254, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2242, d2itwA_, 0.7709, 2.57, 0.210, 300, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AFN941
2243, d5autA_, 0.7708, 2.49, 0.264, 274, 250, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH ANS.
2244, d4mbiA_, 0.7708, 2.44, 0.261, 274, 249, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
2245, d1ywvA_, 0.7708, 2.45, 0.269, 274, 249, CRYSTAL STRUCTURES OF PROTO-ONCOGENE KINASE PIM1: A TARGET OF ABERRANT SOMATIC HYPERMUTATIONS IN DIFFUSE LARGE CELL LYMPHOMA
2246, d1tkiB_, 0.7708, 2.86, 0.223, 321, 256, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
2247, d1tkiA_, 0.7708, 2.86, 0.223, 321, 256, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
2248, d4wsyA_, 0.7707, 2.43, 0.261, 273, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIAZOLAMINE-INDAZOLE INHIBITOR.
2249, d4ftmA_, 0.7707, 2.40, 0.275, 263, 247, CRYSTAL STRUCTURE OF THE CHK1
2250, d3vbxA_, 0.7707, 2.32, 0.262, 268, 248, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2251, d3nsvB_, 0.7707, 2.46, 0.220, 264, 250,  
2252, d5kgeA_, 0.7706, 2.31, 0.262, 273, 248, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 5-(34-DICHLOROPHENYL)- 1~{H}-PYRAZOL-3-AMINE
2253, d4wrsA_, 0.7706, 2.44, 0.261, 273, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AZASPIRO PYRAZINYL-INDAZOLE INHIBITOR.
2254, d4wnpB_, 0.7706, 2.57, 0.297, 272, 249, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2255, d4k1bA_, 0.7706, 2.45, 0.265, 273, 249, STRUCTURE OF PIM-1 KINASE BOUND TO N-(5-(2-FLUOROPHENYL)-1H-PYRROLO[2 3-B]PYRIDIN-3-YL)-5-((((3R4R)-3-FLUOROPIPERIDIN-4-YL)METHYL)AMINO) PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2256, d3ikaA_, 0.7706, 2.94, 0.195, 310, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
2257, d3idcA_, 0.7706, 2.63, 0.253, 341, 253, CRYSTAL STRUCTURE OF (102-265)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
2258, d3gubA1, 0.7706, 2.60, 0.262, 276, 252, CRYSTAL STRUCTURE OF DAPKL93G COMPLEXED WITH N6-(2- PHENYLETHYL)ADENOSINE
2259, d2xynB_, 0.7706, 2.47, 0.220, 264, 250, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
2260, d2gqgA1, 0.7706, 2.59, 0.227, 271, 251, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
2261, d1yxuB_, 0.7706, 2.46, 0.265, 273, 249, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2262, d1yxuA_, 0.7706, 2.43, 0.261, 273, 249, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2263, d3tkhA_, 0.7705, 2.51, 0.274, 269, 248, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S01
2264, d5kgiA_, 0.7704, 2.31, 0.262, 273, 248, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR 2-[34-BIS(CHLORANYL) PHENOXY]ETHANAMINE
2265, d4zy4B_, 0.7704, 2.76, 0.306, 292, 252, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
2266, d4o0sA_, 0.7704, 2.38, 0.302, 265, 248, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2267, d4as0A_, 0.7704, 2.30, 0.262, 273, 248, CYCLOMETALATED PHTHALIMIDES AS PROTEIN KINASE INHIBITORS
2268, d3vbvA_, 0.7704, 2.47, 0.261, 268, 249, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2269, d2yerA_, 0.7704, 2.70, 0.261, 268, 253, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
2270, d2xeyA_, 0.7704, 2.29, 0.272, 252, 246, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2271, d2itpA_, 0.7704, 2.71, 0.206, 305, 253, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AEE788
2272, d1yxuC_, 0.7704, 2.44, 0.261, 272, 249, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2273, d1rqqA_, 0.7704, 2.85, 0.205, 294, 254, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
2274, d5dt3A_, 0.7703, 2.45, 0.297, 263, 249, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
2275, d4xh6A_, 0.7703, 2.43, 0.261, 273, 249, CRYSTAL STRUCTURE OF PROTO-ONCOGENE KINASE PIM1 BOUND TO HISPIDULIN
2276, d3vjnA_, 0.7703, 2.52, 0.199, 297, 251, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH AMPPNP.
2277, d1yxvA_, 0.7703, 2.46, 0.261, 274, 249, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH 34-DIHYDROXY-1- METHYLQUINOLIN-2(1H)-ONE
2278, d2o64A_, 0.7702, 2.46, 0.261, 274, 249, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETAGETIN
2279, d2bikB_, 0.7702, 2.38, 0.266, 272, 248, HUMAN PIM1 PHOSPHORYLATED ON SER261
2280, d1u59A1, 0.7702, 2.66, 0.225, 276, 253, CRYSTAL STRUCTURE OF THE ZAP-70 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2281, d3ppzB_, 0.7701, 2.37, 0.243, 264, 247, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2282, d1xr1A_, 0.7701, 2.48, 0.269, 277, 249, CRYSTAL STRUCTURE OF HPIM-1 KINASE IN COMPLEX WITH AMP-PNP AT 2.1 A RESOLUTION
2283, d5kgkA_, 0.7700, 2.44, 0.265, 273, 249, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 3-(4-METHOXYPHENYL)-1~{H}- PYRAZOL-5-AMINE
2284, d4utdA_, 0.7700, 2.46, 0.305, 266, 249, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION
2285, d4jq8A_, 0.7700, 2.62, 0.210, 303, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4B
2286, d3uytA_, 0.7700, 2.59, 0.190, 287, 253, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2287, d3r01A_, 0.7700, 2.46, 0.261, 274, 249, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2288, d3kf4B_, 0.7700, 2.46, 0.229, 270, 249, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
2289, d3dlsB_, 0.7700, 2.36, 0.263, 280, 247, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2290, d2x8eA_, 0.7700, 2.50, 0.265, 259, 249, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
2291, d4hokI_, 0.7699, 2.78, 0.184, 291, 256, CRYSTAL STRUCTURE OF APO CK1E
2292, d3we8A_, 0.7699, 2.47, 0.265, 273, 249, PIM-1 KINASE IN COMPLEX WITH RUTHENIUM-BASED INHIBITOR
2293, d3b2tB_, 0.7698, 2.92, 0.240, 287, 254, STRUCTURE OF PHOSPHOTRANSFERASE
2294, d5texA_, 0.7697, 2.49, 0.265, 274, 249, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2295, d4ftkA_, 0.7697, 2.41, 0.275, 263, 247, CRYSTAL STRUCTURE OF THE CHK1
2296, d4debA_, 0.7697, 2.40, 0.293, 264, 249, AURORA A IN COMPLEX WITH RK2-17-01
2297, d3jyaA_, 0.7697, 2.35, 0.262, 274, 248, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2298, d3jxwA_, 0.7697, 2.46, 0.261, 274, 249, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2299, d3jpvA_, 0.7697, 2.32, 0.262, 273, 248, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A PYRROLO[23- A]CARBAZOLE LIGAND
2300, d2psqA_, 0.7697, 2.78, 0.237, 287, 253, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
2301, d1yxxA_, 0.7697, 2.46, 0.261, 274, 249, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH (3E)-3-[(4- HYDROXYPHENYL)IMINO]-1H-INDOL-2(3H)-ONE
2302, d1m14A_, 0.7697, 2.60, 0.210, 307, 252, TYROSINE KINASE DOMAIN FROM EPIDERMAL GROWTH FACTOR RECEPTOR
2303, d4rpvA_, 0.7696, 2.44, 0.265, 273, 249, CO-CRYSTAL STRUCTURE OF PIM1 WITH COMPOUND 3
2304, d4mblA_, 0.7696, 2.46, 0.265, 274, 249, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
2305, d2o3pA_, 0.7696, 2.47, 0.265, 274, 249, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETIN
2306, d5kcxA_, 0.7695, 2.47, 0.261, 272, 249, PIM-1 KINASE IN COMPLEX WITH A SELECTIVE N-SUBSTITUTED 7-AZAINDOLE INHIBITOR
2307, d5av4A_, 0.7695, 2.52, 0.264, 274, 250, CRYSTAL STRUCTURE OF DAPK1-GENISTEIN COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2308, d5auzA_, 0.7695, 2.52, 0.264, 274, 250, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH GENISTEIN.
2309, d4fsuA_, 0.7695, 2.49, 0.274, 260, 248, CRYSTAL STRUCTURE OF THE CHK1
2310, d4deeA_, 0.7695, 2.45, 0.293, 271, 249, AURORA A IN COMPLEX WITH ADP
2311, d3r04A_, 0.7695, 2.35, 0.258, 271, 248, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2312, d2itxA_, 0.7695, 2.85, 0.200, 307, 255, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AMP- PNP
2313, d1ol5A_, 0.7695, 2.31, 0.297, 263, 246, STRUCTURE OF AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288 AND BOUND TO TPX2 1-43
2314, d5hu3A_, 0.7694, 2.61, 0.320, 266, 250, DROSOPHILA CAMKII-D136N IN COMPLEX WITH A PHOSPHORYLATED FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
2315, d5auwA_, 0.7694, 2.53, 0.264, 274, 250, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH QUERCETIN.
2316, d4ty1A_, 0.7694, 2.45, 0.261, 273, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AMINOOXADIAZOLE-INDOLE INHIBITOR.
2317, d4id7A_, 0.7694, 2.37, 0.249, 268, 249, ACK1 KINASE IN COMPLEX WITH THE INHIBITOR CIS-3-[8-AMINO-1-(4- PHENOXYPHENYL)IMIDAZO[15-A]PYRAZIN-3-YL]CYCLOBUTANOL
2318, d4hokO_, 0.7694, 2.82, 0.184, 290, 256, CRYSTAL STRUCTURE OF APO CK1E
2319, d3vbwA_, 0.7694, 2.35, 0.262, 264, 248, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2320, d3f9nA_, 0.7694, 2.38, 0.271, 253, 247, CRYSTAL STRUCTURE OF CHK1 KINASE IN COMPLEX WITH INHIBITOR 38
2321, d2c47D1, 0.7694, 2.70, 0.216, 289, 255, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
2322, d5turA_, 0.7693, 2.46, 0.261, 270, 249, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2323, d5dlsA_, 0.7693, 2.42, 0.271, 257, 247, IDENTIFICATION OF NOVEL IN VIVO ACTIVE CHK1 INHIBITORS UTILIZING STRUCTURE GUIDED DRUG DESIGN
2324, d5auuA_, 0.7693, 2.53, 0.264, 274, 250, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH LUTEOLIN.
2325, d4medA_, 0.7693, 2.42, 0.270, 272, 248, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE DERIVATIVES
2326, d4jq7A_, 0.7693, 2.64, 0.210, 303, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 2A
2327, d4ftlA_, 0.7693, 2.54, 0.274, 263, 248, CRYSTAL STRUCTURE OF THE CHK1
2328, d2j0lA_, 0.7693, 2.51, 0.247, 274, 251, CRYSTAL STRUCTURE OF A THE ACTIVE CONFORMATION OF THE KINASE DOMAIN OF FOCAL ADHESION KINASE WITH A PHOSPHORYLATED ACTIVATION LOOP.
2329, d5oq6A_, 0.7692, 2.32, 0.268, 257, 246, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
2330, d5ng0B_, 0.7692, 2.78, 0.224, 282, 255, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
2331, d5dhjA_, 0.7692, 2.45, 0.261, 273, 249, PIM1 IN COMPLEX WITH CPD4 (3-METHYL-5-(PYRIDIN-3-YL)-1H-PYRAZOLO[34- C]PYRIDINE)
2332, d4j8nC_, 0.7692, 2.42, 0.293, 266, 249, AURORA A KINASE APO
2333, d3uytB_, 0.7692, 2.66, 0.190, 286, 253, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2334, d4zy5B_, 0.7691, 2.78, 0.306, 287, 252, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
2335, d4tn6B_, 0.7691, 2.76, 0.184, 285, 256, CK1D IN COMPLEX WITH INHIBITOR
2336, d4jr3A_, 0.7691, 2.65, 0.210, 303, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 3G
2337, d2py3B_, 0.7691, 2.71, 0.234, 284, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2338, d5d9kB_, 0.7690, 2.44, 0.290, 280, 248, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
2339, d4k18A_, 0.7690, 2.45, 0.269, 277, 249, STRUCTURE OF PIM-1 KINASE BOUND TO 5-(4-CYANOBENZYL)-N-(4- FLUOROPHENYL)-7-HYDROXYPYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2340, d4j8nB_, 0.7690, 2.42, 0.293, 266, 249, AURORA A KINASE APO
2341, d3ri1A_, 0.7690, 2.90, 0.239, 285, 255, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
2342, d3r00A_, 0.7690, 2.35, 0.262, 274, 248, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2343, d3jy0A_, 0.7690, 2.35, 0.262, 275, 248, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2344, d3bwfA_, 0.7690, 2.34, 0.262, 273, 248, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AN OSMIUM COMPOUND
2345, d5op4A_, 0.7689, 2.31, 0.268, 259, 246, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDINE LRRK2 INHIBITOR
2346, d4zogA_, 0.7689, 2.69, 0.223, 269, 251, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
2347, d4wnpA_, 0.7689, 2.60, 0.297, 273, 249, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2348, d4j95C_, 0.7689, 2.62, 0.244, 281, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
2349, d4j8nD_, 0.7689, 2.43, 0.293, 265, 249, AURORA A KINASE APO
2350, d4aluA_, 0.7689, 2.35, 0.262, 274, 248, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2351, d4a7cA_, 0.7689, 2.40, 0.266, 273, 248, CRYSTAL STRUCTURE OF PIM1 KINASE WITH ETP46546
2352, d3eqpA_, 0.7689, 2.45, 0.253, 268, 249, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
2353, d5toeA_, 0.7688, 2.50, 0.265, 272, 249, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2354, d4kbkC_, 0.7688, 2.77, 0.191, 280, 256, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
2355, d4jiaA_, 0.7688, 2.77, 0.249, 298, 253, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 9
2356, d4j8nA_, 0.7688, 2.43, 0.293, 266, 249, AURORA A KINASE APO
2357, d3vc4A_, 0.7688, 2.35, 0.262, 274, 248, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2358, d6bqqA1, 0.7687, 2.39, 0.279, 269, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH BI2526
2359, d5l8kA_, 0.7687, 2.64, 0.287, 266, 251, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 2)
2360, d5cavA_, 0.7687, 2.62, 0.210, 306, 252, EGFR KINASE DOMAIN WITH COMPOUND 41A
2361, d4obpA_, 0.7687, 2.58, 0.251, 285, 251, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
2362, d4jx3A_, 0.7687, 2.45, 0.265, 274, 249, CRYSTAL STRUCTURE OF PIM1 KINASE
2363, d4alvA_, 0.7687, 2.35, 0.262, 274, 248, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2364, d3qc4A_, 0.7687, 2.61, 0.263, 276, 251, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
2365, d5kggA_, 0.7686, 2.35, 0.262, 273, 248, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-(5-CHLORANYL-1~{H}-INDOL- 3-YL)ETHANAMINE
2366, d4kbkB_, 0.7686, 2.80, 0.184, 289, 256, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
2367, d2bziB_, 0.7686, 2.43, 0.266, 272, 248, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2
2368, d1k3aA_, 0.7686, 2.87, 0.208, 288, 255, STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR KINASE
2369, d4jx7A_, 0.7685, 2.47, 0.261, 274, 249, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR 2-[(TRANS- 4-AMINOCYCLOHEXYL)AMINO]-4-{[3-(TRIFLUOROMETHYL) PHENYL]AMINO}PYRIDO[43-D]PYRIMIDIN-5(6H)-ONE
2370, d4fsmA_, 0.7685, 2.42, 0.275, 265, 247, CRYSTAL STRUCTURE OF THE CHK1
2371, d3kulB_, 0.7685, 2.47, 0.204, 271, 250, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
2372, d2qohA2, 0.7685, 2.51, 0.225, 270, 249, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
2373, d2o65A_, 0.7685, 2.50, 0.273, 274, 249, CRYSTAL STRUCTURE OF PIM1 WITH PENTAHYDROXYFLAVONE
2374, d2o63A_, 0.7685, 2.50, 0.269, 274, 249, CRYSTAL STRUCTURE OF PIM1 WITH MYRICETIN
2375, d5cxhA1, 0.7684, 2.65, 0.202, 273, 253, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT ORALLY BIOAVAILABLE THIAZOLE INHIBITOR
2376, d4mtaA_, 0.7684, 2.37, 0.258, 273, 248, CRYSTAL STRUCTURE OF PIM-1 KINASE DOMAIN IN COMPLEX WITH 2-METHYL-5- PHENYLFURAN-3-CARBOXYLIC ACID
2377, d4kbcA_, 0.7684, 2.78, 0.187, 288, 256, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
2378, d3uysD_, 0.7684, 2.61, 0.190, 284, 253, CRYSTAL STRUCTURE OF APO HUMAN CK1D
2379, d2j6mA_, 0.7684, 2.55, 0.203, 306, 251, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AEE788
2380, d5mjbB_, 0.7683, 2.64, 0.221, 278, 253, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
2381, d5ipjA_, 0.7683, 2.47, 0.261, 273, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A QUINAZOLINONE-PYRROLOPYRROLONE INHIBITOR.
2382, d4rc3A_, 0.7683, 2.43, 0.266, 271, 248, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2383, d4n6yA_, 0.7683, 2.29, 0.267, 273, 247, PIM1 COMPLEXED WITH A PHENYLCARBOXAMIDE
2384, d4lm5A_, 0.7683, 2.31, 0.263, 264, 247, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH 2-{4-[(3-AMINOPROPYL) AMINO]QUINAZOLIN-2-YL}PHENOL (RESULTING FROM DISPLACEMENT OF SKF86002)
2385, d4hokU_, 0.7683, 2.81, 0.187, 289, 256, CRYSTAL STRUCTURE OF APO CK1E
2386, d3r02A_, 0.7683, 2.38, 0.258, 271, 248, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2387, d2izuA_, 0.7683, 2.72, 0.196, 297, 255, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
2388, d5oprA_, 0.7682, 2.33, 0.268, 258, 246, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIDINE LRRK2 INHIBITOR
2389, d5dr2A1, 0.7682, 2.58, 0.296, 263, 250, AURORA A KINASE IN COMPLEX WITH AA30 AND ATP IN SPACE GROUP P6122
2390, d4riyD_, 0.7682, 2.65, 0.210, 297, 252, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
2391, d4i41A_, 0.7682, 2.31, 0.267, 272, 247, CRYSTAL STRUCTURE OF HUMAN SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE
2392, d4hnfA_, 0.7682, 2.65, 0.186, 289, 253, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
2393, d4dedA_, 0.7682, 2.42, 0.293, 265, 249, AURORA A IN COMPLEX WITH YL1-038-21
2394, d3kf4A_, 0.7682, 2.57, 0.221, 281, 249, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
2395, d5v82A_, 0.7681, 2.35, 0.266, 273, 248, PIM1 KINASE IN COMPLEX WITH CPD17 (1-(6-(44-DIFLUOROPIPERIDIN-3-YL) PYRIDIN-2-YL)-6-(6-METHYLPYRAZIN-2-YL)-1H-PYRAZOLO[43-C]PYRIDINE)
2396, d4k0yA_, 0.7681, 2.35, 0.266, 274, 248, STRUCTURE OF PIM-1 KINASE BOUND TO N-(4-FLUOROPHENYL)-7-HYDROXY-5- (PIPERIDIN-4-YL)PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2397, d4dtkA_, 0.7681, 2.37, 0.258, 273, 248, NOVEL AND SELECTIVE PAN-PIM KINASE INHIBITOR
2398, d5mjbA_, 0.7680, 2.52, 0.219, 276, 251, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
2399, d3up7A_, 0.7680, 2.38, 0.294, 264, 248, AURORA A IN COMPLEX WITH YL1-038-09
2400, d2py3A_, 0.7680, 3.00, 0.231, 282, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2401, d1zwsB_, 0.7680, 2.60, 0.254, 278, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2402, d5wevA_, 0.7679, 2.70, 0.254, 293, 252, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
2403, d5te0A_, 0.7679, 2.41, 0.250, 316, 248, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH BIBF 1120
2404, d5l3aA_, 0.7679, 2.68, 0.250, 290, 252, FRAGMENT-BASED DISCOVERY OF 6-ARYLINDAZOLE JAK INHIBITORS
2405, d4l3lA_, 0.7679, 2.59, 0.297, 291, 249, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN (ZINC ANOMALOUS)
2406, d4gmyA_, 0.7679, 2.78, 0.253, 298, 253, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH 26-DICHLORO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
2407, d3a99A_, 0.7679, 2.49, 0.261, 273, 249, STRUCTURE OF PIM-1 KINASE CRYSTALLIZED IN THE PRESENCE OF P27KIP1 CARBOXY-TERMINAL PEPTIDE
2408, d2yakA_, 0.7679, 2.60, 0.266, 277, 252, STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OSV)
2409, d2iztA_, 0.7679, 2.71, 0.192, 296, 255, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
2410, d5ugxA_, 0.7678, 2.82, 0.237, 297, 253, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
2411, d4hgsA1, 0.7678, 2.72, 0.196, 301, 255, CRYSTAL STRUCTURE OF CK1GS WITH COMPOUND 13
2412, d3u9nA_, 0.7678, 2.42, 0.271, 257, 247, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
2413, d1zwsF_, 0.7678, 2.58, 0.254, 278, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2414, d5x18A_, 0.7677, 2.80, 0.195, 294, 256, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
2415, d5oryA_, 0.7677, 2.40, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2416, d5dn3A_, 0.7677, 2.45, 0.294, 264, 248, AURORA A IN COMPLEX WITH ATP AND AA35.
2417, d4rc4A_, 0.7677, 2.44, 0.266, 272, 248, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2418, d4hokA_, 0.7677, 2.81, 0.184, 290, 256, CRYSTAL STRUCTURE OF APO CK1E
2419, d3c4eD_, 0.7677, 2.36, 0.262, 273, 248, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2420, d3bhhC1, 0.7677, 2.70, 0.292, 284, 253, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2421, d6brcB_, 0.7676, 2.40, 0.289, 260, 246, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
2422, d6babA_, 0.7676, 2.83, 0.295, 290, 254, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2423, d5vc5A_, 0.7676, 2.53, 0.231, 261, 247, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PD- 166285
2424, d5dnrA_, 0.7676, 2.54, 0.297, 264, 249, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P41212
2425, d3vjoA_, 0.7676, 2.58, 0.204, 298, 250, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH AMPPNP.
2426, d3sxsA1, 0.7676, 2.45, 0.206, 261, 248, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEXED WITH PP2
2427, d3dcvA_, 0.7676, 2.45, 0.266, 273, 248, CRYSTAL STRUCTURE OF HUMAN PIM1 KINASE COMPLEXED WITH 4-(4- HYDROXY-3-METHYL-PHENYL)-6-PHENYLPYRIMIDIN-2(1H)-ONE
2428, d2bujB1, 0.7676, 2.63, 0.243, 277, 251, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
2429, d5diaA_, 0.7675, 2.37, 0.262, 273, 248, PIM1 IN COMPLEX WITH CPD36 ((1S3S)-N1-(6-(5-(PYRIDIN-3-YL)-1H- PYRAZOLO[34-C]PYRIDIN-3-YL)PYRIDIN-2-YL)CYCLOHEXANE-13-DIAMINE)
2430, d5ax9C_, 0.7675, 2.33, 0.246, 282, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2431, d4bbeD_, 0.7675, 2.68, 0.250, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2432, d1zwsG_, 0.7675, 2.59, 0.254, 278, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2433, d1oplB2, 0.7675, 2.59, 0.220, 267, 250, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
2434, d5op2A_, 0.7674, 2.45, 0.268, 263, 250, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2435, d4w9wA_, 0.7674, 2.35, 0.259, 306, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH SMALL MOLECULE AZD-7762
2436, d4tw9A_, 0.7674, 2.77, 0.187, 290, 256, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
2437, d4riwD_, 0.7674, 2.64, 0.206, 297, 252, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
2438, d3kckA_, 0.7674, 2.64, 0.254, 285, 252, A NOVEL CHEMOTYPE OF KINASE INHIBITORS
2439, d3cr0A_, 0.7674, 2.50, 0.223, 257, 247, WEE1 KINASE COMPLEX WITH INHIBITOR PD259_809
2440, d2zm3A2, 0.7674, 2.77, 0.216, 299, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2441, d2xiyA_, 0.7674, 2.46, 0.266, 273, 248, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-2 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2442, d4wnpD_, 0.7673, 2.67, 0.297, 272, 249, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2443, d3wf9A_, 0.7673, 2.55, 0.298, 287, 248, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 1-OXO-1-[(4-SULFAMOYLPHENYL)AMINO]PROPAN-2-YL-2-METHYL-1 234-TETRAHYDROACRIDINE-9-CARBOXYLATE
2444, d3gqiA_, 0.7673, 2.79, 0.237, 304, 253, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
2445, d2wtkC1, 0.7673, 2.49, 0.279, 261, 247, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
2446, d2g2hA_, 0.7673, 2.66, 0.219, 272, 251, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2447, d5iisA_, 0.7672, 2.46, 0.266, 273, 248, DESIGN SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIP OF POTENT PAN- PIM KINASE INHIBITORS DERIVED FROM THE PYRIDYL-AMIDE SCAFFOLD
2448, d5eolA_, 0.7672, 2.49, 0.261, 273, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A MACROCYCLIC QUINOXALINE-PYRROLODIHYDROPIPERIDINONE INHIBITOR
2449, d4zk5A_, 0.7672, 2.58, 0.255, 286, 251, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
2450, d4txcA_, 0.7672, 2.63, 0.266, 276, 252, CRYSTAL STRUCTURE OF DAPK1 KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
2451, d4fswA_, 0.7672, 2.53, 0.275, 265, 247, CRYSTAL STRUCTURE OF THE CHK1
2452, d4bbeB_, 0.7672, 2.70, 0.254, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2453, d2zm3D2, 0.7672, 2.72, 0.209, 292, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2454, d1zwsD_, 0.7672, 2.59, 0.254, 278, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2455, d1xqzA_, 0.7672, 2.50, 0.269, 277, 249, CRYSTAL STRUCTURE OF HPIM-1 KINASE AT 2.1 A RESOLUTION
2456, d1gjoA_, 0.7672, 2.74, 0.243, 280, 251, THE FGFR2 TYROSINE KINASE DOMAIN
2457, d5opsA_, 0.7671, 2.30, 0.269, 258, 245, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
2458, d5hg8A_, 0.7671, 3.05, 0.199, 300, 256, EGFR (L858R T790M V948R) IN COMPLEX WITH N-[3-({2-[(1-METHYL-1H- PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- 2-ENAMIDE
2459, d4rc2A_, 0.7671, 2.45, 0.266, 272, 248, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2460, d4g16A1, 0.7671, 2.73, 0.196, 301, 255, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2- YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE
2461, d4bbeC_, 0.7671, 2.70, 0.254, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2462, d2xj0A_, 0.7671, 2.52, 0.261, 274, 249, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-4 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2463, d1wvxA_, 0.7671, 2.57, 0.263, 275, 251, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2464, d1oecA_, 0.7671, 2.72, 0.243, 280, 251, FGFR2 KINASE DOMAIN
2465, d5hg5A_, 0.7670, 3.09, 0.202, 302, 257, EGFR (L858R T790M V948R) IN COMPLEX WITH N-{3-[(2-{[4-(4- METHYLPIPERAZIN-1-YL)PHENYL]AMINO}-7H-PYRROLO[23-D]PYRIMIDIN-4-YL) OXY]PHENYL}PROP-2-ENAMIDE
2466, d4rblA_, 0.7670, 2.46, 0.270, 271, 248, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2467, d2brhA_, 0.7670, 2.46, 0.275, 257, 247, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2468, d1wvwA_, 0.7670, 2.54, 0.267, 275, 251, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2469, d5x17A_, 0.7669, 2.80, 0.191, 290, 256, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
2470, d5d7aB_, 0.7669, 2.40, 0.249, 286, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2471, d3wf8A_, 0.7669, 2.62, 0.305, 287, 249, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 2-OXO-2-[(4-SULFAMOYLPHENYL)AMINO]ETHYL 78910- TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE-11-CARBOXYLATE
2472, d3uytC_, 0.7669, 2.76, 0.191, 286, 256, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2473, d2z60A1, 0.7669, 2.68, 0.227, 280, 251, CRYSTAL STRUCTURE OF THE T315I MUTANT OF ABL KINASE BOUND WITH PPY-A
2474, d2pwlB_, 0.7669, 2.74, 0.238, 286, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
2475, d2pwlA_, 0.7669, 2.83, 0.241, 284, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
2476, d1yxuD_, 0.7669, 2.37, 0.262, 273, 248, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2477, d5d9kA_, 0.7668, 2.35, 0.297, 280, 246, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
2478, d4uxlA_, 0.7668, 2.42, 0.234, 288, 248, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH PF-06463922
2479, d5u6bB1, 0.7667, 2.69, 0.209, 289, 254, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
2480, d5e8uA1, 0.7667, 2.69, 0.210, 303, 252, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F)
2481, d5d7aA_, 0.7667, 2.39, 0.253, 289, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2482, d3sxrA1, 0.7667, 2.54, 0.209, 257, 249, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
2483, d3q4zA1, 0.7667, 2.31, 0.280, 281, 246, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
2484, d2of4A_, 0.7667, 2.67, 0.220, 271, 250, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 1 BOUND TO LCK
2485, d2izsA_, 0.7667, 2.73, 0.192, 298, 255, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
2486, d4gfgA1, 0.7666, 2.65, 0.202, 273, 253, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R9021
2487, d3vbqA_, 0.7666, 2.41, 0.258, 271, 248, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2488, d3bgpA_, 0.7666, 2.33, 0.267, 272, 247, HUMAN PIM-1 COMPLEXED WITH A BENZOISOXAZOLE INHIBITOR VX1
2489, d2xizA_, 0.7666, 2.34, 0.267, 273, 247, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-3 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2490, d2ckeC_, 0.7666, 2.92, 0.239, 300, 255, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2491, d2c47B_, 0.7666, 2.72, 0.209, 289, 254, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
2492, d5walA1, 0.7665, 2.64, 0.219, 285, 251, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
2493, d5e8wA1, 0.7665, 2.77, 0.210, 302, 252, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
2494, d5d7aC_, 0.7665, 2.34, 0.254, 286, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2495, d4nfnA_, 0.7665, 2.78, 0.191, 293, 257, HUMAN TAU TUBULIN KINASE 1 (TTBK1) COMPLEXED WITH 3-({5-[(4-AMINO-4- METHYLPIPERIDIN-1-YL)METHYL]PYRROLO[21-F][124]TRIAZIN-4-YL}AMINO)- 5-BROMOPHENOL
2496, d2pzpA_, 0.7665, 2.95, 0.232, 280, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
2497, d1ir3A_, 0.7665, 2.97, 0.192, 300, 255, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH PEPTIDE SUBSTRATE AND ATP ANALOG
2498, d4yznA_, 0.7664, 2.50, 0.232, 269, 246, HUMANIZED ROCO4 BOUND TO COMPOUND 19
2499, d4rixD_, 0.7664, 2.66, 0.210, 297, 252, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
2500, d4ckiA1, 0.7664, 2.81, 0.238, 288, 252, CRYSTAL STRUCTURE OF ONCOGENIC RET TYROSINE KINASE M918T BOUND TO ADENOSINE
2501, d3jvsA_, 0.7664, 2.36, 0.273, 256, 245, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
2502, d2ivtA1, 0.7664, 2.81, 0.238, 283, 252, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
2503, d1gagA_, 0.7664, 2.96, 0.192, 300, 255, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
2504, d4tl0A_, 0.7663, 2.88, 0.251, 300, 255, CRYSTAL STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 WITH A CRUCIAL PHOSPHOMIMICKING MUTATION
2505, d4lg4C_, 0.7663, 2.62, 0.270, 288, 252, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2506, d4jajA_, 0.7663, 2.54, 0.301, 265, 249, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH BENZO[C][1 8]NAPHTHYRIDIN-6(5H)-ONE
2507, d4ftaA_, 0.7663, 2.53, 0.275, 264, 247, CRYSTAL STRUCTURE OF THE CHK1
2508, d4btjB_, 0.7663, 2.80, 0.187, 293, 257, TTBK1 IN COMPLEX WITH ATP
2509, d6b16B_, 0.7662, 2.50, 0.296, 281, 247, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
2510, d5u6bD1, 0.7662, 2.70, 0.209, 289, 254, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
2511, d5orzA_, 0.7662, 2.42, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2512, d5j9yA_, 0.7662, 2.59, 0.199, 300, 251, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1B
2513, d4iaaA_, 0.7662, 2.45, 0.270, 272, 248, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE
2514, d2pz5B_, 0.7662, 2.70, 0.235, 280, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2515, d2pz5A_, 0.7662, 2.96, 0.232, 280, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2516, d5oseA_, 0.7661, 2.43, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2517, d5osdA_, 0.7661, 2.43, 0.294, 266, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2518, d5orpA_, 0.7661, 2.43, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2519, d3ug2A_, 0.7661, 2.68, 0.195, 299, 251, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH GEFITINIB
2520, d2of2A_, 0.7661, 2.68, 0.220, 271, 250, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 8 BOUND TO LCK
2521, d5fqdF_, 0.7660, 2.85, 0.199, 294, 256, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
2522, d4lg4A_, 0.7660, 2.63, 0.277, 289, 253, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2523, d4jrvA_, 0.7660, 2.51, 0.205, 300, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4C
2524, d4hglA1, 0.7660, 2.74, 0.196, 301, 255, CRYSTAL STRUCTURE OF CK1G3 WITH COMPOUND 1
2525, d4bbeA_, 0.7660, 2.86, 0.255, 288, 255, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2526, d3t9iA_, 0.7660, 2.44, 0.270, 273, 248, PIM1 COMPLEXED WITH A NOVEL 36-DISUBSTITUTED INDOLE AT 2.6 ANG RESOLUTION
2527, d2x2mA1, 0.7660, 2.72, 0.240, 281, 250, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
2528, d2chlA_, 0.7660, 2.74, 0.192, 298, 255, STRUCTURE OF CASEIN KINASE 1 GAMMA 3
2529, d1opkA3, 0.7660, 2.76, 0.215, 291, 251, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
2530, d5osfA_, 0.7659, 2.43, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2531, d5orrA_, 0.7659, 2.42, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2532, d5oq7B_, 0.7659, 2.33, 0.271, 256, 247, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2533, d4ckjA1, 0.7659, 2.83, 0.238, 287, 252, CRYSTAL STRUCTURE OF RET TYROSINE KINASE DOMAIN BOUND TO ADENOSINE
2534, d4bznA_, 0.7659, 2.36, 0.263, 272, 247, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO(12-A) PYRAZINONE INHIBITOR
2535, d3bgzA_, 0.7659, 2.37, 0.263, 267, 247, HUMAN PIM-1 KINASE IN COMPLEX WITH DIPHENYL INDOLE INHIBITOR VX3
2536, d2q0bA_, 0.7659, 2.87, 0.237, 280, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2537, d2psqB_, 0.7659, 2.89, 0.236, 286, 254, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
2538, d2c47A_, 0.7659, 2.67, 0.206, 288, 253, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
2539, d5os3A_, 0.7658, 2.43, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2540, d5orwA_, 0.7658, 2.43, 0.298, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2541, d4xhkB_, 0.7658, 2.34, 0.267, 269, 247, PIM1 KINASE IN COMPLEX WITH COMPOUND 1S
2542, d4gh2A_, 0.7658, 2.33, 0.278, 266, 245, CRYSTAL STRUCTURE OF THE CHK1
2543, d4bbfC_, 0.7658, 2.87, 0.251, 288, 255, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2544, d4bbfB_, 0.7658, 2.86, 0.255, 288, 255, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2545, d2x2kA1, 0.7658, 2.83, 0.238, 284, 252, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
2546, d2q0bB_, 0.7658, 2.77, 0.234, 282, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2547, d2pzpB_, 0.7658, 2.71, 0.239, 282, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
2548, d2objA_, 0.7658, 2.37, 0.263, 272, 247, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH INHIBITOR
2549, d2izrA_, 0.7658, 2.75, 0.192, 298, 255, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
2550, d2csnA_, 0.7658, 2.80, 0.180, 293, 256, BINARY COMPLEX OF CASEIN KINASE-1 WITH CKI7
2551, d5vuaB_, 0.7657, 2.37, 0.259, 270, 247, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
2552, d5ih5A_, 0.7657, 2.78, 0.199, 286, 256, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A
2553, d5dwrA_, 0.7657, 2.47, 0.266, 273, 248, IDENTIFICATION OF N-(4-((1R3S5S)-3-AMINO-5-METHYLCYCLOHEXYL)PYRIDIN- 3-YL)-6-(26-DIFLUOROPHENYL)-5-FLUOROPICOLINAMIDE (PIM447) A POTENT AND SELECTIVE PROVIRAL INSERTION SITE OF MOLONEY MURINE LEUKEMIA (PIM) 12 AND 3 KINASE INHIBITOR IN CLINICAL TRIALS FOR HEMATOLOGICAL MALIGNANCIES
2554, d4uv0A_, 0.7657, 2.78, 0.252, 300, 254, STRUCTURE OF A SEMISYNTHETIC PHOSPHORYLATED DAPK
2555, d3lm5A1, 0.7657, 2.39, 0.248, 267, 246, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) IN COMPLEX WITH QUERCETIN
2556, d3f2aA_, 0.7657, 2.34, 0.263, 276, 247, CRYSTAL STRUCTURE OF HUMAN PIM-1 IN COMPLEX WITH DAPPA
2557, d2pzrA_, 0.7657, 2.95, 0.228, 280, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2558, d1yrpB_, 0.7657, 2.58, 0.255, 275, 251, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
2559, d1yrpA_, 0.7657, 2.58, 0.255, 275, 251, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
2560, d5orvA_, 0.7656, 2.44, 0.298, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2561, d5ih6A_, 0.7656, 2.77, 0.187, 286, 256, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A DERIVATIVE
2562, d4btmB_, 0.7656, 2.79, 0.187, 293, 257, TTBK1 IN COMPLEX WITH INHIBITOR
2563, d2jiuA_, 0.7656, 2.83, 0.200, 303, 255, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
2564, d2ckeD_, 0.7656, 2.91, 0.239, 300, 255, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2565, d1yhsA_, 0.7656, 2.30, 0.268, 267, 246, CRYSTAL STRUCTURE OF PIM-1 BOUND TO STAUROSPORINE
2566, d4n70A_, 0.7655, 2.37, 0.263, 274, 247, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
2567, d4lmuA_, 0.7655, 2.39, 0.267, 265, 247, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH THE INHIBITOR QUERCETIN (RESULTING FROM DISPLACEMENT OF SKF86002)
2568, d3bymA_, 0.7655, 2.69, 0.220, 271, 250, X-RAY CO-CRYSTAL STRUCTURE AMINOBENZIMIDAZOLE TRIAZINE 1 BOUND TO LCK
2569, d3bhyA1, 0.7655, 2.46, 0.259, 267, 247, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH A BETA-CARBOLINE LIGAND
2570, d3bgqA_, 0.7655, 2.50, 0.266, 272, 248, HUMAN PIM-1 KINASE IN COMPLEX WITH AN TRIAZOLO PYRIDAZINE INHIBITOR VX2
2571, d2qg5A1, 0.7655, 2.73, 0.266, 268, 252, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
2572, d1zwsH_, 0.7655, 2.63, 0.254, 278, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2573, d1oplA3, 0.7655, 2.77, 0.215, 291, 251, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
2574, d5os0A_, 0.7654, 2.44, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2575, d5oroA_, 0.7654, 2.44, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2576, d5ornA_, 0.7654, 2.44, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2577, d4ftjA_, 0.7654, 2.43, 0.276, 266, 246, CRYSTAL STRUCTURE OF THE CHK1
2578, d4alwA_, 0.7654, 2.58, 0.261, 273, 249, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2579, d2x2lA1, 0.7654, 2.85, 0.238, 282, 252, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
2580, d1yi4A_, 0.7654, 2.31, 0.272, 267, 246, STRUCTURE OF PIM-1 BOUND TO ADENOSINE
2581, d1jktA_, 0.7654, 2.71, 0.261, 276, 253, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2582, d5os5A_, 0.7653, 2.44, 0.294, 267, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2583, d5os1A_, 0.7653, 2.44, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2584, d5e90A1, 0.7653, 2.69, 0.212, 300, 250, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249F S280T Y282FS287NA350CL352F) IN COMPLEX WITH 3-AMINO-6- [4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2- CARBOXAMIDE
2585, d4x2kA1, 0.7653, 2.77, 0.210, 302, 252, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2586, d4x2jA1, 0.7653, 2.77, 0.210, 302, 252, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2587, d4gihA1, 0.7653, 2.78, 0.222, 287, 252, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}BENZAMIDE
2588, d4g17A1, 0.7653, 2.75, 0.196, 301, 255, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-TERT-BUTYLPHENYL)AMINO]-1H- BENZIMIDAZOLE-6-CARBONITRILE
2589, d2yabB_, 0.7653, 2.86, 0.256, 299, 254, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
2590, d2x2mB1, 0.7653, 2.67, 0.241, 274, 249, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
2591, d2dq7X_, 0.7653, 2.46, 0.235, 262, 247, CRYSTAL STRUCTURE OF FYN KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
2592, d2ckeB_, 0.7653, 2.94, 0.239, 300, 255, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2593, d1yxtA_, 0.7653, 2.56, 0.261, 274, 249, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMPPNP
2594, d5uglA_, 0.7652, 2.87, 0.241, 285, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
2595, d5orxA_, 0.7652, 2.44, 0.298, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2596, d4fsqA_, 0.7652, 2.44, 0.276, 263, 246, CRYSTAL STRUCTURE OF THE CHK1
2597, d3nrmA_, 0.7652, 2.53, 0.289, 263, 249, IMIDAZO[12-A]PYRAZINE-BASED AURORA KINASE INHIBITORS
2598, d5x18B_, 0.7651, 2.86, 0.195, 294, 256, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
2599, d5uhnA_, 0.7651, 2.92, 0.237, 282, 253, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
2600, d4j95A_, 0.7651, 2.71, 0.244, 279, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
2601, d4bzoA_, 0.7651, 2.49, 0.266, 272, 248, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO- PYRAZINONE INHIBITOR
2602, d3pa4A_, 0.7651, 2.54, 0.274, 257, 248, X-RAY CRYSTAL STRUCTURE OF COMPOUND 2A BOUND TO HUMAN CHK1 KINASE DOMAIN
2603, d1zwsC_, 0.7651, 2.66, 0.254, 278, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2604, d5e8yA_, 0.7650, 2.68, 0.232, 298, 250, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH STAUROSPORINE
2605, d4x2nA1, 0.7650, 2.77, 0.210, 302, 252, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2606, d4n6zA_, 0.7650, 2.51, 0.266, 272, 248, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
2607, d4hokE_, 0.7650, 2.86, 0.184, 291, 256, CRYSTAL STRUCTURE OF APO CK1E
2608, d5orsA_, 0.7649, 2.44, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2609, d3pa3A_, 0.7649, 2.54, 0.274, 259, 248, X-RAY CRYSTAL STRUCTURE OF COMPOUND 70 BOUND TO HUMAN CHK1 KINASE DOMAIN
2610, d3kmmA_, 0.7649, 2.58, 0.221, 270, 249, STRUCTURE OF HUMAN LCK KINASE WITH A SMALL MOLECULE INHIBITOR
2611, d4zs0A_, 0.7648, 2.24, 0.303, 257, 244, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO SB-6-OH
2612, d4x2gA1, 0.7648, 2.78, 0.210, 302, 252, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2613, d4li5A1, 0.7648, 2.79, 0.210, 303, 252, EGFR-K IN COMPLEX WITH N-[3-[[5-CHLORO-4-(1H-INDOL-3-YL)PYRIMIDIN-2- YL]AMINO]-4-METHOXY-PHENYL] PROP-2-ENAMIDE
2614, d4k33A_, 0.7648, 2.83, 0.241, 293, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 3 (FGFR3) KINASE DOMAIN HARBORING THE K650E MUTATION A GAIN-OF-FUNCTION MUTATION RESPONSIBLE FOR THANATOPHORIC DYSPLASIA TYPE II AND SPERMATOCYTIC SEMINOMA
2615, d2z2wA_, 0.7648, 2.49, 0.224, 260, 246, HUMAND WEE1 KINASE COMPLEXED WITH INHIBITOR PF0335770
2616, d2xj1A_, 0.7648, 2.49, 0.266, 273, 248, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INIBITOR
2617, d4twcA_, 0.7647, 2.80, 0.191, 293, 256, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
2618, d4hokG_, 0.7647, 2.85, 0.184, 290, 256, CRYSTAL STRUCTURE OF APO CK1E
2619, d4gj3A1, 0.7647, 2.79, 0.218, 287, 252, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
2620, d4f1oA1, 0.7647, 2.61, 0.230, 274, 248, CRYSTAL STRUCTURE OF THE L1180T MUTANT ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO APPCP
2621, d2xj2A_, 0.7647, 2.38, 0.263, 273, 247, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2622, d1pkgA_, 0.7647, 2.75, 0.223, 290, 251, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
2623, d6bleA1, 0.7646, 2.56, 0.286, 263, 248, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CP673451
2624, d5fqdC_, 0.7646, 2.87, 0.199, 294, 256, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
2625, d5e8zA1, 0.7646, 2.71, 0.216, 300, 250, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3- AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3- YL]PYRAZINE-2-CARBOXAMIDE
2626, d5amnA1, 0.7646, 2.84, 0.238, 282, 252, THE DISCOVERY OF 2-SUBSTITUTED PHENOL QUINAZOLINES AS POTENT AND SELECTIVE RET KINASE INHIBITORS
2627, d4x2fA1, 0.7646, 2.78, 0.210, 302, 252, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2628, d4gj2A1, 0.7646, 2.79, 0.222, 287, 252, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
2629, d4btjA_, 0.7646, 2.87, 0.191, 292, 257, TTBK1 IN COMPLEX WITH ATP
2630, d3ppzA_, 0.7646, 2.21, 0.255, 264, 243, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2631, d2wotA_, 0.7646, 2.72, 0.216, 303, 250, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
2632, d2wotA1, 0.7646, 2.72, 0.216, 301, 250, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
2633, d2w4kA_, 0.7646, 2.83, 0.252, 301, 254, X-RAY STRUCTURE OF A DAP-KINASE 2-302
2634, d5o12A_, 0.7645, 2.34, 0.272, 264, 246, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
2635, d5ax9A_, 0.7645, 2.28, 0.252, 282, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2636, d4giiA1, 0.7645, 2.80, 0.222, 287, 252, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
2637, d3ri1B_, 0.7645, 2.75, 0.238, 283, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
2638, d2zm3C2, 0.7645, 2.84, 0.216, 295, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2639, d4x0mA1, 0.7644, 2.78, 0.210, 302, 252, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2640, d4hokS_, 0.7644, 2.87, 0.195, 286, 256, CRYSTAL STRUCTURE OF APO CK1E
2641, d4hokK_, 0.7644, 2.88, 0.187, 290, 256, CRYSTAL STRUCTURE OF APO CK1E
2642, d4btmA_, 0.7644, 2.83, 0.187, 292, 257, TTBK1 IN COMPLEX WITH INHIBITOR
2643, d3sxrB1, 0.7644, 2.51, 0.206, 255, 248, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
2644, d2yabA_, 0.7644, 2.86, 0.260, 299, 254, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
2645, d2x0gA_, 0.7644, 2.94, 0.250, 318, 256, X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX
2646, d1ol7A_, 0.7644, 2.40, 0.296, 261, 247, STRUCTURE OF HUMAN AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288
2647, d5mjaB_, 0.7643, 2.56, 0.223, 274, 251, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
2648, d4j99A_, 0.7643, 2.82, 0.243, 280, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
2649, d3ug1A_, 0.7643, 2.43, 0.202, 296, 247, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN THE APO FORM
2650, d2xf0A_, 0.7643, 2.30, 0.270, 251, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2651, d2qohB2, 0.7643, 2.76, 0.226, 280, 252, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
2652, d2a2aD_, 0.7643, 2.92, 0.239, 303, 255, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2653, d5c26A1, 0.7642, 2.78, 0.202, 271, 253, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 1
2654, d4ytfA_, 0.7642, 2.69, 0.258, 283, 252, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
2655, d4cegA_, 0.7642, 2.47, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA A 122-403 C290A C393A BOUND TO ADP
2656, d4bn1A_, 0.7642, 2.33, 0.285, 261, 246, CRYSTAL STRUCTURE OF V174M MUTANT OF AURORA-A KINASE
2657, d3lm0A1, 0.7642, 2.47, 0.243, 271, 247, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B)
2658, d2ckeA_, 0.7642, 2.94, 0.239, 301, 255, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2659, d5w4wD_, 0.7641, 2.65, 0.187, 287, 252, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2660, d5ortA_, 0.7641, 2.45, 0.298, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2661, d5ar2B_, 0.7641, 2.88, 0.224, 285, 255, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
2662, d4l46A_, 0.7641, 2.52, 0.308, 317, 247, CRYSTAL STRUCTURES OF HUMAN P70S6K1-WT
2663, d3byoA_, 0.7641, 2.69, 0.220, 270, 250, X-RAY CO-CRYSTAL STRUCTURE OF 2-AMINO-6-PHENYLPYRIMIDO[5  4 :56]PYRIMIDO[12-A]BENZIMIDAZOL-5(6H)-ONE 25 BOUND TO LCK
2664, d2xezA_, 0.7641, 2.31, 0.270, 249, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2665, d1yi3A_, 0.7641, 2.31, 0.268, 267, 246, CRYSTAL STRUCTURE OF PIM-1 BOUND TO LY294002
2666, d5o13A_, 0.7640, 2.33, 0.268, 270, 246, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
2667, d4twpA_, 0.7640, 2.43, 0.231, 266, 247, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
2668, d4trlA_, 0.7640, 2.46, 0.210, 268, 248, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
2669, d1zwsA_, 0.7640, 2.66, 0.250, 278, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2670, d5oq8A_, 0.7639, 2.50, 0.265, 261, 249, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2671, d4hokC_, 0.7639, 2.84, 0.184, 289, 256, CRYSTAL STRUCTURE OF APO CK1E
2672, d3iokA_, 0.7639, 2.70, 0.258, 285, 252, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
2673, d6bqlA1, 0.7638, 2.49, 0.271, 276, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH TAE-226
2674, d5kziA_, 0.7638, 2.43, 0.258, 273, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN IMIDAZOPYRIDAZINE INHIBITOR.
2675, d5gtzA_, 0.7638, 2.83, 0.202, 317, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH JTS-1-39
2676, d4gvjA1, 0.7638, 2.84, 0.226, 288, 252, TYK2 (JH1) IN COMPLEX WITH ADENOSINE DI-PHOSPHATE
2677, d4f0fA1, 0.7638, 2.58, 0.226, 274, 248, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM
2678, d2yaaB_, 0.7638, 2.89, 0.260, 299, 254, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
2679, d5os6A_, 0.7637, 2.46, 0.298, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2680, d5os4A_, 0.7637, 2.46, 0.294, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2681, d4ythA_, 0.7637, 2.68, 0.254, 287, 252, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
2682, d4f1mA1, 0.7637, 2.62, 0.226, 274, 248, CRYSTAL STRUCTURE OF THE G1179S ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM.
2683, d5es1A_, 0.7636, 2.20, 0.333, 304, 240, CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
2684, d4wsqA_, 0.7636, 2.39, 0.247, 317, 247, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2685, d3bi6A_, 0.7636, 2.51, 0.224, 258, 246, WEE1 KINASE COMPLEX WITH INHIBITOR PD352396
2686, d3ac5A_, 0.7636, 2.71, 0.220, 270, 250, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2687, d2a2aC_, 0.7636, 2.95, 0.239, 303, 255, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2688, d1csnA_, 0.7636, 2.86, 0.180, 293, 256, BINARY COMPLEX OF CASEIN KINASE-1 WITH MGATP
2689, d5l8lA_, 0.7635, 2.56, 0.297, 263, 249, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 1)
2690, d4wnoA_, 0.7635, 2.70, 0.297, 272, 249, STRUCTURE OF ULK1 BOUND TO AN INHIBITOR
2691, d3lvpC_, 0.7635, 2.83, 0.209, 293, 254, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
2692, d3dqwB_, 0.7635, 2.64, 0.244, 278, 250, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
2693, d2xixA_, 0.7635, 2.47, 0.267, 272, 247, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-1 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2694, d5vc4A_, 0.7634, 2.55, 0.215, 261, 247, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB-ISOMER
2695, d5tt7A1, 0.7634, 2.42, 0.206, 270, 248, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
2696, d4zy6B_, 0.7634, 2.55, 0.300, 280, 247, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
2697, d4hokM_, 0.7634, 2.90, 0.184, 291, 256, CRYSTAL STRUCTURE OF APO CK1E
2698, d3uixA_, 0.7634, 2.33, 0.264, 266, 246, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2699, d3cqeA_, 0.7634, 2.51, 0.224, 258, 246, WEE1 KINASE COMPLEX WITH INHIBITOR PD074291
2700, d2zm1A_, 0.7634, 2.72, 0.220, 270, 250, CRYSTAL STRUCTURE OF IMIDAZO PYRAZIN 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2701, d2wmrA_, 0.7634, 2.32, 0.270, 254, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2702, d2hziA_, 0.7634, 2.68, 0.220, 268, 250, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
2703, d1zwsE_, 0.7634, 2.65, 0.250, 278, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2704, d1qpdA_, 0.7634, 2.62, 0.221, 270, 249, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
2705, d5opbA_, 0.7633, 2.51, 0.268, 262, 250, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH INDAZOLE LRRK2 INHIBITOR
2706, d4kb8D_, 0.7633, 2.64, 0.187, 278, 251, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
2707, d4hokQ_, 0.7633, 2.88, 0.184, 290, 256, CRYSTAL STRUCTURE OF APO CK1E
2708, d5ih4A_, 0.7632, 2.82, 0.199, 286, 256, HUMAN CASEIN KINASE 1 ISOFORM DELTA APO (KINASE DOMAIN)
2709, d4hzrA_, 0.7632, 2.30, 0.257, 261, 245, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
2710, d4gfmA_, 0.7632, 2.71, 0.254, 289, 252, JAK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
2711, d3we4A_, 0.7632, 2.63, 0.306, 286, 248, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRIMIDINE DERIVATIVE PF-4708671 2-{[4-(5-ETHYLPYRIMIDIN-4-YL)PIPERAZIN-1- YL]METHYL}-5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOLE
2712, d2wmxA_, 0.7632, 2.25, 0.272, 248, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2713, d2ivuA1, 0.7632, 2.81, 0.239, 283, 251, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR ZD6474
2714, d3ac2A_, 0.7631, 2.73, 0.220, 270, 250, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2715, d2pvyC_, 0.7631, 2.72, 0.237, 285, 249, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
2716, d2ofuA_, 0.7631, 2.71, 0.220, 272, 250, X-RAY CRYSTAL STRUCTURE OF 2-AMINOPYRIMIDINE CARBAMATE 43 BOUND TO LCK
2717, d4l42A_, 0.7630, 2.67, 0.297, 299, 249, CRYSTAL STRUCTURES OF HUMAN P70S6K1-PIF
2718, d3lckA_, 0.7630, 2.62, 0.221, 270, 249, THE KINASE DOMAIN OF HUMAN LYMPHOCYTE KINASE (LCK) ACTIVATED FORM (AUTO-PHOSPHORYLATED ON TYR394)
2719, d3dqwA_, 0.7630, 2.65, 0.244, 278, 250, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
2720, d1qpcA_, 0.7630, 2.62, 0.221, 270, 249, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
2721, d4xeyB2, 0.7629, 2.73, 0.200, 264, 250, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
2722, d4nt4A1, 0.7629, 2.80, 0.195, 299, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF GILGAMESH ISOFORM I FROM DROSOPHILA MELANOGASTER
2723, d4dhfA_, 0.7629, 2.52, 0.296, 258, 247, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
2724, d3ac1A_, 0.7629, 2.62, 0.221, 270, 249, CRYSTAL STRUCTURE OF PYRAZIN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2725, d2zybA_, 0.7629, 2.61, 0.221, 270, 249, CRYSTAL STRUCTURE OF PHENYLIMIDAZO PYRAZIN 2 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2726, d2ym5A_, 0.7629, 2.27, 0.272, 248, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2727, d2hziB_, 0.7629, 2.52, 0.219, 264, 247, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
2728, d1y57A3, 0.7629, 2.59, 0.241, 285, 249, STRUCTURE OF UNPHOSPHORYLATED C-SRC IN COMPLEX WITH AN INHIBITOR
2729, d5vubB_, 0.7628, 2.47, 0.263, 269, 247, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
2730, d6bqpA1, 0.7627, 2.47, 0.287, 262, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CRENOLANIB
2731, d5cwzB_, 0.7627, 2.47, 0.249, 284, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
2732, d4kbaD_, 0.7627, 2.66, 0.195, 274, 251, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
2733, d4d0wA_, 0.7627, 2.71, 0.258, 289, 252, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
2734, d3f5pD1, 0.7627, 2.80, 0.208, 296, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2735, d2x7fA_, 0.7627, 2.18, 0.259, 276, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2736, d2a2aA_, 0.7627, 2.96, 0.239, 304, 255, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2737, d1u54B_, 0.7627, 2.31, 0.261, 261, 245, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
2738, d4l45A_, 0.7626, 2.50, 0.306, 317, 245, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389E
2739, d3f5pH1, 0.7626, 2.80, 0.208, 298, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2740, d3f5pC1, 0.7626, 2.80, 0.208, 300, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2741, d3f5pA1, 0.7626, 2.81, 0.208, 298, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2742, d2zm4A_, 0.7626, 2.72, 0.220, 270, 250, CRYSTAL STRUCTURE OF IMIDAZO QUINOXALINE 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK ACTIVATED FORM (AUTO- PHOSPHORYLATED ON TYR394)
2743, d2qg5D1, 0.7626, 2.61, 0.264, 267, 250, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
2744, d4l3jA_, 0.7625, 2.70, 0.297, 291, 249, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN
2745, d4ftnA_, 0.7625, 2.45, 0.278, 253, 245, CRYSTAL STRUCTURE OF THE CHK1
2746, d3clyA_, 0.7625, 2.96, 0.236, 289, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAINS TRAPPED IN TRANS-PHOSPHORYLATION REACTION
2747, d2ydkA_, 0.7625, 2.65, 0.268, 263, 250, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
2748, d4z16B_, 0.7624, 2.63, 0.253, 276, 249, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
2749, d3acjA_, 0.7624, 2.62, 0.221, 270, 249, CRYSTAL STRUCTURE OF IMIDAZO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2750, d3ac3A_, 0.7624, 2.62, 0.221, 270, 249, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2751, d2pzrB_, 0.7624, 2.79, 0.234, 282, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2752, d2c47C_, 0.7624, 2.61, 0.207, 282, 251, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
2753, d1qpjA_, 0.7624, 2.63, 0.221, 265, 249, CRYSTAL STRUCTURE OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH STAUROSPORINE.
2754, d5vc6A_, 0.7623, 2.50, 0.220, 259, 245, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
2755, d3kulA_, 0.7623, 2.47, 0.206, 267, 248, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
2756, d3e63A_, 0.7623, 2.72, 0.258, 290, 252, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
2757, d3ackA_, 0.7623, 2.62, 0.221, 270, 249, CRYSTAL STRUCTURE OF PYRROLO PYRAZINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2758, d2hk5A2, 0.7623, 2.59, 0.242, 268, 248, HCK KINASE IN COMPLEX WITH LCK TARGETTED INHIBITOR PG-1009247
2759, d5v5yA_, 0.7622, 2.47, 0.234, 259, 244, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH MK1775
2760, d5usqA_, 0.7622, 2.63, 0.217, 299, 249, ALK-5 KINASE INHIBITOR COMPLEX
2761, d4rx7A1, 0.7622, 2.57, 0.204, 270, 250, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR
2762, d4fl1A_, 0.7622, 2.46, 0.206, 268, 248, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
2763, d4d0xA_, 0.7622, 2.71, 0.258, 291, 252, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
2764, d3ad5A_, 0.7622, 2.63, 0.221, 270, 249, CRYSTAL STRUCTURE OF TRIAZOLONE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2765, d2yaaA_, 0.7622, 2.90, 0.260, 300, 254, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
2766, d5imeA1, 0.7621, 2.12, 0.293, 279, 242, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
2767, d5e8sA1, 0.7621, 2.63, 0.217, 299, 249, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
2768, d4ytcA_, 0.7621, 2.72, 0.254, 284, 252, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
2769, d4kbkD_, 0.7621, 2.66, 0.187, 281, 251, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
2770, d3f5pT1, 0.7621, 2.78, 0.209, 294, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2771, d2ivvA1, 0.7621, 2.72, 0.241, 277, 249, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR PP1
2772, d2fo0A3, 0.7621, 2.73, 0.223, 291, 251, ORGANIZATION OF THE SH3-SH2 UNIT IN ACTIVE AND INACTIVE FORMS OF THE C-ABL TYROSINE KINASE
2773, d5o11A_, 0.7620, 2.34, 0.268, 268, 246, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
2774, d3f5pG1, 0.7620, 2.81, 0.208, 298, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2775, d2x4fB_, 0.7620, 2.77, 0.253, 288, 253, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
2776, d3op5A_, 0.7619, 2.95, 0.138, 320, 260, HUMAN VACCINIA-RELATED KINASE 1
2777, d3eyhA_, 0.7619, 2.72, 0.240, 285, 250, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
2778, d3bceC_, 0.7619, 2.71, 0.212, 286, 250, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
2779, d3ad4A_, 0.7619, 2.62, 0.221, 270, 249, CRYSTAL STRUCTURE OF METHOXY BENZOFURAN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2780, d1x8bA_, 0.7619, 2.48, 0.224, 259, 245, STRUCTURE OF HUMAN WEE1A KINASE: KINASE DOMAIN COMPLEXED WITH INHIBITOR PD0407824
2781, d5vucB_, 0.7618, 2.50, 0.263, 269, 247, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
2782, d5i3oB_, 0.7618, 2.49, 0.258, 302, 248, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2783, d4enyA_, 0.7618, 2.37, 0.260, 261, 246, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH (2E5Z)-2-(2- CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-METHOXYBENZYLIDENE)THIAZOLIDIN-4- ONE
2784, d4enxA_, 0.7618, 2.37, 0.260, 266, 246, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH INHIBITOR (2E5Z)-2- (2-CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-NITROBENZYLIDENE)THIAZOLIDIN-4- ONE
2785, d3op5B_, 0.7618, 2.95, 0.138, 319, 260, HUMAN VACCINIA-RELATED KINASE 1
2786, d3f5pB1, 0.7618, 2.81, 0.208, 297, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2787, d3ad6A_, 0.7618, 2.62, 0.221, 272, 249, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2788, d3ac4A_, 0.7618, 2.62, 0.221, 270, 249, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2789, d2clqA_, 0.7618, 2.50, 0.273, 263, 245, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2790, d1qpeA_, 0.7618, 2.63, 0.221, 270, 249, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
2791, d3nz0A1, 0.7617, 2.72, 0.224, 283, 250, NON-PHOSPHORYLATED TYK2 KINASE WITH CMP6
2792, d3ac8A_, 0.7617, 2.63, 0.221, 270, 249, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2793, d2xzsA_, 0.7617, 2.92, 0.252, 301, 254, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
2794, d2x4fA_, 0.7617, 2.78, 0.253, 289, 253, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
2795, d1mq4A_, 0.7617, 2.47, 0.291, 261, 247, CRYSTAL STRUCTURE OF AURORA-A PROTEIN KINASE
2796, d1ckiA_, 0.7617, 2.85, 0.191, 292, 256, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
2797, d6bu6A_, 0.7616, 2.96, 0.142, 322, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
2798, d5ci7A_, 0.7616, 2.69, 0.298, 276, 248, STRUCTURE OF ULK1 BOUND TO A SELECTIVE INHIBITOR
2799, d5aepA_, 0.7616, 2.72, 0.254, 287, 252, NOVEL PYRROLE CARBOXAMIDE INHIBITORS OF JAK2 AS POTENTIAL TREATMENT OF MYELOPROLIFERATIVE DISORDERS
2800, d4tn6A_, 0.7616, 2.91, 0.187, 292, 256, CK1D IN COMPLEX WITH INHIBITOR
2801, d4dhfB_, 0.7616, 2.43, 0.297, 258, 246, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
2802, d3uysA_, 0.7616, 2.67, 0.183, 281, 251, CRYSTAL STRUCTURE OF APO HUMAN CK1D
2803, d2y0aA_, 0.7616, 2.84, 0.252, 300, 254, STRUCTURE OF DAPK1 CONSTRUCT RESIDUES 1-304
2804, d1u4dB_, 0.7616, 2.22, 0.259, 262, 243, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
2805, d4wnpC_, 0.7615, 2.68, 0.298, 271, 248, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2806, d4fstA_, 0.7615, 2.41, 0.275, 253, 244, CRYSTAL STRUCTURE OF THE CHK1
2807, d3naxA_, 0.7615, 2.67, 0.255, 278, 251, PDK1 IN COMPLEX WITH INHIBITOR MP7
2808, d4py1A_, 0.7614, 2.87, 0.230, 289, 252, CRYSTAL STRUCTURE OF TYK2 IN COMPLEX WITH COMPOUND 15 6-((25- DIMETHOXYPHENYL)THIO)-3-(1-METHYL-1H-PYRAZOL-4-YL)-[124]TRIAZOLO[4 3-B]PYRIDAZINE
2809, d4j99D_, 0.7614, 2.76, 0.245, 281, 249, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
2810, d3f5pF1, 0.7614, 2.82, 0.208, 298, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2811, d3e62A_, 0.7614, 2.81, 0.249, 291, 253, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
2812, d2bvaA_, 0.7614, 2.20, 0.258, 272, 244, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
2813, d1xbcA1, 0.7614, 2.41, 0.206, 267, 247, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH STAUROSPORIN
2814, d4xg6A1, 0.7613, 2.59, 0.204, 270, 250, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2815, d3e64A_, 0.7613, 2.73, 0.258, 291, 252, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
2816, d5ukfA_, 0.7612, 2.96, 0.142, 322, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
2817, d5u94A_, 0.7612, 2.39, 0.265, 263, 245, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PASTA KINASE PKNB IN COMPLEX WITH THE POTENTIAL THERAPUTIC KINASE INHIBITOR GSK690693.
2818, d5deyB_, 0.7612, 2.53, 0.300, 281, 247, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
2819, d3ma3A_, 0.7612, 2.32, 0.269, 266, 245, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A NAPHTHO-DIFURAN LIGAND
2820, d5uoxA_, 0.7611, 2.58, 0.278, 263, 245, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2821, d5tozA_, 0.7611, 2.62, 0.248, 278, 250, JAK3 WITH COVALENT INHIBITOR PF-06651600
2822, d5orlA_, 0.7611, 2.49, 0.302, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2823, d5objA_, 0.7611, 2.46, 0.305, 260, 246, AURORA A KINASE IN COMPLEX WITH 2-(3-FLUOROPHENYL)QUINOLINE-4- CARBOXYLIC ACID AND ATP
2824, d4zimB1, 0.7611, 2.85, 0.253, 292, 253, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
2825, d4e4mD_, 0.7611, 2.79, 0.258, 296, 252, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2826, d3jy9A_, 0.7611, 2.68, 0.259, 282, 251, JANUS KINASE 2 INHIBITORS
2827, d2ym6A_, 0.7611, 2.31, 0.272, 253, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2828, d5v24B_, 0.7610, 2.59, 0.278, 263, 245, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2829, d4xg7A1, 0.7610, 2.64, 0.203, 265, 251, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2830, d4jikA_, 0.7610, 2.37, 0.270, 256, 244, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22A (R)-2-(4-CHLOROPHENYL)-8- (PIPERIDIN-3-YLAMINO)IMIDAZO[12-C]PYRIMIDINE-5-CARBOXAMIDE BOUND TO HUMAN CHK1 KINASE DOMAIN
2831, d3f5pE1, 0.7610, 2.82, 0.208, 298, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2832, d4jboA_, 0.7609, 2.64, 0.297, 266, 249, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
2833, d4e4mB_, 0.7609, 2.80, 0.258, 296, 252, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2834, d2vz6A1, 0.7609, 2.88, 0.303, 285, 251, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
2835, d5nk5A_, 0.7608, 2.70, 0.206, 287, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1M
2836, d5i3rB_, 0.7608, 2.50, 0.258, 302, 248, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2837, d4yc8A_, 0.7608, 2.72, 0.209, 259, 249, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
2838, d4kbaB_, 0.7608, 2.62, 0.184, 285, 250, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
2839, d2a2aB_, 0.7608, 3.01, 0.239, 303, 255, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2840, d5nkeA_, 0.7607, 2.70, 0.206, 292, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3A
2841, d5cy3A1, 0.7607, 2.68, 0.203, 274, 251, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT AND ORALLY BIOAVAILABLE BENZISOTHIAZOLE INHIBITOR
2842, d4ytiA_, 0.7607, 2.69, 0.255, 284, 251, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
2843, d4bbfD_, 0.7607, 2.78, 0.250, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2844, d3umwA_, 0.7607, 2.41, 0.268, 264, 246, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDAZOL-3-YL)METHYLENE]-6-METHOXY-7-(PIPERAZIN-1-YLMETHYL)BENZOFURAN- 3(2H)-ONE
2845, d3lxlA_, 0.7607, 2.66, 0.248, 281, 250, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
2846, d5lmaA_, 0.7606, 2.50, 0.190, 267, 248, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
2847, d5c27A1, 0.7606, 2.77, 0.202, 271, 252, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 2
2848, d4wnmA1, 0.7606, 2.52, 0.209, 269, 249, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT TRIAZOLOPYRIDINE INHIBITOR
2849, d2wouA_, 0.7606, 2.60, 0.218, 299, 248, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
2850, d2wouA1, 0.7606, 2.60, 0.218, 297, 248, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
2851, d2b4sB_, 0.7606, 3.06, 0.197, 294, 254, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
2852, d1ckjA_, 0.7605, 2.86, 0.195, 296, 256, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
2853, d5usyB_, 0.7604, 2.70, 0.260, 287, 250, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
2854, d5j95A_, 0.7604, 2.51, 0.250, 284, 248, MAP4K4 IN COMPLEX WITH INHIBITOR
2855, d4kbaC_, 0.7604, 2.71, 0.190, 277, 252, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
2856, d4bbfA_, 0.7604, 2.79, 0.250, 288, 252, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2857, d2wmtA_, 0.7604, 2.31, 0.267, 248, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2858, d4hzrB_, 0.7603, 2.35, 0.261, 258, 245, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
2859, d2ya9A_, 0.7603, 3.02, 0.247, 299, 255, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
2860, d5nkhA_, 0.7602, 2.71, 0.206, 295, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3E
2861, d5ghvB_, 0.7602, 2.32, 0.200, 265, 245, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2862, d5e91A_, 0.7602, 2.74, 0.233, 297, 249, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4- (MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE
2863, d4xg5B_, 0.7602, 2.32, 0.200, 265, 245,  
2864, d4rixB_, 0.7602, 2.63, 0.217, 293, 249, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
2865, d4kb8B_, 0.7602, 2.64, 0.184, 285, 250, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
2866, d4e4mA_, 0.7602, 2.92, 0.249, 296, 253, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2867, d4dflA1, 0.7602, 2.41, 0.206, 262, 247, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A SULFONAMIDOPYRAZINE PIPERIDINE INHIBITOR
2868, d4xg3A_, 0.7601, 2.45, 0.206, 262, 248, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2869, d2ym3A_, 0.7601, 2.27, 0.269, 247, 242, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2870, d2auhA1, 0.7601, 3.09, 0.196, 294, 255, CRYSTAL STRUCTURE OF THE GRB14 BPS REGION IN COMPLEX WITH THE INSULIN RECEPTOR TYROSINE KINASE
2871, d6bruA_, 0.7600, 2.99, 0.146, 322, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
2872, d5ghvA_, 0.7600, 2.32, 0.200, 265, 245, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2873, d4xg5A_, 0.7600, 2.32, 0.200, 265, 245,  
2874, d4u42A_, 0.7600, 2.47, 0.255, 282, 247, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
2875, d4rioA_, 0.7600, 2.67, 0.247, 285, 251, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE CARBOXAMIDE INHIBITOR
2876, d4e4mE_, 0.7600, 2.92, 0.249, 296, 253, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2877, d4e20A_, 0.7600, 2.80, 0.220, 282, 250, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
2878, d3dk3B_, 0.7600, 2.74, 0.217, 269, 249, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
2879, d2b4sD_, 0.7600, 3.03, 0.198, 294, 253, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
2880, d5cxzA1, 0.7599, 2.42, 0.206, 267, 247, SYK CATALYTIC DOMAIN COMPLEXED WITH NAPHTHYRIDINE INHIBITOR
2881, d4kb8C_, 0.7599, 2.72, 0.190, 277, 252, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
2882, d3sv0A_, 0.7599, 2.91, 0.180, 294, 256, CRYSTAL STRUCTURE OF CASEIN KINASE-1 LIKE PROTEIN IN PLANT
2883, d3kxzA_, 0.7599, 2.80, 0.220, 263, 250, THE COMPLEX CRYSTAL STRUCTURE OF LCK WITH A PROBE MOLECULE W259
2884, d5dosA_, 0.7598, 2.43, 0.302, 259, 245, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
2885, d4riwB_, 0.7598, 2.59, 0.206, 293, 248, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
2886, d3io7A_, 0.7598, 2.70, 0.259, 282, 251, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
2887, d5friA1, 0.7597, 2.66, 0.213, 299, 249, ALK5 IN COMPLEX WITHA AN N-(4-ANILINO-2-PYRIDYL)ACETAMIDE INHIBITOR.
2888, d5e8tA1, 0.7597, 2.76, 0.212, 300, 250, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
2889, d4w9xA_, 0.7597, 2.42, 0.260, 300, 246, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH BARICITINIB
2890, d4hvgA_, 0.7597, 2.64, 0.248, 281, 250, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-2-HYDROXY-12-DIMETHYL-PROPYL)- AMIDE
2891, d3zewA_, 0.7597, 2.37, 0.216, 269, 245, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
2892, d2a27D_, 0.7597, 2.97, 0.251, 304, 255, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2893, d1bi8C_, 0.7597, 2.37, 0.483, 264, 242, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
2894, d1bi8A_, 0.7597, 2.37, 0.483, 264, 242, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
2895, d4xg3B_, 0.7596, 2.54, 0.198, 267, 248, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2896, d3fqhA_, 0.7596, 2.48, 0.206, 262, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
2897, d3f5pI1, 0.7596, 2.80, 0.209, 293, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2898, d2x6dA_, 0.7596, 2.36, 0.291, 255, 244, AURORA-A BOUND TO AN INHIBITOR
2899, d2wmwA_, 0.7596, 2.25, 0.273, 247, 242, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2900, d5usyA_, 0.7595, 2.76, 0.252, 287, 250, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
2901, d5lwmA_, 0.7595, 2.80, 0.245, 290, 253, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 4 (FM381)
2902, d5cf5B1, 0.7595, 2.86, 0.253, 292, 253, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2903, d3r7oA1, 0.7595, 2.96, 0.217, 295, 253, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG
2904, d2bdwA_, 0.7595, 2.82, 0.297, 309, 256, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
2905, d5x17B_, 0.7594, 2.90, 0.191, 289, 256, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
2906, d4pv0A1, 0.7594, 2.48, 0.206, 266, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH AN IMIDAZOPYRAZINE INHIBITOR
2907, d3dk7B_, 0.7594, 2.71, 0.225, 268, 249, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
2908, d1u54A_, 0.7594, 2.44, 0.252, 262, 246, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
2909, d5lwnA_, 0.7593, 2.80, 0.245, 290, 253, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 5 (FM409)
2910, d5cf4B_, 0.7593, 2.88, 0.253, 291, 253, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2911, d4wkqA1, 0.7593, 2.52, 0.206, 294, 247, 1.85 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN WITH GEFITINIB
2912, d3f5pS1, 0.7593, 2.80, 0.209, 294, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2913, d3f5pM1, 0.7593, 2.83, 0.208, 294, 255, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2914, d2w1iB_, 0.7593, 2.88, 0.250, 284, 252, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2915, d5cwzA_, 0.7592, 2.52, 0.253, 284, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
2916, d4iwdA1, 0.7592, 2.92, 0.217, 295, 253, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-8033 ANALOG
2917, d5tr6A1, 0.7591, 2.44, 0.206, 268, 247, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
2918, d4riyB_, 0.7591, 2.62, 0.206, 293, 248, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
2919, d3dqwC_, 0.7591, 2.60, 0.234, 275, 248, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
2920, d5dt4A_, 0.7590, 2.43, 0.302, 259, 245, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
2921, d4f1tA1, 0.7590, 2.63, 0.227, 267, 247, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO THE ROCK INHIBITOR H1152
2922, d4dfnA1, 0.7590, 2.49, 0.206, 268, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH AN ADAMANTYLPYRAZINE INHIBITOR
2923, d2ya9B_, 0.7590, 3.02, 0.247, 299, 255, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
2924, d5oq7A_, 0.7589, 2.49, 0.274, 259, 248, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2925, d2a27H_, 0.7589, 2.89, 0.252, 304, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2926, d2a27F_, 0.7589, 2.89, 0.252, 303, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2927, d5mqvC_, 0.7588, 2.88, 0.191, 288, 256, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
2928, d2a27A_, 0.7588, 3.03, 0.239, 304, 255, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2929, d3dqwD_, 0.7587, 2.59, 0.234, 276, 248, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
2930, d2w1iA_, 0.7587, 2.79, 0.247, 284, 251, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2931, d2a27B_, 0.7587, 2.90, 0.252, 303, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2932, d5tiuA1, 0.7586, 2.44, 0.206, 262, 247, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH INHIBITOR
2933, d5gmpA_, 0.7586, 2.75, 0.205, 305, 249, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH XTF-262
2934, d3q6wA1, 0.7586, 2.93, 0.217, 293, 253, STRUCTURE OF DUALLY-PHOSPHORYLATED MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG WITH SPECIFICITY FOR THE ACTIVATED RECEPTOR
2935, d3krrA1, 0.7586, 2.78, 0.258, 290, 252, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT QUINOXALINE ATP SITE INHIBITOR
2936, d2a27C_, 0.7585, 2.93, 0.240, 303, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2937, d5ax9B_, 0.7584, 2.22, 0.251, 274, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2938, d5ar5A_, 0.7584, 2.72, 0.227, 284, 251, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
2939, d4rx9A1, 0.7584, 2.46, 0.202, 264, 247, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT PYRIMIDINE INHIBITOR
2940, d4rssA_, 0.7584, 2.64, 0.196, 269, 250, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE SYK WITH AN INHIBITOR
2941, d4l44A_, 0.7584, 2.68, 0.302, 321, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM II)
2942, d4kbkA_, 0.7584, 2.66, 0.184, 283, 250, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
2943, d2a27G_, 0.7584, 2.98, 0.251, 303, 255, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2944, d4jjrB_, 0.7582, 2.84, 0.180, 283, 256, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
2945, d2pvyB_, 0.7582, 2.63, 0.239, 286, 247, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
2946, d1iasB_, 0.7582, 2.81, 0.208, 324, 250, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
2947, d3vf8A_, 0.7581, 2.46, 0.206, 265, 247, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH PYRAZOLYLBENZIMIDAZOLE INHIBITOR 416
2948, d3bceA_, 0.7581, 2.68, 0.213, 285, 249, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
2949, d2ym7A_, 0.7581, 2.38, 0.276, 248, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2950, d4d1sA_, 0.7580, 2.59, 0.259, 280, 247, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
2951, d1xbaA1, 0.7580, 2.46, 0.206, 265, 247, CRYSTAL STRUCTURE OF APO SYK TYROSINE KINASE DOMAIN
2952, d1ckiB_, 0.7580, 2.87, 0.191, 286, 256, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
2953, d5eakA_, 0.7579, 2.61, 0.322, 305, 242, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
2954, d2a27E_, 0.7579, 2.91, 0.252, 303, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2955, d3uysB_, 0.7578, 2.62, 0.181, 279, 249, CRYSTAL STRUCTURE OF APO HUMAN CK1D
2956, d1ckjB_, 0.7578, 2.86, 0.187, 293, 256, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
2957, d5fedA_, 0.7577, 2.49, 0.203, 288, 246, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
2958, d5e92A_, 0.7576, 2.84, 0.232, 298, 250, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH AMPPNP
2959, d3vf9A_, 0.7576, 2.47, 0.206, 265, 247, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 027
2960, d3q32A_, 0.7576, 2.82, 0.254, 291, 252, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
2961, d5j79A_, 0.7575, 2.56, 0.226, 283, 248, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
2962, d4yjoA_, 0.7575, 2.47, 0.190, 267, 247, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222
2963, d2io6A_, 0.7575, 2.38, 0.227, 252, 242, WEE1 KINASE COMPLEXED WITH INHIBITOR PD330961
2964, d3f5pK1, 0.7574, 2.79, 0.209, 292, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2965, d2ym8A_, 0.7573, 2.26, 0.270, 246, 241, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2966, d3nyxA1, 0.7572, 2.71, 0.207, 285, 251, NON-PHOSPHORYLATED TYK2 JH1 DOMAIN WITH QUINOLINE-THIADIAZOLE- THIOPHENE INHIBITOR
2967, d4r5sA_, 0.7571, 2.80, 0.203, 299, 251, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH FIIN-3
2968, d4ftqA_, 0.7571, 2.42, 0.276, 254, 243, CRYSTAL STRUCTURE OF THE CHK1
2969, d3pa5A_, 0.7571, 2.49, 0.275, 255, 244, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
2970, d2dylA_, 0.7571, 2.34, 0.230, 272, 243, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 7 ACTIVATED MUTANT (S287D T291D)
2971, d2dwbA_, 0.7571, 2.35, 0.307, 259, 244, AURORA-A KINASE COMPLEXED WITH AMPPNP
2972, d5uorB_, 0.7570, 2.62, 0.279, 262, 244, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2973, d4wsqB_, 0.7570, 2.48, 0.247, 310, 247, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2974, d4p2wB_, 0.7570, 2.27, 0.206, 253, 243,  
2975, d2x8iA_, 0.7570, 2.53, 0.267, 261, 247, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
2976, d2ituA_, 0.7570, 2.76, 0.200, 304, 250, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AFN941
2977, d1u46B_, 0.7570, 2.23, 0.264, 257, 242, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
2978, d5os2A_, 0.7569, 2.41, 0.298, 261, 245, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2979, d5drdA_, 0.7569, 2.47, 0.306, 259, 245, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
2980, d3ot8A_, 0.7569, 2.43, 0.276, 251, 243, X-RAY CRYSTAL STRUCTURE OF COMPOUND 17R BOUND TO HUMAN CHK1 KINASE DOMAIN
2981, d3f5pL1, 0.7569, 2.80, 0.209, 292, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2982, d3bceB_, 0.7569, 2.61, 0.211, 286, 247, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
2983, d6btwA_, 0.7568, 2.99, 0.151, 317, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
2984, d3dk6A_, 0.7568, 2.74, 0.218, 262, 248, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
2985, d4l43A_, 0.7567, 2.51, 0.307, 316, 244, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM I)
2986, d3pjcA_, 0.7567, 2.71, 0.252, 286, 250, CRYSTAL STRUCTURE OF JAK3 COMPLEXED WITH A POTENT ATP SITE INHIBITOR SHOWING HIGH SELECTIVITY WITHIN THE JANUS KINASE FAMILY
2987, d2in6A_, 0.7567, 2.39, 0.227, 256, 242, WEE1 KINASE COMPLEX WITH INHIBITOR PD311839
2988, d5ikwA_, 0.7566, 2.51, 0.259, 297, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2989, d3srvB_, 0.7566, 2.44, 0.199, 263, 246, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
2990, d3qc4B1, 0.7566, 2.40, 0.287, 268, 244, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
2991, d3lxnA_, 0.7566, 2.85, 0.224, 287, 250, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
2992, d3lvpB_, 0.7566, 3.12, 0.211, 295, 256, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
2993, d3f5pR1, 0.7566, 2.84, 0.209, 293, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2994, d2ittA_, 0.7566, 2.82, 0.200, 302, 250, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AEE788
2995, d2itnA_, 0.7566, 2.82, 0.200, 304, 250, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AMP-PNP
2996, d1k2pA_, 0.7566, 2.54, 0.186, 258, 247, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
2997, d5uvfB_, 0.7565, 2.96, 0.155, 316, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
2998, d5ukfC_, 0.7565, 3.04, 0.150, 317, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
2999, d5tq3B_, 0.7565, 2.86, 0.258, 285, 252, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3000, d5dt0A_, 0.7565, 2.49, 0.306, 259, 245, AURORA A KINASE IN COMPLEX WITH JNJ-7706621 IN SPACE GROUP P6122
3001, d2ydjA_, 0.7565, 2.31, 0.273, 252, 242, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
3002, d5d9lA_, 0.7564, 2.54, 0.298, 299, 245, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BIS-PHENOL PYRAZOLE
3003, d1rw8A_, 0.7564, 2.94, 0.216, 301, 250, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH ATP SITE INHIBITOR
3004, d4mneB_, 0.7563, 2.69, 0.196, 270, 250, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3005, d3q32B1, 0.7563, 2.93, 0.249, 293, 253, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
3006, d3lxpA_, 0.7563, 2.80, 0.226, 285, 248, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3007, d5uvfA_, 0.7562, 3.01, 0.147, 317, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
3008, d5ttvA_, 0.7562, 2.68, 0.249, 280, 249, JAK3 WITH COVALENT INHIBITOR 6
3009, d5hznG_, 0.7562, 2.96, 0.206, 296, 252, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3010, d5ar2A_, 0.7562, 2.57, 0.226, 277, 248, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
3011, d5hznC_, 0.7561, 2.96, 0.206, 296, 252, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3012, d4xg4A_, 0.7561, 2.34, 0.201, 264, 244, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3013, d3bizA_, 0.7561, 2.41, 0.223, 250, 242, WEE1 KINASE COMPLEX WITH INHIBITOR PD331618
3014, d1iasD_, 0.7561, 2.95, 0.206, 330, 252, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3015, d5di1A_, 0.7560, 2.61, 0.254, 285, 248, MAP4K4 IN COMPLEX WITH AN INHIBITOR
3016, d4rx8A1, 0.7560, 2.51, 0.202, 266, 247, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR2
3017, d4bicB_, 0.7560, 2.39, 0.278, 259, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3018, d3tzmA_, 0.7560, 2.67, 0.219, 295, 247, TGF-BETA RECEPTOR TYPE 1 IN COMPLEX WITH SB431542
3019, d3pp0B_, 0.7560, 2.84, 0.194, 296, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
3020, d2xzsB_, 0.7560, 2.86, 0.254, 293, 252, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
3021, d5ttuA_, 0.7559, 2.56, 0.251, 271, 247, JAK3 WITH COVALENT INHIBITOR 7
3022, d5ng2B_, 0.7559, 2.68, 0.221, 278, 249, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
3023, d5cf6A_, 0.7559, 2.80, 0.255, 285, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3024, d3dk7A_, 0.7559, 2.79, 0.217, 265, 249, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3025, d3dk3A_, 0.7559, 2.55, 0.227, 266, 247, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3026, d3lxkA_, 0.7558, 2.72, 0.248, 279, 250, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3027, d5vdkA_, 0.7557, 2.55, 0.254, 260, 244, CRYSTAL STRUCTURE OF HUMAN WEE2 KINASE DOMAIN IN COMPLEX WITH MK1775
3028, d5lmbA_, 0.7557, 2.49, 0.206, 264, 247, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
3029, d5cf5A1, 0.7557, 2.82, 0.255, 286, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3030, d4e6qA_, 0.7557, 2.92, 0.249, 296, 253, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
3031, d3dk6B_, 0.7557, 2.69, 0.220, 259, 246, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3032, d5hznD_, 0.7556, 2.94, 0.206, 304, 252, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3033, d1yvjA_, 0.7556, 2.71, 0.247, 288, 251, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN IN COMPLEX WITH A STAUROSPORINE ANALOGUE
3034, d5hznH_, 0.7555, 2.94, 0.206, 303, 252, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3035, d5e8vA_, 0.7555, 2.72, 0.238, 296, 248, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A)
3036, d3f5pJ1, 0.7555, 2.82, 0.209, 292, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3037, d4xg9B_, 0.7554, 2.44, 0.211, 265, 246, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3038, d2wmuA_, 0.7554, 2.30, 0.270, 246, 241, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3039, d2itvA_, 0.7554, 2.83, 0.200, 303, 250, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AMP-PNP
3040, d6bp0A_, 0.7553, 3.02, 0.147, 317, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3041, d4ivaA_, 0.7553, 2.91, 0.245, 290, 253, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-[(8AS)- 2-[(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(8AH)- YL]CYCLOHEXANECARBONITRILE
3042, d3zbfA_, 0.7553, 2.45, 0.238, 281, 244, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH CRIZOTINIB
3043, d1vjyA_, 0.7553, 2.86, 0.216, 299, 250, CRYSTAL STRUCTURE OF A NAPHTHYRIDINE INHIBITOR OF HUMAN TGF- BETA TYPE I RECEPTOR
3044, d5mqvF_, 0.7552, 2.86, 0.201, 286, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3045, d5hznE_, 0.7552, 3.04, 0.206, 296, 253, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3046, d4kbcB_, 0.7552, 2.82, 0.194, 277, 252, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
3047, d4at3A1, 0.7552, 2.71, 0.225, 286, 249, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N
3048, d4aqcB_, 0.7552, 2.96, 0.253, 295, 253, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
3049, d3umxA_, 0.7552, 2.51, 0.273, 261, 245, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDOL-3-YL)METHYLENE]-7-(AZEPAN-1-YLMETHYL)-6-HYDROXYBENZOFURAN- 3(2H)-ONE
3050, d1py5A_, 0.7552, 2.97, 0.216, 301, 250, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH INHIBITOR
3051, d5hznA_, 0.7551, 3.05, 0.202, 296, 253, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3052, d3zepA_, 0.7551, 2.72, 0.255, 274, 247, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3053, d3eygA_, 0.7551, 2.64, 0.243, 280, 247, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3054, d4xg2A1, 0.7550, 2.34, 0.201, 258, 244, CRYSTAL STRUCTURE OF LIGAND-FREE SYK
3055, d4f09A_, 0.7550, 2.90, 0.249, 288, 253, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3056, d5t68B_, 0.7549, 2.36, 0.201, 264, 244, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
3057, d5dewB_, 0.7549, 2.63, 0.291, 281, 247, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
3058, d4lg4F_, 0.7549, 2.22, 0.278, 276, 241, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3059, d6bu6D_, 0.7548, 3.05, 0.150, 318, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3060, d4g5jA_, 0.7548, 2.52, 0.204, 307, 245, CRYSTAL STRUCTURE OF EGFR KINASE IN COMPLEX WITH BIBW2992
3061, d5dpvA_, 0.7547, 2.35, 0.305, 257, 243, AURORA A KINASE IN COMPLEX WITH AA35 AND JNJ-7706621 IN SPACE GROUP P6122
3062, d3zepC_, 0.7547, 2.75, 0.254, 276, 248, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3063, d2ityA1, 0.7547, 2.73, 0.198, 299, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH IRESSA
3064, p5oatF_, 0.7546, 2.88, 0.231, 359, 251, PINK1 STRUCTURE
3065, d4qt1A_, 0.7546, 2.61, 0.250, 277, 248, JAK3 KINASE DOMAIN IN COMPLEX WITH 1-[(3S)-1-ISOBUTYLSULFONYL-3- PIPERIDYL]-3-(5H-PYRROLO[23-B]PYRAZIN-2-YL)UREA
3066, d4hvhA_, 0.7546, 2.62, 0.250, 278, 248, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-2-HYDROXY-12-DIMETHYL-PROPYL
3067, d4hvdA_, 0.7546, 2.62, 0.250, 276, 248, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-122-TRIMETHYL-PROPYL)-AMIDE
3068, d4g5pA_, 0.7546, 2.77, 0.202, 299, 252, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
3069, d2clqB_, 0.7544, 2.39, 0.282, 259, 241, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
3070, d3kcfE_, 0.7543, 2.98, 0.206, 330, 252, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3071, d6bp0B_, 0.7542, 2.99, 0.152, 304, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3072, d5i9vA_, 0.7542, 2.33, 0.214, 279, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AGS
3073, d4yjqA_, 0.7542, 2.90, 0.195, 264, 251, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000224
3074, d4bicA_, 0.7542, 2.49, 0.281, 260, 242, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3075, d5hznF_, 0.7541, 2.97, 0.206, 296, 252, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3076, d5hznB_, 0.7541, 2.97, 0.206, 296, 252, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3077, d5cf6B1, 0.7541, 2.85, 0.255, 288, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3078, d4yjtA_, 0.7541, 2.71, 0.197, 268, 249, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233
3079, d4lqmA_, 0.7541, 2.83, 0.192, 305, 250, EGFR L858R IN COMPLEX WITH PD168393
3080, d6bu6C_, 0.7540, 2.95, 0.152, 315, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3081, d5t68A1, 0.7540, 2.44, 0.200, 264, 245, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
3082, d5eakB_, 0.7540, 2.40, 0.326, 300, 239, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
3083, d2vz6B1, 0.7540, 2.88, 0.291, 288, 251, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
3084, d5v19B_, 0.7539, 2.46, 0.277, 260, 242, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3085, d5k00A_, 0.7539, 2.32, 0.329, 311, 240, MELK IN COMPLEX WITH NVS-MELK5
3086, d5feeA_, 0.7539, 2.49, 0.204, 287, 245, EGFR KINASE DOMAIN T790M MUTANT IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
3087, d1iasC_, 0.7539, 2.87, 0.212, 330, 250, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3088, d6babC_, 0.7538, 2.75, 0.298, 284, 248, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
3089, d5i9uA_, 0.7538, 2.43, 0.213, 281, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
3090, d4yjrA_, 0.7538, 2.91, 0.195, 263, 251, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000225
3091, d2j5fA_, 0.7538, 2.91, 0.202, 308, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 34-JAB
3092, d1iasE_, 0.7538, 2.96, 0.215, 330, 251, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3093, d3kcfB_, 0.7537, 2.89, 0.208, 324, 250, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3094, d6bruC_, 0.7536, 2.98, 0.147, 315, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3095, d2qnjA1, 0.7536, 2.66, 0.322, 317, 245, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
3096, d2j4zB_, 0.7536, 2.45, 0.310, 269, 242, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
3097, d5i3oA_, 0.7535, 2.59, 0.258, 302, 248, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3098, d4yjvA_, 0.7535, 2.91, 0.195, 263, 251, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000250
3099, d4mneC_, 0.7535, 2.60, 0.202, 260, 247, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3100, d4i6qA_, 0.7535, 2.65, 0.250, 277, 248, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-PHENOXY-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-1-CYCLOPROPYL-ETHYL)-AMIDE
3101, d4e6qB_, 0.7534, 2.94, 0.257, 296, 253, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
3102, d4bibB_, 0.7534, 2.39, 0.279, 258, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3103, d3srvA_, 0.7534, 2.56, 0.206, 262, 247, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
3104, d1p4fA_, 0.7534, 2.57, 0.260, 269, 246, DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT
3105, d6bp0C_, 0.7533, 2.96, 0.152, 315, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3106, d4aqcA_, 0.7533, 2.90, 0.254, 289, 252, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
3107, d3kcfC_, 0.7533, 3.02, 0.206, 330, 252, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3108, d2wzjA_, 0.7533, 2.48, 0.314, 310, 242, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3109, d2fumA_, 0.7532, 2.49, 0.261, 263, 245, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3110, d4ftoA_, 0.7531, 2.50, 0.276, 252, 243, CRYSTAL STRUCTURE OF THE CHK1
3111, d5ng0A_, 0.7530, 2.70, 0.222, 274, 248, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
3112, d5mjaA_, 0.7530, 2.52, 0.224, 271, 246, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
3113, d5dr9A_, 0.7530, 2.43, 0.309, 257, 243, AURORA A KINASE IN COMPLEX WITH AA29 AND JNJ-7706621 IN SPACE GROUP P6122
3114, d3zepD_, 0.7530, 2.68, 0.256, 272, 246, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3115, d3fqsA1, 0.7530, 2.40, 0.201, 264, 244, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R406
3116, d1u46A_, 0.7530, 2.35, 0.256, 255, 242, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
3117, d4ixpA_, 0.7529, 3.13, 0.316, 334, 253, CRYSTAL STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK)
3118, d5tq8A_, 0.7528, 2.88, 0.254, 291, 252, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3119, d5tq5A_, 0.7528, 2.87, 0.258, 291, 252, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3120, d4f08A_, 0.7528, 2.96, 0.253, 288, 253, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3121, d1iasA_, 0.7528, 3.08, 0.209, 330, 253, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3122, d5up3A_, 0.7527, 2.40, 0.283, 258, 240, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3123, d5lmbB_, 0.7527, 2.56, 0.191, 261, 246, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
3124, d4zimA_, 0.7527, 2.87, 0.255, 285, 251, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
3125, d2zv2A_, 0.7527, 2.30, 0.288, 256, 243, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2 BETA CAMKK2 KINASE DOMAIN IN COMPLEX WITH STO-609
3126, d2jitA_, 0.7527, 2.86, 0.182, 299, 253, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
3127, d6btwC_, 0.7526, 2.99, 0.147, 315, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
3128, d4mneG_, 0.7526, 2.77, 0.198, 259, 248, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3129, d1o6yA_, 0.7525, 2.36, 0.260, 260, 242, CATALYTIC DOMAIN OF PKNB KINASE FROM MYCOBACTERIUM TUBERCULOSIS
3130, d5ar5B_, 0.7524, 2.54, 0.228, 279, 246, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
3131, d4z16A_, 0.7524, 2.54, 0.254, 271, 244, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3132, d4p2wA_, 0.7524, 2.24, 0.212, 250, 241,  
3133, d4f08B_, 0.7524, 2.98, 0.253, 288, 253, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3134, d4bidB_, 0.7522, 2.39, 0.279, 258, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3135, d5mqvA_, 0.7521, 2.85, 0.198, 286, 253, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3136, d4z16C_, 0.7521, 2.55, 0.254, 271, 244, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3137, d2itzA_, 0.7521, 2.88, 0.200, 302, 250, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH IRESSA
3138, d5ttsA_, 0.7520, 2.56, 0.252, 274, 246, JAK3 WITH COVALENT INHIBITOR 4
3139, d5imeB_, 0.7520, 2.49, 0.298, 280, 242, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
3140, d4lg4B_, 0.7520, 2.58, 0.270, 284, 244, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3141, d4fynA1, 0.7520, 2.40, 0.201, 263, 244, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 3-(8-{4- [ETHYL-(2-HYDROXY-ETHYL)-AMINO]-PHENYLAMINO}-IMIDAZO[12-A]PYRAZIN-5- YL)-PHENOL
3142, d5vd2A_, 0.7519, 2.67, 0.233, 258, 245, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PF- 03814735
3143, d5tq3A_, 0.7519, 2.84, 0.260, 282, 250, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3144, d5dr6A_, 0.7519, 2.46, 0.309, 257, 243, AURORA A KINASE IN COMPLEX WITH AA30 AND JNJ-7706621 IN SPACE GROUP P6122
3145, d6bu6B_, 0.7518, 3.00, 0.140, 307, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3146, d2fumB_, 0.7518, 2.50, 0.262, 262, 244, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3147, d4zp5A_, 0.7517, 2.67, 0.254, 284, 248, MAP4K4 IN COMPLEX WITH INHIBITOR
3148, d4puzA_, 0.7517, 2.62, 0.191, 263, 246, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
3149, d2wzjC_, 0.7517, 2.52, 0.314, 310, 242, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3150, d4asxA1, 0.7516, 2.77, 0.231, 295, 247, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
3151, d5i3rA_, 0.7515, 2.62, 0.258, 302, 248, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3152, d2wzjF_, 0.7515, 2.52, 0.314, 310, 242, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3153, d4z16D_, 0.7514, 2.59, 0.258, 271, 244, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3154, d3tjcB_, 0.7514, 2.90, 0.255, 287, 251, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
3155, d2w1gA1, 0.7514, 2.37, 0.303, 254, 241, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3156, d1u4dA_, 0.7514, 2.37, 0.256, 258, 242, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
3157, d5vc3A_, 0.7513, 2.73, 0.232, 260, 246, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
3158, d4wrgA1, 0.7513, 2.44, 0.210, 287, 243, 1.9 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN
3159, d4o0rB_, 0.7513, 2.59, 0.317, 282, 243, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3160, d3zosA_, 0.7513, 2.91, 0.216, 301, 250, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
3161, d3lctA_, 0.7513, 3.01, 0.178, 308, 253, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3162, d3kcfA_, 0.7513, 2.94, 0.208, 328, 250, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3163, d2np8A_, 0.7513, 2.40, 0.305, 256, 243, STRUCTURAL BASIS FOR THE INHIBITION OF AURORA A KINASE BY A NOVEL CLASS OF HIGH AFFINITY DISUBSTITUTED PYRIMIDINE INHIBITORS
3164, d4lg4E_, 0.7512, 2.53, 0.289, 275, 246, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3165, d5nkgA_, 0.7511, 2.73, 0.211, 292, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3D
3166, d5ng2A_, 0.7511, 2.59, 0.215, 274, 246, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
3167, d4bieB_, 0.7511, 2.37, 0.280, 257, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3168, d5nkfA_, 0.7510, 2.74, 0.211, 291, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3B
3169, d5mqvB_, 0.7510, 2.92, 0.193, 287, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3170, d3kcfD_, 0.7510, 3.03, 0.206, 330, 252, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3171, d5cf4A_, 0.7508, 2.86, 0.256, 283, 250, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3172, d2zvaA1, 0.7508, 2.81, 0.235, 260, 247, LYN TYROSINE KINASE DOMAIN-DASATINIB COMPLEX
3173, d1xbbA1, 0.7508, 2.44, 0.201, 266, 244, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH GLEEVEC
3174, d5fm3A_, 0.7507, 3.01, 0.234, 276, 248, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
3175, d4ji9A_, 0.7507, 2.85, 0.260, 284, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
3176, d4jjrA_, 0.7506, 2.76, 0.196, 284, 250, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
3177, d4px6A1, 0.7505, 2.44, 0.201, 261, 244, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT PYRIDOPYRIMIDINONE INHIBITOR
3178, d4ji9B_, 0.7505, 2.97, 0.251, 288, 251, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
3179, d4e26A_, 0.7505, 2.61, 0.203, 270, 246, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
3180, d2qnjB1, 0.7505, 2.54, 0.321, 321, 243, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
3181, d6eimA_, 0.7504, 2.59, 0.317, 286, 243, HUMAN STK10 BOUND TO GW683134A
3182, d5ia2A_, 0.7504, 2.66, 0.211, 287, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 66
3183, d4yjpA_, 0.7504, 2.57, 0.195, 263, 246, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223
3184, d4o0tB_, 0.7503, 2.70, 0.297, 280, 246, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3185, d5vt1A1, 0.7502, 2.67, 0.283, 264, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO A BENZAMIDE INHIBITOR
3186, d3fqeA1, 0.7502, 2.50, 0.200, 265, 245, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH YM193306
3187, d2cmwA_, 0.7502, 2.83, 0.195, 294, 251, STRUCTURE OF HUMAN CASEIN KINASE 1 GAMMA-1 IN COMPLEX WITH 2-(2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9- ISOPROPYLPURINE (CASP TARGET)
3188, d4i0sA1, 0.7501, 2.45, 0.201, 263, 244, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(6- CHLORO-1-METHYL-1H-INDAZOL-3-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID ISOPROPYLAMIDE
3189, d3lvpA_, 0.7501, 2.94, 0.215, 289, 251, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3190, d6bruD_, 0.7499, 3.07, 0.147, 311, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3191, d3l9pA_, 0.7499, 3.02, 0.178, 303, 253, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3192, d2wzjB_, 0.7499, 2.58, 0.314, 310, 242, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3193, d2b7aA_, 0.7499, 2.89, 0.256, 284, 250, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
3194, d3socB1, 0.7498, 2.74, 0.228, 294, 246, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
3195, d3hmiA_, 0.7498, 2.86, 0.216, 268, 250, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
3196, d3fqhB_, 0.7498, 2.49, 0.193, 258, 244, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
3197, d3fe3B_, 0.7498, 2.41, 0.322, 317, 242, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
3198, d1yi6B_, 0.7498, 2.76, 0.246, 274, 248, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
3199, d1mruA_, 0.7498, 2.66, 0.266, 269, 244, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
3200, d4hviA_, 0.7496, 2.62, 0.252, 274, 246, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-1-METHYL-2-OXO-2-PIPERIDIN-1-YL- ETHYL)-AMIDE
3201, d3uzpB_, 0.7496, 2.80, 0.187, 284, 251, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
3202, d3eknA_, 0.7496, 3.01, 0.194, 297, 252, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
3203, d1wvyA_, 0.7496, 2.92, 0.254, 273, 252, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
3204, d1k2pB_, 0.7496, 2.60, 0.190, 258, 247, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
3205, d5mqvD_, 0.7495, 2.94, 0.193, 287, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3206, d4mkcA_, 0.7495, 3.17, 0.185, 303, 254, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE COMPLEXED WITH LDK378
3207, d3lcsA_, 0.7495, 3.05, 0.182, 304, 253, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3208, d1jktB_, 0.7495, 2.96, 0.261, 276, 253, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
3209, d5j79B_, 0.7494, 2.55, 0.220, 277, 245, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
3210, d4xg8A_, 0.7494, 2.49, 0.212, 258, 245, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3211, d3rvgA_, 0.7494, 2.71, 0.263, 285, 247, CRYSTALS STRUCTURE OF JAK2 WITH A 1-AMINO-5H-PYRIDO[43-B]INDOL-4- CARBOXAMIDE INHIBITOR
3212, d1b6cF_, 0.7494, 3.10, 0.215, 326, 251, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
3213, d5nk6A_, 0.7493, 2.67, 0.212, 284, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2D
3214, d5cf8B1, 0.7493, 2.91, 0.256, 287, 250, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3215, d5cf8A1, 0.7493, 2.84, 0.257, 284, 249, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3216, d4wa9B1, 0.7492, 2.51, 0.230, 263, 244, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
3217, d4p7eB_, 0.7492, 2.95, 0.255, 285, 251, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
3218, d2j4zA_, 0.7491, 2.50, 0.306, 263, 242, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
3219, d3zfxA_, 0.7490, 2.52, 0.230, 267, 244, CRYSTAL STRUCTURE OF EPHB1
3220, d2ydjB_, 0.7490, 2.38, 0.274, 251, 241, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
3221, d4jbqA_, 0.7489, 2.39, 0.303, 257, 241, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3222, d4fyoA1, 0.7489, 2.41, 0.202, 263, 243, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH N-{(S)-1- [7-(34-DIMETHOXY-PHENYLAMINO)-THIAZOLO[54-D]PYRIMIDIN-5-YL]- PYRROLIDIN-3-YL}-TEREPHTHALAMIC ACID
3223, d4rvtA_, 0.7488, 2.58, 0.257, 281, 245, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
3224, d3zfxD_, 0.7488, 2.53, 0.230, 265, 244, CRYSTAL STRUCTURE OF EPHB1
3225, d5mqvE_, 0.7487, 2.91, 0.198, 287, 253, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3226, d4yjuA_, 0.7487, 2.62, 0.191, 262, 246, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249
3227, d4u40A_, 0.7487, 2.87, 0.255, 295, 251, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
3228, d4fz6A1, 0.7487, 2.46, 0.201, 262, 244, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH [6-((S)-2- METHYL-PYRROLIDIN-1-YL)-PYRIDIN-2-YL]-(6-PHENYL-IMIDAZO[12- B]PYRIDAZIN-8-YL)-AMINE
3229, d5nkbA_, 0.7486, 2.76, 0.207, 285, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4A
3230, d5ih8A_, 0.7485, 2.30, 0.332, 306, 238, MELK IN COMPLEX WITH NVS-MELK1
3231, d4i0rA1, 0.7485, 2.47, 0.201, 260, 244, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(345- TRIMETHOXY-PHENYL)-5H-PYRROLO[23-B]PYRAZINE-7-CARBOXYLIC ACID ISOPROPYLAMIDE
3232, d4bc6A_, 0.7485, 2.79, 0.320, 285, 244, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO NOVEL BOSUTINIB ISOFORM 1 PREVIOUSLY THOUGHT TO BE BOSUTINIB
3233, d2r0iB_, 0.7485, 2.33, 0.325, 300, 237, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
3234, d2r0iA_, 0.7485, 2.31, 0.325, 300, 237, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
3235, d2b7aB_, 0.7485, 2.94, 0.255, 287, 251, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
3236, d4puzB_, 0.7484, 2.52, 0.200, 265, 245, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
3237, d4j8mA_, 0.7484, 2.47, 0.308, 265, 240, AURORA A IN COMPLEX WITH CD532
3238, d4hgtA_, 0.7484, 2.76, 0.192, 283, 250, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
3239, d4byiA_, 0.7484, 2.39, 0.299, 254, 241, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
3240, d4b9dB1, 0.7484, 2.85, 0.275, 291, 251, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
3241, d3zosB1, 0.7484, 3.02, 0.215, 301, 251, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
3242, d3zhpD_, 0.7484, 2.62, 0.255, 264, 247, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3243, d4c62A_, 0.7483, 2.71, 0.268, 273, 246, INHIBITORS OF JAK2 KINASE DOMAIN
3244, d3q4tB1, 0.7483, 2.76, 0.228, 293, 246, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
3245, d3d15A_, 0.7482, 2.41, 0.289, 256, 242, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-(3-CHLORO-PHENYL)-3-{5-[2-(THIENO[32- D]PYRIMIDIN-4-YLAMINO)- ETHYL]-THIAZOL-2-YL}-UREA [SNS-314]
3246, d6bp0D_, 0.7481, 3.14, 0.155, 311, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3247, d5nk9A_, 0.7481, 2.77, 0.207, 285, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2E
3248, d4bieA_, 0.7481, 2.45, 0.280, 257, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3249, d4bhnB_, 0.7481, 2.43, 0.285, 257, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3250, d3zmmA_, 0.7481, 2.71, 0.268, 273, 246, INHIBITORS OF JAK2 KINASE DOMAIN
3251, d3uytD_, 0.7481, 2.64, 0.194, 268, 247, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
3252, d5nk1A_, 0.7480, 2.80, 0.211, 284, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1K
3253, d4p90A_, 0.7480, 2.17, 0.273, 272, 238, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
3254, d4apcB1, 0.7480, 2.85, 0.275, 291, 251, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
3255, d3zepB_, 0.7480, 2.72, 0.257, 268, 245, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3256, d2wzjE_, 0.7480, 2.56, 0.314, 310, 242, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3257, d1fvrB_, 0.7480, 2.58, 0.216, 300, 245, TIE2 KINASE DOMAIN
3258, d4e1zA_, 0.7479, 2.86, 0.221, 288, 249, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
3259, d1b6cD_, 0.7479, 3.06, 0.216, 326, 250, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
3260, d5ih9A_, 0.7478, 2.22, 0.329, 308, 237, MELK IN COMPLEX WITH NVS-MELK8A
3261, d5ar4B_, 0.7478, 2.61, 0.220, 279, 246, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
3262, d4hgeA_, 0.7478, 2.90, 0.256, 284, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
3263, d4f4pA1, 0.7478, 2.46, 0.209, 260, 244, SYK IN COMPLEX WITH LIGAND LASW836
3264, d1fvrA_, 0.7478, 2.42, 0.218, 299, 243, TIE2 KINASE DOMAIN
3265, d5kbqB_, 0.7477, 2.66, 0.295, 273, 244, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
3266, d3wf7A_, 0.7477, 2.83, 0.312, 288, 247, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PURINE DERIVATIVE 1-(9H-PURIN-6-YL)-N-[3-(TRIFLUOROMETHYL)PHENYL]PIPERIDINE- 4-CARBOXAMIDE
3267, d4p7eA_, 0.7476, 2.92, 0.256, 281, 250, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
3268, d3zhpC1, 0.7476, 2.64, 0.255, 267, 247, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3269, d5khwA_, 0.7475, 2.62, 0.245, 276, 245, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
3270, d4asxB1, 0.7475, 2.90, 0.222, 296, 248, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
3271, d3lpbA_, 0.7475, 2.85, 0.257, 278, 249, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
3272, d6bruB_, 0.7474, 2.92, 0.150, 301, 253, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3273, d5nk2A_, 0.7474, 2.61, 0.213, 290, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2B
3274, d3fupA_, 0.7474, 2.92, 0.256, 284, 250, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3275, d5i9xA_, 0.7473, 2.80, 0.215, 284, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH BOSUTINIB (SKI-606)
3276, d5am7A_, 0.7473, 2.86, 0.241, 294, 249, FGFR1 MUTANT WITH AN INHIBITOR
3277, d3dj7A_, 0.7473, 2.47, 0.288, 257, 243, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 130.
3278, d2qocA_, 0.7473, 2.53, 0.204, 283, 245, HUMAN EPHA3 KINASE DOMAIN PHOSPHORYLATED AMP-PNP BOUND STRUCTURE
3279, d5ugxB_, 0.7472, 2.75, 0.245, 282, 245, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
3280, d4useA_, 0.7472, 2.78, 0.311, 286, 244, HUMAN STK10 (LOK) WITH SB-633825
3281, d5wfjA_, 0.7470, 2.58, 0.253, 265, 245, THE JAK3 KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR
3282, d5nk7A_, 0.7470, 2.83, 0.211, 284, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2A
3283, d4u5jB_, 0.7470, 2.48, 0.245, 267, 241, C-SRC IN COMPLEX WITH RUXOLITINIB
3284, d4o0wA_, 0.7470, 2.38, 0.299, 259, 241, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3285, d4mneF_, 0.7470, 2.70, 0.192, 258, 245, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3286, d2hz4B1, 0.7470, 2.60, 0.234, 248, 244, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
3287, d1mruB_, 0.7470, 2.68, 0.266, 271, 244, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
3288, d4yjsA_, 0.7469, 2.57, 0.200, 257, 245, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226
3289, d3r21A_, 0.7469, 2.44, 0.303, 254, 241, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
3290, d3d14A1, 0.7469, 2.47, 0.288, 257, 243, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-{5-[2-(THIENO[32-D]PYRIMIDIN-4-YLAMINO)- ETHYL]- THIAZOL-2-YL}-3-(3-TRIFLUOROMETHYL-PHENYL)-UREA
3291, d3tjcA_, 0.7468, 2.93, 0.256, 284, 250, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
3292, d6eimB_, 0.7467, 2.72, 0.318, 295, 245, HUMAN STK10 BOUND TO GW683134A
3293, d5ei6A1, 0.7467, 2.34, 0.310, 261, 239, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3294, d2ym4A_, 0.7467, 2.39, 0.276, 251, 239, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3295, d5uvfC_, 0.7466, 2.97, 0.150, 301, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
3296, d2w1fA1, 0.7466, 2.39, 0.304, 253, 240, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3297, d5ek7B_, 0.7465, 2.62, 0.212, 286, 245, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
3298, d4zauA_, 0.7464, 2.41, 0.207, 283, 241, AZD9291 COMPLEX WITH WILD TYPE EGFR
3299, d3tt0A_, 0.7464, 3.04, 0.235, 305, 251, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
3300, d3c4fA_, 0.7464, 2.86, 0.241, 290, 249, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
3301, d1mqbB_, 0.7464, 2.48, 0.214, 265, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
3302, d5am6A1, 0.7463, 2.88, 0.241, 294, 249, NATIVE FGFR1 WITH AN INHIBITOR
3303, d4v0gA_, 0.7463, 2.69, 0.262, 267, 244, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
3304, d3d2iA_, 0.7463, 2.42, 0.289, 255, 242, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH 1-{5-[2-(1-METHYL-1H- PYRAZOLO[43-D]PYRIMIDIN-7-YLAMINO)-ETHYL]-THIAZOL-2-YL}-3- (3-TRIFLUOROMETHYL-PHENYL)-UREA
3305, d5ew8A_, 0.7462, 2.86, 0.237, 291, 249, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
3306, d4hgeB_, 0.7462, 2.97, 0.256, 288, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
3307, d3r22A_, 0.7462, 2.55, 0.293, 255, 242, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
3308, d5nk4A_, 0.7461, 2.72, 0.208, 290, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2C
3309, d5f1zA1, 0.7461, 2.48, 0.223, 280, 242, STRUCTURE OF TYK2 WITH INHIBITOR 16: 3-AZANYL-5-[(2~{S})-3- METHYLBUTAN-2-YL]-7-[1-METHYL-5-(2-OXIDANYLPROPAN-2-YL)PYRAZOL-3-YL]- 1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
3310, d4z55A_, 0.7461, 3.05, 0.187, 294, 251, ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE DERIVATIVE OF LDK378
3311, d4hgtB_, 0.7461, 2.78, 0.180, 280, 250, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
3312, d4fz7A1, 0.7461, 2.46, 0.202, 261, 243, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 6-((1R2S)- 2-AMINO-CYCLOHEXYLAMINO)-4-(6-ETHYL-PYRIDIN-2-YLAMINO)-PYRIDAZINE-3- CARBOXYLIC ACID AMIDE
3313, d2wzjD_, 0.7461, 2.48, 0.315, 313, 241, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3314, d5oneA_, 0.7460, 2.57, 0.312, 257, 240, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH FMF-03-145-1 (COMPOUND 2)
3315, d2xngA_, 0.7460, 2.31, 0.305, 253, 239, STRUCTURE OF AURORA-A BOUND TO A SELECTIVE IMIDAZOPYRAZINE INHIBITOR
3316, d4u43A_, 0.7459, 2.73, 0.253, 287, 249, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
3317, d4d55A_, 0.7459, 2.43, 0.257, 260, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3318, d5nkcA_, 0.7458, 2.58, 0.214, 286, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2H
3319, d5ajqB_, 0.7458, 2.36, 0.325, 267, 240, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
3320, d4i0tA1, 0.7458, 2.45, 0.202, 262, 243, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(5678- TETRAHYDRO-IMIDAZO[15-A]PYRIDIN-1-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID TERT-BUTYLAMIDE
3321, d3zfxH_, 0.7458, 2.53, 0.226, 266, 243, CRYSTAL STRUCTURE OF EPHB1
3322, d3js2A_, 0.7458, 2.85, 0.237, 295, 249, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
3323, d3cekA1, 0.7458, 2.43, 0.308, 252, 240, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK)
3324, d3c4fB_, 0.7458, 2.87, 0.237, 290, 249, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
3325, d2wtvC_, 0.7457, 2.64, 0.306, 261, 242, AURORA-A INHIBITOR STRUCTURE
3326, d1fgkA_, 0.7457, 2.85, 0.241, 278, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
3327, d2xa4A_, 0.7456, 2.73, 0.272, 276, 246, INHIBITORS OF JAK2 KINASE DOMAIN
3328, d4f63A_, 0.7455, 2.86, 0.241, 278, 249, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
3329, d4b9dA1, 0.7455, 2.92, 0.255, 286, 251, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
3330, d4aotA1, 0.7455, 2.42, 0.336, 276, 241, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
3331, d5w86C_, 0.7454, 2.58, 0.260, 273, 242, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
3332, d5c8mA_, 0.7454, 2.66, 0.197, 302, 244, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 17
3333, d2hz0A_, 0.7454, 2.97, 0.209, 265, 249, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
3334, d2eb3A_, 0.7454, 2.80, 0.203, 294, 246, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (L858R) IN COMPLEX WITH AMPPNP
3335, d1fgiA_, 0.7454, 2.87, 0.237, 283, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
3336, d4c61A_, 0.7453, 2.80, 0.268, 272, 246, INHIBITORS OF JAK2 KINASE DOMAIN
3337, d3kfaB1, 0.7453, 2.75, 0.238, 283, 244, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3338, d3kfaA1, 0.7453, 2.75, 0.238, 283, 244, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3339, d1yi6A_, 0.7453, 2.74, 0.235, 274, 247, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
3340, d1bi7A_, 0.7453, 2.65, 0.467, 269, 242, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURE OF THE CDK6-P16INK4A TUMOR SUPPRESSOR COMPLEX
3341, d4rwiA_, 0.7452, 2.93, 0.237, 305, 249, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
3342, d4qqjA_, 0.7452, 2.91, 0.241, 282, 249, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN HARBORING THE V550L GATE-KEEPER MUTATION
3343, d4f64A_, 0.7452, 2.88, 0.241, 278, 249, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
3344, d3fe3A_, 0.7452, 2.67, 0.324, 317, 244, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
3345, d1agwA_, 0.7452, 2.86, 0.241, 278, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
3346, d3rhxA_, 0.7451, 2.86, 0.241, 289, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
3347, d5vndB_, 0.7450, 3.09, 0.234, 295, 252, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
3348, d3tjdB_, 0.7450, 3.02, 0.251, 287, 251, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
3349, d3fupB_, 0.7450, 3.02, 0.255, 287, 251, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3350, d3emgA_, 0.7450, 2.35, 0.195, 255, 241, DISCOVERY AND SAR OF NOVEL 4-THIAZOLYL-2- PHENYLAMINOPYRIMIDINES AS POTENT INHIBITORS OF SPLEEN TYROSINE KINASE (SYK)
3351, d5obrA_, 0.7449, 2.54, 0.307, 255, 241, AURORA A KINASE IN COMPLEX WITH 2-(3-CHLORO-5-FLUOROPHENYL)QUINOLINE- 4-CARBOXYLIC ACID AND JNJ-7706621
3352, d5nk3A_, 0.7449, 2.74, 0.211, 281, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1L
3353, d5n84A1, 0.7449, 2.55, 0.304, 253, 240, TTK KINASE DOMAIN IN COMPLEX WITH MPS-BAY2B
3354, d4qrcA_, 0.7449, 2.88, 0.242, 297, 248, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 4 IN COMPLEX WITH PONATINIB
3355, d4e26B_, 0.7449, 2.56, 0.202, 264, 243, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
3356, d2c6eA_, 0.7449, 2.43, 0.312, 251, 240, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
3357, d1zmwA_, 0.7449, 2.58, 0.315, 302, 238, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
3358, d5i9zA_, 0.7448, 2.73, 0.213, 273, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DANUSERTIB (PHA739358)
3359, d5ehlA1, 0.7448, 2.36, 0.305, 254, 239, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3360, d3ky2A1, 0.7448, 2.93, 0.237, 305, 249, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
3361, d4rwkA1, 0.7447, 3.02, 0.236, 307, 250, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
3362, d4e6dA_, 0.7447, 2.89, 0.261, 286, 249, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
3363, d3lvpD_, 0.7447, 2.60, 0.213, 282, 244, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3364, d5owrA_, 0.7446, 2.75, 0.318, 282, 242, HUMAN STK10 BOUND TO DASATINIB
3365, d5caqA_, 0.7446, 2.69, 0.197, 301, 244, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 33
3366, d4rwjA1, 0.7446, 2.93, 0.237, 306, 249, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
3367, d3ohtA_, 0.7446, 3.08, 0.319, 331, 254, CRYSTAL STRUCTURE OF SALMO SALAR P38ALPHA
3368, d6btwB_, 0.7445, 2.99, 0.154, 301, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
3369, d5vo6A_, 0.7445, 2.68, 0.248, 271, 246, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR
3370, d5j7bA_, 0.7445, 2.60, 0.220, 277, 245, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
3371, d5ftoA1, 0.7445, 2.99, 0.184, 297, 250, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH ENTRECTINIB
3372, d4uwyA_, 0.7445, 3.02, 0.236, 296, 250, FGFR1 APO STRUCTURE
3373, d4gk4A_, 0.7445, 2.49, 0.206, 275, 243, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 90
3374, d2wtvB_, 0.7445, 2.43, 0.308, 261, 240, AURORA-A INHIBITOR STRUCTURE
3375, d2w1eA1, 0.7445, 2.38, 0.310, 252, 239, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3376, d1b6cB_, 0.7445, 3.12, 0.216, 326, 250, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
3377, d5nkdA_, 0.7444, 2.61, 0.214, 287, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2I
3378, d5aafA_, 0.7444, 2.36, 0.300, 254, 240, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14A)
3379, d3hmmA_, 0.7444, 2.75, 0.212, 293, 245, STRUCTURE OF ALK5 + GW855857
3380, d5canA_, 0.7443, 2.69, 0.197, 301, 244, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 27
3381, d4c8bB_, 0.7443, 2.69, 0.216, 281, 245, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
3382, d3ohtB_, 0.7443, 3.08, 0.319, 331, 254, CRYSTAL STRUCTURE OF SALMO SALAR P38ALPHA
3383, d3js2B_, 0.7443, 2.87, 0.241, 291, 249, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
3384, d2zmcA_, 0.7443, 2.33, 0.310, 260, 239, CRYSTAL STRUCTURE OF HUMAN MITOTIC CHECKPOINT KINASE MPS1 CATALYTIC DOMAIN APO FORM
3385, d5ek7A_, 0.7442, 2.64, 0.212, 286, 245, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
3386, d3zfxE_, 0.7442, 2.52, 0.227, 262, 242, CRYSTAL STRUCTURE OF EPHB1
3387, d2fgiA_, 0.7442, 2.84, 0.234, 274, 248, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
3388, d5a46B_, 0.7441, 2.89, 0.237, 297, 249, FGFR1 IN COMPLEX WITH DOVITINIB
3389, d4zsaA_, 0.7441, 2.91, 0.241, 289, 249, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
3390, d4u5jA_, 0.7441, 2.63, 0.251, 267, 243, C-SRC IN COMPLEX WITH RUXOLITINIB
3391, d4j95D_, 0.7441, 2.66, 0.248, 271, 242, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
3392, d5nttA1, 0.7440, 2.47, 0.312, 268, 240, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604Y MUTANT IN COMPLEX WITH NMS-P715
3393, d4uwcB_, 0.7440, 2.89, 0.241, 301, 249, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
3394, d4c02A_, 0.7440, 2.89, 0.231, 313, 247, CRYSTAL STRUCTURE OF HUMAN ACVR1 (ALK2) IN COMPLEX WITH FKBP12.6 AND DORSOMORPHIN
3395, d4aszA1, 0.7440, 2.88, 0.225, 286, 249, CRYSTAL STRUCTURE OF APO TRKB KINASE DOMAIN
3396, d3tjdA_, 0.7440, 2.97, 0.256, 284, 250, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
3397, d5ei2A_, 0.7439, 2.34, 0.311, 256, 238, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3398, d4v0gB_, 0.7439, 2.67, 0.263, 272, 243, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
3399, d4uwcA_, 0.7439, 2.90, 0.237, 300, 249, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
3400, d4gk3A_, 0.7439, 2.46, 0.207, 275, 242, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 87
3401, d3socA1, 0.7439, 2.89, 0.231, 296, 247, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
3402, d2wmsA_, 0.7439, 2.33, 0.277, 243, 238, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3403, d2ivsB1, 0.7439, 2.75, 0.247, 272, 243, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
3404, d5ihaA_, 0.7438, 2.25, 0.335, 303, 236, MELK IN COMPLEX WITH NVS-MELK8F
3405, d3oy3A1, 0.7438, 2.76, 0.238, 283, 244, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
3406, d3ckwA_, 0.7438, 2.20, 0.282, 255, 238, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24)
3407, d5j7bB_, 0.7437, 2.64, 0.220, 281, 245, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
3408, d4xg9A_, 0.7437, 2.40, 0.195, 259, 241, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3409, d3lpbB1, 0.7437, 2.77, 0.264, 283, 246, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
3410, d3hmpA_, 0.7437, 2.33, 0.311, 258, 238, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH A QUINAZOLIN LIGAND COMPOUND 4
3411, d5hcyA_, 0.7436, 2.75, 0.196, 302, 245, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-CARBOXAMIDE AZAINDOLE COMPOUND 13
3412, d4qpsA_, 0.7436, 2.35, 0.264, 270, 239, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
3413, d5n87A1, 0.7435, 2.48, 0.301, 252, 239, TTK KINASE DOMAIN IN COMPLEX WITH NTRC 0066-0
3414, d3oy3B1, 0.7435, 2.75, 0.238, 283, 244, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
3415, d3wf5A_, 0.7434, 2.36, 0.318, 277, 239, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-BENZIMIDAZOL-2-YL)PIPERIDIN-1- YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
3416, d3k5uA_, 0.7434, 2.38, 0.300, 260, 240, IDENTIFICATION SAR STUDIES AND X-RAY COCRYSTAL ANALYSIS OF A NOVEL FURANO-PYRIMIDINE AURORA KINASE A INHIBITOR
3417, d5cwzC_, 0.7433, 2.28, 0.255, 271, 239, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
3418, d4xcuA1, 0.7433, 2.91, 0.246, 287, 248, CRYSTAL STRUCTURE OF FGFR4 WITH AN IRREVERSIBLE INHIBITOR
3419, d3pp0A_, 0.7433, 2.82, 0.197, 286, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
3420, d3dqxA_, 0.7433, 2.64, 0.251, 267, 243, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
3421, d5ew8B_, 0.7432, 3.04, 0.232, 290, 250, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
3422, d4apcA1, 0.7432, 2.94, 0.255, 289, 251, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
3423, d3h10A_, 0.7432, 2.64, 0.306, 268, 242, AURORA A INHIBITOR COMPLEX
3424, d3gfwA1, 0.7432, 2.25, 0.304, 249, 237, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYROLO-PYRIDIN LIGAND
3425, d2qluA1, 0.7432, 2.89, 0.224, 295, 246, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE II KINASE DOMAIN FROM HUMAN
3426, d5ar7B_, 0.7431, 2.61, 0.224, 278, 245, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
3427, d4qqtA_, 0.7431, 2.80, 0.240, 283, 246, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 TYROSINE KINASE DOMAIN
3428, d4at4A1, 0.7431, 2.86, 0.225, 289, 249, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429
3429, d3q4tA1, 0.7431, 2.90, 0.231, 294, 247, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
3430, d3f69B_, 0.7431, 2.85, 0.233, 282, 249, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
3431, d4tt7A_, 0.7430, 3.13, 0.192, 291, 250, CRYSTAL STRUCTURE OF HUMAN ALK WITH A COVALENT MODIFICATION
3432, d3wf6A_, 0.7430, 2.38, 0.318, 277, 239, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-INDOL-3-YL)-36- DIHYDROPYRIDIN-1(2H)-YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
3433, d4uwbA_, 0.7429, 2.93, 0.237, 299, 249, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
3434, d3zfxI_, 0.7429, 2.48, 0.228, 263, 241, CRYSTAL STRUCTURE OF EPHB1
3435, d3op5D_, 0.7429, 3.11, 0.144, 302, 257, HUMAN VACCINIA-RELATED KINASE 1
3436, d3ik3A1, 0.7429, 2.77, 0.234, 279, 244, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
3437, d5w86D_, 0.7428, 2.53, 0.261, 272, 241, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
3438, d5w5oM_, 0.7428, 2.50, 0.226, 276, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3439, d4cnhB_, 0.7428, 2.92, 0.202, 293, 248, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
3440, d5xdlA_, 0.7427, 2.70, 0.193, 292, 243, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH CO-1686
3441, d5oy6D_, 0.7427, 3.00, 0.234, 292, 248, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
3442, d4zjiB_, 0.7427, 2.52, 0.309, 276, 243, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
3443, d4zegA_, 0.7427, 2.25, 0.308, 260, 237, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
3444, d2qo9A_, 0.7427, 2.51, 0.206, 277, 243, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION PHOSPHORYLATED AMP-PNP BOUND
3445, d5w86B_, 0.7426, 2.56, 0.261, 267, 241, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
3446, d5em7A_, 0.7426, 2.68, 0.198, 300, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 13: 4-[(2- METHOXYPHENYL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
3447, d5e1eA_, 0.7426, 2.76, 0.244, 279, 246, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
3448, d5casA_, 0.7426, 2.68, 0.198, 299, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41A
3449, d4cd0A_, 0.7426, 2.83, 0.186, 295, 247, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPANE-12-DIOL
3450, d1ol6A_, 0.7426, 2.22, 0.301, 245, 236, STRUCTURE OF UNPHOSPHORYLATED D274N MUTANT OF AURORA-A
3451, d5tq4A_, 0.7425, 2.98, 0.254, 290, 252, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3452, d5iuiA_, 0.7425, 3.13, 0.187, 303, 252, CRYSTAL STRUCTURE OF ANAPLASTIC LYPHOMA KINASE (ALK) IN COMPLEX WITH 4
3453, d4zjiA_, 0.7425, 2.55, 0.309, 278, 243, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
3454, d4qpsC_, 0.7425, 2.71, 0.256, 276, 246, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
3455, d1zmwB_, 0.7425, 2.62, 0.315, 302, 238, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
3456, d5aagA_, 0.7424, 2.39, 0.304, 253, 240, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14B)
3457, d4u0iA_, 0.7424, 2.65, 0.221, 297, 244, CRYSTAL STRUCTURE OF KIT IN COMPLEX WITH PONATINIB
3458, d5c8nA_, 0.7423, 2.67, 0.198, 300, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 23
3459, d4bhnA_, 0.7423, 2.49, 0.290, 256, 238, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3460, d3wyxA_, 0.7423, 2.61, 0.312, 258, 240, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 6- ((3-(CYANOMETHOXY)-4-(1-METHYL-1H-PYRAZOL-4-YL)PHENYL)AMINO)-2- (CYCLOHEXYLAMINO)NICOTINONITRILE
3461, d3vw6A_, 0.7423, 2.38, 0.283, 255, 237, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
3462, d3f6xD_, 0.7423, 2.50, 0.250, 267, 240, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3463, d5v19A_, 0.7422, 2.20, 0.289, 250, 235, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3464, d1zmvB_, 0.7422, 2.30, 0.315, 296, 235, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
3465, d4fobA_, 0.7421, 2.98, 0.185, 295, 249, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 1
3466, d3fdnA_, 0.7421, 2.46, 0.299, 261, 241, STRUCTURE-BASED DRUG DESIGN OF NOVEL AURORA KINASE A INHIBITORS: STRUCTURE BASIS FOR POTENCY AND SPECIFICITY
3467, d1zmuB_, 0.7421, 2.33, 0.319, 296, 235, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
3468, d4hvsA1, 0.7419, 2.69, 0.225, 323, 244, CRYSTAL STRUCTURE OF KIT KINASE DOMAIN WITH A SMALL MOLECULE INHIBITOR PLX647
3469, d4uwbB_, 0.7418, 3.06, 0.232, 299, 250, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
3470, d3ik3B1, 0.7418, 2.79, 0.234, 285, 244, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
3471, d2vx0A_, 0.7418, 2.78, 0.206, 273, 247, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3472, d5i9yA_, 0.7417, 2.57, 0.215, 287, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DASATINIB
3473, d5capA_, 0.7417, 2.80, 0.204, 303, 245, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 30
3474, d4oa2A_, 0.7417, 2.86, 0.220, 280, 246,  
3475, d3dbqA_, 0.7417, 2.45, 0.305, 259, 239, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN
3476, d5ehyA1, 0.7416, 2.44, 0.307, 251, 238, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3477, d4xg8C_, 0.7416, 2.36, 0.196, 254, 240, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3478, d4at5A1, 0.7416, 2.85, 0.225, 291, 249, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580
3479, d2vwyA_, 0.7416, 2.89, 0.214, 274, 248, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3480, d1lufA_, 0.7416, 2.52, 0.228, 275, 241, CRYSTAL STRUCTURE OF THE MUSK TYROSINE KINASE: INSIGHTS INTO RECEPTOR AUTOREGULATION
3481, d4h58B_, 0.7415, 2.57, 0.203, 262, 241, BRAF IN COMPLEX WITH COMPOUND 3
3482, d4dfyE_, 0.7415, 2.55, 0.268, 312, 246, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
3483, d4c4jA1, 0.7415, 2.37, 0.311, 258, 238, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3484, d5khxA_, 0.7414, 2.84, 0.246, 276, 248, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH PF-4950736
3485, d5ap6A1, 0.7414, 2.24, 0.312, 259, 237, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3486, d2vx1A_, 0.7414, 2.78, 0.202, 274, 247, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3487, d5khwB_, 0.7413, 2.71, 0.245, 276, 245, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
3488, d5aadA_, 0.7413, 2.38, 0.293, 252, 239, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (7A)
3489, d4zloB_, 0.7413, 2.12, 0.294, 263, 235, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
3490, d4rj4A_, 0.7413, 2.69, 0.198, 299, 243, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 6
3491, d4equB_, 0.7413, 2.38, 0.322, 282, 236, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
3492, d4bi0A1, 0.7413, 2.37, 0.308, 251, 237, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3493, d5hx8A_, 0.7412, 2.86, 0.242, 291, 248, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
3494, d5c8kA_, 0.7412, 2.69, 0.198, 300, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 1
3495, d4bi1A1, 0.7412, 2.39, 0.308, 249, 237, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3496, d4bf2B_, 0.7412, 2.28, 0.289, 252, 235, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3497, d3hmnA_, 0.7412, 2.46, 0.303, 255, 238, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH ATP
3498, d2z7rA_, 0.7412, 2.21, 0.314, 265, 236, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO STAUROSPORINE
3499, d2xruA_, 0.7412, 2.40, 0.305, 253, 239, AURORA-A T288E COMPLEXED WITH PHA-828300
3500, d2vwzA_, 0.7412, 2.78, 0.202, 274, 247, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3501, d5ia3A_, 0.7411, 2.41, 0.212, 275, 240, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH PD173955
3502, d4yhtB_, 0.7411, 2.50, 0.203, 258, 241, BRAF COMPLEXED WITH AN INHIBITOR
3503, d2wmqA_, 0.7411, 2.25, 0.275, 246, 236, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3504, d2vwxA_, 0.7411, 2.78, 0.202, 274, 247, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3505, d2hakF_, 0.7411, 2.64, 0.326, 318, 242, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
3506, d1b6cH_, 0.7411, 3.17, 0.216, 326, 250, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
3507, d5w5oE_, 0.7410, 2.57, 0.222, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3508, d3q4zB_, 0.7410, 2.65, 0.289, 279, 242, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
3509, d1zmuA_, 0.7410, 2.46, 0.305, 293, 236, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
3510, d5hicA_, 0.7409, 2.74, 0.197, 302, 244, EGFR KINASE DOMAIN MUTANT TMLR WITH A IMIDAZOPYRIDINYL- AMINOPYRIMIDINE INHIBITOR
3511, d4kb8A_, 0.7409, 2.64, 0.201, 265, 244, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
3512, d3m11A_, 0.7409, 2.38, 0.305, 256, 239, CRYSTAL STRUCTURE OF AURORA A KINASE COMPLEXED WITH INHIBITOR
3513, d2zv8A1, 0.7409, 2.71, 0.231, 256, 242, LYN TYROSINE KINASE DOMAIN-AMP-PNP COMPLEX
3514, d5ia0B_, 0.7408, 2.49, 0.215, 266, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
3515, d5ajqA_, 0.7408, 2.67, 0.328, 280, 244, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
3516, d4usfB1, 0.7408, 2.83, 0.283, 283, 247, HUMAN SLK WITH SB-440719
3517, d3f6xB_, 0.7408, 2.46, 0.251, 267, 239, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3518, d5lpzA_, 0.7407, 2.82, 0.220, 283, 245, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1196) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
3519, d5ehoA1, 0.7407, 2.25, 0.314, 255, 236, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3520, d4e6dB_, 0.7407, 2.95, 0.257, 286, 249, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
3521, d4bhzA1, 0.7407, 2.38, 0.308, 248, 237, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3522, d5am7B_, 0.7406, 2.88, 0.243, 287, 247, FGFR1 MUTANT WITH AN INHIBITOR
3523, d4bi2A1, 0.7406, 2.38, 0.308, 250, 237, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3524, d3hmoA_, 0.7406, 2.35, 0.304, 257, 237, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH THE INHIBITOR STAUROSPORINE
3525, d3dqxB_, 0.7406, 2.67, 0.251, 268, 243, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
3526, d2wtvD_, 0.7406, 2.60, 0.311, 262, 241, AURORA-A INHIBITOR STRUCTURE
3527, d5vamA_, 0.7405, 2.64, 0.197, 269, 244, BRAF IN COMPLEX WITH RAF709
3528, d5f20A_, 0.7405, 2.43, 0.221, 274, 240, STRUCTURE OF TYK2 WITH INHIBITOR 4: 3-AZANYL-5-(2-METHYLPHENYL)-7-(1- METHYLPYRAZOL-3-YL)-1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
3529, d5ap0A1, 0.7405, 2.38, 0.304, 250, 237, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3530, d4prjA_, 0.7405, 2.49, 0.300, 251, 240, AURORA A KINASE DOMAIN WITH COMPOUND 2 (N-[1-(3-CYANOBENZYL)-1H- PYRAZOL-4-YL]-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
3531, d4cljA_, 0.7405, 2.94, 0.181, 295, 248, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
3532, d1zmvA_, 0.7405, 2.32, 0.302, 293, 235, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
3533, d1t45A_, 0.7405, 2.78, 0.229, 331, 245, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C- KIT TYROSINE KINASE
3534, d5n7vA1, 0.7404, 2.42, 0.311, 257, 238, TTK KINASE DOMAIN IN COMPLEX WITH MPI-0479605
3535, d5grnA_, 0.7404, 2.96, 0.206, 285, 247, CRYSTAL STRUCTURE OF PDGFRA IN COMPLEX WITH WQ-C-159
3536, d5calA_, 0.7404, 2.70, 0.198, 300, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 24
3537, d4c4fA1, 0.7404, 2.43, 0.304, 250, 237, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3538, d2j7tA_, 0.7404, 2.74, 0.321, 285, 240, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO SU11274
3539, d1t46A_, 0.7404, 2.68, 0.221, 297, 244, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
3540, d5hcxA_, 0.7403, 2.71, 0.198, 298, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH AZABENZIMIDAZOLE COMPOUND 7
3541, d3h10B_, 0.7403, 2.68, 0.306, 267, 242, AURORA A INHIBITOR COMPLEX
3542, d2wtvA_, 0.7403, 2.61, 0.311, 262, 241, AURORA-A INHIBITOR STRUCTURE
3543, d5n9sA1, 0.7402, 2.43, 0.311, 256, 238, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1161909
3544, d4hniA_, 0.7402, 2.83, 0.193, 284, 249, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
3545, d4g2fA_, 0.7402, 2.46, 0.207, 275, 241, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 7
3546, d4cvaA1, 0.7402, 2.33, 0.300, 250, 237, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
3547, d4c4iA1, 0.7402, 2.31, 0.312, 250, 237, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3548, d3g6hA_, 0.7402, 2.58, 0.253, 266, 241, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
3549, d2zmdA_, 0.7402, 2.40, 0.311, 259, 238, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN T686A MUTANT IN COMPLEX WITH SP600125 INHIBITOR
3550, d5njzA_, 0.7401, 2.57, 0.212, 273, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1G
3551, d4rj8A_, 0.7401, 2.67, 0.198, 298, 242, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 8
3552, d5w5oO_, 0.7400, 2.65, 0.230, 276, 244, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3553, d4ymjA1, 0.7400, 2.68, 0.231, 267, 242, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
3554, d5tq6A_, 0.7399, 2.96, 0.254, 274, 248, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3555, d5ihcA_, 0.7399, 2.48, 0.329, 305, 237, MELK IN COMPLEX WITH NVS-MELK12B
3556, d4f0iB_, 0.7399, 2.71, 0.214, 294, 243, CRYSTAL STRUCTURE OF APO TRKA
3557, d3op5C_, 0.7399, 3.13, 0.148, 308, 257, HUMAN VACCINIA-RELATED KINASE 1
3558, d4mxxA_, 0.7398, 2.46, 0.243, 266, 239, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3559, d4k77A_, 0.7398, 2.91, 0.242, 282, 248, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
3560, d3h9fA1, 0.7398, 2.36, 0.311, 256, 238, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYRIMIDO-DIAZEPIN LIGAND
3561, d3eqhA_, 0.7398, 3.16, 0.254, 314, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH U0126 ADP AND MG2P
3562, d5w5oA_, 0.7397, 2.60, 0.222, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3563, d5e1eB_, 0.7397, 2.84, 0.243, 280, 247, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
3564, d3vw6B_, 0.7397, 2.35, 0.292, 253, 236, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
3565, d5wo4A_, 0.7396, 2.90, 0.242, 292, 248, JAK1 COMPLEXED WITH COMPOUND 28
3566, d5w86A_, 0.7396, 2.62, 0.261, 269, 241, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
3567, d3q4uB1, 0.7396, 3.04, 0.230, 298, 248, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3568, d3mdyC_, 0.7396, 2.80, 0.211, 320, 246, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
3569, d1k9aE3, 0.7396, 2.51, 0.233, 268, 240, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3570, d3eqfA_, 0.7395, 2.89, 0.258, 314, 248, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH K252A AND MG2P
3571, d3d4qA_, 0.7395, 2.59, 0.203, 264, 241, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
3572, d5uhnB_, 0.7394, 2.76, 0.244, 269, 242, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
3573, d5em6A_, 0.7394, 2.71, 0.198, 301, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 19: 4-[(2- AZANYLPYRIMIDIN-4-YL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]- 2-OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
3574, d3ppkB_, 0.7394, 2.53, 0.203, 264, 241, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
3575, d5vndA_, 0.7393, 2.90, 0.226, 302, 248, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
3576, d5m57A1, 0.7393, 2.19, 0.286, 253, 234, NEK2 BOUND TO ARYLAMINOPURINE 6
3577, d5cauA_, 0.7393, 2.69, 0.198, 297, 242, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41B
3578, d4fodA_, 0.7393, 2.97, 0.185, 308, 248, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 36
3579, d5w5oJ_, 0.7392, 2.61, 0.226, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3580, d4i5cA_, 0.7392, 2.85, 0.243, 279, 247, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3581, d4focA_, 0.7392, 3.01, 0.185, 296, 248, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 2
3582, d3wyyA_, 0.7392, 2.57, 0.314, 258, 239, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH (E)- 3-(4-((6-(((3S5S7S)-ADAMANTAN-1-YL)AMINO)-4-AMINO-5-CYANOPYRIDIN-2- YL)AMINO)-2-(CYANOMETHOXY)PHENYL)-N-(2-METHOXYETHYL)ACRYLAMIDE
3583, d2i1mA_, 0.7392, 3.06, 0.206, 311, 247, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
3584, d4fk6A_, 0.7391, 3.04, 0.240, 285, 250, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
3585, d4ckrA1, 0.7391, 3.02, 0.221, 294, 249, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH DDR1-IN-1
3586, d4c4eA1, 0.7391, 2.30, 0.314, 253, 236, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3587, d4bkiA1, 0.7391, 3.02, 0.221, 294, 249,  
3588, d3prfA_, 0.7390, 2.44, 0.197, 262, 239, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
3589, d3g0fB_, 0.7390, 2.75, 0.230, 293, 244, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
3590, d5j7hA_, 0.7389, 2.72, 0.193, 291, 244, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) BOUND BY BRIGATINIB
3591, d3g0eA1, 0.7389, 2.84, 0.229, 330, 245, KIT KINASE DOMAIN IN COMPLEX WITH SUNITINIB
3592, d5mrbA1, 0.7388, 2.51, 0.319, 259, 238, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH CPD-5
3593, d5m51A1, 0.7388, 2.19, 0.282, 253, 234, NEK2 BOUND TO ARYLAMINOPURINE COMPOUND 8
3594, d4mxzB_, 0.7388, 2.44, 0.252, 264, 238, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3595, d4mxyB_, 0.7388, 2.44, 0.252, 264, 238, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3596, d4e4nB_, 0.7388, 2.86, 0.243, 280, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
3597, d3zz2A_, 0.7388, 2.74, 0.325, 281, 240,  
3598, d3wj6A_, 0.7388, 2.91, 0.243, 282, 247,  
3599, d3vquA_, 0.7388, 2.57, 0.314, 258, 239, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4- [(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2- YL)AMINO]BENZAMIDE
3600, d3gxlA_, 0.7388, 2.51, 0.208, 285, 240, ALK-5 KINASE COMPLEX WITH GW857175
3601, d2w1dA1, 0.7388, 2.31, 0.312, 251, 237, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3602, d5w5oK_, 0.7387, 2.62, 0.226, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3603, d5hhwA_, 0.7387, 2.94, 0.190, 306, 247, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH CIS-(R)-7-(3-(AZETIDIN-1-YLMETHYL)CYCLOBUTYL)-5-(3-((TETRAHYDRO-2H- PYRAN-2-YL)METHOXY)PHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE.
3604, d5ap3A1, 0.7387, 2.47, 0.304, 250, 237, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3605, d5a46A_, 0.7387, 2.89, 0.239, 289, 247, FGFR1 IN COMPLEX WITH DOVITINIB
3606, d4rwlA_, 0.7387, 2.87, 0.243, 282, 247, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
3607, d4oa6A_, 0.7387, 2.85, 0.220, 279, 245,  
3608, d4o6lA_, 0.7387, 2.45, 0.312, 257, 237, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
3609, d4c3rA_, 0.7387, 2.39, 0.297, 252, 239, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP
3610, d3mdyA_, 0.7387, 2.94, 0.230, 320, 248, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
3611, d3d4qB_, 0.7387, 2.60, 0.203, 264, 241, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
3612, d2helA_, 0.7387, 2.35, 0.192, 256, 239, CRYSTAL STRUCTURE OF A MUTANT EPHA4 KINASE DOMAIN (Y742A)
3613, d5w5oD_, 0.7386, 2.62, 0.226, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3614, d3g0fA_, 0.7386, 2.76, 0.230, 291, 244, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
3615, d2bdfB_, 0.7386, 2.67, 0.252, 265, 242, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
3616, d5b7vA_, 0.7385, 2.91, 0.239, 282, 247, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
3617, d4v05B_, 0.7385, 2.76, 0.233, 286, 245, FGFR1 IN COMPLEX WITH AZD4547.
3618, d4e5wB_, 0.7385, 2.77, 0.244, 278, 246, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
3619, d5uglB_, 0.7384, 2.76, 0.248, 271, 242, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
3620, d4fnwA_, 0.7384, 3.02, 0.190, 304, 248, CRYSTAL STRUCTURE OF THE APO F1174L ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3621, d4b8lA_, 0.7384, 2.43, 0.304, 249, 237, AURORA B KINASE P353G MUTANT
3622, d2etmB_, 0.7384, 2.47, 0.254, 263, 240, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
3623, d5edpA_, 0.7383, 2.69, 0.198, 295, 243, EGFR KINASE (T790M/L858R) APO
3624, d4zjjA_, 0.7383, 2.82, 0.305, 280, 246, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
3625, d4ivdB_, 0.7383, 2.86, 0.243, 280, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
3626, d4fk6B_, 0.7383, 2.99, 0.244, 284, 250, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
3627, d2jitB_, 0.7383, 3.21, 0.171, 312, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
3628, d4k77B_, 0.7382, 2.86, 0.243, 280, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
3629, d3mygA_, 0.7382, 2.38, 0.307, 252, 238, AURORA A KINASE COMPLEXED WITH SCH 1473759
3630, d5uorA_, 0.7381, 2.35, 0.289, 249, 235, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3631, d4rj7A_, 0.7381, 2.64, 0.199, 295, 241, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 1
3632, d2zv9A1, 0.7381, 2.74, 0.231, 255, 242, LYN TYROSINE KINASE DOMAIN-PP2 COMPLEX
3633, d5wr7A_, 0.7380, 2.77, 0.222, 301, 243, CRYSTAL STRUCTURE OF TRK-A COMPLEXED WITH A SELECTIVE INHIBITOR CH7057288
3634, d5w5oI_, 0.7380, 2.53, 0.223, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3635, d5w5oH_, 0.7380, 2.53, 0.223, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3636, d5w5oG_, 0.7380, 2.64, 0.226, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3637, d4cv9A1, 0.7380, 2.48, 0.303, 250, 238, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
3638, d3lw0A_, 0.7380, 2.93, 0.212, 292, 245, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3639, d4rj6A_, 0.7379, 2.69, 0.198, 297, 242, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 4
3640, d3lw0C_, 0.7379, 2.94, 0.212, 292, 245, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3641, d3b2wA_, 0.7379, 2.80, 0.230, 261, 244, CRYSTAL STRUCTURE OF PYRIMIDINE AMIDE 11 BOUND TO LCK
3642, d2wtkF1, 0.7379, 2.30, 0.272, 250, 235, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
3643, d5hx8B_, 0.7378, 2.88, 0.243, 279, 247, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
3644, d5hczA_, 0.7378, 2.74, 0.198, 300, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-AZETIDINYL AZAINDAZOLE COMPOUND 21
3645, d4js8A_, 0.7378, 2.51, 0.311, 259, 238, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401348
3646, d3lw0D_, 0.7378, 2.94, 0.212, 292, 245, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3647, d3aoxA_, 0.7378, 2.94, 0.190, 298, 247, X-RAY CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CH5424802
3648, d2w5bA1, 0.7378, 2.63, 0.283, 263, 240, HUMAN NEK2 KINASE ATPGAMMAS-BOUND
3649, d4o6lB_, 0.7377, 2.38, 0.314, 256, 236, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
3650, d4e5wA1, 0.7377, 2.87, 0.243, 291, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
3651, d4mxoA_, 0.7376, 2.50, 0.247, 266, 239, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
3652, d4c4gA1, 0.7376, 2.23, 0.306, 247, 235, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3653, d3etaB_, 0.7376, 2.98, 0.199, 292, 246, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
3654, d5uoxB_, 0.7375, 2.37, 0.285, 252, 235, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3655, d5tq7A_, 0.7375, 2.92, 0.251, 275, 247, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3656, d5bvkA_, 0.7375, 3.20, 0.220, 278, 250, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3657, d5ap5A1, 0.7375, 2.28, 0.305, 248, 236, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3658, d3lw0B_, 0.7375, 2.94, 0.212, 292, 245, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3659, d3d7uC1, 0.7375, 2.49, 0.238, 255, 239, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
3660, d3d7uA1, 0.7375, 2.49, 0.238, 255, 239, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
3661, d1k9aA3, 0.7375, 2.49, 0.234, 267, 239, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3662, d5ap1A1, 0.7374, 2.37, 0.315, 264, 238, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3663, d4ivcB_, 0.7374, 2.87, 0.243, 280, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
3664, d4h58A_, 0.7374, 2.47, 0.204, 263, 240, BRAF IN COMPLEX WITH COMPOUND 3
3665, d3zzeA_, 0.7374, 3.04, 0.215, 286, 247, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH N - ((3Z)-4-CHLORO-7-METHYL-2-OXO-12-DIHYDRO-3H-INDOL-3- YLIDENE)-2-(4-HYDROXYPHENYL)PROPANOHYDRAZIDE
3666, d5lpvA_, 0.7373, 2.87, 0.220, 282, 246, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH AMPPNP AND MN FROM ARABIDOPSIS THALIANA
3667, d5ljjA1, 0.7373, 2.51, 0.308, 260, 237, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH REVERSINE
3668, d5kmnA1, 0.7373, 2.62, 0.216, 290, 241, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
3669, d4uynA_, 0.7373, 2.28, 0.315, 249, 235, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
3670, d4cmuA_, 0.7373, 3.05, 0.185, 294, 248, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (10R)-7-AMINO-12-FLUORO-1310 16-TETRAMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(43- H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
3671, d4ccuA_, 0.7373, 2.99, 0.202, 292, 247, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPAN-2-OL
3672, d4c62B_, 0.7373, 2.60, 0.266, 271, 241, INHIBITORS OF JAK2 KINASE DOMAIN
3673, d2fb8A_, 0.7373, 2.54, 0.203, 259, 241, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
3674, d2bdjA_, 0.7373, 2.53, 0.251, 254, 239, SRC KINASE IN COMPLEX WITH INHIBITOR AP23464
3675, d5nkaA_, 0.7372, 2.34, 0.210, 271, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2G
3676, d5aaeA_, 0.7371, 2.37, 0.307, 252, 238, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14D)
3677, d5aabA_, 0.7371, 2.96, 0.190, 293, 247, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3678, d4usdB_, 0.7371, 2.58, 0.329, 267, 243, HUMAN STK10 (LOK) WITH SB-633825
3679, d4cmoA_, 0.7371, 2.86, 0.187, 295, 246, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 2-((1R)-1-((3-AMINO-6-(2- METHOXYPYRIDIN- -YL)PYRAZIN-2-YL)OXY)ETHYL)-4-FLUORO-N-METHYLBENZAMIDE
3680, d2xneA_, 0.7371, 2.22, 0.297, 246, 236, STRUCTURE OF AURORA-A BOUND TO AN IMIDAZOPYRAZINE INHIBITOR
3681, d2xa4B_, 0.7371, 2.66, 0.269, 275, 242, INHIBITORS OF JAK2 KINASE DOMAIN
3682, d2oiqB_, 0.7371, 2.58, 0.258, 265, 240, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
3683, d5t0pB_, 0.7370, 2.48, 0.253, 263, 237, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
3684, d5bvoA_, 0.7370, 3.15, 0.219, 276, 251, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3685, d4k8aB_, 0.7370, 2.50, 0.254, 258, 240, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
3686, d4gu6A_, 0.7370, 2.86, 0.250, 271, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
3687, d3uqgA_, 0.7370, 2.42, 0.253, 263, 237, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
3688, d5w5oL_, 0.7369, 2.65, 0.226, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3689, d5n93A1, 0.7369, 2.40, 0.291, 256, 237, TTK KINASE DOMAIN IN COMPLEX WITH TC-MPS1-12
3690, d5lpwA_, 0.7369, 2.83, 0.230, 280, 244, CRYSTAL STRUCTURE OF THE APO-BRI1 KINASE DOMAIN (865-1160)
3691, d4o0uA_, 0.7369, 2.60, 0.302, 259, 242, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3692, d4kbaA_, 0.7369, 2.60, 0.198, 263, 242, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
3693, d4jbpA_, 0.7369, 2.49, 0.301, 255, 239, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3694, d3ppkA_, 0.7369, 2.48, 0.205, 262, 239, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
3695, d3fzrA_, 0.7369, 2.64, 0.207, 261, 242, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-431396
3696, d2j0mB_, 0.7369, 2.30, 0.253, 257, 237, CRYSTAL STRUCTURE A TWO-CHAIN COMPLEX BETWEEN THE FERM AND KINASE DOMAINS OF FOCAL ADHESION KINASE.
3697, d6btwD_, 0.7368, 3.30, 0.154, 307, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
3698, d5tq6B_, 0.7368, 2.96, 0.263, 271, 247, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3699, d5ar7A_, 0.7368, 2.77, 0.224, 278, 245, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
3700, d5aaaA_, 0.7368, 2.87, 0.191, 294, 246, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3701, d4ztsA_, 0.7368, 2.43, 0.303, 249, 238, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1142
3702, d4oa9A_, 0.7368, 2.94, 0.220, 280, 246,  
3703, d3et7A_, 0.7368, 2.63, 0.202, 261, 242, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-2318841
3704, d1muoA_, 0.7368, 2.45, 0.308, 251, 237, CRYSTAL STRUCTURE OF AURORA-2 AN ONCOGENIC SERINE- THREONINE KINASE
3705, d5ap7A1, 0.7367, 2.36, 0.309, 253, 236, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3706, d4ymjB1, 0.7367, 2.68, 0.232, 272, 241, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
3707, d2xvdA_, 0.7367, 2.66, 0.222, 270, 243, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3708, d5a4cB1, 0.7366, 3.13, 0.229, 284, 249, FGFR1 LIGAND COMPLEX
3709, d3w1fA_, 0.7366, 2.40, 0.295, 259, 237, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 5-(5- ETHOXY-6-(1-METHYL-1H-PYRAZOL-4-YL)-1H-INDAZOL-3-YL)-2- METHYLBENZENESULFONAMIDE
3710, d3q4uC_, 0.7366, 2.97, 0.220, 296, 246, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3711, d1jqhA_, 0.7366, 2.99, 0.201, 291, 249, IGF-1 RECEPTOR KINASE DOMAIN
3712, d5kmlA1, 0.7365, 2.62, 0.216, 290, 241, TRKA JM-KINASE WITH 1-(5-METHYL-3-PHENYL-12-OXAZOL-4-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
3713, d5aa9A_, 0.7365, 2.88, 0.191, 295, 246, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
3714, d4v05A_, 0.7365, 2.87, 0.236, 287, 246, FGFR1 IN COMPLEX WITH AZD4547.
3715, d4ivbB_, 0.7365, 2.89, 0.243, 280, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
3716, d4c61B_, 0.7365, 2.61, 0.270, 274, 241, INHIBITORS OF JAK2 KINASE DOMAIN
3717, d4anqA_, 0.7365, 2.97, 0.190, 293, 247, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3718, d3cjgA_, 0.7365, 2.65, 0.219, 280, 242, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
3719, d2fb8B_, 0.7365, 2.41, 0.205, 259, 239, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
3720, d1p4oA_, 0.7365, 3.02, 0.206, 308, 247, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
3721, d6eixA_, 0.7364, 3.33, 0.231, 312, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE Q207E MUTANT OF ACVR1 (ALK2) IN COMPLEX WITH A 2-AMINOPYRIDINE INHIBITOR K02288
3722, d5edqA_, 0.7364, 2.79, 0.201, 298, 244, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 15: ~{N}-(7- CHLORANYL-1~{H}-INDAZOL-3-YL)-77-DIMETHYL-2-(1~{H}-PYRAZOL-4-YL)- 5~{H}-FURO[34-D]PYRIMIDIN-4-AMINE
3723, d4cliA_, 0.7364, 2.98, 0.186, 294, 247, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-21016-TRIMETHYL-15 -OXO-10151617-TETRAHYDRO-2H-84-(METHENO)PYRAZOLO(43-H) (2511)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
3724, d4aotB1, 0.7364, 2.73, 0.333, 277, 243, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
3725, d3zlsA_, 0.7364, 3.12, 0.255, 315, 251, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 6
3726, d5w5oP_, 0.7363, 2.65, 0.222, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3727, d5w5oF_, 0.7363, 2.55, 0.223, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3728, d5ia4A_, 0.7363, 2.84, 0.204, 269, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH FORETINIB (XL880)
3729, d5caoA_, 0.7363, 2.65, 0.199, 300, 241, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 29
3730, d4ehzA_, 0.7363, 2.93, 0.246, 290, 248, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3731, d4bf2A_, 0.7363, 2.45, 0.288, 253, 236, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3732, d4ansA_, 0.7363, 2.97, 0.194, 293, 247, STRUCTURE OF L1196MG1269A DOUBLE MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3733, d3wj6B_, 0.7363, 2.84, 0.237, 277, 245,  
3734, d3h0zA_, 0.7363, 2.45, 0.308, 248, 237, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3735, d3e8nA1, 0.7363, 3.27, 0.261, 290, 253, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) COMPLEXED WITH A POTENT INHIBITOR RDEA119 AND MGATP
3736, d5w5oC_, 0.7362, 2.66, 0.222, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3737, d4mxoB_, 0.7362, 2.49, 0.244, 264, 238, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
3738, d4lmnA1, 0.7362, 3.32, 0.257, 291, 253, CRYSTAL STRUCTURE OF MEK1 KINASE BOUND TO GDC0973
3739, d3uojB_, 0.7362, 2.45, 0.312, 263, 237, AURORA A IN COMPLEX WITH RPM1715
3740, d5oxgD_, 0.7361, 3.17, 0.229, 293, 249, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3741, d4e4nA1, 0.7361, 2.86, 0.244, 290, 246, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
3742, d3zmmB_, 0.7361, 2.63, 0.266, 274, 241, INHIBITORS OF JAK2 KINASE DOMAIN
3743, d3uojA_, 0.7361, 2.53, 0.315, 263, 238, AURORA A IN COMPLEX WITH RPM1715
3744, d2qobA_, 0.7361, 2.63, 0.198, 279, 243, HUMAN EPHA3 KINASE DOMAIN BASE STRUCTURE
3745, d5xy1A1, 0.7360, 2.58, 0.238, 252, 239, CRYSTAL STRUCTURE OF LYN KINASE DOMAIN IN COMPLEX WITH N-(1H-INDAZOL- 6-YL)-8-(PIPERIDIN-4-YLOXY)-6-PROPYLQUINAZOLIN-2-AMINE
3746, d5ar4A_, 0.7360, 2.60, 0.219, 274, 242, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
3747, d4yhtA_, 0.7360, 2.45, 0.205, 256, 239, BRAF COMPLEXED WITH AN INHIBITOR
3748, d4usdA_, 0.7360, 2.54, 0.326, 268, 242, HUMAN STK10 (LOK) WITH SB-633825
3749, d4dfyA_, 0.7360, 2.54, 0.270, 310, 244, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
3750, d3d94A_, 0.7360, 2.89, 0.205, 288, 244, CRYSTAL STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE IN COMPLEX WITH PQIP
3751, d2zv7A1, 0.7360, 2.66, 0.228, 256, 241, LYN TYROSINE KINASE DOMAIN APO FORM
3752, d2wkmA_, 0.7360, 3.05, 0.215, 286, 247, X-RAY STRUCTURE OF PHA-00665752 BOUND TO THE KINASE DOMAIN OF C-MET
3753, d2w5aA1, 0.7360, 2.67, 0.279, 259, 240, HUMAN NEK2 KINASE ADP-BOUND
3754, d1jqhC_, 0.7360, 3.00, 0.201, 291, 249, IGF-1 RECEPTOR KINASE DOMAIN
3755, d5wo4B_, 0.7359, 2.91, 0.243, 280, 247, JAK1 COMPLEXED WITH COMPOUND 28
3756, d5a9uA_, 0.7359, 3.01, 0.186, 292, 247, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
3757, d4p2kA_, 0.7359, 2.61, 0.202, 259, 242, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
3758, d4oacA_, 0.7359, 2.94, 0.220, 280, 246,  
3759, d4ctbA_, 0.7359, 2.87, 0.191, 292, 246, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (5R)-8-AMINO-3-FLUORO-519-DIMETHYL-20-OXO-5181920- TETRAHYDRO-711-(AZENO)PYRIDO(2 1 :23)IMIDAZO(45-H)(2511) BENZOXADIAZACYCLOTETRADECINE-14-CARBONITRILE
3760, d3lauA1, 0.7359, 2.26, 0.312, 250, 234, CRYSTAL STRUCTURE OF AURORA2 KINASE IN COMPLEX WITH A GSK3BETA INHIBITOR
3761, d5ap2A1, 0.7358, 2.34, 0.314, 253, 236, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3762, d4c4hA1, 0.7358, 2.17, 0.308, 245, 234, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3763, d2wgjA_, 0.7358, 3.02, 0.220, 289, 246, X-RAY STRUCTURE OF PF-02341066 BOUND TO THE KINASE DOMAIN OF C-MET
3764, d2etmA_, 0.7358, 2.77, 0.259, 262, 243, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
3765, d5bvwA_, 0.7357, 3.07, 0.222, 274, 248, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3766, d5aa8A_, 0.7357, 3.01, 0.190, 292, 247, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12- FLUORO-21016-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H- 84-(METHENO)PYRAZOLO(43-H)(2511) BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
3767, d4u43B_, 0.7357, 3.32, 0.236, 302, 254, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
3768, d4twoA_, 0.7357, 2.52, 0.207, 278, 241, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 164
3769, d4cv8A1, 0.7357, 2.38, 0.304, 252, 237, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
3770, d3q4uD_, 0.7357, 3.16, 0.229, 299, 249, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3771, d2hakE_, 0.7357, 2.59, 0.328, 318, 241, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
3772, d5kz0A_, 0.7356, 2.94, 0.187, 293, 246, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-[(1R)- 1-{[2-AMINO-5-(13-DIMETHYL-1H-PYRAZOL-4-YL)PYRIDIN-3-YL]OXY}ETHYL]- 4-FLUORO-NN-DIMETHYLBENZAMIDE
3773, d5edrA_, 0.7356, 2.70, 0.198, 299, 242, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 27: ~{N}-(1~{H}- INDAZOL-3-YL)-77-DIMETHYL-2-(2-METHYLPYRAZOL-3-YL)-5~{H}-FURO[34- D]PYRIMIDIN-4-AMINE
3774, d5bvnA_, 0.7356, 3.24, 0.214, 278, 252, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3775, d4ibmA_, 0.7356, 2.87, 0.196, 301, 245, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
3776, d4c7tA_, 0.7356, 2.74, 0.260, 259, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
3777, d2jkmA_, 0.7356, 2.54, 0.259, 260, 239, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
3778, d2hiwA1, 0.7356, 2.77, 0.231, 270, 242, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
3779, d5ftqA1, 0.7355, 2.95, 0.187, 292, 246, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH CMPD 17
3780, d4k6zA_, 0.7355, 2.86, 0.244, 279, 246, THE JAK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 37
3781, d4ivcA1, 0.7355, 2.88, 0.244, 290, 246, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
3782, d2qokA_, 0.7355, 2.52, 0.212, 281, 241, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:S768A TRIPLE MUTANT
3783, d1p4oB_, 0.7355, 2.94, 0.207, 314, 246, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
3784, d5w5oB_, 0.7354, 2.66, 0.222, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3785, d5oxgC1, 0.7354, 3.18, 0.229, 299, 249, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3786, d4p5qA_, 0.7354, 2.48, 0.208, 275, 240, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
3787, d4nkaB_, 0.7354, 3.06, 0.219, 287, 247, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
3788, d4c8bA_, 0.7354, 2.73, 0.218, 279, 243, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
3789, d4bggB_, 0.7354, 3.11, 0.230, 293, 248, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3790, d2x9fA_, 0.7354, 2.64, 0.219, 265, 242, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3791, d1m7nB_, 0.7354, 2.92, 0.207, 299, 246, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
3792, d5b7vB_, 0.7353, 2.75, 0.238, 277, 244, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
3793, d4u41A_, 0.7353, 2.76, 0.259, 275, 243, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
3794, d3unzB_, 0.7353, 2.55, 0.315, 263, 238, AURORA A IN COMPLEX WITH RPM1679
3795, d3unzA_, 0.7353, 2.55, 0.315, 263, 238, AURORA A IN COMPLEX WITH RPM1679
3796, d3eqgA_, 0.7353, 3.23, 0.254, 314, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH PD ADP AND MG2P
3797, d3beaA_, 0.7353, 2.79, 0.205, 310, 244, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH A PYRIMIDINOPYRIDONE INHIBITOR
3798, d2jiuB_, 0.7353, 3.43, 0.162, 309, 259, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
3799, d5aacA_, 0.7352, 3.01, 0.186, 292, 247, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3800, d4bggA_, 0.7352, 3.12, 0.230, 296, 248, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3801, d4ap7A_, 0.7352, 3.03, 0.220, 289, 246, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( (6-(4- FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN-3-YL)METHYL) PHENOL
3802, d4gu9B_, 0.7351, 2.61, 0.253, 255, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
3803, d4arkA1, 0.7351, 3.27, 0.254, 290, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH  A SMALL MOLECULE INHIBITOR AND ADP
3804, d3uo6B_, 0.7351, 2.43, 0.316, 264, 237, AURORA A IN COMPLEX WITH YL5-083
3805, d3uo6A_, 0.7351, 2.43, 0.316, 264, 237, AURORA A IN COMPLEX WITH YL5-083
3806, d3k5vA1, 0.7351, 2.75, 0.232, 281, 241, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
3807, d3a62A_, 0.7351, 2.23, 0.319, 263, 235, CRYSTAL STRUCTURE OF PHOSPHORYLATED P70S6K1
3808, d5ap4A1, 0.7350, 2.37, 0.314, 253, 236, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3809, d4ei4B_, 0.7350, 2.92, 0.243, 280, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
3810, d4aojA_, 0.7350, 2.36, 0.210, 260, 238, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
3811, d3cohB_, 0.7350, 2.52, 0.304, 247, 237, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
3812, d1iepA1, 0.7350, 2.71, 0.231, 270, 242, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
3813, d5xp7A_, 0.7349, 2.55, 0.255, 265, 239, C-SRC IN COMPLEX WITH ATP-CHCL
3814, d4aojC_, 0.7349, 2.34, 0.218, 261, 238, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
3815, d4anlA_, 0.7349, 2.98, 0.190, 292, 247, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE
3816, d3prfB_, 0.7349, 2.51, 0.197, 262, 239, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
3817, d3eqcA_, 0.7349, 3.15, 0.255, 312, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH COMPOUND 1 ATP-GS AND MG2P
3818, d1opjB1, 0.7349, 2.85, 0.239, 284, 243, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
3819, d5na0A1, 0.7348, 2.40, 0.301, 250, 236, TTK KINASE DOMAIN IN COMPLEX WITH A PEG-LINKED PYRIMIDO-INDOLIZINE
3820, d4zjjB_, 0.7348, 2.56, 0.311, 277, 241, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
3821, d3eqdA_, 0.7348, 2.94, 0.258, 315, 248, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ATP-GS AND MG2P
3822, p2y4iC_, 0.7348, 3.19, 0.251, 313, 251, KSR2-MEK1 HETERODIMER
3823, d2uv2A1, 0.7348, 2.51, 0.282, 286, 238, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 4-(4-( 5-CYCLOPROPYL-1H-PYRAZOL-3-YLAMINO)-QUINAZOLIN-2-YLAMINO)- PHENYL)-ACETONITRILE
3824, d2hakD_, 0.7348, 2.36, 0.332, 309, 238, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
3825, d5iuhA_, 0.7347, 2.73, 0.186, 285, 242, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5D
3826, d5ia5A_, 0.7347, 2.76, 0.201, 273, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH GOLVATINIB (E7050)
3827, d4uzhA1, 0.7347, 2.31, 0.312, 250, 234, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
3828, d4rwlB_, 0.7347, 3.13, 0.230, 285, 248, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
3829, d3zclA_, 0.7347, 3.04, 0.220, 289, 246, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-3-(1-(1H-PYRROLO(23-B)PYRIDIN-3-YL)ETHYL)-N-ISOPROPYL-( 124)TRIAZOLO(43-B)PYRIDAZIN-6-AMINE
3830, d5nadA1, 0.7346, 2.26, 0.302, 253, 235, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1217389
3831, d4mnfA_, 0.7346, 2.48, 0.206, 257, 238, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
3832, d3zlxA_, 0.7346, 3.03, 0.253, 312, 249, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 18
3833, d5oxgB_, 0.7345, 3.13, 0.230, 296, 248, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3834, d4mxzA_, 0.7345, 2.58, 0.251, 266, 239, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3835, d4mxyA_, 0.7345, 2.58, 0.251, 266, 239, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3836, d3cohA_, 0.7345, 2.52, 0.304, 247, 237, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
3837, d4nk9B_, 0.7344, 3.18, 0.219, 282, 247, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
3838, d4ivbA1, 0.7344, 2.88, 0.244, 290, 246, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
3839, d3uohB_, 0.7344, 2.56, 0.315, 264, 238, AURORA A IN COMPLEX WITH RPM1722
3840, d3uohA_, 0.7344, 2.56, 0.315, 264, 238, AURORA A IN COMPLEX WITH RPM1722
3841, d3eqiA_, 0.7344, 2.94, 0.254, 315, 248, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ADP AND MG2P
3842, d3en4B_, 0.7344, 2.59, 0.255, 266, 239, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
3843, d3dv3A_, 0.7344, 3.22, 0.259, 288, 251, MEK1 WITH PF-04622664 BOUND
3844, d2c6dA_, 0.7344, 2.51, 0.315, 254, 238, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH ADPNP
3845, d5nk0A_, 0.7343, 2.34, 0.215, 273, 237, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1J
3846, d4o2pB_, 0.7343, 2.58, 0.255, 265, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
3847, d4i5cB1, 0.7343, 2.90, 0.244, 290, 246, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3848, d4ag8A_, 0.7343, 2.95, 0.216, 296, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6- YLSULFANYL)-BENZAMIDE)
3849, d3txoA_, 0.7343, 2.82, 0.271, 317, 240, PKC ETA KINASE IN COMPLEX WITH A NAPHTHYRIDINE
3850, d1iepB1, 0.7343, 2.67, 0.232, 270, 241, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
3851, d5l4qB_, 0.7342, 2.34, 0.253, 287, 237, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
3852, d4bkjB1, 0.7342, 3.09, 0.225, 296, 249, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
3853, d3og7B_, 0.7342, 2.48, 0.214, 254, 238, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
3854, d3l8vA_, 0.7342, 2.93, 0.216, 293, 245, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A BIARYLAMINE BASED INHIBITOR
3855, d2j51A_, 0.7342, 2.50, 0.277, 288, 238, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 5- AMINO-3-((4-(AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-124-TRIAZOLE-1-CARBOTHIOAMIDE
3856, d1m7nA_, 0.7342, 2.96, 0.207, 299, 246, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
3857, d1fpuA1, 0.7342, 2.78, 0.230, 271, 243, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
3858, d3zlwA_, 0.7341, 3.04, 0.253, 312, 249, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 3
3859, d3v5qB1, 0.7341, 2.59, 0.230, 262, 239, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
3860, d3pp1A1, 0.7341, 3.28, 0.249, 290, 253, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGATP
3861, d3krjA_, 0.7341, 2.80, 0.206, 304, 243, CFMS TYROSINE KINASE IN COMPLEX WITH 4-CYANO-1H-IMIDAZOLE-2-CARBOXYLIC ACID (2-CYCLOHEX-1-ENYL-4-PIPERIDIN-4-YL-PHENYL)-AMIDE
3862, d5v24A_, 0.7340, 2.37, 0.286, 249, 234, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3863, d4u7zA1, 0.7340, 3.32, 0.261, 290, 253, MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK1) BOUND TO G805
3864, d3gxjA_, 0.7340, 2.81, 0.206, 288, 243,  
3865, d2hiwB1, 0.7340, 2.65, 0.232, 270, 241, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
3866, d3my0N1, 0.7339, 3.07, 0.228, 299, 246, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3867, d2hyyA_, 0.7339, 2.67, 0.224, 263, 241, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
3868, d1jqhB_, 0.7339, 3.00, 0.202, 287, 248, IGF-1 RECEPTOR KINASE DOMAIN
3869, d4r7hA_, 0.7338, 2.86, 0.213, 308, 244, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX3397
3870, d4gt5A_, 0.7338, 2.75, 0.215, 290, 242, CRYSTAL STRUCTURE OF THE INACTIVE TRKA KINASE DOMAIN
3871, d3h3cA_, 0.7338, 2.47, 0.209, 263, 239, CRYSTAL STRUCTURE OF PYK2 IN COMPLEX WITH SULFOXIMINE- SUBSTITUTED TRIFLUOROMETHYLPYRIMIDINE ANALOG
3872, d2yhvA_, 0.7338, 3.02, 0.190, 291, 247, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE
3873, d4y95A1, 0.7337, 2.80, 0.182, 265, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3874, d3wzkA_, 0.7337, 2.52, 0.311, 258, 238, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH N- CYCLOPROPYL-4-(8-((THIOPHEN-2-YLMETHYL)AMINO)IMIDAZO[12-A]PYRAZIN-3- YL)BENZAMIDE
3875, d3my0M1, 0.7337, 3.31, 0.220, 297, 250, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3876, d1pkgB_, 0.7336, 2.78, 0.232, 277, 241, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
3877, d1k9aD3, 0.7336, 2.57, 0.225, 268, 240, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3878, d5oy6B_, 0.7335, 3.07, 0.235, 292, 247, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
3879, d5kmjA_, 0.7335, 2.66, 0.217, 300, 240, TRKA JM-KINASE WITH {N}-(2-PYRIDYLMETHYL)-2-[2-(2-THIENYL)INDOL-1- YL]ACETAMIDE
3880, d4ztrA_, 0.7335, 2.40, 0.300, 249, 237, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1141
3881, d3wzeA_, 0.7335, 2.79, 0.222, 298, 243, KDR IN COMPLEX WITH LIGAND SORAFENIB
3882, d3my0L1, 0.7335, 3.28, 0.221, 295, 249, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3883, d5lpyA_, 0.7334, 2.90, 0.221, 282, 244, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ATP FROM ARABIDOPSIS THALIANA
3884, d3zlyA_, 0.7334, 3.04, 0.257, 310, 249, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 8
3885, d3mblA_, 0.7334, 3.31, 0.245, 290, 253, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGADP
3886, d2ja0A_, 0.7334, 2.46, 0.283, 285, 237,  
3887, d5l8jA_, 0.7333, 2.51, 0.277, 253, 238, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 S93R
3888, d4obqA_, 0.7333, 2.56, 0.264, 275, 239, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
3889, d4kabB_, 0.7333, 2.64, 0.253, 258, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
3890, d4bidA_, 0.7333, 2.53, 0.280, 254, 236, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3891, d3zfxB_, 0.7333, 2.31, 0.225, 254, 236, CRYSTAL STRUCTURE OF EPHB1
3892, d3qriA1, 0.7333, 2.77, 0.232, 270, 241, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
3893, p3eocA2, 0.7333, 0.34, 1.000, 216, 214, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
3894, d2jfmA_, 0.7333, 2.44, 0.283, 287, 237, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (UNLIGANDED FORM)
3895, d2j50B_, 0.7333, 2.62, 0.303, 249, 238, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
3896, d2j50A_, 0.7333, 2.62, 0.303, 249, 238, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
3897, d5uvfD_, 0.7332, 3.21, 0.152, 296, 256, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
3898, d5ia1A_, 0.7332, 2.46, 0.210, 261, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH MLN8054
3899, d5i9wA_, 0.7332, 2.40, 0.207, 267, 237, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ANP
3900, d3zfxF_, 0.7332, 2.32, 0.225, 254, 236, CRYSTAL STRUCTURE OF EPHB1
3901, d2ijmB_, 0.7332, 2.48, 0.255, 261, 239, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
3902, d5vamB_, 0.7331, 2.54, 0.197, 260, 239, BRAF IN COMPLEX WITH RAF709
3903, d4nkaA_, 0.7331, 2.86, 0.230, 279, 244, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
3904, d4b0gA_, 0.7331, 2.11, 0.306, 247, 232, COMPLEX OF AURORA-A BOUND TO AN IMIDAZOPYRIDINE-BASED INHIBITOR
3905, d3zxzA_, 0.7331, 3.02, 0.220, 289, 245, X-RAY STRUCTURE OF PF-04217903 BOUND TO THE KINASE DOMAIN OF C-MET
3906, d3zbxA_, 0.7331, 3.05, 0.220, 282, 246, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR 6- ((6-(4-FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN- 3-YL)METHYL)QUINOLINE.
3907, d1fpuB1, 0.7331, 2.69, 0.224, 266, 241, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
3908, d4y95D_, 0.7330, 2.77, 0.174, 265, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3909, d4nk9A_, 0.7330, 2.82, 0.226, 281, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
3910, d4ctcA_, 0.7330, 2.88, 0.192, 288, 245, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 7-AMINO-3-CYCLOPROPYL-12-FLUORO- 11016-TRIMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(4 3-H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
3911, d3vo3A_, 0.7330, 2.96, 0.216, 303, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH IMIDAZO[1 2-B]PYRIDAZINE DERIVATIVE
3912, d3o23A_, 0.7330, 2.88, 0.197, 293, 244, HUMAN UNPHOSPHORYLATED IGF1-R KINASE DOMAIN IN COMPLEX WITH AN HYDANTOIN INHIBITOR
3913, p3ej1A2, 0.7330, 0.37, 1.000, 216, 214, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
3914, d3d7tB_, 0.7330, 2.60, 0.234, 265, 239, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
3915, d2yfxA_, 0.7330, 2.94, 0.187, 292, 246, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3916, d5j9zA_, 0.7329, 2.70, 0.216, 291, 241, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1A
3917, d5fdxA_, 0.7329, 3.11, 0.220, 280, 250, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
3918, d4oabA_, 0.7329, 2.92, 0.220, 279, 245,  
3919, d4ivdA1, 0.7329, 2.86, 0.245, 289, 245, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
3920, d4aoiA_, 0.7329, 3.06, 0.220, 289, 246, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( 3-((1H- PYRROLO(23-B)PYRIDIN-3-YL)METHYL)-(124)TRIAZOLO( 43-B)(124) TRIAZIN-6-YL)BENZONITRILE
3921, d3uokB_, 0.7329, 2.46, 0.316, 265, 237, AURORA A IN COMPLEX WITH YL5-81-1
3922, d3uokA_, 0.7329, 2.46, 0.316, 265, 237, AURORA A IN COMPLEX WITH YL5-81-1
3923, d3my0B_, 0.7329, 3.25, 0.221, 295, 249, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3924, d3fzpA_, 0.7329, 2.42, 0.210, 259, 238, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH ATPGS
3925, d3etaA_, 0.7329, 3.03, 0.199, 293, 246, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
3926, d4y95C1, 0.7328, 2.78, 0.182, 265, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3927, d4oboA_, 0.7328, 2.86, 0.262, 275, 244, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
3928, d4fg7A_, 0.7328, 2.15, 0.289, 250, 232, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-293 IN COMPLEX WITH ATP
3929, d3nw6A_, 0.7328, 2.79, 0.205, 301, 244, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11A)
3930, p3eocC2, 0.7328, 0.38, 1.000, 214, 214, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
3931, p5x02A_, 0.7327, 2.73, 0.218, 305, 243, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR FF- 10101
3932, d4y95B1, 0.7327, 2.78, 0.182, 265, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3933, d4bibA_, 0.7327, 2.54, 0.284, 254, 236, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3934, d6b4wA_, 0.7326, 2.37, 0.305, 259, 236, TTK IN COMPLEX WITH INHIBITOR
3935, d5bx0A_, 0.7326, 3.05, 0.261, 315, 249, AN AUTOMATED MICROSCALE THERMOPHORESIS SCREENING APPROACH FOR FRAGMENT-BASED LEAD DISCOVERY
3936, d4ccbA_, 0.7326, 2.94, 0.189, 287, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 3-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(5-METHYL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE
3937, d4bkjA1, 0.7326, 3.12, 0.221, 294, 249, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
3938, d4asdA_, 0.7326, 2.87, 0.217, 305, 244, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SORAFENIB (BAY 43-9006)
3939, d2hznA2, 0.7326, 2.70, 0.225, 268, 240, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AFG210
3940, d5oxgA_, 0.7325, 3.18, 0.230, 293, 248, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3941, d4rwiB_, 0.7325, 2.84, 0.238, 280, 244, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
3942, d4ehzB_, 0.7325, 2.93, 0.243, 280, 247, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3943, d4bggD_, 0.7325, 3.11, 0.232, 286, 246, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3944, d3vntA_, 0.7325, 2.87, 0.217, 301, 244, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
3945, d2jflA_, 0.7325, 2.45, 0.278, 286, 237, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE ( DIPHOSPHORYLATED FORM) BOUND TO 5- AMINO-3-((4-( AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-12 4-TRIAZOLE-1-CARBOTHIOAMIDE
3946, d1k9aB3, 0.7325, 2.55, 0.234, 267, 239, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3947, d4r7iA_, 0.7324, 2.84, 0.214, 290, 243, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR GLEEVEC
3948, d3u6jA1, 0.7324, 2.88, 0.216, 305, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
3949, d2w96B_, 0.7324, 3.13, 0.488, 267, 246, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
3950, d5a4cA_, 0.7323, 2.93, 0.233, 294, 245, FGFR1 LIGAND COMPLEX
3951, d4mcvB_, 0.7323, 2.57, 0.256, 265, 238, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
3952, d4e4lD_, 0.7323, 2.96, 0.247, 281, 247, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3953, d4brxA_, 0.7323, 2.77, 0.248, 259, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
3954, d4agcA_, 0.7323, 2.86, 0.217, 304, 244, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-( 3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)- BENZAMIDE)
3955, d3my0A1, 0.7323, 3.29, 0.221, 295, 249, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3956, d3h10D_, 0.7323, 2.47, 0.312, 255, 237, AURORA A INHIBITOR COMPLEX
3957, p3ej1C2, 0.7323, 0.41, 1.000, 215, 214, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
3958, d2p55A2, 0.7323, 3.23, 0.251, 288, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3959, d5kmiA_, 0.7322, 2.71, 0.217, 300, 240, TRKA JM-KINASE WITH 1-(9{H}-FLUOREN-9-YL)-3-(2-METHYL-4-PHENYL- PYRIMIDIN-5-YL)UREA
3960, d5iugA_, 0.7322, 2.80, 0.194, 285, 242, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5A
3961, d4hw7A_, 0.7322, 2.85, 0.214, 289, 243, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX647-OME
3962, d4bb4A_, 0.7322, 2.55, 0.221, 265, 240, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3963, d3ii5A_, 0.7322, 2.76, 0.199, 262, 241, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
3964, d2x9eA_, 0.7322, 2.52, 0.304, 253, 237, HUMAN MPS1 IN COMPLEX WITH NMS-P715
3965, d1s9iB_, 0.7322, 3.05, 0.258, 291, 248, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
3966, d5lpbA_, 0.7321, 2.90, 0.221, 280, 244, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
3967, d5hezB_, 0.7321, 3.09, 0.252, 289, 246, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
3968, d4rj5A_, 0.7321, 2.68, 0.196, 296, 240, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 5
3969, d4hniB_, 0.7321, 2.85, 0.194, 284, 247, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
3970, d4fnxA_, 0.7321, 3.05, 0.186, 292, 247, CRYSTAL STRUCTURE OF THE APO R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3971, d4cnhA_, 0.7321, 2.93, 0.189, 285, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
3972, d2yjsA_, 0.7321, 2.94, 0.192, 286, 245, STRUCTURE OF C1156Y MUTANT ANAPLASTIC LYMPHOMA KINASE
3973, d4tygA1, 0.7320, 3.05, 0.240, 290, 246, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
3974, d4pmmA1, 0.7320, 2.59, 0.218, 281, 239, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N-(3-CYCLOPROPYL- 1-PHENYL-1H-PYRAZOL-5-YL)-2-{4-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1- YL)PHENYL]-1H-123-TRIAZOL-1-YL}ACETAMIDE
3975, d2bdfA_, 0.7320, 2.57, 0.251, 261, 239, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
3976, d5kmoA1, 0.7319, 2.63, 0.218, 290, 239, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(2- PYRIDYL)UREA
3977, d4cmtA_, 0.7319, 2.94, 0.193, 284, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(3-(METHYLSULFONYL)PHENYL)PYRIDIN-2-AMINE
3978, d3zm4A_, 0.7319, 2.97, 0.255, 309, 247, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 1
3979, d3uolB_, 0.7319, 2.61, 0.315, 263, 238, AURORA A IN COMPLEX WITH SO2-162
3980, d2gsfA_, 0.7319, 2.52, 0.208, 281, 240, THE HUMAN EPHA3 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
3981, d5w5oN_, 0.7318, 2.48, 0.230, 272, 239, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3982, d4nksA_, 0.7318, 2.86, 0.230, 265, 244, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
3983, d3oomA_, 0.7318, 3.25, 0.229, 297, 249, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00507
3984, d3el8A_, 0.7318, 2.52, 0.249, 263, 237, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
3985, d3vvhA1, 0.7317, 2.95, 0.251, 286, 247, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
3986, d5ia0C_, 0.7316, 2.44, 0.211, 269, 237, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
3987, d3uolA_, 0.7316, 2.67, 0.310, 263, 239, AURORA A IN COMPLEX WITH SO2-162
3988, d3b8rA1, 0.7316, 2.58, 0.225, 282, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
3989, d2jkkA_, 0.7316, 2.64, 0.258, 258, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
3990, d1irkA_, 0.7316, 2.99, 0.192, 303, 245, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN RECEPTOR
3991, d4nksB_, 0.7315, 2.78, 0.240, 271, 242, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
3992, d4equA_, 0.7315, 2.27, 0.328, 274, 232, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
3993, d2xp2A_, 0.7315, 2.96, 0.193, 285, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB (PF-02341066)
3994, d2jkqA_, 0.7315, 2.57, 0.259, 258, 239, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
3995, d2ijmA_, 0.7315, 2.64, 0.254, 260, 240, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
3996, d4u81A1, 0.7314, 3.25, 0.255, 288, 251, MEK1 KINASE BOUND TO SMALL MOLECULE INHIBITOR G659
3997, d4p90B_, 0.7314, 2.51, 0.315, 262, 235, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
3998, d3gqlA_, 0.7314, 3.00, 0.216, 287, 245, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
3999, d5am6B_, 0.7313, 2.68, 0.245, 280, 241, NATIVE FGFR1 WITH AN INHIBITOR
4000, d4zsaB_, 0.7313, 2.82, 0.238, 282, 244, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
4001, d5nkiA_, 0.7312, 2.51, 0.211, 268, 237, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4B
4002, d5k9iB_, 0.7312, 2.58, 0.245, 262, 237, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
4003, d5jfsA_, 0.7312, 2.60, 0.210, 277, 238, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-00593174
4004, d3eqbA1, 0.7312, 3.21, 0.247, 288, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
4005, d5p9fA_, 0.7311, 2.80, 0.187, 266, 241, BTK IN COMPLEX WITH GDC-0834
4006, d5l4qA_, 0.7311, 2.40, 0.253, 293, 237, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
4007, d2ogvA_, 0.7311, 2.99, 0.204, 317, 245, CRYSTAL STRUCTURE OF THE AUTOINHIBITED HUMAN C-FMS KINASE DOMAIN
4008, d1opjA1, 0.7311, 3.04, 0.242, 282, 244, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
4009, d4ypsA1, 0.7310, 2.71, 0.213, 275, 239, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
4010, d3v5qA1, 0.7310, 2.60, 0.223, 260, 238, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
4011, d2c6eB_, 0.7310, 2.45, 0.306, 246, 235, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
4012, d5jfvA_, 0.7309, 2.59, 0.214, 277, 238, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05206283
4013, d4v04B_, 0.7309, 3.10, 0.215, 287, 246, FGFR1 IN COMPLEX WITH PONATINIB.
4014, d5e1sA_, 0.7308, 2.66, 0.187, 284, 240, THE CRYSTAL STRUCTURE OF INSR TYROSINE KINASE IN COMPLEX WITH THE INHIBITOR BI 885578
4015, d4zjiD_, 0.7308, 3.08, 0.305, 280, 246, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4016, d4mwiA_, 0.7308, 2.46, 0.206, 266, 238, CRYSTAL STRUCTURE OF THE HUMAN MLKL PSEUDOKINASE DOMAIN
4017, d4mnfB_, 0.7308, 2.54, 0.210, 257, 238, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
4018, d4fnyA_, 0.7308, 2.69, 0.192, 273, 240, CRYSTAL STRUCTURE OF THE R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
4019, d4agdA_, 0.7308, 2.97, 0.212, 303, 245, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SUNITINIB (SU11248) (N-2- DIETHYLAMINOETHYL)-5-((Z)-(5-FLUORO-2-OXO-1H-INDOL-3- YLIDENE)METHYL)-24-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE)
4020, d2yjrA_, 0.7308, 2.61, 0.205, 278, 239, STRUCTURE OF F1174L MUTANT ANAPLASTIC LYMPHOMA KINASE
4021, d2i0vA_, 0.7308, 2.88, 0.210, 303, 243, C-FMS TYROSINE KINASE IN COMPLEX WITH A QUINOLONE INHIBITOR
4022, d4uxqA_, 0.7307, 3.10, 0.227, 286, 247, FGFR4 IN COMPLEX WITH PONATINIB
4023, d1s9jA1, 0.7307, 3.23, 0.259, 288, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
4024, d4f0iA_, 0.7306, 2.63, 0.218, 284, 239, CRYSTAL STRUCTURE OF APO TRKA
4025, d3v04A1, 0.7306, 3.27, 0.263, 288, 251, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
4026, d3uc3A_, 0.7306, 2.46, 0.287, 272, 237, THE CRYSTAL STRUCTURE OF SNF1-RELATED KINASE 2.3
4027, d5em5A_, 0.7305, 2.68, 0.200, 298, 240, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 2: 4-[2-(4- CHLOROPHENYL)ETHYLAMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
4028, d3my0U1, 0.7305, 3.27, 0.222, 284, 248, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4029, d3ewhA1, 0.7305, 2.99, 0.220, 295, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDYL-PYRIMIDINE BENZIMIDAZOLE INHIBITOR
4030, d1fgiB_, 0.7305, 2.99, 0.238, 272, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
4031, d5t0pA_, 0.7304, 2.47, 0.250, 264, 236, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4032, d4uwyB_, 0.7304, 2.72, 0.244, 273, 242, FGFR1 APO STRUCTURE
4033, d4dceA_, 0.7304, 2.82, 0.181, 288, 243, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
4034, d4aseA_, 0.7304, 2.89, 0.221, 305, 244, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH TIVOZANIB (AV-951)
4035, d3zfxG_, 0.7304, 2.32, 0.226, 253, 235, CRYSTAL STRUCTURE OF EPHB1
4036, d3zc5A_, 0.7304, 3.00, 0.220, 289, 245, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-6-(1-(6-(1-METHYL-1H-PYRAZOL-4-YL)-(124)TRIAZOLO(43- B)PYRIDAZIN-3-YL)ETHYL)QUINOLINE.
4037, d2e2bA1, 0.7304, 2.79, 0.221, 266, 240, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
4038, d5nk8A_, 0.7303, 2.46, 0.211, 266, 237, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2F
4039, d4zjiC_, 0.7303, 3.04, 0.302, 281, 245, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4040, d4gu6B_, 0.7303, 2.64, 0.250, 258, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
4041, d4f64B_, 0.7303, 2.91, 0.239, 272, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
4042, d3gvuA1, 0.7303, 2.66, 0.230, 261, 239, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH GLEEVEC
4043, d2g15A_, 0.7303, 3.29, 0.225, 301, 249, STRUCTURAL CHARACTERIZATION OF AUTOINHIBITED C-MET KINASE
4044, d5xp7B_, 0.7302, 2.60, 0.248, 267, 238, C-SRC IN COMPLEX WITH ATP-CHCL
4045, d4rfyA_, 0.7302, 2.78, 0.174, 263, 241, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(MORPHOLINE-4- CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-34- DIHYDROISOQUINOLIN-1-ONE
4046, d3wzdA_, 0.7302, 2.71, 0.216, 278, 241, KDR IN COMPLEX WITH LIGAND LENVATINIB
4047, d3gqlB_, 0.7302, 2.85, 0.218, 276, 243, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
4048, d3cthA_, 0.7302, 2.90, 0.212, 295, 245, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
4049, d5xgmA_, 0.7301, 2.70, 0.204, 288, 240, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH GO6976
4050, d4zloA_, 0.7301, 2.87, 0.314, 277, 242, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
4051, d4yneA1, 0.7301, 2.49, 0.224, 276, 237, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
4052, d4f63B_, 0.7301, 2.68, 0.241, 271, 241, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
4053, d4ehzD_, 0.7301, 2.98, 0.243, 280, 247, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4054, d2xb7A_, 0.7301, 2.73, 0.203, 286, 241, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH NVP- TAE684
4055, d5dg5A_, 0.7300, 2.84, 0.215, 297, 242, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
4056, d4rwkB_, 0.7300, 2.95, 0.234, 282, 244, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
4057, d4jt3A_, 0.7300, 2.63, 0.304, 254, 237, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 400740
4058, d3rhxB_, 0.7300, 2.99, 0.238, 275, 244, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
4059, d3h0yA_, 0.7300, 2.42, 0.297, 250, 236, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4060, d3g5dB_, 0.7300, 2.35, 0.252, 257, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
4061, d3f6xC_, 0.7300, 2.47, 0.250, 265, 236, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4062, d1agwB_, 0.7300, 3.00, 0.238, 272, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
4063, d3f6xA_, 0.7299, 2.36, 0.251, 264, 235, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4064, d2qonA_, 0.7299, 2.55, 0.208, 281, 240, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742A TRIPLE MUTANT
4065, d1mqbA_, 0.7299, 2.51, 0.205, 263, 239, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
4066, d1f3mC_, 0.7299, 2.85, 0.314, 287, 245, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
4067, d5ia0A_, 0.7298, 2.43, 0.203, 263, 237, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
4068, d5hezD_, 0.7298, 3.10, 0.268, 289, 246, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4069, d3v01A1, 0.7298, 3.27, 0.263, 288, 251, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
4070, d1fgkB_, 0.7298, 3.01, 0.238, 272, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
4071, d5oy6C_, 0.7297, 3.13, 0.235, 291, 247, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4072, d5kmmA1, 0.7297, 2.64, 0.218, 300, 239, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(1- NAPHTHYL)UREA
4073, d5htiA_, 0.7297, 2.83, 0.215, 290, 242, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH LXM108
4074, d4u80A_, 0.7297, 3.27, 0.251, 286, 251, MEK 1 KINASE BOUND TO G799
4075, d4rfzA_, 0.7297, 2.78, 0.174, 263, 241, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-8-FLUORO-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5- (MORPHOLINE-4-CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3- PYRIDYL]PHENYL]ISOQUINOLIN-1-ONE
4076, d4mxcA_, 0.7297, 2.85, 0.214, 290, 243, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4077, d5tq7B_, 0.7296, 2.79, 0.259, 269, 243, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4078, d4zk5B_, 0.7296, 3.22, 0.246, 294, 252, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
4079, d4mcvA_, 0.7296, 2.73, 0.262, 267, 240, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
4080, d5oy6A_, 0.7295, 3.13, 0.235, 291, 247, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4081, d4pmpA1, 0.7295, 2.57, 0.218, 276, 238, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 1-CYCLOPROPYL-1- [3-(13-THIAZOL-2-YL)BENZYL]-3-[4-(TRIFLUOROMETHOXY)PHENYL]UREA
4082, d4otrA_, 0.7295, 2.79, 0.174, 263, 241, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-CYCLOPROPYL-2- [3-[5-[[5-(4-ETHYLPIPERAZIN-1-YL)-2-PYRIDYL]AMINO]-1-METHYL-6-OXO-3- PYRIDYL]-2-(HYDROXYMETHYL)PHENYL]-8-FLUORO-ISOQUINOLIN-1-ONE
4083, d2fumD_, 0.7295, 2.49, 0.248, 258, 238, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
4084, d5u9dA_, 0.7294, 2.86, 0.181, 271, 243, DISCOVERY OF A POTENT BTK INHIBITOR WITH A NOVEL BINDING MODE USING PARALLEL SELECTIONS WITH A DNA-ENCODED CHEMICAL LIBRARY
4085, d5kmkA1, 0.7294, 2.64, 0.218, 302, 239, TRKA JM-KINASE WITH 2-FLUORO-{N}-[2-(4-FLUOROPHENYL)-6-METHYL-3- PYRIDYL]-4-(TRIFLUOROMETHYL)BENZAMIDE
4086, d3my0C1, 0.7294, 3.29, 0.222, 298, 248, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4087, d5jfxA_, 0.7293, 2.50, 0.211, 277, 237, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-06273340
4088, d5dg5B_, 0.7293, 2.66, 0.217, 297, 240, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
4089, d4pmsA1, 0.7293, 2.52, 0.218, 279, 238, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 4-NAPHTHALEN-1-YL- 1-[(5-PHENYL-124-OXADIAZOL-3-YL)METHYL]-1H-PYRROLO[32-C]PYRIDINE- 2-CARBOXYLIC ACID
4090, d4otqA_, 0.7293, 2.73, 0.179, 263, 240, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 1-[5-[3-(7-TERT- BUTYL-4-OXO-QUINAZOLIN-3-YL)-2-METHYL-PHENYL]-1-METHYL-2-OXO-3- PYRIDYL]-3-METHYL-UREA
4091, d3wzjA_, 0.7293, 2.49, 0.301, 257, 236, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(6- (CYCLOHEXYLAMINO)-8-(((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)AMINO) IMIDAZO[12-B]PYRIDAZIN-3-YL)-N-CYCLOPROPYLBENZAMIDE
4092, d3f69A_, 0.7293, 2.62, 0.253, 270, 241, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
4093, d5jfwA_, 0.7292, 2.62, 0.210, 277, 238, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05247452
4094, d4fnzA_, 0.7292, 2.78, 0.178, 287, 242, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PIPERIDINE-CARBOXAMIDE INHIBITOR 2
4095, d3ky2B_, 0.7292, 3.05, 0.238, 280, 244, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
4096, d2z7sA_, 0.7292, 2.00, 0.322, 256, 230, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO PURVALNOL A
4097, d2fgiB_, 0.7292, 3.00, 0.238, 272, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
4098, d4rg0A_, 0.7291, 2.77, 0.170, 263, 241, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[8-FLUORO-2- [2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(4-METHYLPIPERAZIN-1-YL)-2- PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-1-OXO-34-DIHYDROISOQUINOLIN- 6-YL]-2-METHYL-PROPANENITRILE
4099, d4aojB_, 0.7291, 2.40, 0.216, 258, 236, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
4100, d4v01B_, 0.7290, 2.86, 0.227, 275, 242, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
4101, d4v01A_, 0.7290, 2.91, 0.226, 273, 243, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
4102, d5p9kA_, 0.7289, 2.95, 0.189, 271, 244, CRYSTAL STRUCTURE OF BTK WITH CNX 774
4103, d5p9gA_, 0.7289, 2.71, 0.179, 265, 240, STRUCTURE OF BTK WITH RN486
4104, d4bggC_, 0.7289, 3.14, 0.236, 279, 246, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
4105, d3tudA1, 0.7289, 2.57, 0.188, 255, 239, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH N-(4-METHYL-3-(8-METHYL-7- OXO-2-(PHENYLAMINO)-78-DIHYDROPYRIDO[23-D]PYRIMIDIN-6-YL)PHENYL)-3- (TRIFLUOROMETHYL)BENZAMIDE
4106, d3my0S1, 0.7289, 3.05, 0.230, 293, 244, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4107, d3mtfB_, 0.7289, 3.30, 0.229, 298, 249, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
4108, d2nryB_, 0.7289, 3.22, 0.270, 286, 248, CRYSTAL STRUCTURE OF IRAK-4
4109, d4v04A_, 0.7288, 2.89, 0.226, 290, 243, FGFR1 IN COMPLEX WITH PONATINIB.
4110, d3my0D1, 0.7288, 3.06, 0.230, 297, 244, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4111, d2w5hA1, 0.7288, 2.63, 0.287, 257, 237, HUMAN NEK2 KINASE APO
4112, d1i44A_, 0.7288, 2.80, 0.198, 282, 242, CRYSTALLOGRAPHIC STUDIES OF AN ACTIVATION LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
4113, d5p9iA_, 0.7287, 2.83, 0.178, 271, 242, BTK1 SOAKED WITH IBRUTINIB-REV
4114, d3q4uA_, 0.7287, 3.28, 0.229, 298, 249, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4115, d2oibB_, 0.7287, 2.96, 0.259, 278, 243, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4116, d2iwiB_, 0.7287, 1.99, 0.265, 249, 230, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4117, d4ot5A_, 0.7286, 2.80, 0.174, 263, 241, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4-TERT-BUTYL-N- (3-{8-[4-(4-METHYL-PIPERAZINE-1-CARBONYL)-PHENYLAMINO]-IMIDAZO[12- A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
4118, d4k8aA_, 0.7286, 2.49, 0.253, 251, 237, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
4119, d4e4lE_, 0.7286, 2.96, 0.244, 280, 246, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
4120, d3ggfA_, 0.7286, 3.05, 0.274, 275, 248, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
4121, d3geqB1, 0.7286, 2.64, 0.256, 270, 238, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
4122, d2reiA1, 0.7286, 2.45, 0.211, 274, 237, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7)
4123, d5hezA_, 0.7285, 2.99, 0.265, 287, 245, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4124, d4dceB_, 0.7285, 2.66, 0.179, 284, 240, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
4125, d3w10A_, 0.7285, 2.64, 0.285, 263, 239, AURORA KINASE A COMPLEXED TO PYRAZOLE AMINOQUINOLINE I
4126, d3my0G1, 0.7285, 3.24, 0.223, 293, 247, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4127, d3my0E1, 0.7285, 3.23, 0.219, 293, 247, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4128, d1f3mD_, 0.7285, 2.82, 0.299, 285, 244, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
4129, d4usfA1, 0.7284, 2.85, 0.287, 275, 244, HUMAN SLK WITH SB-440719
4130, d4rwjB_, 0.7284, 3.05, 0.234, 282, 244, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
4131, d3vvhC1, 0.7284, 3.45, 0.256, 282, 254, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
4132, d5ar8B_, 0.7283, 2.83, 0.222, 274, 243, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
4133, d3my0R1, 0.7283, 3.24, 0.219, 293, 247, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4134, d3ms9B1, 0.7283, 2.61, 0.227, 267, 238, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
4135, d3cs9A_, 0.7283, 2.67, 0.231, 264, 238, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4136, d5fdpA_, 0.7281, 3.23, 0.219, 285, 251, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2099 INHIBITOR AT 2.25 ANGSTROMS RESOLUTION.
4137, d3nw5A_, 0.7281, 2.97, 0.204, 302, 245, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11B)
4138, d3g6gA_, 0.7281, 2.48, 0.246, 264, 236, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
4139, d1uwhA_, 0.7281, 2.68, 0.201, 264, 239, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
4140, d4d4sB_, 0.7280, 2.66, 0.259, 260, 239, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4141, d3qrkA1, 0.7280, 2.71, 0.238, 268, 239, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DP- 987
4142, d2w9fB_, 0.7280, 3.00, 0.465, 261, 243, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4143, d3tl8D_, 0.7279, 3.41, 0.207, 306, 251, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4144, d3bz3A_, 0.7279, 2.76, 0.253, 259, 241, CRYSTAL STRUCTURE ANALYSIS OF FOCAL ADHESION KINASE WITH A METHANESULFONAMIDE DIAMINOPYRIMIDINE INHIBITOR
4145, d3an0A_, 0.7279, 3.50, 0.228, 291, 254,  
4146, d2iwiA_, 0.7278, 2.21, 0.268, 244, 231, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4147, d2i0yA_, 0.7278, 2.72, 0.208, 289, 240, CFMS TYROSINE KINASE (FGF KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
4148, d5l6oA_, 0.7277, 2.73, 0.203, 267, 241, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 3)
4149, d3my0Q1, 0.7277, 3.09, 0.225, 293, 244, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4150, d3vn9A_, 0.7276, 3.51, 0.228, 291, 254, RIFINED CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED MAP2K6 IN A PUTATIVE AUTO-INHIBITION STATE
4151, d3my0H1, 0.7276, 3.26, 0.223, 293, 247, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4152, d5hezC_, 0.7274, 3.10, 0.260, 289, 246, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4153, d4ztqA_, 0.7274, 2.40, 0.302, 247, 235, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK932
4154, d4u44B_, 0.7274, 3.25, 0.246, 296, 252, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
4155, d3dajA_, 0.7274, 2.27, 0.297, 245, 232, CRYSTAL STRUCTURE OF AURORA A COMPLEXED WITH AN INHIBITOR DISCOVERED THROUGH SITE-DIRECTED DYNAMIC TETHERING
4156, d3my0P_, 0.7273, 3.05, 0.222, 290, 243, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4157, d3k5vB1, 0.7273, 2.78, 0.230, 279, 239, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
4158, d1uwhB_, 0.7273, 2.69, 0.201, 264, 239, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
4159, d4ot6A_, 0.7272, 2.82, 0.174, 265, 241, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4- METHANESULFONYL-N-(3-{8-[4-(MORPHOLINE-4-CARBONYL)-PHENYLAMINO]- IMIDAZO[12-A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
4160, d4gk2A_, 0.7272, 2.48, 0.207, 265, 237, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 66
4161, d4f65B_, 0.7272, 2.90, 0.226, 279, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
4162, d5vgoA1, 0.7271, 2.80, 0.187, 264, 241, BRUTON S TYROSINE KINASE (BTK) WITH COMPOUND G-744
4163, d4ei4A1, 0.7271, 2.90, 0.246, 288, 244, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
4164, d5j95B_, 0.7270, 3.28, 0.246, 300, 252, MAP4K4 IN COMPLEX WITH INHIBITOR
4165, d4z3vA_, 0.7270, 2.81, 0.174, 271, 241, FRAGMENT-BASED DISCOVERY OF A SMALL MOLECULE REVERSIBLE INHIBITOR OF BRUTON S TYROSINE KINASE
4166, d3u6iA_, 0.7269, 2.85, 0.198, 281, 242, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 58A
4167, d3my0F1, 0.7269, 3.01, 0.226, 293, 243, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4168, d2qu5A_, 0.7269, 2.92, 0.230, 292, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
4169, d2oiqA_, 0.7269, 2.57, 0.241, 265, 237, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
4170, d5fdxB_, 0.7268, 3.15, 0.219, 274, 247, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
4171, d4h1jA_, 0.7268, 2.75, 0.193, 263, 244, CRYSTAL STRUCTURE OF PYK2 WITH THE PYRAZOLE 13A
4172, d3svvA_, 0.7268, 2.54, 0.242, 261, 236, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
4173, d3oriB_, 0.7268, 2.81, 0.245, 267, 241, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4174, d2a19B1, 0.7268, 2.66, 0.252, 261, 238, PKR KINASE DOMAIN- EIF2ALPHA- AMP-PNP COMPLEX.
4175, d3my0O1, 0.7265, 3.04, 0.235, 296, 243, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4176, d3l8pA_, 0.7265, 2.41, 0.237, 292, 236, CRYSTAL STRUCTURE OF CYTOPLASMIC KINASE DOMAIN OF TIE2 COMPLEXED WITH INHIBITOR CEP11207
4177, d5kupA1, 0.7264, 2.78, 0.178, 264, 241, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 9
4178, d4ehzC_, 0.7264, 2.99, 0.244, 278, 246, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4179, d3rhkA_, 0.7264, 3.00, 0.197, 298, 244, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
4180, d3oriA_, 0.7264, 2.89, 0.244, 267, 242, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4181, d3mj2A_, 0.7264, 2.73, 0.217, 259, 240, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR BMS-509744
4182, d1k9aF3, 0.7264, 2.57, 0.224, 264, 237, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4183, d5l6pA_, 0.7263, 2.82, 0.202, 274, 242, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 6)
4184, d4rx5A1, 0.7263, 2.82, 0.183, 264, 241, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 23
4185, d4kaoB_, 0.7263, 2.47, 0.253, 254, 237, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
4186, d4dymA_, 0.7263, 3.26, 0.231, 293, 247, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00135
4187, d3vvhB1, 0.7263, 3.45, 0.256, 289, 254, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
4188, d3qquA_, 0.7263, 3.05, 0.208, 285, 245, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4189, d4ztmA_, 0.7262, 3.12, 0.257, 287, 245, IRAK4-INHIBITOR CO-STRUCTURE
4190, d4pdoA_, 0.7262, 2.42, 0.208, 261, 236, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4191, d3mtfA_, 0.7262, 3.29, 0.230, 296, 248, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
4192, d3h9rA_, 0.7262, 2.82, 0.237, 312, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TYPE I ACTIVIN RECEPTOR (ACVR1) IN COMPLEX WITH FKBP12 AND DORSOMORPHIN
4193, d3genA_, 0.7262, 2.81, 0.183, 264, 241, THE 1.6 A CRYSTAL STRUCTURE OF HUMAN BRUTON S TYROSINE KINASE BOUND TO A PYRROLOPYRIMIDINE-CONTAINING COMPOUND
4194, d5ew9A_, 0.7261, 2.86, 0.274, 257, 241, CRYSTAL STRUCTURE OF AURORA A KINASE DOMAIN BOUND TO MK-5108
4195, d4pdoB_, 0.7261, 2.42, 0.208, 261, 236, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4196, d3pxkB_, 0.7261, 2.50, 0.257, 258, 237, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
4197, d5j87A_, 0.7260, 2.96, 0.189, 263, 243, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
4198, d3nw7A_, 0.7260, 2.96, 0.209, 297, 244, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (34)
4199, d2wqbA_, 0.7260, 2.67, 0.221, 289, 240, STRUCTURE OF THE TIE2 KINASE DOMAIN IN COMPLEX WITH A THIAZOLOPYRIMIDINE INHIBITOR
4200, d4tyjA1, 0.7259, 2.69, 0.235, 275, 238, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
4201, d4aw5A_, 0.7259, 2.47, 0.224, 261, 237, COMPLEX OF THE EPHB4 KINASE DOMAIN WITH AN OXINDOLE INHIBITOR
4202, d3i81A_, 0.7259, 2.82, 0.207, 296, 242, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH BMS-754807 [1-(4-((5-CYCLOPROPYL- 1H-PYRAZOL-3-YL)AMINO)PYRROLO[21-F][124]TRIAZIN-2-YL)-N- (6-FLUORO-3-PYRIDINYL)-2-METHYL-L-PROLINAMIDE]
4203, d3cc6A_, 0.7259, 2.84, 0.197, 269, 244, CRYSTAL STRUCTURE OF KINASE DOMAIN OF PROTEIN TYROSINE KINASE 2 BETA (PTK2B)
4204, d2xbaA_, 0.7259, 2.93, 0.189, 283, 243, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PHA-E429
4205, d5up3B_, 0.7258, 2.13, 0.297, 243, 229, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4206, d5eobA_, 0.7258, 3.08, 0.220, 288, 245, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4207, d4d2rA_, 0.7258, 2.91, 0.205, 300, 244, HUMAN IGF IN COMPLEX WITH A DYRK1B INHIBITOR
4208, d2rl5A1, 0.7258, 2.95, 0.211, 290, 242, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A 23-DIHYDRO-14-BENZOXAZINE INHIBITOR
4209, d1k9aC3, 0.7258, 2.60, 0.227, 266, 238, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4210, d5p9jA_, 0.7257, 2.89, 0.183, 263, 241, BTK1 COCRYSTALLIZED WITH IBRUTINIB
4211, d3db8A_, 0.7257, 2.33, 0.263, 261, 232, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 041
4212, d5di1B_, 0.7256, 3.28, 0.246, 300, 252, MAP4K4 IN COMPLEX WITH AN INHIBITOR
4213, d3d2kA_, 0.7256, 2.36, 0.300, 245, 233, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH [7-(2-{2-[3-(3-CHLORO- PHENYL)-UREIDO]-THIAZOL-5-YL}-ETHYLAMINO)-PYRAZOLO[43- D]PYRIMIDIN-1-YL]-ACETIC ACID
4214, d4zp5B_, 0.7255, 3.29, 0.246, 300, 252, MAP4K4 IN COMPLEX WITH INHIBITOR
4215, d4k9yA_, 0.7255, 3.06, 0.231, 271, 247, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-[4-(6-AMINO- PURIN-9-YL)-PHENYL]-3-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-UREA
4216, d4gfoA1, 0.7255, 2.49, 0.229, 270, 236, TYK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
4217, d3ocsA1, 0.7255, 2.84, 0.183, 262, 241, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI1746
4218, d3my0I1, 0.7255, 3.24, 0.220, 292, 246, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4219, d3dtwA1, 0.7255, 2.57, 0.218, 281, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
4220, d3dbdA_, 0.7255, 2.32, 0.263, 261, 232, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 094
4221, d3rhkB_, 0.7254, 2.99, 0.197, 299, 244, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
4222, d5d12A_, 0.7253, 2.35, 0.253, 260, 233, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
4223, d4o2pA_, 0.7253, 2.61, 0.233, 265, 236, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
4224, d1y8gA_, 0.7253, 2.69, 0.318, 292, 233, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: INACTIVE DOUBLE MUTANT WITH SELENOMETHIONINE
4225, d3f3tB_, 0.7252, 2.39, 0.252, 259, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
4226, d5ew3B_, 0.7251, 2.56, 0.223, 266, 238, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
4227, d5ew3A_, 0.7251, 2.57, 0.223, 274, 238, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
4228, d4d58B_, 0.7251, 2.65, 0.261, 261, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4229, d3vapA_, 0.7251, 2.53, 0.305, 249, 236, SYNTHESIS AND SAR STUDIES OF IMIDAZO-[12-A]-PYRAZINE AURORA KINASE INHIBITORS WITH IMPROVED OFF TARGET KINASE SELECTIVITY
4230, d3pixA_, 0.7251, 2.88, 0.195, 268, 241, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-ISOPROPYL-7- (4-METHYL-PIPERAZIN-1-YL)-4-(5-METHYL-2H-PYRAZOL-3-YLAMINO)-2H- PHTHALAZIN-1-ONE
4231, d3p86A_, 0.7251, 2.42, 0.244, 250, 234, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
4232, d3geqA1, 0.7251, 2.60, 0.254, 269, 236, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
4233, d2wd1A_, 0.7251, 3.07, 0.225, 289, 244, HUMAN C-MET KINASE IN COMPLEX WITH AZAINDOLE INHIBITOR
4234, d2p2hA1, 0.7251, 3.02, 0.213, 289, 244, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDINYL-TRIAZINE INHIBITOR
4235, d5ko1A_, 0.7250, 2.45, 0.208, 265, 236, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 4.
4236, d3u6hA_, 0.7250, 2.85, 0.207, 280, 241, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 26
4237, d2xkfA1, 0.7250, 2.32, 0.286, 242, 231, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 2
4238, d5m53A1, 0.7249, 2.38, 0.293, 248, 232, NEK2 BOUND TO ARYLAMINOPURINE INHIBITOR 11
4239, d4u40B_, 0.7249, 3.35, 0.241, 299, 253, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
4240, d4g5pB_, 0.7249, 3.24, 0.167, 303, 252, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
4241, d3uqfA_, 0.7249, 2.49, 0.248, 260, 234, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
4242, d3my0V1, 0.7249, 2.93, 0.232, 281, 241, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4243, d3be2A1, 0.7249, 2.66, 0.218, 285, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZAMIDE INHIBITOR
4244, d2xkdA1, 0.7249, 2.27, 0.277, 243, 231, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 12
4245, d2jkoA_, 0.7249, 2.57, 0.248, 256, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4246, d5ur1A_, 0.7248, 2.90, 0.237, 278, 241, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
4247, d5bpyA1, 0.7248, 2.97, 0.185, 262, 243, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
4248, d4m67A_, 0.7248, 2.40, 0.213, 264, 235, CRYSTAL STRUCTURE OF THE HUMAN MLKL KINASE-LIKE DOMAIN
4249, d3oxzA1, 0.7248, 2.68, 0.237, 267, 236, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN BOUND WITH A DFG-OUT INHIBITOR AP24534
4250, d5xgnB_, 0.7247, 3.47, 0.152, 308, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
4251, d3g5dA_, 0.7247, 2.30, 0.254, 256, 232, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
4252, d2qoqA_, 0.7247, 2.54, 0.202, 284, 238, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BASE AMP-PNP BOUND STRUCTURE
4253, d4r1vA_, 0.7246, 3.12, 0.220, 289, 245, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITORS
4254, d4d4vB_, 0.7246, 2.58, 0.257, 255, 237, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4255, d3ii5B_, 0.7246, 2.63, 0.203, 257, 237, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
4256, d3b8rB_, 0.7246, 2.47, 0.220, 267, 236, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4257, d2hakC_, 0.7246, 2.49, 0.332, 310, 238, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4258, d4yo6C_, 0.7245, 3.14, 0.266, 286, 244, IRAK4-INHIBITOR CO-STRUCTURE
4259, d4wunB_, 0.7245, 2.77, 0.225, 268, 240, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
4260, d3zfxC_, 0.7245, 2.31, 0.227, 248, 233, CRYSTAL STRUCTURE OF EPHB1
4261, d4x7qB_, 0.7244, 2.02, 0.265, 243, 230, PIM2 KINASE IN COMPLEX WITH COMPOUND 1S
4262, d4otfA1, 0.7244, 2.86, 0.183, 261, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH GDC0834
4263, d4f65A_, 0.7244, 3.00, 0.232, 279, 241, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
4264, d3uqgB_, 0.7244, 2.40, 0.258, 257, 233, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
4265, d3t9tA_, 0.7244, 2.87, 0.198, 263, 242, CRYSTAL STRUCTURE OF BTK MUTANT (F435TK596R) COMPLEXED WITH IMIDAZO[15-A]QUINOXALINE
4266, d3g6gB_, 0.7244, 2.52, 0.234, 263, 235, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
4267, d5tehA_, 0.7243, 2.38, 0.232, 261, 233, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
4268, d5t1tC_, 0.7243, 3.10, 0.269, 286, 245, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4269, d5p9hA_, 0.7243, 2.80, 0.187, 264, 240, BTK1 COCRYSTALLIZED WITH RN983
4270, d4obqB_, 0.7243, 3.33, 0.246, 293, 252, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
4271, d4d5hB_, 0.7243, 2.68, 0.261, 260, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4272, d3my0T1, 0.7243, 3.23, 0.220, 291, 245, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4273, d1uwjA_, 0.7243, 2.69, 0.192, 264, 239, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
4274, d5fxsA1, 0.7242, 2.89, 0.205, 307, 244, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
4275, d4kabA_, 0.7242, 2.52, 0.250, 255, 236, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
4276, d4gg7A_, 0.7242, 2.91, 0.207, 278, 242, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4277, d4d4yB_, 0.7242, 2.68, 0.261, 260, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4278, d2oibD_, 0.7242, 3.23, 0.248, 288, 246, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4279, d5hzeA_, 0.7241, 3.04, 0.248, 305, 246, MEK1 ADOPTS DFG-OUT CONFORMATION WHEN BOUND TO AN ANALOG OF E6201.
4280, d5fboA_, 0.7241, 2.54, 0.186, 255, 236, BTK-INHIBITOR CO-STRUCTURE
4281, d5dbxA_, 0.7241, 3.34, 0.255, 284, 243, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
4282, d4gu9A_, 0.7241, 2.52, 0.250, 252, 236, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
4283, d1uwjB_, 0.7241, 2.87, 0.204, 263, 240, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
4284, d4yhfA_, 0.7240, 2.84, 0.174, 268, 241, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
4285, d4yhfB_, 0.7239, 2.90, 0.178, 269, 241, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
4286, d3b8qA1, 0.7239, 2.62, 0.214, 285, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4287, d4wunA_, 0.7238, 2.88, 0.229, 282, 240, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
4288, d4mxxB_, 0.7238, 2.47, 0.226, 260, 234, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4289, d3zewB_, 0.7238, 2.30, 0.219, 252, 233, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
4290, d2oj9A_, 0.7238, 3.01, 0.204, 295, 245, STRUCTURE OF IGF-1R KINASE DOMAIN COMPLEXED WITH A BENZIMIDAZOLE INHIBITOR
4291, d1y8gB_, 0.7238, 2.67, 0.323, 292, 232, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: INACTIVE DOUBLE MUTANT WITH SELENOMETHIONINE
4292, d4zlzA_, 0.7237, 2.87, 0.178, 270, 241, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH A SUBSTITUTED CINNOLINE
4293, d4e4lB_, 0.7237, 2.98, 0.245, 279, 245, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
4294, d3a4pA_, 0.7237, 3.07, 0.230, 285, 243, HUMAN C-MET KINASE DOMAIN COMPLEXED WITH 6-BENZYLOXYQUINOLINE INHIBITOR
4295, d5t1sC_, 0.7236, 3.14, 0.263, 284, 243, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4296, d5fbnC_, 0.7236, 2.83, 0.176, 256, 239, BTK KINASE DOMAIN WITH INHIBITOR 1
4297, d3ormA_, 0.7236, 2.89, 0.241, 266, 241, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN D76A MUTANT
4298, d2xyuA_, 0.7236, 2.57, 0.190, 260, 237, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH VUF 12058
4299, d4d4vA_, 0.7235, 2.54, 0.249, 256, 237, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4300, d3ma6B_, 0.7235, 3.07, 0.298, 266, 242, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
4301, d3is5F1, 0.7235, 3.23, 0.294, 259, 245, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4302, d3cpbA1, 0.7235, 2.57, 0.211, 278, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
4303, d3b8qB_, 0.7235, 2.62, 0.218, 271, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4304, d4kioC1, 0.7234, 2.52, 0.221, 249, 235, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4305, d3cjfA_, 0.7234, 2.68, 0.205, 276, 239, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
4306, d3c4dB1, 0.7234, 2.45, 0.200, 256, 235,  
4307, d4zlyA_, 0.7233, 2.89, 0.178, 270, 242, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE BOUND TO A CINNOLINE FRAGMENT
4308, d4d5kB_, 0.7233, 2.62, 0.257, 256, 237, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4309, d3krlA_, 0.7233, 2.72, 0.210, 281, 238, CFMS TYROSINE KINASE IN COMPLEX WITH 5-CYANO-FURAN-2-CARBOXYLIC ACID [4-(4-METHYL-PIPERAZIN-1-YL)-2-PIPERIDIN-1-YL-PHENYL]-AMIDE
4310, d5uq0A_, 0.7232, 2.79, 0.238, 266, 239, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
4311, d5j87C_, 0.7232, 2.80, 0.183, 261, 240, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
4312, d4twnA1, 0.7232, 2.64, 0.213, 275, 239, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH BIRB796
4313, d4rvtB_, 0.7232, 3.26, 0.238, 297, 252, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
4314, d3ugcA_, 0.7232, 2.71, 0.266, 274, 237, STRUCTURAL BASIS OF JAK2 INHIBITION BY THE TYPE II INHIBTOR NVP-BBT594
4315, d3daeB_, 0.7232, 2.46, 0.298, 246, 235, CRYSTAL STRUCTURE OF PHOSPHORYLATED SNF1 KINASE DOMAIN
4316, d2e2bB1, 0.7232, 2.54, 0.234, 258, 235, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
4317, d1p14A_, 0.7232, 2.75, 0.201, 287, 239, CRYSTAL STRUCTURE OF A CATALYTIC-LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
4318, d4xs2A_, 0.7231, 3.09, 0.258, 283, 244, IRAK4-INHIBITOR CO-STRUCTURE
4319, d3h0zC_, 0.7231, 2.42, 0.305, 246, 233, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4320, d4e4lA_, 0.7230, 2.98, 0.242, 277, 244, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
4321, d3mssA1, 0.7230, 2.55, 0.230, 260, 235, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4322, d1rjbA_, 0.7230, 2.64, 0.224, 298, 237, CRYSTAL STRUCTURE OF FLT3
4323, d3tt0B_, 0.7229, 2.66, 0.244, 272, 238, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
4324, d3qgwA_, 0.7229, 2.56, 0.213, 244, 235, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
4325, d4nwmB_, 0.7227, 2.97, 0.186, 261, 242, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
4326, d4dbnA_, 0.7227, 2.55, 0.203, 257, 236, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
4327, d3dzqA_, 0.7227, 2.65, 0.193, 268, 238, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH INHIBITOR AWL-II- 38.3
4328, d4gg5A_, 0.7226, 2.73, 0.210, 274, 238, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4329, d2y6oA_, 0.7226, 2.49, 0.191, 263, 236, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH DASATINIB.
4330, d4u45B_, 0.7225, 3.36, 0.250, 295, 252, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
4331, d3tz8B_, 0.7225, 2.58, 0.247, 263, 235, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
4332, d3bqrA1, 0.7225, 2.97, 0.248, 273, 242, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH AN IMIDAZO-PYRIDAZINE LIGAND
4333, d1s9iA_, 0.7225, 3.31, 0.260, 303, 250, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
4334, d5hu9A1, 0.7224, 3.01, 0.224, 262, 241, CRYSTAL STRUCTURE OF ABL1 IN COMPLEX WITH CHMFL-074
4335, d4tyeA_, 0.7224, 2.94, 0.226, 292, 243, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
4336, d3pxkA_, 0.7224, 2.49, 0.250, 256, 236, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
4337, d2nruA_, 0.7224, 3.24, 0.258, 293, 248, CRYSTAL STRUCTURE OF IRAK-4
4338, d5jkgA_, 0.7223, 2.43, 0.234, 266, 235, THE CRYSTAL STRUCTURE OF FGFR4 KINASE DOMAIN IN COMPLEX WITH LY2874455
4339, d4kspA_, 0.7223, 2.59, 0.199, 257, 236, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
4340, d3qgyA1, 0.7223, 2.51, 0.214, 244, 234, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
4341, d3ekkA_, 0.7223, 2.80, 0.200, 285, 240, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
4342, d3cs9D_, 0.7223, 2.69, 0.232, 263, 237, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4343, d5kbrB_, 0.7222, 2.45, 0.297, 260, 232, PAK1 IN COMPLEX WITH 7-AZAINDOLE INHIBITOR
4344, d5j87D_, 0.7222, 2.91, 0.183, 263, 241, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
4345, d3mssC1, 0.7222, 2.62, 0.229, 260, 236, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4346, d3gqlC_, 0.7222, 2.89, 0.219, 275, 242, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
4347, d1r0pA_, 0.7222, 3.18, 0.226, 301, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH THE MICROBIAL ALKALOID K-252A
4348, d3ms9A1, 0.7221, 2.57, 0.230, 261, 235, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
4349, d3cp9A1, 0.7221, 2.63, 0.227, 281, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4350, d2oicD_, 0.7221, 2.97, 0.257, 284, 241, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
4351, d5kbrA_, 0.7220, 2.14, 0.310, 259, 229, PAK1 IN COMPLEX WITH 7-AZAINDOLE INHIBITOR
4352, d5j87B_, 0.7220, 2.96, 0.182, 274, 242, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
4353, d4ztnC_, 0.7220, 3.04, 0.272, 284, 243, IRAK4-INHIBITOR CO-STRUCTURE
4354, d4i4eA_, 0.7220, 2.52, 0.242, 254, 236, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH HINGE BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
4355, d3w16A_, 0.7220, 2.46, 0.298, 249, 235, STRUCTURE OF AURORA KINASE A COMPLEXED TO PYRAZOLE-AMINOQUINOLINE INHIBITOR III
4356, d3tubA_, 0.7220, 2.68, 0.193, 253, 238, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-3-((1R2S)-2- PHENYLCYCLOPROPYL)UREA
4357, d3qlgB_, 0.7220, 2.35, 0.250, 260, 232, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
4358, d3fmeA1, 0.7220, 2.82, 0.245, 267, 237, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (MEK6) ACTIVATED MUTANT (S207D T211D)
4359, d3f3uA_, 0.7220, 2.50, 0.244, 261, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
4360, d3ce3A_, 0.7220, 3.10, 0.211, 293, 246, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOPYRIDINEPYRIDONE BASED INHIBITOR
4361, p5w5qB_, 0.7219, 3.31, 0.230, 297, 252, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
4362, d4ztnA_, 0.7219, 3.15, 0.258, 286, 244, IRAK4-INHIBITOR CO-STRUCTURE
4363, d3dkfA1, 0.7219, 3.03, 0.232, 293, 241, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
4364, d3c1xA_, 0.7219, 2.74, 0.206, 290, 238, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOTRIAZINE BASED INHIBITOR
4365, d2fumC_, 0.7219, 2.53, 0.242, 254, 236, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
4366, d5ng3A_, 0.7218, 3.18, 0.222, 283, 248, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
4367, d4fc0A_, 0.7218, 2.49, 0.200, 254, 235, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
4368, d3slsA1, 0.7218, 3.26, 0.252, 289, 250, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
4369, d5csxA_, 0.7217, 2.84, 0.207, 261, 241, CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370
4370, d4d4sA_, 0.7217, 2.61, 0.253, 255, 237, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4371, d3qlgA_, 0.7217, 2.45, 0.240, 259, 233, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
4372, d3daeA_, 0.7217, 2.48, 0.298, 248, 235, CRYSTAL STRUCTURE OF PHOSPHORYLATED SNF1 KINASE DOMAIN
4373, d2nruB_, 0.7217, 3.26, 0.258, 294, 248, CRYSTAL STRUCTURE OF IRAK-4
4374, d5ct7A_, 0.7216, 2.68, 0.203, 257, 236, BRAF IN COMPLEX WITH RAF265
4375, d3p9jA_, 0.7215, 2.47, 0.298, 249, 235, AURORA A KINASE DOMAIN WITH PHTHALAZINONE PYRAZOLE INHIBITOR
4376, d3oroA_, 0.7215, 2.92, 0.242, 272, 240, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 4)
4377, d3hyhA_, 0.7215, 2.46, 0.309, 238, 233, CRYSTAL STRUCTURE OF THE PROTEIN KINASE DOMAIN OF YEAST AMP-ACTIVATED PROTEIN KINASE SNF1
4378, d5t1sA_, 0.7214, 3.17, 0.264, 280, 246, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4379, d4yo6A_, 0.7214, 3.17, 0.257, 286, 245, IRAK4-INHIBITOR CO-STRUCTURE
4380, d4ibmB_, 0.7214, 2.85, 0.207, 294, 241, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
4381, d3tl8G_, 0.7214, 3.55, 0.207, 301, 251, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4382, d3my0W1, 0.7214, 3.15, 0.226, 280, 243, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4383, d3qquD_, 0.7213, 3.04, 0.212, 292, 245, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4384, d3mssB1, 0.7213, 2.58, 0.230, 260, 235, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4385, d3famB_, 0.7213, 2.47, 0.309, 239, 233,  
4386, d3dtwB_, 0.7213, 2.65, 0.219, 269, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
4387, d2z7qA_, 0.7213, 2.08, 0.323, 255, 229, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK-1 BOUND TO AMP-PCP
4388, d2eueB_, 0.7213, 2.47, 0.309, 239, 233,  
4389, d4nwmA_, 0.7212, 2.98, 0.186, 261, 242, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
4390, d4eevA_, 0.7212, 2.58, 0.215, 283, 237, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH LY2801653
4391, d3o50A_, 0.7212, 2.35, 0.302, 246, 232, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4392, d3mssD1, 0.7212, 2.58, 0.230, 260, 235, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4393, d3d5vA_, 0.7212, 2.33, 0.260, 260, 231, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
4394, d3c4cB1, 0.7212, 2.47, 0.200, 256, 235, B-RAF KINASE IN COMPLEX WITH PLX4720
4395, d3f3vA_, 0.7211, 2.52, 0.244, 261, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4396, d2x7fE_, 0.7211, 2.07, 0.263, 251, 228, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
4397, d3q6uA1, 0.7210, 2.80, 0.212, 281, 240, STRUCTURE OF THE APO MET RECEPTOR KINASE IN THE DUALLY-PHOSPHORYLATED ACTIVATED STATE
4398, d3fztA_, 0.7210, 2.69, 0.195, 259, 241, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-4618433
4399, d2yn8B_, 0.7210, 2.40, 0.209, 260, 234, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4400, d2oh4A1, 0.7210, 2.80, 0.217, 296, 240, CRYSTAL STRUCTURE OF VEGFR2 WITH A BENZIMIDAZOLE-UREA INHIBITOR
4401, d4hcuA_, 0.7209, 3.03, 0.230, 263, 244, CRYSTAL STRUCTURE OF ITK IN COMPLEXT WITH COMPOUND 40
4402, d3qquB_, 0.7209, 3.17, 0.216, 288, 245, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4403, d3ggfB_, 0.7209, 3.02, 0.263, 270, 247, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
4404, d3f66A_, 0.7209, 3.23, 0.220, 288, 245, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
4405, d3f3wA_, 0.7209, 2.52, 0.244, 261, 234, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4406, d2nruC_, 0.7209, 3.36, 0.261, 293, 249, CRYSTAL STRUCTURE OF IRAK-4
4407, d3octA_, 0.7208, 2.38, 0.193, 244, 233, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE MUTANT V555R IN COMPLEX WITH DASATINIB
4408, d4xi2A2, 0.7207, 2.96, 0.182, 274, 242, CRYSTAL STRUCTURE OF AN AUTO-INHIBITED FORM OF BRUTON S TRYROSINE KINASE
4409, d3qriB_, 0.7206, 2.75, 0.233, 262, 236, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
4410, d3f3wB_, 0.7206, 2.51, 0.244, 260, 234, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4411, d1vzoA_, 0.7206, 2.93, 0.267, 319, 240, THE STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF MSK1 REVEALS A NOVEL AUTOINHIBITORY CONFORMATION FOR A DUAL KINASE PROTEIN
4412, d4y73C_, 0.7205, 3.22, 0.264, 290, 246, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4413, d4u3yB_, 0.7205, 3.34, 0.249, 300, 253, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
4414, d3efkA_, 0.7205, 2.84, 0.217, 276, 240, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
4415, d5lohA_, 0.7204, 2.55, 0.316, 248, 234, KINASE DOMAIN OF HUMAN GREATWALL
4416, d4d2sA_, 0.7204, 2.32, 0.312, 249, 231, HUMAN TTK IN COMPLEX WITH A DYRK1B INHIBITOR
4417, d3cs9B_, 0.7204, 2.45, 0.228, 247, 232, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4418, d3byuA_, 0.7204, 2.61, 0.226, 256, 235, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE REVERSE AMIDE 23
4419, d2p2iA2, 0.7204, 2.60, 0.232, 283, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
4420, d1jpaA_, 0.7204, 2.46, 0.196, 273, 235, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
4421, d4useB_, 0.7203, 2.69, 0.316, 278, 234, HUMAN STK10 (LOK) WITH SB-633825
4422, d3qlfB_, 0.7203, 2.37, 0.237, 258, 232, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
4423, d3pj2A_, 0.7203, 2.50, 0.189, 248, 233, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[4-(2- DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-6-(4-FLUORO-PHENOXY)-8-METHYL-8H- PYRIDO[23-D]PYRIMIDIN-7-ONE
4424, d3f3vB_, 0.7203, 2.53, 0.248, 262, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4425, d2qu6B_, 0.7203, 2.61, 0.215, 260, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
4426, d3fzoA_, 0.7202, 2.90, 0.198, 262, 243, CRYSTAL STRUCTURE OF PYK2-APO PROLINE-RICH TYROSINE KINASE
4427, d5fd2A_, 0.7201, 2.99, 0.202, 264, 242, B-RAF WILD-TYPE KINASE DOMAIN IN COMPLEX WITH A PURINYLPYRIDINYLAMINO- BASED INHIBITOR
4428, d3o50B_, 0.7201, 2.49, 0.308, 249, 234, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4429, d3idpA_, 0.7201, 2.77, 0.202, 255, 238, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
4430, d3g6hB_, 0.7201, 2.55, 0.252, 259, 234, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
4431, d5swhA_, 0.7200, 2.40, 0.234, 258, 231, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4432, d4ztlD_, 0.7200, 3.26, 0.262, 285, 248, IRAK4-INHIBITOR CO-STRUCTURE
4433, d4hctA_, 0.7200, 3.05, 0.230, 265, 244, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 52
4434, d4afeA1, 0.7200, 2.30, 0.277, 245, 231, NEK2 BOUND TO HYBRID COMPOUND 21
4435, d3f3tA_, 0.7200, 2.58, 0.244, 261, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
4436, d5t3qA1, 0.7199, 2.88, 0.192, 277, 240, CRYSTAL STRUCTURE OF THE C-MET KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
4437, d5fbnD_, 0.7199, 2.77, 0.169, 255, 237, BTK KINASE DOMAIN WITH INHIBITOR 1
4438, d4d5hA_, 0.7199, 2.59, 0.250, 255, 236, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4439, d3tz8A_, 0.7199, 2.54, 0.244, 261, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
4440, d3oezA_, 0.7199, 2.53, 0.239, 261, 234, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
4441, d2y6mA_, 0.7199, 2.58, 0.191, 262, 236, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN
4442, d2nruD_, 0.7199, 3.27, 0.258, 293, 248, CRYSTAL STRUCTURE OF IRAK-4
4443, d2cl1A_, 0.7199, 2.54, 0.282, 250, 234,  
4444, d1snuA_, 0.7199, 2.48, 0.219, 245, 233, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4445, d4hcvA_, 0.7198, 2.92, 0.211, 263, 242, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 53
4446, d3of0A_, 0.7198, 2.49, 0.236, 260, 233, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
4447, d2x81A_, 0.7198, 2.42, 0.296, 242, 233, STRUCTURE OF AURORA A IN COMPLEX WITH MLN8054
4448, d5kx8C_, 0.7197, 3.15, 0.269, 287, 245, IRAK4-INHIBITOR CO-STRUCTURE
4449, d4dggA_, 0.7197, 2.48, 0.240, 261, 233, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
4450, d3dkoA1, 0.7197, 2.52, 0.208, 272, 236, COMPLEX BETWEEN THE KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7) AND INHIBITOR ALW-II-49-7
4451, d5c9cA_, 0.7196, 2.75, 0.208, 254, 236, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
4452, d3v5lC1, 0.7196, 2.52, 0.222, 242, 234, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4453, d3slsB1, 0.7196, 3.37, 0.247, 291, 251, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
4454, d3dkgA_, 0.7196, 3.04, 0.224, 281, 241, STRUCTURE OF MUTANT(Y1248L) MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
4455, d1sm2A_, 0.7196, 2.47, 0.219, 245, 233, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4456, d4ztnD_, 0.7195, 3.25, 0.257, 285, 245, IRAK4-INHIBITOR CO-STRUCTURE
4457, d4mf1B1, 0.7195, 2.52, 0.218, 244, 234, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
4458, d2xnpA1, 0.7195, 2.38, 0.276, 245, 232, STRUCTURE OF NEK2 BOUND TO CCT244858
4459, d2xnnA1, 0.7195, 2.41, 0.280, 243, 232, STRUCTURE OF NEK2 BOUND TO CCT242430
4460, d5p9mA_, 0.7194, 2.79, 0.176, 271, 238, BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059
4461, d3tz9A_, 0.7194, 2.54, 0.248, 261, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
4462, d5h3qA_, 0.7193, 2.68, 0.215, 302, 237, CRYSTAL STRUCTURE OF TRKA KINASE WITH LIGAND
4463, d3tucA_, 0.7193, 2.76, 0.185, 257, 238, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-BENZYL-N-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
4464, d5eydA_, 0.7192, 3.36, 0.233, 289, 245, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH AMG 337
4465, d4oboB_, 0.7192, 3.34, 0.238, 297, 252, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
4466, d3is5A1, 0.7192, 2.90, 0.305, 254, 239, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4467, d4c3pA_, 0.7191, 2.63, 0.286, 264, 234, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO TPX2 AND AMPPCP
4468, d5fxqA1, 0.7190, 3.03, 0.213, 301, 244, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
4469, d4yp8C_, 0.7190, 3.10, 0.266, 287, 244, IRAK4-INHIBITOR CO-STRUCTURE
4470, d4dbnB_, 0.7190, 2.63, 0.199, 263, 236, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
4471, d3qquC_, 0.7190, 3.07, 0.212, 293, 245, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4472, d3ikaB_, 0.7190, 3.52, 0.149, 310, 255, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
4473, d3cpcA1, 0.7190, 2.62, 0.219, 277, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4474, d2qo2A_, 0.7190, 2.53, 0.203, 282, 236, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED APO STRUCTURE
4475, d2exeA_, 0.7190, 2.39, 0.289, 262, 228, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED CLK3
4476, p5lqeC2, 0.7189, 0.83, 0.976, 213, 212, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
4477, d4d4yA_, 0.7189, 2.66, 0.253, 255, 237, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4478, d3en4A_, 0.7189, 2.38, 0.242, 257, 231, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
4479, d3el8B_, 0.7189, 2.34, 0.260, 259, 231, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
4480, d5lohB_, 0.7188, 2.45, 0.319, 250, 232, KINASE DOMAIN OF HUMAN GREATWALL
4481, d3piyA_, 0.7188, 2.52, 0.193, 262, 233, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH R406
4482, p5uq1A2, 0.7187, 0.94, 0.977, 214, 213, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
4483, d4obpB_, 0.7187, 3.18, 0.249, 290, 249, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
4484, d5ur1B_, 0.7186, 2.72, 0.227, 265, 238, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
4485, d4d5kA_, 0.7186, 2.66, 0.253, 255, 237, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4486, d3cpbB_, 0.7186, 2.58, 0.217, 263, 235, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
4487, d3cp9B_, 0.7186, 2.65, 0.211, 269, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4488, d2qo7A_, 0.7186, 2.55, 0.203, 278, 236, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED AMP-PNP BOUND
4489, d5kx8A_, 0.7185, 3.21, 0.254, 285, 244, IRAK4-INHIBITOR CO-STRUCTURE
4490, d4xyfA_, 0.7185, 3.32, 0.230, 290, 244, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (S)-5-(8-FLUORO-3-(1-(3-(2- METHOXYETHOXY)QUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43-A]PYRIDIN-6- YL)-3-METHYLISOXAZOLE
4491, d4kspB_, 0.7185, 2.66, 0.199, 256, 236, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
4492, d3q96B_, 0.7185, 2.65, 0.203, 262, 236, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
4493, d2xk4A1, 0.7185, 2.41, 0.276, 244, 232, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 17
4494, d5p9lA_, 0.7184, 2.67, 0.182, 252, 236, BTK1 IN COMPLEX WITH CC 292
4495, d2henB1, 0.7184, 2.60, 0.195, 258, 236, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4496, d5imxA_, 0.7183, 2.52, 0.192, 266, 234, ANAPLASTIC LYMPHOMA KINASE (ALK) CATALYTIC DOMAIN COMPLEXED WITH NOVEL INHIBITOR 3-SULFONYLPYRAZOL-4-AMINO PYRIMIDINE
4497, d5i8aA1, 0.7183, 2.41, 0.220, 265, 232, TRKA WITH (6~{R})-3-METHYLSULFANYL-6-PHENYL-1-(1~{H}-PYRAZOL-3-YL)-6 7-DIHYDRO-5~{H}-THIENO[34-C]PYRIDIN-4-ONE
4498, d4l7sB1, 0.7183, 2.49, 0.219, 248, 233, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
4499, d4i4fA_, 0.7183, 2.71, 0.253, 255, 237, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH AN ALLOSTERIC BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
4500, d4fc0B_, 0.7183, 2.63, 0.199, 263, 236, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
4501, d3eflA1, 0.7183, 2.56, 0.225, 279, 236, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
4502, d2xnmA1, 0.7183, 2.44, 0.289, 250, 232, STRUCTURE OF NEK2 BOUND TO CCT
4503, d4p5zA_, 0.7182, 2.52, 0.196, 267, 235, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
4504, d4l7sA1, 0.7182, 2.54, 0.222, 248, 234, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
4505, d4h58C_, 0.7182, 2.88, 0.196, 272, 240, BRAF IN COMPLEX WITH COMPOUND 3
4506, d3idpB_, 0.7182, 2.79, 0.206, 256, 238, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
4507, d3qgyB1, 0.7181, 2.47, 0.215, 244, 233, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
4508, d4p4cA_, 0.7180, 2.50, 0.200, 266, 235, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
4509, d5fxrA1, 0.7179, 2.97, 0.214, 299, 243, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
4510, d3oriD_, 0.7179, 3.00, 0.244, 267, 242, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4511, d3eflB_, 0.7179, 2.57, 0.208, 263, 236, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
4512, d3d7tA_, 0.7179, 2.45, 0.233, 249, 232, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4513, d3ctjA_, 0.7179, 2.79, 0.206, 289, 238, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
4514, d5eycA_, 0.7178, 3.34, 0.230, 288, 244, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH NAPHTHYRIDINONE INHIBITOR 5
4515, d3q96A_, 0.7178, 2.63, 0.204, 253, 235, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
4516, d2henD1, 0.7178, 2.60, 0.195, 258, 236, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4517, d4u41B_, 0.7177, 3.36, 0.238, 297, 252, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
4518, d4d58A_, 0.7177, 2.62, 0.254, 255, 236, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4519, d1snxA_, 0.7177, 2.52, 0.215, 245, 233, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4520, d4deiA_, 0.7176, 3.17, 0.219, 287, 242, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 24
4521, d2vwvA_, 0.7176, 2.39, 0.215, 255, 233, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4522, d2nryC_, 0.7176, 2.97, 0.254, 280, 240, CRYSTAL STRUCTURE OF IRAK-4
4523, d4ebwA_, 0.7175, 2.87, 0.248, 259, 238, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
4524, d4mneD_, 0.7174, 3.43, 0.264, 285, 250, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4525, p4cfxC2, 0.7174, 0.85, 0.976, 215, 212, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
4526, p4cfxA2, 0.7174, 0.84, 0.976, 215, 212, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
4527, d3mpmA_, 0.7174, 2.73, 0.212, 257, 236, LCK COMPLEXED WITH A PYRAZOLOPYRIMIDINE
4528, p4e3cF1, 0.7173, 3.58, 0.257, 290, 253, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4529, d3cpcB_, 0.7173, 2.56, 0.217, 262, 235, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4530, d4ztmC_, 0.7172, 3.04, 0.262, 282, 240, IRAK4-INHIBITOR CO-STRUCTURE
4531, d4m0zA_, 0.7172, 3.04, 0.210, 264, 243, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 5 {4- (CARBAMOYLAMINO)-1-(7-METHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE}
4532, d3f66B_, 0.7172, 2.88, 0.227, 269, 238, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
4533, d1mp8A_, 0.7172, 2.48, 0.235, 252, 234, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE (FAK)
4534, d4pqnA_, 0.7171, 2.40, 0.221, 240, 231, ITK KINASE DOMAIN WITH COMPOUND GNE-9822
4535, d3vw8A_, 0.7171, 3.03, 0.221, 303, 240, CRYSTAL STRUCTURE OF HUMAN C-MET KINASE DOMAIN WITH ITS INHIBITOR
4536, d3tl8H_, 0.7171, 3.41, 0.210, 303, 248, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4537, d3oriC_, 0.7171, 3.02, 0.244, 267, 242, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4538, d5uitB_, 0.7170, 3.14, 0.259, 283, 243, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
4539, d3oezB_, 0.7170, 2.51, 0.240, 261, 233, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
4540, d5dbxB_, 0.7169, 3.15, 0.259, 282, 239, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
4541, d4mneH_, 0.7169, 3.43, 0.264, 275, 250, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4542, d4m12A_, 0.7169, 3.12, 0.217, 264, 244, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 7 [4- (CARBAMOYLAMINO)-1-(7-ETHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
4543, d1snxB_, 0.7169, 2.53, 0.219, 245, 233, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4544, d5kx7B_, 0.7168, 3.31, 0.267, 286, 247, IRAK4-INHIBITOR CO-STRUCTURE
4545, d5k75D_, 0.7168, 3.15, 0.266, 280, 244, IRAK4 IN COMPLEX WITH COMPOUND 1
4546, d4pp9B1, 0.7168, 2.53, 0.219, 246, 233, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
4547, d4m13A_, 0.7168, 3.04, 0.214, 264, 243, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 8 [4- (CARBAMOYLAMINO)-1-(7-PROPOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
4548, d3c4dA1, 0.7168, 2.67, 0.203, 257, 236,  
4549, d4qq5A1, 0.7167, 2.93, 0.212, 272, 241, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
4550, d4f0gA1, 0.7167, 2.77, 0.230, 260, 235, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM
4551, d3c4cA1, 0.7167, 2.76, 0.198, 257, 237, B-RAF KINASE IN COMPLEX WITH PLX4720
4552, d2yn8A_, 0.7166, 2.37, 0.207, 253, 232, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4553, d5jrsA1, 0.7165, 2.78, 0.181, 257, 237, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
4554, d4qqcA1, 0.7165, 2.87, 0.222, 271, 239, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
4555, d3zfyA_, 0.7165, 2.86, 0.205, 260, 239, CRYSTAL STRUCTURE OF EPHB3
4556, d3w2sA_, 0.7165, 3.33, 0.198, 307, 247, EGFR KINASE DOMAIN WITH COMPOUND4
4557, d5ng3D_, 0.7163, 3.15, 0.224, 278, 246, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
4558, d4c3pD_, 0.7163, 2.89, 0.288, 260, 236, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO TPX2 AND AMPPCP
4559, d4a4xA1, 0.7163, 2.36, 0.277, 245, 231, NEK2-EDE BOUND TO CCT248662
4560, d5uiqC_, 0.7162, 3.09, 0.269, 280, 242, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4561, d4mneE_, 0.7162, 3.48, 0.263, 286, 251, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4562, d4c3fA_, 0.7162, 2.75, 0.212, 257, 236, STRUCTURE OF LCK IN COMPLEX WITH A COMPOUND DISCOVERED BY VIRTUAL FRAGMENT LINKING
4563, d3tl8A_, 0.7162, 3.47, 0.205, 300, 249, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4564, d3is5B1, 0.7162, 2.90, 0.303, 255, 238, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4565, d5uq0B_, 0.7161, 2.74, 0.229, 256, 236, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
4566, d4ebvA1, 0.7161, 2.79, 0.249, 261, 237, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
4567, d3dpkA_, 0.7161, 2.68, 0.213, 279, 235, CFMS TYROSINE KINASE IN COMPLEX WITH A PYRIDOPYRIMIDINONE INHIBITOR
4568, d2xk3A1, 0.7161, 2.30, 0.271, 239, 229, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 35
4569, d2qodA_, 0.7161, 2.53, 0.200, 274, 235, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y602F MUTANT
4570, d5k76B_, 0.7160, 3.04, 0.258, 281, 240, IRAK4 IN COMPLEX WITH COMPOUND 28
4571, d4u3zA_, 0.7160, 3.65, 0.213, 282, 253, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
4572, d4mneA_, 0.7160, 3.49, 0.267, 286, 251, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4573, d4m14A_, 0.7160, 3.11, 0.209, 263, 244, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE]
4574, p4e3cC1, 0.7160, 3.55, 0.261, 290, 253, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4575, d5k75C_, 0.7159, 3.13, 0.259, 282, 243, IRAK4 IN COMPLEX WITH COMPOUND 1
4576, d5b2kA_, 0.7159, 2.38, 0.236, 264, 233, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
4577, d2qoiA_, 0.7159, 2.53, 0.200, 274, 235, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F DOUBLE MUTANT
4578, d2hyyC1, 0.7159, 2.63, 0.226, 249, 234, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4579, d5swhB_, 0.7158, 2.57, 0.241, 261, 232, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4580, d2pl0A_, 0.7158, 2.93, 0.230, 268, 239, LCK BOUND TO IMATINIB
4581, d1yomA_, 0.7158, 2.47, 0.229, 260, 231, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
4582, d5w85B_, 0.7157, 3.09, 0.267, 279, 243, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)
4583, d4xmoA_, 0.7157, 3.32, 0.230, 289, 243, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (R)-5-(8-FLUORO-3-(1- FLUORO-1-(3-METHOXYQUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43- A]PYRIDIN-6-YL)-3-METHYLISOXAZOLE
4584, d2wqnA_, 0.7157, 2.75, 0.290, 259, 238, STRUCTURE OF ADP-BOUND HUMAN NEK7
4585, d5w84A_, 0.7156, 3.08, 0.264, 279, 242, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 4)
4586, d4q9sA_, 0.7156, 2.51, 0.243, 252, 235, CRYSTAL STRUCTURE OF HUMAN FOCAL ADHESION KINASE (FAK) BOUND TO COMPOUND1 (35-DIHYDRO[124]TRIAZINO[34-C][14]BENZOXAZIN-2(1H)- ONE)
4587, d5y8uA_, 0.7155, 2.45, 0.245, 267, 233, CRYSTAL STRUCTURE OF THE C276S MUTANT OF MAP2K7
4588, d5t1tA_, 0.7155, 3.19, 0.258, 283, 244, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4589, d5c9cB_, 0.7155, 2.71, 0.204, 251, 235, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
4590, d4m15A_, 0.7155, 3.12, 0.230, 263, 244, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE] AND ADP
4591, d3w2rA_, 0.7155, 2.96, 0.194, 297, 242, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 4
4592, d2qofA_, 0.7155, 2.54, 0.200, 280, 235, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F MUTANT
4593, d2xm9A_, 0.7154, 3.02, 0.286, 287, 234, STRUCTURE OF A SMALL MOLECULE INHIBITOR WITH THE KINASE DOMAIN OF CHK2
4594, d2qooA_, 0.7154, 2.54, 0.200, 273, 235, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742F TRIPLE MUTANT
4595, d4u42B_, 0.7153, 2.60, 0.255, 265, 235, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
4596, d4ybjA_, 0.7152, 2.54, 0.246, 255, 232, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
4597, d3tz9B_, 0.7152, 2.48, 0.233, 259, 232, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
4598, d2nryD_, 0.7152, 3.15, 0.260, 282, 242, CRYSTAL STRUCTURE OF IRAK-4
4599, d2henA1, 0.7152, 2.61, 0.195, 258, 236, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4600, d5t1tD_, 0.7151, 3.24, 0.261, 283, 245, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4601, d5sysB_, 0.7151, 2.52, 0.237, 258, 232, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
4602, d3zutA_, 0.7151, 2.74, 0.264, 281, 239, THE STRUCTURE OF OST1 (D160A) KINASE
4603, d3f3uB_, 0.7151, 2.48, 0.246, 259, 232, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
4604, d3bysA_, 0.7150, 2.61, 0.223, 255, 233, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE AMIDE 10B
4605, d5itaB_, 0.7149, 2.76, 0.207, 252, 237, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
4606, d2hyyB1, 0.7149, 2.64, 0.231, 252, 234, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4607, d5mo4A3, 0.7148, 2.64, 0.227, 271, 233, ABL1 KINASE (T334I_D382N) IN COMPLEX WITH ASCIMINIB AND NILOTINIB
4608, d4ztlC_, 0.7148, 3.05, 0.278, 282, 241, IRAK4-INHIBITOR CO-STRUCTURE
4609, d4zjjD_, 0.7148, 3.02, 0.299, 274, 241, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4610, d4m0yA_, 0.7148, 3.07, 0.226, 263, 243, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 1 [4- (CARBAMOYLAMINO)-1-(NAPHTHALEN-1-YL)-1H-PYRAZOLE-3-CARBOXAMIDE]
4611, p5lqeA2, 0.7147, 0.83, 0.976, 212, 211, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
4612, d4rfmA1, 0.7147, 2.81, 0.228, 248, 237, ITK KINASE DOMAIN IN COMPLEX WITH COMPOUND 1 N-{1-[(11-DIOXO-1-THIAN- 2-YL)(PHENYL)METHYL]-1H- PYRAZOL-4-YL}-55-DIFLUORO-5A-METHYL-1H4H 4AH5H5AH6H-CYCLOPROPA[F]INDAZOLE-3-CARBOXAMIDE
4613, d4knbA_, 0.7147, 2.96, 0.222, 273, 239, C-MET IN COMPLEX WITH OSI LIGAND
4614, d2r4bA_, 0.7147, 3.00, 0.198, 292, 242, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
4615, d4u3zB_, 0.7146, 3.27, 0.244, 294, 250, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
4616, d2qu6A1, 0.7146, 2.61, 0.226, 276, 235, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
4617, d2henC1, 0.7146, 2.62, 0.195, 258, 236, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4618, d2vwwA_, 0.7145, 2.39, 0.216, 253, 232, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4619, d2og8B2, 0.7145, 2.63, 0.232, 247, 233, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
4620, d4rmzA_, 0.7144, 3.29, 0.268, 284, 246, CRYSTAL STRUCTURE OF IRAK-4
4621, d3zuuA_, 0.7144, 2.75, 0.264, 281, 239, THE STRUCTURE OF OST1 (D160A S175D) KINASE IN COMPLEX WITH GOLD
4622, d2xk8A1, 0.7144, 2.38, 0.275, 238, 229, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 15
4623, d5k75B_, 0.7143, 3.03, 0.264, 274, 239, IRAK4 IN COMPLEX WITH COMPOUND 1
4624, d5j5sA_, 0.7143, 2.53, 0.241, 258, 232, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
4625, d4h1mA_, 0.7143, 2.73, 0.213, 256, 239, CRYSTAL STRUCTURE OF PYK2 WITH THE INDOLE 10C
4626, d4eqmB_, 0.7143, 2.96, 0.240, 269, 242, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4627, d5kx8D_, 0.7142, 3.18, 0.259, 283, 243, IRAK4-INHIBITOR CO-STRUCTURE
4628, d4d4rB_, 0.7142, 3.12, 0.236, 270, 246, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4629, d4bdiA1, 0.7142, 2.97, 0.288, 289, 233, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4630, p5yj9D_, 0.7141, 3.15, 0.256, 333, 242, CRYSTAL STRUCTURE OF TRIBOLIUM CASTANEUM PINK1 KINASE DOMAIN IN COMPLEX WITH AMP-PNP 
4631, d5w85A_, 0.7141, 3.03, 0.266, 278, 241, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)
4632, d5t18A1, 0.7141, 2.81, 0.182, 259, 236, CRYSTAL STRUCTURE OF BRUTON AGAMMABULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-986142 AKA (2S)-6-FLUORO-5-[3-(8-FLUORO-1-METHYL-24-DIOXO- 1234-TETRAHYDROQUINAZOLIN-3-YL)-2-METHYLPHENYL]-2-(2- HYDROXYPROPAN-2-YL)-2349-TETRAHYDRO-1H-CARBAZOLE-8-CARBOXAMIDE
4633, d4xs2D_, 0.7141, 3.14, 0.256, 277, 242, IRAK4-INHIBITOR CO-STRUCTURE
4634, d4pp9A1, 0.7141, 2.52, 0.220, 245, 232, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
4635, d4eqmA_, 0.7141, 2.89, 0.245, 269, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4636, p3c4wB3, 0.7141, 2.56, 0.247, 287, 231, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
4637, d5hlwA_, 0.7140, 3.12, 0.221, 284, 240, CRYSTAL STRUCTURE OF C-MET MUTANT Y1230H IN COMPLEX WITH COMPOUND 14
4638, d4ztmD_, 0.7140, 3.18, 0.265, 282, 245, IRAK4-INHIBITOR CO-STRUCTURE
4639, d4y73A_, 0.7140, 3.23, 0.255, 289, 243, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4640, d4rmzB_, 0.7140, 3.21, 0.266, 282, 244, CRYSTAL STRUCTURE OF IRAK-4
4641, d1vr2A_, 0.7140, 2.84, 0.210, 275, 238, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN
4642, d4yp8A_, 0.7139, 3.28, 0.260, 284, 246, IRAK4-INHIBITOR CO-STRUCTURE
4643, d3pizA_, 0.7139, 2.39, 0.196, 245, 230, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH (5-AMINO-1-O- TOLYL-1H-PYRAZOL-4-YL)-[3-(1-METHANESULFONYL-PIPERIDIN-4-YL)-PHENYL]- METHANONE
4644, d5valA_, 0.7138, 2.68, 0.200, 254, 235, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
4645, d5t1sD_, 0.7138, 3.16, 0.263, 281, 243, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4646, d5ng3B_, 0.7138, 3.09, 0.225, 275, 244, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
4647, d5cenA_, 0.7138, 2.82, 0.271, 281, 236, CRYSTAL STRUCTURE OF DLK (KINASE DOMAIN)
4648, d3lq8A_, 0.7138, 2.71, 0.209, 278, 235, STRUCTURE OF THE KINASE DOMAIN OF C-MET BOUND TO XL880 (GSK1363089)
4649, d4byjA_, 0.7137, 2.44, 0.297, 246, 232, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
4650, d4uy9A_, 0.7136, 3.15, 0.276, 313, 243, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
4651, d4eqmC_, 0.7136, 2.90, 0.245, 269, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4652, d2r4bB_, 0.7136, 2.97, 0.199, 291, 241, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
4653, d3wzuA_, 0.7135, 2.52, 0.239, 270, 234, THE STRUCTURE OF MAP2K7 IN COMPLEX WITH 5Z-7-OXOZEAENOL
4654, d2oibC_, 0.7135, 3.02, 0.261, 278, 241, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4655, d5ct7B_, 0.7134, 2.54, 0.197, 254, 233, BRAF IN COMPLEX WITH RAF265
4656, d4ztlA_, 0.7133, 3.14, 0.267, 280, 243, IRAK4-INHIBITOR CO-STRUCTURE
4657, d4d4rA_, 0.7133, 2.64, 0.237, 251, 236, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4658, d2hakA_, 0.7133, 2.89, 0.328, 309, 241, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4659, d4yo6D_, 0.7131, 3.24, 0.258, 285, 244, IRAK4-INHIBITOR CO-STRUCTURE
4660, d4dehA_, 0.7131, 3.33, 0.227, 286, 242, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 3
4661, d5j5sB_, 0.7130, 2.55, 0.246, 258, 232, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
4662, d5hx6A_, 0.7129, 3.19, 0.220, 259, 241, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
4663, d1yomB_, 0.7129, 2.56, 0.237, 261, 232, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
4664, d1yolB_, 0.7129, 2.47, 0.230, 253, 230, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
4665, d6b8uA_, 0.7126, 2.85, 0.203, 253, 237, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
4666, d4eqmF_, 0.7126, 2.91, 0.258, 268, 240, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4667, d4a9tA1, 0.7126, 3.06, 0.286, 288, 234, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4668, d2vwuA_, 0.7126, 2.41, 0.216, 253, 232, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4669, d2rioA_, 0.7126, 2.42, 0.313, 396, 230, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4670, d1jpaB_, 0.7126, 2.44, 0.190, 269, 232, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
4671, d3p08A_, 0.7125, 2.95, 0.202, 252, 238, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
4672, d5tehB_, 0.7124, 2.60, 0.244, 262, 234, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
4673, d4uy9B_, 0.7124, 3.17, 0.276, 315, 243, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
4674, d3qtiA_, 0.7124, 3.15, 0.230, 292, 239, C-MET KINASE IN COMPLEX WITH NVP-BVU972
4675, d5valB_, 0.7123, 2.60, 0.201, 254, 234, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
4676, d4eqmD_, 0.7123, 2.96, 0.253, 268, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4677, d3is5C1, 0.7123, 3.15, 0.304, 254, 240, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4678, d2wqmA_, 0.7122, 2.82, 0.290, 258, 238, STRUCTURE OF APO HUMAN NEK7
4679, d4r6vA1, 0.7121, 2.95, 0.212, 271, 240, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-3 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
4680, d3efkB_, 0.7121, 2.78, 0.212, 272, 236, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
4681, d3efjA_, 0.7121, 2.96, 0.217, 276, 240, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
4682, d4lg4D_, 0.7120, 2.08, 0.280, 250, 225, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4683, d2wtiA_, 0.7120, 2.98, 0.279, 286, 233, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4684, d5to8A_, 0.7119, 2.44, 0.207, 250, 232, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
4685, d5a6nA1, 0.7119, 2.88, 0.239, 270, 238, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH COMPOUND 2
4686, d4pmtA1, 0.7119, 2.67, 0.214, 269, 234, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N~4~-(4-MORPHOLIN- 4-YLPHENYL)-N~6~-(PYRIDIN-3-YLMETHYL)PYRIDO[32-D]PYRIMIDINE-46- DIAMINE
4687, d2xnoA1, 0.7119, 2.37, 0.271, 243, 229, STRUCTURE OF NEK2 BOUND TO CCT243779
4688, d2javA1, 0.7119, 2.36, 0.287, 245, 230, HUMAN KINASE WITH PYRROLE-INDOLINONE LIGAND
4689, d5sysA_, 0.7118, 2.63, 0.246, 258, 232, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
4690, d4cqeB_, 0.7117, 2.63, 0.205, 248, 234, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
4691, d5d11B_, 0.7116, 2.31, 0.259, 255, 228, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
4692, d4eqmE_, 0.7116, 3.04, 0.248, 268, 242, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4693, d3dy7A_, 0.7115, 3.28, 0.254, 260, 244, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
4694, d2p2iB_, 0.7115, 2.51, 0.202, 263, 233, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
4695, d2oibA_, 0.7115, 3.13, 0.272, 280, 243, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4696, d5k72A_, 0.7114, 2.98, 0.264, 277, 239, IRAK4 IN COMPLEX WITH COMPOUND 21
4697, d4degA_, 0.7114, 3.31, 0.228, 286, 241, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDAZINE INHIBITOR 2
4698, d3w18B_, 0.7112, 2.19, 0.305, 236, 226, STRUCTURE OF AURORA KINASE A COMPLEXED TO BENZOIMIDAZOLE-INDAZOLE INHIBITOR XIII
4699, d2rfnB_, 0.7112, 2.95, 0.213, 269, 239, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
4700, d3v8tB1, 0.7111, 2.52, 0.216, 242, 231, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
4701, d2og8A_, 0.7111, 2.68, 0.227, 246, 233, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
4702, d3h0zB_, 0.7110, 2.43, 0.304, 240, 230, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4703, d2xkeA1, 0.7110, 2.01, 0.281, 235, 224, STRUCTURE OF NEK2 BOUND TO AMINIPYRAZINE COMPOUND 5
4704, d5t1sB_, 0.7109, 3.03, 0.259, 282, 239, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4705, d3vs7A3, 0.7109, 2.87, 0.254, 267, 236, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
4706, d3vs1A3, 0.7109, 2.94, 0.249, 268, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
4707, d3u51A_, 0.7109, 2.69, 0.240, 256, 233, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
4708, d3dxnA_, 0.7109, 3.32, 0.298, 258, 242, CRYSTAL STRUCTURE OF THE CALCIUM-DEPENDENT KINASE FROM TOXOPLASMA GONDII 541.M00134 KINASE DOMAIN.
4709, d3miyB1, 0.7108, 2.29, 0.219, 238, 228, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
4710, d5flfE_, 0.7107, 2.71, 0.230, 258, 235, DISEASE LINKED MUTATION IN FGFR
4711, d4agwB_, 0.7107, 2.54, 0.234, 257, 231, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
4712, d3efjB_, 0.7107, 2.94, 0.209, 275, 239, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
4713, d2xk6A1, 0.7107, 2.27, 0.278, 235, 227, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 36
4714, d2rfnA_, 0.7107, 2.95, 0.213, 268, 239, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
4715, d4ztnB_, 0.7105, 3.07, 0.259, 282, 239, IRAK4-INHIBITOR CO-STRUCTURE
4716, d5uitA_, 0.7104, 3.21, 0.260, 284, 242, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
4717, d5k7gC_, 0.7104, 3.15, 0.273, 283, 242, IRAK4 IN COMPLEX WITH AZ3862
4718, d3svvB_, 0.7104, 2.60, 0.246, 257, 232, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
4719, d3f82A_, 0.7104, 2.65, 0.219, 278, 233, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH N- (4-(2-AMINO-3-CHLOROPYRIDIN-4-YLOXY)-3-FLUOROPHENYL)-4- ETHOXY-1-(4-FLUOROPHENYL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
4720, d3efwB_, 0.7104, 2.38, 0.307, 242, 228, STRUCTURE OF AURORAA WITH PYRIDYL-PYRIMIDINE UREA INHIBITOR
4721, d2oidB_, 0.7104, 2.94, 0.253, 272, 237, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
4722, d5a6nB1, 0.7103, 2.85, 0.253, 265, 237, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH COMPOUND 2
4723, d4othA_, 0.7102, 2.40, 0.288, 305, 229, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH RO-31-8220
4724, d4mf1A1, 0.7102, 2.53, 0.216, 241, 231, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
4725, d3fzsA_, 0.7102, 2.69, 0.211, 254, 237, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH BIRB796
4726, d2wtdA_, 0.7102, 2.93, 0.280, 285, 232, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4727, d2wtcA_, 0.7102, 2.94, 0.280, 284, 232, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4728, d2hyyD1, 0.7101, 2.68, 0.227, 251, 233, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4729, d5d11A_, 0.7100, 2.35, 0.246, 254, 228, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
4730, d4a9rA_, 0.7100, 3.06, 0.283, 285, 233, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4731, d5k9iA_, 0.7097, 2.65, 0.245, 258, 233, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
4732, d3v5lD1, 0.7097, 2.61, 0.224, 244, 232, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4733, d2rioB_, 0.7097, 2.41, 0.319, 395, 229, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4734, d1r1wA_, 0.7097, 2.98, 0.233, 287, 236, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET
4735, d5knjB_, 0.7096, 2.50, 0.198, 259, 232, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 1.
4736, d4zjjC_, 0.7096, 3.20, 0.296, 276, 240, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4737, d4cqeA_, 0.7096, 2.77, 0.209, 250, 235, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
4738, d3v5lB1, 0.7096, 2.50, 0.225, 239, 231, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4739, d4kaoA_, 0.7095, 2.75, 0.236, 252, 237, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
4740, d4a9uA1, 0.7095, 2.99, 0.279, 286, 233, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4741, d3zfyB_, 0.7094, 2.78, 0.209, 255, 235, CRYSTAL STRUCTURE OF EPHB3
4742, d3famA_, 0.7094, 2.47, 0.306, 235, 229,  
4743, d2eueA_, 0.7094, 2.47, 0.306, 235, 229,  
4744, d1ywnA_, 0.7094, 2.58, 0.210, 279, 233, VEGFR2 IN COMPLEX WITH A NOVEL 4-AMINO-FURO[23-D]PYRIMIDINE
4745, d5eymB_, 0.7093, 3.07, 0.246, 292, 240, MEK1 IN COMPLEX WITH BI 847325
4746, d5a6oA_, 0.7093, 2.82, 0.242, 265, 236, CRYSTAL STRUCTURE OF THE APO FORM OF THE UNPHOSPHORYLATED HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3)
4747, d3zuuB_, 0.7093, 2.83, 0.268, 282, 239, THE STRUCTURE OF OST1 (D160A S175D) KINASE IN COMPLEX WITH GOLD
4748, d3vrzB3, 0.7093, 2.92, 0.232, 269, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
4749, d3hyhB_, 0.7093, 2.45, 0.306, 233, 229, CRYSTAL STRUCTURE OF THE PROTEIN KINASE DOMAIN OF YEAST AMP-ACTIVATED PROTEIN KINASE SNF1
4750, d5itaA_, 0.7092, 2.52, 0.216, 250, 232, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
4751, d5a6oB1, 0.7091, 2.84, 0.250, 264, 236, CRYSTAL STRUCTURE OF THE APO FORM OF THE UNPHOSPHORYLATED HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3)
4752, d2qolA_, 0.7091, 2.63, 0.192, 271, 234, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596:Y602:S768G TRIPLE MUTANT
4753, d4x7hA_, 0.7090, 2.89, 0.268, 256, 235, CO-CRYSTAL STRUCTURE OF PERK BOUND TO N-{5-[(67-DIMETHOXYQUINOLIN-4- YL)OXY]PYRIDIN-2-YL}-1-METHYL-3-OXO-2-PHENYL-5-(PYRIDIN-4-YL)-23- DIHYDRO-1H-PYRAZOLE-4-CARBOXAMIDE INHIBITOR
4754, d2cn5A1, 0.7090, 3.00, 0.284, 281, 232, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH ADP
4755, d3zutB_, 0.7089, 2.84, 0.268, 282, 239, THE STRUCTURE OF OST1 (D160A) KINASE
4756, d4agwA_, 0.7088, 2.57, 0.238, 258, 231, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
4757, d3u51B_, 0.7088, 2.68, 0.241, 255, 232, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
4758, d2qi8A_, 0.7088, 2.35, 0.259, 255, 228, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
4759, d5k76A_, 0.7087, 3.03, 0.266, 270, 237, IRAK4 IN COMPLEX WITH COMPOUND 28
4760, d3vs3B3, 0.7087, 3.10, 0.230, 271, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
4761, d2bmcD_, 0.7087, 2.87, 0.292, 256, 233, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4762, d1snuB_, 0.7087, 2.55, 0.221, 241, 231, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4763, d2c0tB3, 0.7085, 2.89, 0.233, 268, 236, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
4764, d5ng3C_, 0.7084, 3.12, 0.227, 272, 242, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
4765, d5jsmB1, 0.7084, 3.03, 0.213, 259, 239, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4766, d4kioA1, 0.7084, 2.39, 0.223, 238, 229, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4767, d3vs7B3, 0.7084, 2.84, 0.247, 266, 235, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
4768, d3vs1B3, 0.7083, 2.98, 0.257, 268, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
4769, d1sm2B_, 0.7083, 2.57, 0.221, 241, 231, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4770, d3plsA_, 0.7082, 3.25, 0.229, 298, 245, RON IN COMPLEX WITH LIGAND AMP-PNP
4771, d2xbjA_, 0.7082, 2.92, 0.286, 286, 231, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4772, d2wtjA1, 0.7082, 3.05, 0.283, 286, 233, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4773, d2c0tA3, 0.7082, 2.89, 0.229, 268, 236, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
4774, d5eymA_, 0.7081, 2.99, 0.247, 292, 239, MEK1 IN COMPLEX WITH BI 847325
4775, d2xkcA1, 0.7080, 2.12, 0.272, 236, 224, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 14
4776, d5k7gD_, 0.7079, 3.17, 0.269, 283, 242, IRAK4 IN COMPLEX WITH AZ3862
4777, d3vs0B3, 0.7079, 2.89, 0.233, 268, 236, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
4778, d3en5B_, 0.7079, 2.66, 0.249, 261, 233, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
4779, d2xk7A1, 0.7079, 2.34, 0.282, 238, 227, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 23
4780, d5u6bA_, 0.7078, 3.04, 0.212, 270, 241, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
4781, d5tx5A_, 0.7078, 3.20, 0.221, 259, 240, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
4782, d5cswA_, 0.7078, 2.66, 0.206, 254, 233, B-RAF IN COMPLEX WITH DABRAFENIB
4783, d4x7jA_, 0.7078, 2.98, 0.264, 257, 235, CO-CRYSTAL STRUCTURE OF PERK WITH 2-AMINO-N-[4-METHOXY-3- (TRIFLUOROMETHYL)PHENYL]-4-METHYL-3-[2-(METHYLAMINO)QUINAZOLIN-6- YL]BENZAMIDE INHIBITOR
4784, d3zxtA_, 0.7078, 2.44, 0.268, 249, 228, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN IN COMPLEX WITH AMPPCP-MG
4785, d3vs2A3, 0.7078, 2.92, 0.233, 268, 236, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
4786, d4itjB_, 0.7077, 3.25, 0.207, 276, 242, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
4787, d2c0iA3, 0.7077, 2.88, 0.233, 268, 236, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
4788, d2bmcE_, 0.7077, 2.91, 0.292, 256, 233, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4789, d3v5lA1, 0.7076, 2.48, 0.222, 238, 230, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4790, d5jrqA1, 0.7075, 2.98, 0.213, 257, 239, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
4791, d4xs2C_, 0.7075, 3.11, 0.271, 281, 240, IRAK4-INHIBITOR CO-STRUCTURE
4792, d3vrzA3, 0.7074, 2.98, 0.249, 268, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
4793, d5hieB_, 0.7073, 2.94, 0.195, 259, 236, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4794, d4kioD1, 0.7073, 2.41, 0.223, 240, 229, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4795, d3qgwB_, 0.7073, 2.51, 0.213, 240, 230, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
4796, d3pj1A_, 0.7073, 2.24, 0.199, 241, 226, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 3-(26-DICHLORO- PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-1-METHYL-34- DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
4797, d2bmcC_, 0.7073, 2.75, 0.294, 257, 231, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4798, d2bmcA_, 0.7071, 2.77, 0.280, 256, 232, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4799, d2bmcF_, 0.7070, 2.76, 0.286, 257, 231, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4800, d4ybjB_, 0.7069, 2.43, 0.246, 253, 228, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
4801, d3zfmA_, 0.7069, 2.50, 0.199, 248, 231, CRYSTAL STRUCTURE OF EPHB2
4802, d3pyyA1, 0.7069, 2.72, 0.233, 251, 232, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
4803, d3p08B_, 0.7069, 2.93, 0.199, 258, 236, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
4804, d4gt4B_, 0.7067, 2.97, 0.205, 273, 239, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
4805, d5tobA_, 0.7066, 2.33, 0.206, 245, 228, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
4806, d4kioB1, 0.7066, 2.36, 0.224, 237, 228, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4807, d2bmcB_, 0.7066, 2.78, 0.280, 258, 232, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4808, d5hnvA1, 0.7065, 2.86, 0.205, 278, 234, CRYSTAL STRUCTURE OF PPKA
4809, d4x7lA_, 0.7065, 2.94, 0.268, 260, 235, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-4-METHYL-3-[2- (METHYLAMINO)-13-BENZOTHIAZOL-6-YL]BENZOYL}-1-METHYL-25-DIPHENYL-1 2-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
4810, d4x7kA_, 0.7065, 2.94, 0.268, 260, 235, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-3-[5-FLUORO-2- (METHYLAMINO)QUINAZOLIN-6-YL]-4-METHYLBENZOYL}-1-METHYL-25-DIPHENYL- 12-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
4811, d4bdfA1, 0.7065, 3.00, 0.290, 284, 231, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4812, d1yolA_, 0.7065, 2.49, 0.231, 256, 229, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
4813, d5k75A_, 0.7063, 2.86, 0.256, 271, 234, IRAK4 IN COMPLEX WITH COMPOUND 1
4814, d3vs0A3, 0.7063, 2.93, 0.233, 268, 236, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
4815, d4yp8D_, 0.7062, 3.51, 0.267, 285, 247, IRAK4-INHIBITOR CO-STRUCTURE
4816, d4y73D_, 0.7062, 3.35, 0.270, 288, 244, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4817, d3vs3A3, 0.7062, 2.99, 0.232, 269, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
4818, d3vs2B3, 0.7062, 2.90, 0.229, 268, 236, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
4819, d3efwA_, 0.7062, 2.36, 0.304, 240, 227, STRUCTURE OF AURORAA WITH PYRIDYL-PYRIMIDINE UREA INHIBITOR
4820, d2c0oB3, 0.7062, 2.89, 0.233, 268, 236, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
4821, d2c0oA3, 0.7062, 2.91, 0.233, 268, 236, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
4822, d3v8wA1, 0.7061, 2.65, 0.208, 241, 231, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
4823, d3vs4A3, 0.7060, 3.06, 0.231, 270, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
4824, d3v8wB1, 0.7060, 2.53, 0.222, 240, 230, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
4825, d3qrjB1, 0.7060, 2.72, 0.246, 252, 232, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
4826, d3mn3A_, 0.7060, 2.55, 0.319, 252, 232, AN INHIBITED CONFORMATION FOR THE PROTEIN KINASE DOMAIN OF THE SACCHAROMYCES CEREVISIAE AMPK HOMOLOG SNF1
4827, d2yzaA_, 0.7060, 2.85, 0.277, 258, 235, CRYSTAL STRUCTURE OF KINASE DOMAIN OF HUMAN 5 -AMP-ACTIVATED PROTEIN KINASE ALPHA-2 SUBUNIT MUTANT (T172D)
4828, d4itiB_, 0.7059, 3.21, 0.207, 270, 241, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
4829, d4a9sA_, 0.7059, 2.95, 0.277, 282, 231, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4830, d3w18A_, 0.7059, 2.33, 0.298, 234, 225, STRUCTURE OF AURORA KINASE A COMPLEXED TO BENZOIMIDAZOLE-INDAZOLE INHIBITOR XIII
4831, d3uc4A_, 0.7059, 3.05, 0.261, 295, 241, THE CRYSTAL STRUCTURE OF SNF1-RELATED KINASE 2.6
4832, d4x7nA_, 0.7058, 2.95, 0.268, 259, 235, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-[2-AMINO-4-METHYL-3-(2- METHYLQUINOLIN-6-YL)BENZOYL]-1-METHYL-25-DIPHENYL-12-DIHYDRO-3H- PYRAZOL-3-ONE INHIBITOR
4833, p3hdmA_, 0.7058, 3.05, 0.272, 285, 239, CRYSTAL STRUCTURE OF SERUM AND GLUCOCORTICOID-REGULATED KINASE 1 IN COMPLEX WITH COMPOUND 1
4834, d2c0iB3, 0.7058, 3.00, 0.249, 268, 237, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
4835, d4nifD_, 0.7057, 2.95, 0.286, 313, 234, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
4836, d2wqoA1, 0.7057, 2.11, 0.274, 234, 223, STRUCTURE OF NEK2 BOUND TO THE AMINOPYRIDINE CCT241950
4837, d2hw7A1, 0.7057, 2.46, 0.249, 269, 225, CRYSTAL STRUCTURE OF MNK2-D228G IN COMPLEX WITH STAUROSPORINE
4838, d5o21B_, 0.7056, 3.48, 0.237, 273, 245, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
4839, d5uisB_, 0.7054, 2.99, 0.266, 274, 237, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
4840, d1xkkA_, 0.7054, 3.33, 0.184, 289, 244, EGFR KINASE DOMAIN COMPLEXED WITH A QUINAZOLINE INHIBITOR- GW572016
4841, d2x7fD_, 0.7053, 2.17, 0.259, 236, 224, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
4842, d5h0gA3, 0.7052, 3.02, 0.231, 281, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-N4-DIMETHYLPENTANAMIDE
4843, d5k7gA_, 0.7051, 3.07, 0.264, 277, 239, IRAK4 IN COMPLEX WITH AZ3862
4844, d4ithB_, 0.7051, 3.27, 0.207, 270, 242, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
4845, d3miyA1, 0.7051, 2.36, 0.220, 237, 227, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
4846, d5u6bC_, 0.7050, 3.07, 0.212, 270, 241, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
4847, d3cs9C_, 0.7050, 2.53, 0.245, 243, 229, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4848, d4fg8B_, 0.7049, 2.88, 0.282, 268, 234, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
4849, d3ulzA_, 0.7049, 3.26, 0.195, 291, 241, CRYSTAL STRUCTURE OF APO BAK1
4850, d4bdhA_, 0.7048, 2.98, 0.287, 282, 230, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4851, d3c7qA_, 0.7048, 2.90, 0.203, 286, 236, STRUCTURE OF VEGFR2 KINASE DOMAIN IN COMPLEX WITH BIBF1120
4852, d2a1aB1, 0.7048, 2.97, 0.248, 266, 238, PKR KINASE DOMAIN-EIF2ALPHA COMPLEX
4853, d5jsmA1, 0.7047, 3.15, 0.212, 262, 240, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4854, d4yfiB_, 0.7047, 2.50, 0.211, 262, 228, TNNI3K COMPLEXED WITH INHIBITOR 1
4855, d4y73B_, 0.7047, 3.33, 0.259, 289, 243, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4856, d3dj6A_, 0.7047, 2.78, 0.289, 252, 232, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 823.
4857, d4otiA_, 0.7046, 2.41, 0.291, 303, 227, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH TOFACITINIB
4858, d3vs6A3, 0.7046, 2.98, 0.232, 269, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
4859, d5uiuB_, 0.7045, 3.34, 0.266, 287, 244, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 30
4860, d5cswB_, 0.7045, 2.50, 0.217, 252, 230, B-RAF IN COMPLEX WITH DABRAFENIB
4861, d4dggB_, 0.7045, 2.65, 0.247, 259, 231, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
4862, p4d28C_, 0.7045, 2.96, 0.318, 279, 239, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
4863, d4bdgA1, 0.7045, 3.03, 0.286, 285, 231, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4864, d3vryA3, 0.7045, 2.99, 0.232, 269, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
4865, d5bpyB1, 0.7044, 2.87, 0.172, 246, 233, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
4866, d3qtiB_, 0.7044, 2.90, 0.236, 280, 233, C-MET KINASE IN COMPLEX WITH NVP-BVU972
4867, d5uiuA_, 0.7043, 3.35, 0.266, 286, 244, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 30
4868, d4bdjA_, 0.7043, 2.95, 0.283, 282, 230, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4869, d3pj3A_, 0.7043, 2.31, 0.187, 240, 225, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-METHYL-5-[(E)- (3-PHENYL-ACRYLOYL)AMINO]-N-(2-PHENYL-3H-IMIDAZO[45-B]PYRIDIN-6-YL)- BENZAMIDE
4870, d3k54A_, 0.7043, 2.27, 0.195, 243, 226, STRUCTURES OF HUMAN BRUTON S TYROSINE KINASE IN ACTIVE AND INACTIVE CONFORMATIONS SUGGESTS A MECHANISM OF ACTIVATION FOR TEC FAMILY KINASES.
4871, d3a60A_, 0.7043, 2.26, 0.305, 263, 226, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED P70S6K1 (FORM I)
4872, d2oidD_, 0.7043, 2.95, 0.264, 274, 235, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
4873, d4zseA_, 0.7042, 3.27, 0.180, 297, 244, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
4874, d2yitA_, 0.7042, 3.06, 0.280, 286, 232, STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 IN COMPLEX WITH PV1162 A NOVEL INHIBITOR
4875, d2wqeA_, 0.7042, 2.46, 0.303, 241, 228, STRUCTURE OF S155R AURORA-A SOMATIC MUTANT
4876, d5hieA_, 0.7041, 2.74, 0.206, 258, 233, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4877, d5h0eA3, 0.7041, 3.03, 0.231, 281, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANAMIDE
4878, d4itjA_, 0.7041, 3.19, 0.218, 261, 239, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
4879, d3u4wA_, 0.7041, 3.14, 0.241, 275, 241, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC4B
4880, d3el7A_, 0.7041, 2.57, 0.249, 254, 229, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 3
4881, d5d12B_, 0.7040, 2.42, 0.251, 253, 227, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
4882, d5o21A_, 0.7039, 3.44, 0.238, 272, 244, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
4883, d5d10A_, 0.7039, 2.40, 0.243, 248, 226, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL236
4884, d4ludB3, 0.7039, 2.81, 0.235, 264, 234, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
4885, d3vs4B3, 0.7039, 3.00, 0.232, 269, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
4886, d3aqvA_, 0.7039, 3.06, 0.268, 267, 239, HUMAN AMP-ACTIVATED PROTEIN KINASE ALPHA 2 SUBUNIT KINASE DOMAIN (T172D) COMPLEXED WITH COMPOUND C
4887, d5we8A_, 0.7038, 3.24, 0.255, 270, 239, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH N-{(3R)-1-[(4-CHLOROPHENYL) METHYL]PYRROLIDIN-3-YL}-2-(3-METHOXYPHENYL)-N-METHYLQUINOLINE-4- CARBOXAMIDE (COMPOUND 8)
4888, d5h09A3, 0.7036, 3.03, 0.231, 281, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-ETHYL2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOATE
4889, d3pozA_, 0.7036, 3.22, 0.193, 293, 243, EGFR KINASE DOMAIN COMPLEXED WITH TAK-285
4890, d2j90A1, 0.7036, 2.66, 0.259, 259, 232, CRYSTAL STRUCTURE OF HUMAN ZIP KINASE IN COMPLEX WITH A TETRACYCLIC PYRIDONE INHIBITOR (PYRIDONE 6)
4891, d4ztmB_, 0.7035, 3.04, 0.257, 280, 237, IRAK4-INHIBITOR CO-STRUCTURE
4892, d4gt4A_, 0.7033, 2.98, 0.206, 274, 238, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
4893, d4bdeA1, 0.7033, 2.95, 0.278, 282, 230, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4894, d5h0bA3, 0.7032, 3.05, 0.227, 281, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOIC ACID
4895, d4xs2B_, 0.7032, 3.05, 0.253, 278, 237, IRAK4-INHIBITOR CO-STRUCTURE
4896, d4bdcA_, 0.7032, 2.97, 0.283, 283, 230, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4897, d3dj5A_, 0.7032, 2.80, 0.289, 252, 232, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 290.
4898, p5uq3A2, 0.7031, 1.01, 0.967, 210, 209, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1-P27 TERNARY COMPLEX
4899, d4zseC_, 0.7031, 3.15, 0.186, 301, 242, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
4900, d5hx6B_, 0.7030, 3.12, 0.216, 264, 236, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
4901, d3vs6B3, 0.7030, 2.98, 0.232, 269, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
4902, d3dkcA1, 0.7030, 3.54, 0.190, 310, 247, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH ATP
4903, d5h0hA3, 0.7029, 3.05, 0.231, 281, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-NN4-TRIMETHYLPENTANAMIDE
4904, d3v5jA1, 0.7029, 2.57, 0.218, 239, 229, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
4905, d2qq7A_, 0.7027, 2.30, 0.267, 251, 225, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN WITH IRREVERSIBLE INHIBITOR
4906, d5jsmD1, 0.7026, 3.09, 0.214, 255, 238, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4907, d4af3A_, 0.7026, 2.90, 0.281, 253, 231, HUMAN AURORA B KINASE IN COMPLEX WITH INCENP AND VX-680
4908, d3uimA_, 0.7026, 3.29, 0.199, 291, 241, STRUCTURAL BASIS FOR THE IMPACT OF PHOSPHORYLATION ON PLANT RECEPTOR- LIKE KINASE BAK1 ACTIVATION
4909, p4d28B_, 0.7025, 3.05, 0.325, 277, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
4910, d3vs5A3, 0.7025, 2.97, 0.233, 268, 236, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
4911, d2rfeD_, 0.7025, 3.07, 0.193, 278, 238, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
4912, d4u97A_, 0.7024, 3.00, 0.263, 272, 236, CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4913, d4lggB_, 0.7024, 2.53, 0.246, 245, 228, STRUCTURE OF 3MB-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
4914, d4bdbA1, 0.7023, 2.99, 0.278, 282, 230, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4915, d4bdaA1, 0.7023, 3.00, 0.283, 283, 230, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4916, d3zzwA_, 0.7023, 3.26, 0.203, 269, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF ROR2
4917, d2rgpA_, 0.7023, 3.17, 0.187, 284, 241, STRUCTURE OF EGFR IN COMPLEX WITH HYDRAZONE A POTENT DUAL INHIBITOR
4918, d5k72C_, 0.7021, 3.12, 0.269, 277, 238, IRAK4 IN COMPLEX WITH COMPOUND 21
4919, d4zseB_, 0.7021, 3.23, 0.186, 313, 242, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
4920, d5t1tB_, 0.7020, 3.15, 0.268, 280, 239, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4921, d3g51A_, 0.7020, 2.78, 0.316, 280, 234, STRUCTURAL DIVERSITY OF THE ACTIVE CONFORMATION OF THE N- TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2
4922, d4ynzB1, 0.7019, 3.19, 0.273, 316, 242, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
4923, d2yirA_, 0.7019, 3.10, 0.280, 286, 232, STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV1352
4924, d5uiqB_, 0.7018, 3.03, 0.262, 272, 237, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4925, d4u9aA_, 0.7018, 3.01, 0.263, 272, 236, SULPHUR ANOMALOUS CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4926, d5hieC_, 0.7017, 2.60, 0.203, 253, 231, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4927, d3udbB_, 0.7017, 2.96, 0.264, 278, 239, CRYSTAL STRUCTURE OF SNRK2.6
4928, d2y4pC_, 0.7017, 2.70, 0.273, 264, 231, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN
4929, d2qi8B_, 0.7016, 2.40, 0.252, 249, 226, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
4930, d5uiqD_, 0.7015, 2.92, 0.260, 271, 235, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4931, d5jsmC1, 0.7015, 2.99, 0.211, 259, 237, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4932, d3cd8A_, 0.7015, 3.10, 0.230, 278, 235, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
4933, d3belA_, 0.7015, 3.12, 0.183, 280, 240, X-RAY STRUCTURE OF EGFR IN COMPLEX WITH OXIME INHIBITOR
4934, d2h6dA_, 0.7015, 2.81, 0.275, 256, 233, PROTEIN KINASE DOMAIN OF THE HUMAN 5 -AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2 (AMPK ALPHA-2 CHAIN)
4935, d1gzoA_, 0.7015, 2.59, 0.289, 271, 232, STRUCTURE OF PROTEIN KINASE B UNPHOSPHORYLATED
4936, d5k72D_, 0.7012, 3.09, 0.266, 276, 237, IRAK4 IN COMPLEX WITH COMPOUND 21
4937, d2rfsA_, 0.7012, 3.11, 0.228, 264, 237, X-RAY STRUCTURE OF SU11274 BOUND TO C-MET
4938, d2hckA3, 0.7012, 3.26, 0.246, 271, 240, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
4939, d5tx5B_, 0.7011, 3.24, 0.212, 263, 236, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
4940, d2ycrA_, 0.7011, 2.97, 0.287, 282, 230, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV976
4941, d1qcfA3, 0.7011, 3.22, 0.240, 281, 242, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH A SRC FAMILY- SELECTIVE TYROSINE KINASE INHIBITOR
4942, d5i4nA1, 0.7010, 3.17, 0.206, 273, 243, CRYSTAL STRUCTURE OF THE E596A V617F MUTANT JAK2 PSEUDOKINASE DOMAIN BOUND TO MG-ATP
4943, d3v5jB1, 0.7010, 2.53, 0.219, 239, 228, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
4944, d2weiA1, 0.7009, 3.16, 0.283, 269, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE IN COMPLEX WITH 3- MB-PP1
4945, d5d7vB1, 0.7008, 3.15, 0.237, 262, 241, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
4946, d4yfiD_, 0.7008, 2.53, 0.207, 261, 227, TNNI3K COMPLEXED WITH INHIBITOR 1
4947, d4m69B_, 0.7007, 3.02, 0.201, 264, 239, CRYSTAL STRUCTURE OF THE MOUSE RIP3-MLKL COMPLEX
4948, p4d28A_, 0.7007, 3.04, 0.322, 274, 239, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
4949, d2ycqA_, 0.7006, 3.08, 0.286, 285, 231, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV1115
4950, d4hjoA_, 0.7005, 3.40, 0.188, 278, 245, CRYSTAL STRUCTURE OF THE INACTIVE EGFR TYROSINE KINASE DOMAIN WITH ERLOTINIB
4951, d3vryB3, 0.7005, 3.03, 0.232, 269, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
4952, d2xk9A_, 0.7005, 3.07, 0.286, 284, 231, STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 (CHK2) IN COMPLEX WITH INHIBITOR PV1533
4953, d2jc6A_, 0.7005, 2.72, 0.278, 278, 230, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4954, d5h2uB1, 0.7004, 3.13, 0.237, 261, 240, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
4955, d4r1yA_, 0.7004, 2.82, 0.225, 265, 231, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITOR
4956, d3uc4B_, 0.7003, 2.96, 0.264, 277, 239, THE CRYSTAL STRUCTURE OF SNF1-RELATED KINASE 2.6
4957, d5uiqA_, 0.7002, 2.98, 0.261, 268, 234, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4958, d3vs5B3, 0.7002, 2.99, 0.233, 268, 236, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
4959, d3udbA_, 0.7002, 2.94, 0.261, 275, 238, CRYSTAL STRUCTURE OF SNRK2.6
4960, d3i5nA_, 0.7002, 3.02, 0.222, 280, 234, CRYSTAL STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR 13
4961, d2w7xA_, 0.7002, 3.08, 0.281, 285, 231, CELLULAR INHIBITION OF CHECKPOINT KINASE 2 AND POTENTIATION OF CYTOTOXIC DRUGS BY NOVEL CHK2 INHIBITOR PV1019
4962, d1gznA_, 0.7002, 2.59, 0.293, 271, 232, STRUCTURE OF PKB KINASE DOMAIN
4963, d1gzkA_, 0.7002, 2.60, 0.297, 271, 232, MOLECULAR MECHANISM FOR THE REGULATION OF PROTEIN KINASE B/ AKT BY HYDROPHOBIC MOTIF PHOSPHORYLATION
4964, d1ad5A3, 0.7002, 3.21, 0.243, 271, 239, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
4965, d5gtyH_, 0.7000, 3.30, 0.198, 300, 242, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
4966, d2ycfA_, 0.6996, 3.10, 0.281, 286, 231, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV1531
4967, d3w33A_, 0.6993, 3.22, 0.199, 297, 241, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 19B
4968, d5hieD_, 0.6992, 2.62, 0.187, 253, 230, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4969, d5uafA_, 0.6991, 2.99, 0.232, 291, 233, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
4970, d5uadA_, 0.6991, 2.99, 0.232, 291, 233, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
4971, d4knbC_, 0.6991, 3.01, 0.226, 271, 234, C-MET IN COMPLEX WITH OSI LIGAND
4972, d5owqA_, 0.6989, 2.59, 0.332, 255, 226, HUMAN STK10 BOUND TO DOVITINIB
4973, d4i24B_, 0.6988, 3.55, 0.192, 304, 245, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
4974, d1bygA_, 0.6988, 2.67, 0.239, 246, 230, KINASE DOMAIN OF HUMAN C-TERMINAL SRC KINASE (CSK) IN COMPLEX WITH INHIBITOR STAUROSPORINE
4975, d5hesA_, 0.6987, 2.97, 0.255, 287, 235, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
4976, d3udbD_, 0.6986, 2.96, 0.261, 279, 238, CRYSTAL STRUCTURE OF SNRK2.6
4977, d3ccnA_, 0.6986, 3.06, 0.232, 275, 233, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
4978, d1ad5B3, 0.6986, 3.22, 0.247, 271, 239, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
4979, d5owqB_, 0.6985, 2.61, 0.327, 254, 226, HUMAN STK10 BOUND TO DOVITINIB
4980, d3zxtC_, 0.6985, 2.77, 0.264, 259, 231, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN IN COMPLEX WITH AMPPCP-MG
4981, d5uisA_, 0.6984, 2.91, 0.265, 269, 234, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
4982, d4yfiC_, 0.6984, 2.63, 0.224, 269, 228, TNNI3K COMPLEXED WITH INHIBITOR 1
4983, d2jc6C_, 0.6984, 2.70, 0.284, 277, 229, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4984, d4ynzA1, 0.6982, 3.08, 0.286, 306, 238, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
4985, d5knjA_, 0.6981, 2.42, 0.206, 252, 228, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 1.
4986, d5d41B_, 0.6981, 3.40, 0.192, 302, 245, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
4987, d4u3yA_, 0.6981, 3.96, 0.211, 295, 251, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
4988, d2o8yB_, 0.6980, 3.02, 0.256, 266, 234, APO IRAK4 KINASE DOMAIN
4989, d2jboA_, 0.6980, 3.02, 0.253, 295, 233, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-1 SOAKING)
4990, d5jt2A1, 0.6979, 3.16, 0.224, 253, 237, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
4991, d2qr8A_, 0.6979, 3.03, 0.295, 298, 234, 2.0A X-RAY STRUCTURE OF C-TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2 (RSK2)
4992, d5h2uD1, 0.6978, 3.25, 0.237, 261, 241, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
4993, d5cnnB_, 0.6978, 3.32, 0.193, 304, 244, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
4994, d3og7A_, 0.6978, 2.66, 0.204, 247, 230, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
4995, d2o8yA_, 0.6978, 3.01, 0.256, 269, 234, APO IRAK4 KINASE DOMAIN
4996, d5d7vD1, 0.6977, 3.28, 0.236, 262, 242, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
4997, d4lghB_, 0.6977, 2.28, 0.251, 247, 223, CRYSTAL STRUCTURE OF 1NM-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
4998, d5jrqB1, 0.6976, 2.79, 0.219, 245, 233, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
4999, d5gtyD_, 0.6976, 3.19, 0.188, 297, 239, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
5000, d1kswA3, 0.6976, 3.28, 0.223, 284, 242, STRUCTURE OF HUMAN C-SRC TYROSINE KINASE (THR338GLY MUTANT) IN COMPLEX WITH N6-BENZYL ADP
